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Neurodegenerative disorders are responsible for the sickness and impaired quality of life of 
nearly one-fifth of the world population and, in part, are responsible for the enormous growth 
in health care costs in the last decade. In these disorders, new therapeutic approaches are thus 
an unmet need. Stem cells have unique characteristics and are a potential solution to help 
treating patients with neurodegenerative disorders. This first chapter will give a short 
introduction of the process of neurodegeneration, most common neurodegenerative disorders, 
and the immune-modulative role of stem cells in these diseases. Inflammation is highlighted 
because of its important role in the pathophysiology of these diseases. Stem cells are no static 
drugs but can adapt easily to local stimuli. To illustrate this in more detail, the hypothesis of stem 
cells as decision-making cells is introduced. Finally, the outline of this book is described with the 






Neurodegeneration is the progressive loss of structure or function of neurons, including their 
death. Neurodegeneration can be found in many different levels of the neuronal circuitry, 
ranging from molecular to systemic level. As research progresses, many similarities appear that 
relate these processes to one another on a sub-cellular level. Discovering these similarities offers 
hope for adequate therapeutic interventions that could ameliorate many, at first glance 
unrelated, diseases. Neurodegenerative diseases are acute or chronic disorders of the central 
nervous system, the brain and/or spinal cord, caused by a trauma (such as spinal cord injury and 
traumatic brain injury), ischemia, or a mixture of genetic and environmental factors (sometimes 
leading to genotypes with various phenotypes such as in typical dopaminergic deficiencies 
(Parkinson disease -PD) or motor neuron disease (amyotrophic lateral sclerosis -ALS), now 
recognized to be a multisystem disorder. The processes leading to the loss of neural tissue are 
described as neurodegeneration.  
 
Figure 1.Secondary degeneration of the axon and neuronal cell body is a multi-pathway mediated process as described by Chitnis and 
Weiner (Chitnis and Weiner 2017) (with permission of the authors and the Journal). The following mechanisms are involved: (i) Nitric oxide 
(NO) produced by macrophages. (ii) Reductions in neuronal ATP production which may lead to failure of the Na+/K+ pump. (iii) activation 
of degradative enzymes, including proteases, phospholipases, and calpains. (iv) production of glutamate by microglia and macrophages. 
(v) Impaired glutamate uptake and degradation of astrocytes, accompanied by a downregulated expression of glutamine synthase (GS) 
and glutamate dehydrogenase (GDH), perpetuates increased extracellular glutamate levels. (vi) Astrocytes produce CCL2 and cytokines 
that further activate microglia and macrophages. In turn, microglia and macrophages consume damaged myelin sheaths and axons. (vii) 
Secondary neuronal cell body degradation can occur by apoptotic or necroptotic mechanisms, triggered in part by immune molecules (e.g., 
TNF-α, TRAIL) that are produced by microglia/macrophages or astrocytes. 
The variety of these processes share a final common pathophysiology: an underlying specific 
etiology-induced necrotic process, boosted through a secondary inflammatory process (Figure 
1) due to both innate and adaptive immune responses (Chitnis and Weiner 2017). 
In acute neurodegenerative disorders (such as traumatic spinal cord injury, traumatic brain injury 
and/or vascular infarcts of the central nervous system) this activation is caused by primary insult-
induced necrosis, whereas in chronic disorders (such as Parkinson disease and/or amyotrophic 
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lateral sclerosis) ongoing activation is elicited by a genetic and/or environmental-driven 
abnormal accumulation of misfolded proteins, mitochondrial dysfunction, oxidative stress 
and/or inflammation. These processes reinforce each other (Lin and Beal 2006, Ganguly, 
Chakrabarti et al. 2017). In many neurodegenerative diseases, damage to the associations of the 
endoplasmic reticulum (ER) with the mitochondria has been described (Stoica, Paillusson et al. 
2016). This damage is linked to activation of glycogen synthase kinase 3β with a reduction of ATP 
and consequent cell death. Targeting GSK3 signaling, therefore, might be regarded a potential 
therapy of neurodegenerative diseases (Duda, Wisniewski et al. 2018). Reduced ER-
mitochondria associations, for instance, are evidenced in transgenic mouse studies with 
mutations at the FUS (fused-in-sarcoma) and TDP-43 (transactive response DNA binding protein 
43 kDa), both inducing a combination of ALS and frontotemporal lobe degeneration (FTLD)-like 
syndromes. Pathological TDP-43 aggregates are the major component of ubiquitin-positive 
cytoplasmic inclusions found in the brains of patients with ALS and FTLD. These aggregates, 
though, are also evidenced in patients suffering Alzheimer’s disease, Parkinson’s disease and 
other synucleinopathies (Stoica, Paillusson et al. 2016). In these disorders, the induced 
mitochondriopathy results in reduced ATP levels with necrosis (Figure 1).These necrotic 
processes and necrotic cells are responsible for the expression/activation of inflammasomes 
(proteins of the immune system responsible for the activation of inflammation), which evoke an 
activation of monocytes, microglia and astrocytes (Lewis, Manning et al. 2012, Orsini, Oliveira et 
al. 2015). Activated microglia, astrocytes, and T-helper cells secrete pro-inflammatory 
chemokines and cytokines and widen the fenestrations in the blood-brain-barrier, enabling free 
passage of these activated monocytes. Activated microglia, astrocytes and infiltrated T-helper 
cells thus regulate cell death and eliminate associated waste materials within the central nervous 
system.  
Microglia play a surveillance role in the homeostasis of the central nervous tissue as can be 
visualized by Figure 2 (Subramaniam and Federoff 2017). The type, location and connections of 
the necrotic cell populations are leading in the variable clinical expression of these 
neurodegenerative processes. The cerebrospinal fluid (CSF) circulating around the damaged 
neural tissue carries  the released cytokines, and the presence of M1-activated macrophages 
(Figure 3), which can pass the opened tight junctions of the blood-brain-barrier, turns CSF toxic 
for neighboring cells (Stamatovic, Keep et al. 2008, Chao, He et al. 2009, Podjaski, Alvarez et al. 
2015). Both innate and adaptive immune responses are involved in the progression of 
neurodegenerative disorders and can promote either neuroprotection or neurotoxicity 
depending on disease stage, evidencing a dual role of inflammation (Zhao, Beers et al. 2013). 
Microglia (M), astrocytes (A) and T-helper cells (Th) thus appear to have central roles in the 
pathogenesis of neurodegenerative processes. When being activated in response to various 
insults, these cells differentiate into a pro-inflammatory (M1, A1 and Th1) phenotype (Frankola, 
Greig et al. 2011, Hagar, Powell et al. 2013). Once the inciting event has been adequately dealt 
with, a lower production of pro-inflammatory cytokines might be responsible for polarization of 
these cells, switching from a pro-inflammatory M1/A1/Th1 (IRM) to an anti-inflammatory 
M2/A2/Th2 (ARM) ‘alternative’ phenotype resolution (a kind of yin and yang) (Kim and Hematti 
2009, Shechter, Miller et al. 2013). However, when the pathogenic stimulus cannot be 
adequately cleared, chronic inflammation develops with persistent IRM activity that can cause 






Figure 2. Schematic of microglial polarization states and function. In normal physiological conditions microglia acquire the surveillance 
phenotype to maintain all CNS cell types including neurons. To maintain this surveillance state, microglia secrete several factors including 
colony stimulating factor 1 receptor (CSF1R), signal regulatory protein CD172 (SIRP1A), chemokine CX3CL1 and CD200R. Upon classical 
activation when triggered by LPS, IFN-γ, or GM-CSF microglia develop into interferon response microglia (IRM) (M1 pro-inflammatory 
microglia)  leading to neurotoxicity by secreting several pro-inflammatory substances (for detailed list, see Table 1). When activated 
alternatively by IL-1, IgG, or IL-10, they become activated response microglia (ARM) (M2 anti-inflammatory microglia) prompting 
neuroprotection through secretion of variety of substances (for detailed list, see Table 1). Arg1, arginase 1; CCL, chemokine (C-C motif) 
ligand; CD, cluster of differentiation; CSF1R, colony stimulating factor 1 receptor; CXCL, chemokine (C-X-C motif) ligand; Fizz1, found in 
inflammatory zone; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon-γ; iNOS, inducible nitric 
oxide synthase; LPS, lipopolysaccharide; MAMPs, microbe-associated molecular patterns; MHC-II, major histocompatibility complex II; 
SIRP1A, signal regulatory protein CD172; SOCS3, suppressor of cytokine signaling-3; TNF-α, tumor necrosis factor-α; Ym1, chitinase-like 
protein (Subramaniam and Federoff 2017)(with permission of the authors and the Journal). 
 
The IRM phenotypes show increased expression of pro-inflammatory cytokines, nitric oxide 
species, TNF-α, and the interleukins IL-1β and IL-6 inclusive, thus increasing the production of 
cytotoxic reactive oxygen species (ROS). ARM microglia secrete anti-inflammatory cytokines 
which annihilate pro-inflammatory tendencies, as well as neurotrophic factors such as glial cell 
line-derived neurotrophic factor (GDDF), brain-derived neurotrophic factor (BDNF), and insulin-
like growth factor-1 (IGF1) (Khalid, Ampie et al. 2017). Macrophages (microglia) react to injury 
and degeneration with immune-phenotypic and morphological changes. they proliferate, form 
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dense clusters around the cell bodies of injured neurons and produce a pro-inflammation signal 
by the expression and secretion of various cytotoxic factors, pro-inflammatory signalling 
molecules, and immune molecules, TNF-α and other inflammatory cytokines inclusive. An 
uncontrolled macrophages response secondary to sustained CNS damage can put neuronal 
survival at risk due to excessive inflammation. A neuroinflammatory response is considered key 
among the etiological factors of the major aged-related neurodegenerative diseases of the 
central nervous tissue, and microglial cells are the key players in these neurodegenerative lesions 
(Eggen, Raj et al. 2013, Li, Tan et al. 2013, Ramirez, de Hoz et al. 2017). Thus, neurodegeneration 
is facilitated by both, the continued production of cytotoxic by-products of a pro-inflammatory 
response and the lack of neurotrophic growth factors.  
 
 
Figure 3.In a normal situation the tight junctions of the blood-brain barrier are closed and the macrophages are circulating in the blood 
stream in a non-activated stage (fig 3a). After an insult of the CNS, neurons get damaged and rupture with the release of all kind of pro-
inflammatory proteins (cytokines), which can freely pass the blood-brain-barrier because of their very small dimensions (fig 3b). Those 
cytokines open the tight junctions of the blood-brain barrier and in parallel activate the macrophages to a pro-inflammatory IRMl (M-1) 
phenotype. Thus activated macrophages can pass the opened tight junctions of the blood-brain-barrier and together with the circulating 
cytokines they are responsible for the clean-up of damaged and dying cells and create a hostile toxic environment (fig 3c). 
So, in chronic neurodegenerative processes cell debris and damaged cells are cleaned-up by the 
activated IRM (M1/A1/Th1) phenotypes. This cleaning-up process triggers further cell death 
(Hooten, Beers et al. 2015). In most neurodegenerative disorders, especially in the more chronic 
disorders, there is a vicious circle: cell death evokes inflammasomes that initiate a cleaning-up 
process by IRMs (M1/A1/Th1 phenotypes), leading to progressive cell death, which in turn 
evokes more inflammasomes To stop this vicious circle and to stop the expression of 
inflammasomes, therefore, is an unmet need (Voet, Srinivasan et al. 2019).  
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As mentioned before, neurodegenerative disorders might be caused by acute, recurrent or 
chronic traumatic, toxic and/or ischemic insults of the central nervous system (CNS). Typical 
chronic progressive neurodegenerative disorders, though, are mainly the consequence of 
genetic or combined genetic and environmental factors, which is the case in dementia, 
parkinsonisms, and amyotrophic lateral sclerosis. Unfortunately, there is no effective therapy 
available for most of these disorders. The financial and psychosocial impact of these diseases on 
the community are high. Nearly 20% of the global population suffers from a neurodegenerative 
disease (Erkkinen, Kim et al. 2018). As the majority of the neurodegenerative diseases is 
correlated with aging, the percentage will be even more than 20% when looking at age groups 
above 65 years of age. The compiled Table 1 presents the incidence, prevalence and life 
expectancy of the main neurodegenerative diseases. This table illustrates clearly the health 
burden for the individual patient but also the economic burden for an aging community. 
 
 
Table 1.  
Incidence, prevalence and life expectancy of the neurodegenerative diseases 
Disease/disorder Incidence Prevalence Life expectancy 
Spinal cord injury 34/1,000,000 person-years 
(Singh, Tetreault et al. 2014, 
Kumar, Lim et al. 2018) 
2.27-5.26/10.000 
inhabitants 
(Furlan, Sakakibara et al. 
2013). 
23.96-26.17 years (Krause, 
Saunders et al. 2012, Chamberlain, 










et al. 2006) 
 
Ischemic Stroke 95-290/100,000 person-years 
(Feigin, Lawes et al. 2003, 
Bejot, Bailly et al. 2016) 
199/10,000 inhabitants 
(Feigin, Lawes et al. 2003, 






(de Lau and Breteler 2006, 
Park, Kim et al. 2019) 
 
 10 years after confirmation 
Parkinson’s disease (de Lau and 








(Mehta, Kaye et al. 2018, 




(Mehta, Kaye et al. 2018, 
Nelson, Topol et al. 2018, 
Gowland, Opie-Martin et 
al. 2019, Longinetti and 
Fang 2019) 
 
30 months from first symptoms 
(Logroscino, Traynor et al. 2010, 






incidence is 2.7–4.1/100,000 
inhabitants (Onyike, Diehl-
Schmid. 2013) 




Life expectancy is poor (3-14 years) 
and comparable to ALS (Onyike, 




Interventions in neurodegeneration 
As stated in the sections above, there is Increasing evidence to suggest that inflammation is 
particularly involved in the pathogenesis of neurodegenerative diseases, and that even if 
inflammation is not a primary causative process, its presence may contribute to the continued 
neuronal loss. This suggestion is quite robust as pro-survival signaling mechanisms from 
neurotrophic factors are effective in attenuating neuronal death in many in vitro and in vivo 
models of neurodegeneration. Individual anti-inflammatory agents, such as steroidal and non-
steroidal anti-inflammatory drugs (N)SAIDs) do not break/resolve the neuro-inflammation. 
Unfortunately, all larger preclinical and clinical phase II/III trials in acute and chronic 
neurodegenerative disorders with (N)SAIDs (non-steroidal and steroidal anti-inflammatory 
drugs), compounds that target inflammatory mechanisms and associated cascades (including 
thalidomide, selective cyclooxygenase-2 inhibitors such as Celecoxib, cyclophosphamide, 
cyclosporine, caspase-reducing drugs, and various neurotrophic factors) so far did only bring 
equivocal and/or worse outcomes (Gilgun-Sherki, Melamed et al. 2006, Hernan, Logroscino et 
al. 2006, Gordon, Moore et al. 2007, McGeer and McGeer 2007, Schwartz and Ziv 2008, Calvo, 
Moglia et al. 2010, Schwartz and Shechter 2010, Bracken 2012, Rosado, Lavor et al. 2014, Ling, 
Murdoch et al. 2016, Collins and Bowser 2017, Fehlings, Wilson et al. 2017, Ulndreaj, Badner et 
al. 2017). Maybe wrong timing of administration, nonselective inhibition of 
cyclooxygenase(COX)-2 inhibitors or Rho-associated protein kinases, sub-optimal dose in target 
site, or limited penetration to the brain through the blood-brain barrier here may have played a 
role in the failed approaches (Lossinsky and Shivers 2004, Stamatovic, Keep et al. 2008, 
Gabathuler 2010). Differences between rodent models and humans aside, perhaps the most 
confounding factor might be that the point(s) of action might be downstream of the 
pathophysiological process and retrospective in terms of neuronal death induction. 
Neuroprotection via pro-survival signaling also might not adequately annihilate the continuing 
pathological insult or might be too late to reverse the demise of compromised neurons and 
neighboring cells (Tang 2017). Although interventions with anti-inflammatory drugs in 
experimental neuro-degenerative animal studies have not resulted in successful clinical trials, a 
more recent approach to treat such disorders in both experimental animals and humans with 
implanting bone marrow-derived stromal cells (bm-SC), however, seems very promising. Such 
transplants supposedly modulate the immune system in both acute (spinal cord injuries) (Tsai, 
Liou et al. 2018, Cofano, Boido et al. 2019, Jin, Medress et al. 2019, Shao, Tu et al. 2019), as well 
as chronic (amyotrophic lateral sclerosis) (Deda, Inci et al. 2009, Mazzini, Vescovi et al. 2016, 
Schroeder, Kepler et al. 2016, Ciervo, Ning et al. 2017, Gashmardi, Hosseini et al. 2017, Sykova, 
Rychmach et al. 2017, Cizkova, Cubinkova et al. 2018, Garbuzova-Davis, Haller et al. 2018, Oh, 
Noh et al. 2018, Gugliandolo, Bramanti et al. 2019), neurodegenerative disorders in both 
experimental animals and patients. 
 
Stem cells 
Recently, cell-based therapies, and especially stem cells, emerged as a promising strategy to 
modulate the immune system in these patients. Stem cells are undifferentiated cells that can 
divide to produce some offspring cells that continue as stem cells, and some cells that are 
destined to differentiate (become specialized) in all kind of target cells. The hall marks of stem 
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cells thus are proliferation and differentiation. Stem cells are needed to develop, assemble and 
repair bodily structures. Without these cells one cannot survive (Hemmat, Lieberman et al. 
2010). Stem cells can be harvested out of adipose tissue (Vilalta, Degano et al. 2008), bone 
marrow (Jager, Hernigou et al. 2010), olfactory mucosa (Murrell, Wetzig et al. 2008), umbilical 
cord blood (Dalous, Larghero et al. 2012) and embryonic tissue (Hentze, Graichen et al. 2007), as 
well as special niches in organs (Gao, Enikolopov et al. 2008, Paspala, Balaji et al. 2009). Another 
way of acquiring stem cells is to reprogram adult somatic cells back into pluripotent stem cells, 
induced pluripotent stem cells (iPSCs). To reach quantitative numbers of stem cells, expanding 
procedures might be used. The exact mechanisms of action of stem cells remain to be elucidated.  
Furthermore, stem cells have the capability of switching on/off processes of cells, and can act 
selective or act situational and adapt to local circumstances (Fischbach, Bluestone et al. 2013). 
They act fundamentally different compared to small molecules such as neurotransmitters and 
biologics such as antibodies, growth factors and or cytokines. Cell-based products can adapt to 
the environment, can target more precise and can influence their environment to help creating 
a more controlled environment. Stem cells are able to modulate immune processes by 
modulating T- and B-cell activity , and are able to secrete or stimulate other cells to secrete 
paracrine factors with the goal to maintain tissue homeostasis (de Munter and Wolters 2013, 
Harting, Srivastava et al. 2018, Ruppert, Nguyen et al. 2018). The action of classical 
drugs/biologics is in contrast determined by their dose at the moment of administration. The 
pharmacokinetics are determined by the elimination time of the drug and tissue penetration of 
the drug. The pharmacokinetics are highly important to avoid side effects (Benet, Bowman et al. 
2019, Farkouh, Riedl et al. 2019).  
 
Table 2. 
Cell-based therapeutics compared to small molecules/biologics (Fischbach, Bluestone et al. 2013) 
Comparisons Small molecules and biologics Stem cells 
Selectivity Molecular recognition 
 
Complex sensing and response systems 
 
Distribution Diffusion and transport-controlled 
Pharmacokinetics/pharmacodynamics  
 
Directed cell migration 







• Closed-loop autoregulation 
  
Therapeutic niche Conditions for which distribution and 
duration of action do not need fine control 
Conditions that require precise dynamic control 
over distribution, level, and duration of action 
 
These interventions have also off-target effects, meaning that they are also penetrating in and 
acting on non-target cells creating those side effects. Cells are able to adapt and make their own 
interpretations and act accordingly. They can stay in a non-active phase (OFF-phase) and when 
certain signal proteins reach a threshold level, can activate themselves (ON phase). The question 
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‘How many cell are needed for a certain effect’ is difficult to answer, because cells act 
dynamically and can activate existing cells to secrete paracrine factors (Kinnaird, Stabile et al. 
2004) or assist in coping with the original insult (Fischbach, Bluestone et al. 2013). Table 2 
compares the characteristics of today’s therapeutic arsenal, cells inclusive (Fischbach, Bluestone 
et al. 2013) in more detail. Bone marrow can be a source of stem cells and is easily accessible for 
collection of hematopoietic (HSCs) and mesenchymal (MSCs) stem cells (Jager, Hernigou et al. 
2010). Hematopoietic stem cells (HSCs) mainly replenish all adult hemato-poietic lineages 
throughout lifetime, and mesenchymal stem cells (MSCs) play crucial roles in maintaining tissue 
homeostasis during physiological turnovers and injuries by their trans-differentiation into tissue-
specific cell types and their anti-inflammatory and regenerative/apocrine actions. MSCs and 
HSCs can promote regeneration; figure 4 illustrates the multitasking capabilities of the cells 
related to neural repair (Wagenaar, Nijboer et al. 2017).  
 
 
Figure 4. Potential mechanisms for mesenchymal stem cells to induce repair of brain injury, including of angiogenesis, stimulation of 
neurogenesis, reduction of apoptosis, neuroinflammation, and gliosis. These pathways are mediated by the secretome of MSCs, which 
consists of growth factors such as vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), hypoxia-inducible 
factor 1 (HIF-1), erythropoietin (EPO), insulin-like growth factor 1 (IGF-1), nerve growth factor (NGF), basic fibroblast growth factor (bFGF) 
and anti-inflammatory cytokines. Modified from Wagenaar et al. (Wagenaar, Nijboer et al. 2017)(with permission of author and Journal) 
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Stem cells are big cells and cannot pass an intact blood-brain barrier and/or cortico-spinal fluid-
brain barrier (Stamatovic, Keep et al. 2008, Jackson, Golding et al. 2010). Their communication 
with other cells takes probably place by communicators, signalling proteins, extracellular vesicles 
that can freely pass the blood-brain barriers. Communicators are soluble factors such as 
cytokines (including chemokines, interferons, interleukins, lymphokines, and tumour necrosis 
factor) and small vesicles containing dedicated proteins (extracellular vesicles). Extracellular 
vesicles (EVs) are small, membrane-bound nanoparticles that can be released from most, if not 
all cells, and that can carry functionally active cargo (proteins, nucleic acids, lipids). The active 
molecules in this cargo showed to modify the recipient cells physiology to react in a paracrine 
and endocrine manner (Dostert, Mesure et al. 2017, Cizkova, Cubinkova et al. 2018, Harting, 
Srivastava et al. 2018, Kim, Oh et al. 2018, Wang, Pei et al. 2018, Beers and Appel 2019). Figure 
5 illustrates a cell with EVs, showing also their  dimensions (Shahjin, Chand et al. 2019). 
 
 
Figure 5. Schematic representation of the biogenesis of extravesicular vesicles subpopulations and HIV, with size ranges. ER: endoplasmic 
reticulum; PM: plasma membrane; MVB: multivesicular bodies (Shahjin, Chand et al. 2019)(with permission of author and Journal) 
 
Another paracrine factor of stem cells relevant to mention in this chapter is VEGF (vascular 
endothelial growth factor) (Friedrich, Walenta et al. 2006, Wragg, Mellad et al. 2008, Zisa, 
Shabbir et al. 2009, Cobellis, Maione et al. 2010), a pro-angiogenetic growth factor. VEGF is seen 
as a secreted protein of stem cells able to promote vascular growth in ischemic tissue. This is 
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relevant for diseases with an acute vascular occlusion such as critical limb ischemia, myocardial 
infarction and ischemic stroke.  
 
In summary, stem cells are very promising as a new therapeutic concept to combat 
neurodegeneration but there are questions, which are relevant to be answered before going into 
translation with a stem cell preparation:  
 
− Which patients can be universally treated with stem cells as a disease modifier in 
diseases in which secondary inflammatory processes play a major role in the 
neurodegenerative process? 
− Which stem cells are best suited to be applied as an intervention? 
− Which is the best route of administration when dealing with neurodegenerative 
diseases? 
− Which is the best dose? 
− Which is the best time in respect to the disease process to administer the stem cells? 
 
Based on a comprehensive evaluation of literature, and based on own experiences, non-
manipulated bone marrow-derived MSCs and HSCs are selected as a concept therapy to be 
applied in the treatment of neuro-degenerative diseases such as spinal cord injury, amyotrophic 
lateral sclerosis and frontotemporal lobe degeneration inclusive. Translational, this preparation 
is called Neuro-Cells. Neuro- being the target area and -Cells the content of fresh living cells. 
Conceptually, this preparation acts like a multi-tasker, taking decisions pending the environment, 
and secreting repair/immune-modulating substances such as paracrine factors and/or 
extracellular vesicular vesicles.  
 
Aims and outlines of this book 
The aim of this thesis is to identify a standardized stem cell product that can be used to treat 
secondary inflammation in neurodegenerative diseases to improve the clinical outcome. 
 
In Chapter 2, the harvesting and manufacturing of the various human stromal/stem cell 
preparations, as well as their characterization, capabilities, functions, and their clinical 
application in human neurodegenerative conditions are comprehensively reviewed. Here, the 
effects of world-wide interventions with human stem cell preparations in animal models of acute 
(traumatic and/or vascular-induced) and chronic (parkinsonism, multiple sclerosis, amyotrophic 
lateral sclerosis) neurodegenerative disorders as well as in patients suffering these disorders are 
also extensively reviewed.  
 
Chapter 3 deals with the angiogenetic capabilities of a human bone marrow-derived stem cell 
preparation in a preclinical model of ischemic limb.  
 
In Chapter 4, the clinical effects of an intrathecal transplantation with negatively selected MSCs 
and HSCs (Neuro-Cells) in rats suffering an acute traumatic balloon compression- as well as 




In Chapter 5, the effects of intrathecal interventions with Neuro-Cells in transgenic FUS (1-358) 
and SOD-1-induced amyotrophic lateral sclerosis (ALS)-like mice as well as in FUS (1-358)-induced 
frontotemporal lobar degeneration (FTLD)-like mice will be discussed in detail. Here, the beauty 
of the experiments was the head-to-head comparison with anti-inflammatory drugs. 
 
Finally, in Chapter 6, we discussed the question why anti-inflammatory signals of bone marrow-
derived stem cells improve neurodegenerative conditions where anti-inflammatory drugs fail. 
We concluded that in preclinical trials, a transplantation with human stem cells might be seen as 
a disease modifier, acting on the secondary inflammatory mechanisms. So, as of now, we have 
cleared the way to test this hypothesis in human trials, as we realize that we not only need more 
human clinical data to substantiate this conclusion, but also better biomarkers for monitoring 
(neuro)-inflammation.  
 
Chapter 7 elaborates on the concept of the decision-making stem cells, which detox the hostile 
cerebrospinal fluid, after displaying the preclinical results. The whole process from the first 
laboratory tests to the proof of concept in the animal experiments allowing to test our 
hypothesis in a clinical trial in patients suffering neurodegenerative disorders, will be addressed. 
Chapter 7.2 provides the reader with a summary of the presented studies looking at the effects 





Cell based therapy in Neurology: the search for the best cells 
 
Introduction chapter 2 
Chapter 2 provides a general introduction of stem cells and their use as an intervention to treat 
traumatic, vascular and neurodegenerative insults of the central nervous system. This chapter 
comprises four separate review articles in which the first one (2.1) highlights the various different 
sources of stem cells and the choice to work with autologous non-manipulated stem cells. 
Especially, the autologous stem cells and their benefits are discussed reflecting the state of the 
art in literature.  
The second article (2.2) presents an overview of the different preclinical and clinical studies 
performed with autologous stem cells in acute neurodegenerative disorders such as traumatic 
spinal cord injury, traumatic brain injury and ischemic stroke will be highlighted. The third article 
(2.3.) give a detailed overview of the literature on stem cell transplantations in the treatment of 
parkinsonistic animal models and patients suffering a chronic neuro-degenerative process 
(parkinsonism). The last, fourth article (2.4.) focuses on more practical issues in stem cell 
transplantation the best choice of cells and the best timing and route of administration.  
Both in acute and chronic neurodegenerative disorders, dying neural tissue provoke 
inflammatory cascades. Indeed, secondary inflammation plays a role in these processes, and 
stem cells are suggested to suppress and/or slow down ongoing inflammation, thereby saving 







2.1. Autologous stem cells in neurology: is there a future? 
 
de Munter JPJM, Wolters ECh (2013) J Neural Transm 120:65-73. 
 
Abstract  
Stem cells seem very promising in the treatment of degenerative neurological diseases for which 
there are currently no or limited therapeutic strategies. However, their clinical application meets 
many regulatory hurdles. This article gives an overview of stem cells, their potential healing 
capacities as well as their identified and potential risks, such as tumour formation, unwanted 
immune responses and the transmission of adventitious agents. As there is no clinical experience 
with embryonic and induced pluripotent stem cells (as the result of their unacceptable risk on 
tumour formation), most attention will be paid to fresh autologous adult stem cells (ASCs). To 
evaluate eventual clinical benefits, preclinical studies are essential, though their value is limited 
as in these studies, various types of stem cells, with different histories of procurement and 
culturing, a reapplied in various concentrations by various routes of administration. On top of 
that, in most animal studies allogenic human, thus non autologous, stem cells are applied, which 
might mask the real effects. More reliable, though small-sized, clinical trials with autologous ASCs 
did show satisfying clinical benefits in regenerative medicine, without major health concerns. 
One should wonder, though, why it is so hard to get compelling evidence for the healing and 
renewing capacities of these stem cells when these cells indeed are really essential for tissue 
repair during life.  
Why so many hurdles have to be taken before health authorities such as the European Medicine 
Agency (EMA) and/or the Food and Drug Administration (FDA) approve stem cells in the 
treatment of (especially no-option) patients. 
 
Introduction 
There is worldwide consensus about stem cells, playing a vital role in tissue repair and plasticity, 
and all of us realize that without these cells, life is not possible (Schofield 1983).  
Over the last 10 years, however, the eventual application of these stem cells as well as their 
regulatory framework (Astori, Soncin et al. 2010) in therapeutic strategies for all kind of end 
stage (neurological) diseases in humans (Zietlow, Lane et al. 2008) has been subject to critical 
discussion. As of yet, these discussions did not lead to a consensus regarding the clinical 
application of stem cells in such disorders. To better understand this discussion, and to elucidate 
these hurdles, we will discuss the various moieties of stem cells, especially those of the 
autologous adult stem cells (ASCs). 
 
Stem cells 
Stem cells are expressed and can be harvested from embryonic tissue, from umbilical cord blood 
and from adult tissue such as peripheral blood, bone marrow, liver and fat tissue. They are not 
specialized in any specific cell type as yet, though share the ability to on the one hand reproduce 
themselves indefinitely and on the other hand to differentiate themselves into any specialized 
cell type (Hemmat, Lieberman et al. 2010). Indeed, their specific strength is defined by their 
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capacity to differentiate into various cell types. This ability for self-renewal makes them 
particularly interesting for expanding.  
During the first four blastomere cleavage phases, embryonic stem cells are the most capable 
stem cells, as they are totipotent, meaning that these cells are able not only to differentiate 
themselves into virtually all cell types needed to constitute a human body (so, cell types within 
all germ layers: endoderm, mesoderm and ectoderm) but also into extra-embryonic cells 
(umbilical cord tissue).  
After the fourth cleavage phase, the embryonic cells lose their totipotency and become 
pluripotent stem cells. Those cells are now only able to differentiate themselves into the three 
essential lineages, but not into extra-embryonic cells. Later on, during development, these cells 
will become multipotent stem cells: initially, they still can differentiate into two of these specific 
lineages, but in due time they even become unipotent cells, cells which may differentiate only in 
cell types limited to one germ layer.  
Finally, when the end stage cell line is formed, differentiation into other cell types is not possible 
anymore and the cells are called nullipotent, although, under certain conditions, they still will be 
able to renew themselves.  
Table 1 presents an overview of the different groups of stem cells with the main characteristics.  
 
Table 1  
The potential stem cells for treatment of neurodegenerative diseases with their main characteristics 
Type Source of harvest Ability to 
differentiate 




Derived from an embryo in 
the first four blastomere 
cleavage phases 
 
Totipotent High High High (indefinitely) 
Embryonic 
stem cells 
Derived from an embryo 
after the fourth blastomere 
cleavage phase 
 




Derived from the umbilical 
cord at birth 
 
 






Derived from already 
specialized human tissue 
 
 
Pluripotent Low High/medium (depends 





Derived from already 
specialized human tissue 
 
 





Derived out of the 
periventricular sub-
ependymal layer and 
subgranular zone of the 
dentate gyrus 
 






Derived from already 
specialized human tissue but 
reprogrammed back to 
embryonic like stem cells 





The application of cells, able to differentiate themselves into highly differentiated cell types, of 
course, seems very attractive in the treatment of neurodegenerative diseases, where clinical 
symptoms express the progressive loss of functional cells, to combat the lack of effective 
therapies. However, not all stem cells seem to be good candidates for human application. As the 
most powerful stem cells, the totipotent cells, deriving from living embryos before the fifth 
blastomere cleavage phase (Hemmat, Lieberman et al. 2010), have the significant disadvantage 
to enable tumor formation (Lee, Tang et al. 2009), not to mention the ethical aspects of using 
embryos to harvest stem cells (Andersson 2011). Another problem is that those embryonic cells 
(from non-autologous donors) might be rejected after clinical application and, therefore, need 
to be combined with immune response inhibitors when applied. The use of pluripotent cord 
blood-derived stem cells seems more attractive, and harvesting them could play a role in the 
preventive storage of genetically matched cell lines for future treatment of degenerative 
diseases limited to the child and or the parents (Riordan, Chan et al. 2007). As we know now, 
long-term storage of these stem cells with additives such as dimethyl sulfoxide (DSMO) does not 
change the viability of the stem cells, even after a freezing period of nearly 18 years 
(Veeraputhiran, Theus et al. 2010). These cells are also considered free of eventual tumor genesis 
and do not need any immune suppressive therapy to prevent rejection after reapplication in the 
donor. Autologous ASCs, mainly mesenchymal and hematopoietic stem cells, though, are 
considered to be most promising, as they do not bear the risk of tumor genesis  and are easily 
harvested out of the iliac crest of the patients. So, these cells do have the same genetic base as 
the patient, and might be applied without immune suppressive medication to prevent graft 
rejection (Barzilay, Levy et al. 2006). On top of that, recent studies with these multipotent stem 
cells produced firm evidence that they might even differentiate into cell types of all lineages 
(Junker, Sommar et al. 2010), suggesting pluripotency. As a matter of fact, ASCs can also be 
reprogrammed to a pluripotent state, by enforcing the expression of embryonic transcription 
factors (Stadtfeld and Hochedlinger 2010), in that way combining the strength of embryonic 
stem cells and the absence of the need to prevent for an immune response. However, one should 
realize that in any case of manipulative and/or expanding procedure (which is the case in induced 
pluripotent stem cells), there is a high risk of aneuploidy (unequal number of chromosomes), 
which limits the differentiation capacity and increases the tumorigenicity (Mayshar, Ben-David 
et al. 2010). Neural stem cells are situated in the periventricular subependymal layer and sub-
granular zone of the dentate gyrus and are multipotent. Neural stem cells can differentiate into 
glial cells, astrocytes and oligodendrocytes. These cells are difficult to harvest, though, and 
limited in number (Andres, Choi et al. 2008). We will discuss the state of art considering the 
harvesting and preparation as well as characterization of autologous ASCs, focusing on 
mesenchymal (MSCs) and hematopoietic stem cells (HSCs). 
 
Autologous adult stem cells 
Harvesting and preparing adult stem cells 
As the bone marrow is one of the major sources of autologous ASCs, harvesting those cells might 
be readily and safely performed by bone marrow biopsy (Siddiq, Pamphilon et al. 2009). Usually, 
the bone marrow aspirate is then filtered and processed by gradient centrifugation. In the 
centrifugate, the buffy coat (the layer between the plasma and the red blood cells with the 
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highest yield of the stem cells with the best therapeutic potential, such as HSCs and MSCs) is 
then isolated for further processing, for instance with cell separators to select and concentrate 
stem cells in a closed system, allowing point-of-care treatment (Scerpa, Daniele et al. 2011). 
Nevertheless, the number of these cells in a centrifuged bone marrow aspirate is rather low, the 
percentage of MSCs usually not exceeding 1 % of HSCs and 0.01 % of the total number of 
mononuclear cells (Pittenger, Mackay et al. 1999). Extrapolated from animal studies, a dose 
between 1.0 and 3.0 x 107 BMMCs (containing 1.0–3.0 x 105 HSCs) per kilogram body weight is 
considered to be adequate in the treatment of human neurological diseases including ischemic 
brain injury (Yang, Strong et al. 2011).  
 
 
Figure 1 Overview mean number of CD34+ cells and 95% confidence interval by age class (own data) 
 
 
Figure 1 gives an overview of the mean number of CD34+ cells (mainly HSCs) calculated per ml 
bone marrow aspirate per age class (own data).  
So, 150–200 ml bone marrow aspirate (containing about 5–10 x 106 HSCs) is needed to prepare 





Figure 2 Overview of the trans-differentiation of adult stem cells (Wright et al. 2010 with permission) 
 
Figure 2 gives an overview of the trans-differentiation of ASCs (Wright, El Masri et al. 2010). Both 
MSCs and HSCs are not only able to transdifferentiate into more specialized cells though, they 
also secrete all kind of proteins/factors, which are important in making the injured neighborhood 
more accessible for local repair mechanisms (Gnecchi, Zhang et al. 2008). 
 
Characterization of adult stem cells 
To characterize MSCs, the Tissue Stem Cell Committee of the International Society for Cellular 
Therapy defined a minimal set of criteria (Dominici, Le Blanc et al. 2006):  
a) MSCs must be plastic-adherent when maintained in standard culture conditions.  
b) MSCs must express the surface molecules CD105, CD73 and CD90, and lack expression of 
CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.  
c) Finally, in vitro, MSCs must be able to differentiate into osteoblasts, adipocytes and 
chondroblasts. 
HSCs are defined by expression of the surfer molecule CD34+, enabling to mark them in 
accordance with the guidelines defined by the International Society of Hematotherapy and Graft 
Engineering (ISHAGE) by flowcytometry with the glycosylated transmembrane protein CD34 
(Keeney, Chin-Yee et al. 1998). 
 
Homing 
There is firm proof that ASCs, and especially MSCs, are capable to move towards injured or 
damaged(cardiac and/or nervous) tissue, a process called homing (Pittenger and Martin 2004). 
Here, stromal cell-derived factor 1 (SDF-1) presumably plays an important role as a chemotactic 
factor, attracting MSCs towards an injured site (Wragg, Mellad et al. 2008). Homing into neural 
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tissue, though, is limited by the blood– brain barrier, which prevents stem cells to penetrate into 
brain tissue (Stamatovic, Keep et al. 2008).Even in case of a defect blood–brain barrier (for 
instance caused by an inflammatory process), there is a limited passage from intravenously 
administrated stem cells through this barrier. In such case, out of 50,000 stem cells administered 
intravenously, only 4,000 (8 %) could be traced in the region of the lesion within the central 
nervous system (Jackson, Golding et al. 2010). 
 
Cell differentiation 
As an organism matures, stem cells are usually downregulated and only express an epigenetic 
profile in which they lose their pluripotency. Both in vitro and in vivo studies, however, showed 
that ASCs under certain conditions are still able to differentiate into neural cells. So, MSCs were 
efficiently transduced into functional neuronal cells producing action potentials, by transfection 
of the notch intracellular domain (NICD) in the presence of basic fibroblast growth factor (bFGF), 
ciliary neurotrophic factor (CNTF) and forskolin (FSK) (Dezawa, Kanno et al. 2004). Under 
influence of a combination of Edaravone (a free radical scavenger), epidermal growth factor 
(EGF) and bFGF, human MSCs also did differentiate into functional neurons (Zeng, Wang et al. 
2011). In vivo, axonal growth with functional recovery is reported in Sprague–Dawley rats with 
a right subtotal cervical hemisection, treated with cultivated MSCs, but not in the placebo 
gelfoam-treated animals (Neuhuber, Timothy Himes et al. 2005). Also, in a rodent stroke model, 
transplantation with both human MSCs and human MSC-derived neural cells induced recovery 
of neurological function without cell fusion (Xu, Miki et al. 2010).  
In vitro experiments suggested that the intrathecal administration of stem cells directly into the 
cerebrospinal fluid might speed up the development of neural like cells (Ye, Zeng et al. 2011). 
 
Expanding capabilities 
As mentioned before, stem cells are able to reproduce themselves indefinitely, making these 
cells particularly interesting for culturing. Especially embryonic cells can be cultured indefinitely 
for many years. ASCs can also be expanded in culture, but the number of successful passages is 
rather limited. This limited replicative capacity is known as the ‘‘Hayflick limit’’, presumably the 
result of chromosomal telomere shortening after each cell division. There is a significant 
difference in maximal life span of bone marrow-derived stem cells of young donors (41 
population doublings) compared to elderly donors (24 population doublings) (Stenderup, 
Justesen et al. 2003). Reproducibility, though, is only one aspect of expanding activities. Another 
aspect is the differentiation into different target cells. Aging has a negative effect on the plasticity 
of autologous ASCs, thereby limiting their application in the treatment of age-related diseases 
(Asumda and Chase 2011). Also, chronic diseases such as diabetes (Dimmeler and Leri 2008), 
Amyotrophic lateral sclerosis (Cho, Noh et al. 2010), or renal failure are known to reduce the 
angiogenic potency of stem cells, thereby further limiting the use of autologous stem cells to 
treat chronic diseases (Li, Kubo et al. 2010). 
 
Immune modulation 
By secreting various immune regulatory factors, stem cells, and especially MSCs, may influence 
the immune response. Pending their production and secretion of interferon-γ (IFN-γ), by 
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modulating inflammation, MSCs might both enhance (low concentration of IFN-γ) and inhibit 
(high concentration IFN-γ) immune responses (Chan, Tang et al. 2006). Moreover, MSCs also 
influence the functioning of B-Cells, T-Cells and NK (natural killer)-cells (Aggarwal and Pittenger 
2005). Although it is assumed that MSCs in contact with T-cells influence the Stat5-
phosphorylation by producing nitric oxide, thereby inhibiting T-cell proliferation (and T-cell 
mediated destruction of human stem cells in the same way as macrophages)(Sato, Ozaki et al. 
2007), the underlying mechanism is still not fully elucidated. 
 
Trophic factors and growth factors 
Pending specific environmental circumstances, stem cells may act like a ‘‘cameleon’’, by 
producing and secreting a variety of trophic factors promoting neuroplasticity (neuroprotection 
and neuro-restoration) and/or differentiating into specialized cells. In acute (ischemic or 
inflammatory) conditions, the release of MSCs and HSCs primarily stimulates neuroprotection by 
the up-regulation of interleukin pathways (Li, Kubo et al. 2010) or the production of 
neuroprotective trophic factors, such as granulocyte macrophage colony stimulating factor (GM-
CSF), which prevent for apoptosis (Huang, Kim et al. 2009). In more chronic conditions, though, 
the same cells mainly promote axonal outgrowth, re-myelination and neo-angiogenesis.  
For instance, in experimental chronic spinal cord lesions, both MSC (in rat) and HSC (in mice) 
transplants stimulate the production of an array of neurotrophic factors by astrocytes, 
promoting the myelinating activity of oligodendrocytes, thus contributing to their functional 
recovery (Koshizuka, Okada et al. 2004). In stable environmental conditions, stem cells thus 
rather stimulate neuro-restoration (Wright, El Masri et al. 2010). Indeed, bone marrow-derived 
stem cells are capable of producing (direct or indirect) chemotrophins relevant for neuro-
restoration, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), 
vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), insulin-like 
growth factor 1 (IGF1), brain natriuretic peptide (BNP),  neurotrophin 3 (NT-3), and stem cell 
factor 1 (SCF1) (Crigler, Robey et al. 2006). Illustrating the direct relationship between axonal 
growth and the secretion of these neurotrophic factors, the growth of axons promoted by neural 
progenitor cells was significantly suppressed when BDNF, NT-3 and NGF were neutralized 
(Kamei, Tanaka et al. 2007). The stem cell-derived production and secretion of chemotrophins, 
thus, might explain the regeneration and functional restoration as shown in experimental animal 
spinal cord injury (Shi, Kazui et al. 2007) and stroke models (Taguchi, Soma et al. 2004). The effect 
of neuroprotection initiated by MSCs is also illustrated in Table 2 presenting an overview of 
preclinical studies concerning multiple sclerosis (Zappia, Casazza et al. 2005, Zhang, Li et al. 2005, 
Gerdoni, Gallo et al. 2007, Kassis, Grigoriadis et al. 2008), Parkinson’s disease (Bouchez, Sensebe 
et al. 2008, Levy, Bahat-Stroomza et al. 2008) and Amyotrophic Lateral Sclerosis (Zhang, Zhou et 
al. 2009, Forostyak, Jendelova et al. 2011).  
In a dog model with spinal cord injury, both autologous and allogenic MSCs were administered 
intrathecally by lumbar puncture, and the outcome was compared with placebo-treated dogs. 
Stem cell-treated dogs did significantly better as placebo-treated dogs, and, interestingly, the 
effects in dogs treated with autologous cells were significantly better as in those treated with 





Table 2  





Characteristics/ dosages applied Outcome (*p<0.05/**p<0.01) 








3 and 8/40 2 doses of 106 MSCs IV (day 3 and 8) 
(n=15/controls n=6) 
CS: MSCs* < controls 
DS: MSCs* <controls 
Macro: MSCs* < controls 
  10,15,24/40 
 
106 MSCs IV at day 10 (n=8), at day 15 (n=8), 











10/100 A: 0.5x106 MSCs IV (n=10) 
B: 2x106 MSCs IV (n=10) 
C: 3x106 MSCs IV (n=10) 
Controls (n=10) 
 
CS: B* < C* < A < controls 
Gerdoni, 






12/60 106 MSCs IV (n=20) 
Controls (n=20) 
CS: MSCs* < controls 
RR: MSCs* < controls 
DS: MSCs* < controls 
Kassis, 
Grigoriadis 





10/61 106 MSCs IT (n=22) 
Controls (n=31) 
MR: MSCs* < controls 
CS: MSCs* < controls 
ALS: MSCs* < controls 
IS: MSCs** < controls 
   106 MSCs IV (n=27) 
Controls (n=24) 
 
MR: MSCs* < controls 
CS: MSCs* < controls 
ALS: MSCs* < controls 
IS: MSCs** < controls 
 









14/35 0.18x106 MSCs IP (n=7) 
Controls (n=7) 








35/125 A: 0.5x106 hMSCs IP (n=7) 
B: 0.5x106 nhMSCs IP (n=7) 
Controls (n=7) 
RB: B* < A < controls 
PBS-controlled studies in SOD-1 expressing rodents (amyotrophic lateral sclerosis) 
 
Zhang, Zhou 






0.5x106 hMSCs IT (n=22) 
Controls (n=21) 
MOD: MSCs = controls 
MS: MSCs = controls 
MNC: MSCs > controls 
   3 doses of 0.5x106 hMSCs IT (day 56,70 and 94) 
(n=21) 
Controls (n=20) 
MOD: MSCs* > controls 
MS: MSCs** > controls 









0.1x106 MSCs IT + 2x106 MSCs IV (n=9) 
Controls (n=8) 
MS: MSCs* > controls 
MF: MSCs* > controls 
MNC: MSCs* > controls 
ALS axonal loss score, CS clinical score, DS demyelination score, hMSC human mesenchymal stem cell, IP intraparenchymal, IS infiltration score, IT intrathecal, IV 
intravenous, Macro macrophages cells/mm2, MS mean survival days, MF motor function, MSCs mesenchymal stem cells, MNC motor neuron counts, MOD mean 
onset disease in days, nhMSCs neural human mesenchymal stem cells, PBS phosphate buffered saline, RB rotational behavior, RR relapse rate, SOD-1 superoxide 
dismutase 1, 6-OHDA 6-hydroxydopamine. 
 
Safety 
As of yet, the clinical application of autologous ASCs, for instance in leukemia patients, has been 
found to be relatively safe (Holowiecki 2008). In allogenic embryonic, umbilical cord or ASCs, 
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though, there is the problem of immunogenicity, which has to be addressed by the concomitant 
application of immune suppressive drugs to prevent rejection after application. Mainly due to 
their increased tumor risk, the application of allogenic embryonic as well as induced pluriform 
stem cells seems not advantageous (Lee, Tang et al. 2009). 
 
Clinical application of autologous adult stem cells in neurological disorders 
Autologous bone marrow-derived ASCs are easy to harvest and to concentrate (with cell 
separators) in a closed system for point of care treatment and are considered relatively safe. As 
the development of ASCs is reported multifactorial, being especially age- and disease-
dependent, as a rule, the application of fresh autologous bone marrow-derived cells in otherwise 
healthy younger patients seems the most promising (Li, Zhu et al. 2010, Asumda and Chase 
2011). As of yet, there is only consensus about the human clinical application of autologous ASCs 
in leukemia. However, compelling evidence of effective therapeutic application of these cells in 
both humans and experimental animals, suffering clinical end stages of ischemic limbs (Van 
Tongeren, Hamming et al. 2008) and/or myocardial infarctions (Assmus, Rolf et al. 2010), will 
expand clinical indications for human application in the next future.  
It is attractive, though, to also consider the application of autologous ASCs in the treatment of a 
limited number of neurological conditions such as traumatic spinal cord and/or brain injuries, 
with no therapeutic options at all (Sekhon and Fehlings 2001), as these conditions often occur in 
younger patients, without chronic diseases limiting the plasticity of autologous stem cells, with 
a dramatically impaired life expectancy (Wyndaele and Wyndaele 2006). So far, the application 
of stem cells in experimental animal models with lesions of the central nervous system, although 
very encouraging (Samdani, Paul et al. 2009), did not establish convincing evidence for clinical 
effectivity. Those experiments are hampered though by both, the intravasal, and not intrathecal, 
application of stem cells, and the use of allogenic, human, and thus not autologous, ASCs.  
Indeed, most experimental animals do not allow for intrathecal application of stem cells, 
although in lesions of the central nervous system, it is considered essential to apply these cells 
in the most adequate (neuronal) environment, as close as possible to the lesion. In such 
conditions, the intrathecal administration of these cells directly into the cerebrospinal fluid is 
supposed to speed up cell differentiation as well as the secretion of relevant neurotrophic 
factors. Earlier experiments in spinal cord injured dogs, treated with both autologous and 
allogenic ASCs, also confirmed the superiority of the application of autologous to allogenic stem 
cells. Unfortunately, however, most animals do not allow to function as both donor and recipient 
of (their own) ASCs. Considering that the proof of concept of the therapeutic effects of 
autologous ASCs in spinal cord and brain injured experimental animals has their limitations 
(Courtine, Bunge et al. 2007); in our opinion, the time is right to start carefully developed double-
blind studies in patients suffering no-therapeutic-option spinal cord and/or brain injuries, with 
autologous ASCs in the context of good defined clinical trials. The intrathecal administration of 
autologous stem cells by lumbar puncture in humans is considered a safe and minimal invasive 
procedure (Bakshi, Barshinger et al. 2006), and in 297 patients with spinal cord injury treated 
with intrathecal application of autologous stem cells, no side effects were reported (Kumar, 





2.2. Autologous adult stem cells in ischemic and traumatic CNS 
disorders 
 
de Munter JPJM, Wolters ECh (2013) J Neural Transm 120:91-102 
 
Abstract  
Ischemic and traumatic insults of the central nervous system both result in definite chronic 
disability, only to some extent responsive to rehabilitation. Recently, the application of 
autologous stem cells (fresh bone marrow-derived mononuclear cells including mesenchymal 
and hematopoietic stem cells) was suggested to provide a strategy to further improve 
neurological recovery in these disorders. During the acute phase, stem cells act mainly by 
neuroprotection with prevention of apoptosis, whereas during the chronic situation they provide 
neuro-restoration by trans-differentiation and/or the secretion of neurotrophic factors. To reach 
these goals, in the acute phase, stem cells (10 million mononuclear cells per kg body weight) 
might be best applied intravenously, as during the first 7 days after the lesion, the blood–brain 
barrier permits passage of cells from the blood into the brain or the spinal cord. In the more 
chronic situation, though, those cells might be applied best intrathecally by lumbar puncture. 
Based on the reported results so far, it seems justified to develop well designed clinical double-
blind trials in chronic spinal cord injury and ischemic stroke patients, as efficacy and safety 
concerns might not be answered by preclinical studies. 
 
Introduction 
Ischemic and traumatic insults of the central nervous system (CNS) both result in definite chronic 
disability with an impaired life expectancy (Strauss, Devivo et al. 2006)only to some extent 
responsive to rehabilitation in order to limit disability and to prevent complications.  
Worldwide, age standardized prevalence for stroke in people aged 65 years or more ranges from 
46 to 73/1,000 (Feigin, Lawes et al. 2003), and prevalence for spinal cord injury is estimated at 
22–36.5/100,000 (Knutsdottir 1993, Hagen, Eide et al. 2010). Up to date, the management in 
stroke patients is based on intra-arterial thrombolysis with a minimal ‘stroke to needle’ time to 
limit ischemic necrosis (Novakovic, Toth et al. 2009), rehabilitation and prevention of re-
infarction of the brain (Broussalis, Killer et al. 2011).  
The management of patients with a spinal cord injury focuses on rehabilitation to secure as much 
as possible functions of the upper and lower extremities and to prevent complications including 
bowel and bladder dysfunctions, venous thrombosis, pathological autonomic reflexes and 
decubitus (Gupta, Bathen et al. 2010). Of course, in both conditions, also psychological help is 
needed to improve coping and reduce suicide (Hagen, Lie et al. 2010). As of yet, for both 
conditions, the transplantation of stem cells is suggested to be very promising (Park, Eve et al. 
2010), as those cells are able to influence the direct environment of damaged neural cells by 
secreting trophic factors (Caplan and Dennis 2006), as well as to penetrate glial scar tissue 
(Huang, Kim et al. 2009), transdifferentiate into functional neurons (Zeng, Wang et al. 2011) and 
promote synaptic connections (Bareyre 2008). Bone marrow hosts heterogeneous populations 
of hematopoietic and non-hematopoietic stem cells suggested to constitute thus a source of 
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repair mechanisms, probably by promoting neuroplasticity (Kucia, Reca et al. 2005). In this 
article, the results of preclinical and clinical trials applying fresh, not expanded, adult stem cells 
in spinal cord injury and ischemic stroke will be reviewed and discussed to motivate new, 
adequate clinical trials in patients suffering these debilitating conditions. 
 
Stem cells 
Adult stem cells (ASC), especially hematopoietic (HSCs) and mesenchymal stem cells (MSCs), are 
pluripotent cells located throughout the body, mainly in the bone marrow (Junker, Sommar et 
al. 2010). Those cells are able to secrete all kind of factors, which influence the direct 
environment of injured cells (Gnecchi, Zhang et al. 2008). For instance, in ischemic conditions, 
both MSCs and HSCs thus may stimulate neovascularization and increase oxygenation (Zhang, 
Zhang et al. 2008). As these cells also have the possibility of transdifferentiating into specific 
(neuronal) cells, in theory they are also able to replace damaged neural tissues (Zeng, Wang et 
al. 2011). These specific properties suggested the use of ASC in the treatment of otherwise no-
treatment-option conditions such as spinal cord or brain injury and ischemic stroke (Zietlow, 
Lane et al. 2008). The therapeutic application of autologous, minimally manipulated stem cells 
was not only found helpful in the treatment of chronic conditions, but also offered significant 
benefits in the acute phase of these conditions (Leistner, Fischer-Rasokat et al. 2011). Autologous 
adult stem cells are easy to harvest from the iliac crest of a patient. After collection, gradient 
centrifugation is used to separate the buffy coat layer, which contains the highest concentration 
of HSCs and MSCs. The thus conceived product is suitable for intravascular/intravenous re-
application into the patient. As a rule, this minimally manipulative procedure is used for 




Traumatic spinal cord injury 
As seen in Table 1, only in one out of five reported studies (Inoue, Honmou et al. 2003), 
autologous bone marrow-derived mononuclear cells (BMMNs) were used to investigate the 
clinical effects of MSCs and HSCs in animal models with a standardized spinal cord compression 
injury. Spinal cord compression, in these studies, was induced by weight drop (Basso, Beattie et 
al. 1996) or balloon compression (Vanicky, Urdzikova et al. 2001). In the other studies, allogenic 
BMMNs were applied. However, in a comparative study with allogenic and autologous MSCs in 
a dog spinal cord injury model, the best clinical outcome was observed with autologous cells 
(Jung, Ha et al. 2009). So, we cannot rule out that the results with allogenic cells are hampered 
by the eventual negative effects of immune suppression and/or by the fact that the donor cells 
have a different genetic origin. Nevertheless, but for one study (Carvalho, Vialle et al. 2008), 
presumably due to the very traumatic procedure of administration of these cells and the short 
term (10 days) of follow-up, significant neurological recovery was established in the four other 
reported studies with both autologous and allogenic HSCs and/or MSCs as compared to placebo, 
irrespective of the method of application (intravenous, intrathecal and/or intraparenchymal). 
Neurological functions were measured by the standardized Basso Beattie Bresnahan Score 
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(Basso, Beattie et al. 1995) or the hindlimb motor scores. Although in one study, 5 weeks after 
transplantation, immunohistochemistry did reveal surviving HSCs in the spinal cord tissue, 
expressing specific markers for oligodendrocytes, astrocytes and neural precursors (Koshizuka, 
Okada et al. 2004), as of yet, the presence of stem cell derived functional neurons has not been 
established (Urdzikova, Jendelova et al. 2006). In the animal groups, MSC and/or HSC transplants 
significantly increased the volume of the intact white matter, but not for the animal groups 
treated with granulocyte colony stimulating factor (G-CSF). G-CSF, also known as colony 
stimulating factor 3 (CSF-3) and commercially available as recombinant human G-CSF (Thomas, 
Liu et al. 2002), stimulates the production and release of granulocytes and stem cells by the bone 
marrow. In the animal study, G-CSF was used to prevent neural cell apoptosis (Pitzer, Klussmann 
et al. 2010). It is questionable if observed neurological recoveries in these studies share the same 
mechanisms of action. In an acute rat model, in which stem cells were applied within 24 h after 
the lesion (Yoshihara, Ohta et al. 2007), a significant higher level of hepatocyte growth factor 
(HGF), a significant lower level of tumor necrotic factor-α (TNF-α), a significant lower number of 
TUNEL-positive cells and a significant higher density of nerve fibers as compared to controls were 
established, suggesting a neuroprotective effect with prevention of apoptosis. In other studies, 
in which stem cells were applied 7 days after the lesion, neuro-restoration might have played a 
major role. As in most of the studies, stem cells were applied in a rather acute situation, and we 
cannot rule out that eventual lesions of the blood–brain(cord) barrier influenced the reported 
outcome in intravenously applied cells. However, a substantial part of thus applied cells will be 
trapped in the lungs and the liver and might not reach the arteries supplying the spinal cord 
(Fischer, Harting et al. 2009). Looking at the different routes of administration used in the 
presented animal models, intrathecal administration into the cerebrospinal fluid seems the most 
favorable way of application, especially in the more chronic cases ([7 days) where the blood–
brain(cord) barrier supposedly is functioning normal again. 
 
Table 1  





SCI study model Characteristics/ 
dosages applied 
Outcome (*p<0.05) 
Traumatic spinal cord injury models 
 
Female Wistar rats 





3/21 Demyelinating L1 IV: 1 ml medium 
1x104/1x105/1x106 
/1x107 BMMN cells 
Remyelination* with IV doses 
>1x106 BMMN’s 
  IP: 1 µl medium 1x102/1x103/ 
1x104 /1x105 BMMN cells 
 










7/42 Compression T7-8 
(20g/5 min) 
IP:3x104 HSCs Hind limb score: 4.2*  
(C: 2.9) / expression neural lineage 
cells 
Male Wistar rats 






7/35 Compression T10 
(balloon/5 min) 
IV: 2x106 expand.MSC BBB score 10-12* (C: 7-9) 
IV: 2x106 BMMN cells BBB score 10-12* (C: 7-9) 
SC: 5 days G-CSF BBB score 10-12* (C: 7-9) 
Male Wistar rats 
(Yoshihara, Ohta 
et al. 2007) 
BMMN: MSC-
HSC allogenic 
1/35 Compression T8-9 
(10g/12.5mm)  
Intraventricular (4th): 5x106 
BMMN cells 
BBB score 15.5* (C: 10) 
Reduction* of cavity at site injury 
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SCI study model Characteristics/ 
dosages applied 
Outcome (*p<0.05) 
Traumatic spinal cord injury models 
 
Male Wistar rats 





14/24 Compression T9-10 
(10g/12.5mm)  
IP): 5x105 BMMN cells Increased BBB score 7% (C: 4.5%) 
Ischemic brain injury models 
 
Long Evans rats 





24h/30 180 min occlusion 
MCA+CCA 
3 months old rats CA: 1x107 
BMMN cells 
Cylinder test asymmetry 2%* (C: 
48%) 
Corner 50±6% (C: 90±5%) 









3-72h/ 14 45 min occlusion 
MCA 
IV: 1x107 BMMN cells  
at 3 h 
 
Minimal (C: 258±55mm3) 
  At 6 h 40±28mm3(C:258±55mm3) 
  At 12 h 80±25mm3(C:258±55mm3) 
  At 24 h 140±18mm3(C:258±55mm3) 
  At 72 h 180±22mm3(C:258±55mm3) 
All: improved morris water maze* 










24h/28of  Thermo-coagulation 
of blood vessels of 
the sensorimotor 
cortex 
IV: 3x107 BMMN cells Cylinder test asymmetry 8%* (C: 
42%) 
Reduced number of degenerating 
neurons* 
Male Sprague-
Dawley rats (Shyu, 
Lin et al. 2006) 
PBMN: HSC 
autolog 
168h/ 35 Occlusion of the 
right MCA + bilateral 
CCA 
IV: 2x105 HSCs Reduction body asymmetry* 
Improved grip strength 1.63* 
(C:0.61)/Increased penumbric 
neovascularization* 
Increased expression trophic 











1.5h/7 90 min occlusion of 
the left CCA, ECA 
and ICA 
CA: 1x107 BMMN cells Reduced infarct volumes 70.7mm3* 
(C: 140.6mm3) 
Improved Rotarod test* 
IV: 1x107 BMMN cells Reduced infarct volumes 
119.0mm3* (C: 140.6mm3) 
 
Long Evans rats 





24h /28 180 min occlusion 
MCA+CCA 
IV: 3.5x105 BMMN cells Cyl: 30% (C: 38%) 
Corner: 72% (C: 80%) 
No reduced infarct volume 
  IV: 3.5x106 BMMN cells Cyl: 18%* (C: 38%) 
Corner: 62%* (C: 80%) 
Reduced infarct volume* 
  IV: 10.5x106 BMMN cells Cyl: 15%* (C: 38%) 
Corner: 60%* (C: 80%) 
Reduced infarct volume* 
  24-168/28 180 min occlusion 
MCA+CCA 
IV: 3.5x106 BMMN cells 24 h Cyl: 12%* (C: 29%) 
Corner: 62%* (C: 78%) 
    IV: 3.5x106 BMMN cells 168h Cyl: 31% (C: 34%) 
Corner: 76% (C: 78%) 
BBB Basso,Beattie and Bresnahan Score, BDNF brain-derived neurotrophic factor, BMMN bone marrow-derived mononuclear, CA carotid artery, CCA common 
carotid artery, CSF cerebrospinal fluid, Cyl cylinder test asymmetry, ECA external carotid artery, G-CSF granulocyte colony stimulating factor, GDNF glial cell line-
derived neurotrophic factor, HSC hematopoietic stem cells, ICA internal carotid artery, IV intravenously, IP intra-parenchymal, MCA middle cerebral artery, MSC 
mesenchymal stem cells, NGF nerve growth factor, Obs observation, PBMN peripheral blood-derived mononuclear cells , SC subcutaneous, SCI spinal cord injury, 
SDF-1 stromal cell-derived factor 1, Trans transplantation, VEGF vascular endothelial growth factor. 
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Ischemic brain injury 
Table 1 gives an overview of animal studies with minimally manipulated autologous and/or 
allogenic stem cells in the treatment of ischemic brain injury, both in the acute and chronic 
phase. In all studies, except for one (Giraldi-Guimaraes, Rezende-Lima et al. 2009), autologous 
bone marrow and/or peripheral blood (Shyu, Lin et al. 2006) mononuclear cells were applied in 
a standardized reperfusion injury model (Aronowski, Strong et al. 1997). Within 7 days after the 
lesion, these cells were applied intravenously or intra-arterially into the artery supplying the 
lesioned side of the brain. Neurological outcome was screened with a battery of sensorimotor 
tests, sensitive to cortical damage, such as the cylinder test asymmetry, the asymmetry-corner 
test (Schallert, Fleming et al. 2000) and/or the treadmill and Morris water maze tests (Yonemori, 
Yamada et al. 1996).  
The observation period was limited to 28 days after transplantation of the cells. All reported 
studies established (mostly) significant neurological improvements as compared to placebo-
treated animals. Best improvements were reached in the more acute models, probably by 
neuroprotection, as insinuated by the significant reduction of the necrotic brain area (Iihoshi, 
Honmou et al. 2004), whereas less impressive improvements were established in the more 
chronic models, most probably by neuro-restoration with neovascularization, as evidenced by 
the increased vascular density in the penumbric area (Shyu, Lin et al. 2006).  
In the acute phase, the direct application of cells in the arteries supplying the affected side of 
the brain seems superior to the intravenous route of application (Kamiya, Ueda et al. 2008). In 
this way, more cells reach the brain by escaping the lung and liver trap (Fischer, Harting et al. 
2009). As in spinal cord lesions, in ischemic brain injuries for good results [107 BMMN cells per 
kg body weight had to be applied intravascularly (Yang, Strong et al. 2011). As a rule, the sooner 
stem cells were applied after the ischemic lesion, the better was the neurological outcome, and 
when applied 7 days after the lesion, in one study, no significant improvement in neurological 
outcome could be reached at all (Yang, Strong et al. 2011). In our opinion, both intravenous 
application and a short observation time may hamper results. Although immediately after the 
stroke there will be an increased permeability of the blood–brain barrier, permitting passive 
penetration of all kind of cells and trophic factors (Stamatovic, Keep et al. 2008), the actual 
passage of stem cells is still limited (Jackson, Golding et al. 2010). So, in the acute stage, 
intraarterial application of stem cells, and in the more chronic stage, the intrathecal 
administration of stem cells into the cerebrospinal fluid, flushing the brain, might give better 
results (Orito, Harada et al. 2010). In chronic stages of stroke, neovascularization seems not to 
play a major role anymore. 
 
Clinical studies 
Traumatic spinal cord injury 
To translate preclinical results into clinical strategies, clinical trials are needed. Table 2a presents 
the results of eight rather small, open label clinical trials in patients with an acute or chronic 
spinal cord injury, treated with not expanded BMMN cells. As a rule, fresh autologous stem cells 
were applied; in one study (Deda, Inci et al. 2008), cells were frozen for a short period to enable 
transport. Yoon et al. (Yoon, Shim et al. 2007) also used granulocyte-macrophage stimulating 
factor (GM-CSF), supposedly providing long term protection of neural cells, inhibition of glial scar 
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formation and stimulation of axonal regeneration by expression of brain-derived neurotrophic 
factor (BDNF) (Bouhy, Malgrange et al. 2006, Hayashi, Ohta et al. 2009). All studies established 
an increase in ASIA motor and sensory scores and there were no serious adverse events 
reported, related to the administration of mononuclear cells. 
In the studies with acute spinal cord injuries, the cells were applied directly into the parenchyma 
and/or intravenously/intravascularly (Park, Shim et al. 2005, Sykova, Homola et al. 2006, Yoon, 
Shim et al. 2007, Geffner, Santacruz et al. 2008). In a more chronic situation, it seems more 
beneficial, however, to apply the cells directly intra-parenchymally (Chernykh, Stupak et al. 2007) 
or intrathecally (Kumar, Kumar et al. 2009, Kishk, Gabr et al. 2010) to pass through the blood–
brain(cord) barrier. A mild increase of neuropathic pain (in 4/12 patients) was reported in a small 
study with chronic ([8 weeks post injury) spinal cord injured patients (Yoon, Shim et al. 2007). 
This could not be reproduced though in a bigger cohort in a more chronic condition ([3 years 
post injury) where only 15 out of 297 patients noticed such increase (Kumar, Kumar et al. 2009). 
Three of the studies were performed with historical or matched controls: one study on acute 
spinal cord injuries (Yoon, Shim et al. 2007) and two on chronic spinal cord injuries, lasting for at 
least 3 years (Chernykh, Stupak et al. 2007, Kishk, Gabr et al. 2010). One of those studies in the 
chronic situation did establish significant clinical improvements expressed as an increase in mean 
ASIA motor and/or sensory score of about 9 and 12 points, respectively (Chernykh, Stupak et al. 
2007). In this study, stem cells were applied both intra-parenchymally and intravenously. In the 
other study, there was a small though not clinically relevant increase in the mean motor and 
sensory ASIA scores, 1 year after intrathecal application of stem cells by lumbar puncture, 
although 27.9 % (12 out of 43) of the patients with a complete ASIA-A spinal cord lesion at 
baseline in that period changed into an incomplete spinal cord injury (11 patients into ASIA-B 
and 1 patient into ASIA-C) compared to only 10 % in the controls (Kishk, Gabr et al. 2010). In 
literature, only 5.6 % (31 out of 571) of patients with a complete spinal cord injury at 1 year 
changed at year 5 to an incomplete lesion without any intervention, rehabilitation not included 
(Kirshblum, Millis et al. 2004). In summary, the few small clinical trials so far seem to be 
promising by showing the feasibility of the application of mononuclear cells in the treatment of 
both acute and chronic spinal cord injured patients. 
 
Table 2a  
Human studies with fresh bone marrow-derived cells for neurological indications 
References Product Study Treatment Outcome (*p<0.05) 
Traumatic spinal cord injury 
 
Park, Shim  
et al. (2005) 
BMMN MSC-
HSC autolog + 
GM-CSF 
 
Open label study in 
acute SCI AIS-A; 
follow-up 6-18 
months 
Acute SCI (N=6) 
IP: 1.9x108 BMMN cells 
SC: GM-CSF for 5 days for 5 
months 
6/6 improved > 5 points in motor and 
sensory ASIA scores 4/6 improved from AIS 
A to C 1/6 improved from AIS A to B, no 
serious adverse events 
 
Sykova, Homola  





Open label study in 
acute (10-30 days post 
injury) SCI; follow-up 1 
year 
IA: 4 patients received 
104.0±55.3x108 BMMN cells 
(CD34+:89.7±70.7x106) 
 
4/4 improved in motor and sensory scores; 
1/4 changed from AIS B to D  
1/4 from AIS A to B. 
 IV: 3 patients received 
104.0±55.3x108 BMMN cells 
(CD34+:89.7±70.7x106) 
 




Table 2a  
continued 
References Product Study Treatment Outcome (*p<0.05) 
 
 
 Open label study in 
chronic (2-17 
months post injury) 
SCI; follow-up 1 year 
IA: 2 patients received 
104.0±55.3x108 BMMN cells 
(CD34+:89.7±70.7x106) 
1/2 IA improved 14 points in ASIA motor 
score 
  IV: 10 patients received 




Yoon, Shim  




Open label study in 
acute (<2 wks), sub-
acute (2-8 wks) and 
chronic (>8 wks) 




Acute SCI (N=17) 
IP: 1.9x108 cells + SC: 5 days 
monthly GM-CSF for 5 months 
5/17 changed from AIS A to B/C 
1/17 reported neuropathic pain 
Subacute (N=6)  
IP: 1.9x108 cells + SC: 5 days 
monthly GM-CSF for 5 months 
2/6 changed from AIS A to B/C 
2/6 reported neuropathic pain 
  Chronic SCI (N=12)  
IP: 1.9x108 cells + SC: 5 days 
monthly GM-CSF for 5 months  
0/12 changed from AIS A to B/C 
4/12 reported neuropathic pain 
   Controls (N=13) 1/13 changed from AIS A to B/C 
1/13 reported neuropathic pain 
     
Chernykh, 
Stupak  








Open label case 
control study in 
chronic (36.4±7.9 
months post injury) 
cervical SCI; Follow-
up: 9.4±4.6 months 
Chronic SCI (N=12) 
IV+CC: mean 10.9x106 cells/ml + 
meningomyeloradiculysis 
 
ASIA mSc: 22.2±3.5 to 31.0±3.2* ASIA 
sSc: 44.3±5.0 to 58.3±7.2* 
Ashworth: 3±0.12 to 2.37±0.16* 




ASIA mSc: 19.6±0.84 to 21.7±0.8 
ASIA sSc: 53.0±7.0 to 58.3±7.2 
Ashworth: 3.1±0.12 to 2.60±0.18 
Change Bartel Scale: 5.60±0.63 
 
Deda, Inci 





Open label study in 
chronic (mean 5.2 
years) SCI AIS-A; 
follow-up 12 
months 
Chronic SCI (N=9) 
IV(1.5ml), S (1.5ml), storage 
foam(3ml) and IP (0.1ml) – 35(21-
67)x106 BMMN cells 
 
7/9 changed from AIS-A to AIS-C 
2/9 changed from AIS-A to AIS-B  
9/9 improved sensory functions 
no adverse events reported. 
Geffner, 
Santacruz  





Open label study in 
acute (5-210 days 
post injury) SCI; 
follow-up 24 
months 
Acute SCI (N=4) 
IP+IT+IV:1.2x106 CD34+/kg body 
weight in 80ml suspension 
3/4 changed from AIS-A to AIS-C 
 Chronic SCI (N=4) 
IP+IT+IV:1.2x106 CD34+/kg body 
weight in 80ml suspension 
 
1/4 changed from AIS-A to AIS-C 
1/4 changed from AIS-C to AIS-D 
1/4 changed from AIS-A to AIS-C 
Kumar, Kumar  
et al. (2009) 
BMMN MSC-HSC 
autolog 
Open label study in 
chronic (mean 2.61 




Chronic SCI (N=297) 
IT: ±3.77x108 BMMN cells (SD 
2.33x108) of which 3.98x106 
CD34+cells (SD 3.17x106) 
 
97/297 reported improvements in 
sensory and motor scales; 15/297 
reported neuropathic pain; No adverse 
events reported; Improvements 
correlated to the number of CD34+ cells. 
 
Kishk, Gabr  







Open label study in 
chronic (mean 
3.6±2.5 years post 
injury); Follow-up: 1 
year 
Chronic SCI (N=43) 
IT: 5-10x106 BMMN cells in monthly 
intervals for 6 months + 
rehabilitation 
11/43 changed from AIS A to B 
1/43 changed from AIS-A to C 
ASIA mSc from 48.7±9.1 to 49.3±9.2 
Improved bladder & bowel functions 
1 serious adverse event reported 
   Controls (N=20) only rehabilitation 2/20 changed from AIS-A to AIS-B 
BMMN bone marrow-derived mononuclear, CC cystic cavity, GCS Glasgow coma Scale, GM-CSF granulocyte macrophage colony stimulating factor, HSC 
hematopoietic stem cells, IA intra-arterial, IP intra-parenchymal, IT intra-thecal, IV intravenously, MCA middle cerebral artery, mSc ASIA motor score, MSC 
mesenchymal stem cells, NIHSS National Institutes of Health Stroke Scale, SA subarachnoid space, SC subcutaneous, SCI spinal cord injury, SA standard deviation, 
sSc ASIA sensory score. 
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Table 2b  
Human studies with fresh bone marrow-derived cells for neurological indications 
References Product Study Treatment Outcome (*p<0.05) 




et al. (2012) 
BMMN MSC-
HSC autolog  
 




up 6 months 
 
Acute stroke (N=20) 
IA (affected MCA): 22.1(5.1-60)x107 
BMMN cells/15ml 
 
Decrease* in median (mean) NIHSS: 15.5 
(17.05) at day 0 to 7.5 (9.9) at day 180. 
No reduction in infarct volume 
2 deaths not related to the treatment 
No serious adverse events reported 
 
Savitz, Misra,  





Open label study in acute 
MCA ischemic stroke; 
follow-up 6 months 
Acute stroke (N=10) 
IV: 7-10x106 BMMN cells (with 1.2-
4.3x105 CD34+ cells/kg body weight in 
30 minutes) 
 
Decrease* in median NIHSS: 13 at day 0 to 
3 at day 180. 
10/10 decreased 1 point in the modified 
Ranking Scale 
7/10 reached Barthel Index ≥90 
No serious adverse events reported 
 
Barbosa da 
Fonseca et al. 
(2010); 






Open label study in 
chronic (59-82 days) MCA 
ischemic stroke; follow-
up 6 months 
Chronic stroke (N=6) 
IA (affected MCA): 2.2x108 (1-
5x108) BMMN cells in 10ml during 
10 minutes. Cells labelled with 
Technetium-99m 
 
Decrease* in mean) NIHSS: 7.5 at day 0 to 
5.8 at day 180. 
No reported adverse events 
Mean radioactive uptake cells as ratio of 
brain/body 1.68±1.71% (range 0.5-5.1%) 
Traumatic brain Injury 
 
   
Cox, 
Baumgartner  
et al.  
(2011)      
BMMN MSC-
HSC autolog 
Open label study in 
children with an acute 
(<48 hours) severe (GCS 
5-8) traumatic brain 
injury; Follow-up 6 
months 
 
Acute traumatic brain injury (N=10) 
IV: 6x106 BMMN cells/kg body 
weight 
Mean Glasgow Outcome Score expanded 
for children changed from 17.5±9.1 to 
7.9±8.1* 
No negative effects on hemodynamics 
No death and no reported adverse events 
BMMN bone marrow-derived mononuclear, CC cystic cavity, GCS Glasgow coma Scale, GM-CSF granulocyte macrophage colony stimulating factor, HSC hematopoietic 
stem cells, IA intra-arterial, IP intra-parenchymal, IT intra-thecal, IV intravenously, MCA middle cerebral artery, MSC mesenchymal stem cells, NIHSS National Institutes 
of Health Stroke Scale, SA subarachnoid space, SC subcutaneous, SCI spinal cord injury, SA standard deviation. 
Traumatic brain injury 
Table 2b shows the results of an open label study with fresh BMMN cells in children with an 
acute (< 8 h), severe (Glasgow Coma Score 5–8) traumatic brain injury. The authors reported a 
significant improvement in the mean Glasgow Outcome Score Expanded for Children (GOSEC) 
from 17.5 to 7.9 points after 6 months. None of the children died, and no serious adverse events 
were mentioned. The bone marrow collection in the acute phase of the brain injury did not cause 
hemodynamic disturbances and was well tolerated (Cox, Baumgartner et al. 2011)). 
 
Ischemic brain injury 
Table 2b also represents the results of three open label clinical studies with application of fresh 
BMMN cells in the treatment of ischemic brain injury. During those studies, without controls, no 
serious adverse events were reported. Clinical meaningful improvements were established in the 
National Institute of Health Stroke Scale (NIHSS) and the modified Rankin Scale (Kasner 2006). 
Mononuclear cells were administered intravenously (Savitz, Misra et al. 2011) or, in order to 
trespass the pulmonary trap, intra-arterially (Barbosa da Fonseca, Gutfilen et al. 2010, Battistella, 
de Freitas et al. 2011, Friedrich, Martins et al. 2011). In the acute setting (Friedrich, Martins et 
al. 2011, Savitz, Misra et al. 2011), after the application of stem cells within 7 days after the onset 
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of the stroke, mean NIHSS decreased dramatically ([7 points). Compared to the normal behavior 
of an ischemic stroke involving the middle cerebral artery, this is a major reduction in 
neurological outcome (Adams, Davis et al. 1999). The change in outcome of six patients suffering 
a chronic ischemic condition after treatment with labeled mononuclear cells, though still 
clinically relevant, was more modest (Barbosa da Fonseca, Gutfilen et al. 2010, Battistella, de 
Freitas et al. 2011). A possible explanation here might be that in the chronic condition the 
restored blood–brain barrier only allows a small uptake of mononuclear cells in the brain, and/or 
that the poor validity of the NIHSS Score, when not measured in the first week after the onset of 
the stroke, only allows questionable results (Bruno, Saha et al. 2006). 
 
Discussion 
BMMN cells include mesenchymal and hematopoietic stem cells and all kind of leucocytes. HSCs 
constitute about 1 % and MSCs about 0.01 % of the total number of mononuclear cells (Pittenger 
and Martin 2004). Extrapolated from animal studies, for the intravenous or intraarterial 
treatment of acute spinal cord and/or brain lesions, >107 BMMN cells/kg body weight (Yang, 
Strong et al. 2011) is considered adequate. In humans, as a rule, at least 150–180 ml bone 
marrow aspirate (with a mean of about 50,000 CD34+ cells (HSC’s)/ml) (de Munter and Wolters 
2013), providing about 107 BMMN cells/kg body weight, might be collected without causing 
hemodynamic disturbances (Savitz, Misra et al. 2011).  
 
From a translational perspective, we may thus conclude that it is possible to harvest enough 
BMMN cells to treat acute CNS lesions by intravascular administration. In our opinion, 
intravascular administration of stem cells is not adequate in the treatment of chronic conditions, 
as an (again) intact blood–brain(cord) barrier may prevent those cells from reaching the 
damaged tissue and to establish repair. Applying these cells intrathecally by lumbar puncture 
might offer a better alternative in these patients, as this (minimally invasive) procedure bypasses 
the blood–brain barrier (Bakshi, Hunter et al. 2004).  
 
As a rule, acute stroke is followed by a spontaneous mobilization of peripheral blood 
mononuclear CD34+ cells (containing mainly HSCs), resulting in a doubling of these cells (Dunac, 
Frelin et al. 2007). This doubling of CD34+ cells, especially in younger patients, comes with some 
recovery of stroke-related neurological deficits. Intra-person variations in this mobilization might 
partly explain the differences in recovery of patients. As of yet, we do not know for sure if such 
a burst of CD34+ cells also follows acute traumatic lesions of the central nervous system, such as 
spinal cord or brain injuries.  
 
From a translational perspective, though, we suggest that the artificial administration of stem 
cells might (further) improve recovery after acute lesions of the nervous system, and that this 
effect is more pronounced in the early stage of the disease.  
In the acute phase of traumatic CNS injuries, the mechanism of action of stem cells consists of 
neuroprotection, preventing apoptosis and thus conserving jeopardized neural cells (Wright, El 




In more chronic conditions, neuro-restoration seems more obvious. The eventual role of trans-
differentiation of MSCs and/or HSCs into fully functioning neurons is still unclear. Applying stem 
cells directly into the cerebrospinal fluid promotes the expression of neural lineage cells (Zeng, 
Wang et al. 2011). Human studies on the clinical effects of exclusively intrathecally applied stem 
cells in chronic spinal cord injuries suggested clinically more meaningful recovery in motor and 
sensory scores as compared to the other studies in the same chronic condition, in which stem 
cells were applied intravascularly (Kumar, Kumar et al. 2009, Kishk, Gabr et al. 2010).  
 
As of now, the abundance of proof of clinical improvements in traumatic and ischemic clinical 
and preclinical CNS lesions such as spinal cord injury and ischemic stroke, after stem cell 
intervention, in our opinion qualifies for the development of adequately designed clinical trials 




2.3.  Cell based therapy in Parkinsonism 
 
de Munter JPJM, Lee C, Wolters ECh (2013) Translat. Neurodegeneration 2:13 
 
Abstract 
Parkinson’s disease (PD) is a synucleinopathy-induced chronic progressive neurodegenerative 
disorder, worldwide affecting about 5 million humans. As of yet, actual therapies are 
symptomatic, and neuro-protective strategies are an unmet need. Due to their capability to 
transdifferentiate, to immune modulate and to increase neuroplasticity by producing 
neurotrophic factors, adult stem cells (ASC) might fill this gap. Preclinical research in 6-
hydroxydopamine (6-OHDA) and/or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
lesioned animals established persistent improvements of motor behaviour after ASC-treatment. 
Histological/histochemical measurements in these animals evidenced an intracerebral applied 
ASC-induced increase of Tyrosine Hydroxylase-positive (TH+) cells with increased striatal 
dopamine levels, suggesting cell rescue. Likewise, clinical experience with subventricular applied 
ASCs in PD patients, although limited, is encouraging, evidencing neuro-rescue especially during 
the early phase of the disease. In multiple system atrophy (MSA) or progressive supranuclear 
palsy (PSP) patients, though, only marginal reduced progression of natural progression could be 
established after subventricular or intra-vasal ASC implantations. 
 
Introduction 
Parkinson’s disease (PD) is the most common chronic progressive neurodegenerative disorder 
after Alzheimer’s disease (Wirdefeldt, Adami et al. 2011), world-wide affecting nearly 5 million 
people aged 50 years or more, and expected to double over the next 20 years (Dorsey, 
Constantinescu et al. 2007) . It comes with a twofold higher mortality rate, mainly due to 
pneumonia, shortening life expectancy with nearly 10 years (Driver, Kurth et al. 2008, Diem-
Zangerl, Seppi et al. 2010). The result of the α-synucleinopathic degeneration of the nervous 
system, starting in the peripheral nervous system and lower brainstem and progressively 
extending over the upper brainstem and neocortex, symptomatology in PD comprises 
dysfunctions of the whole nervous system. It may start with a range of non-motor symptoms 
such as disorders of the autonomic nervous system, olfaction, sleep, mood and  subtle cognitive 
deterioration, before a degeneration of the dopamine producing cells in the upper brainstem 
(nigral substance) may manifest with motor parkinsonism, the clinical hallmark of this disease, 
and way before involvement of the neocortex induces dementia (Wolters, Van Laar et al. 2010). 
PD is mainly recognized when first symptoms of motor parkinsonism (hypokinesia, bradykinesia, 
rigidity, tremor and the loss of postural reflexes) develop as the result of the loss of the majority 
of the dopaminergic neurons of the pars compacta of the Substantia Nigra with a striatal 
dopaminergic depletion of over 80% (Marsden 1996). As of yet, treatment in PD is based on the 
pulsatile (oral) or continuous (subcutaneous, intrajejunal) suppletion of the striatal dopamine 
deficiency with dopamine agonists and/or the dopamine precursor levodopa, mostly in 
combination with a peripheral dopa decarboxylase inhibitor and/or in combination with 
inhibitors of mono-amine oxidase B (MAO-B) and/or catechol-O-methyl transferase (COMT), in 
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order to restore striatal dopaminergic denervation (Fox, Katzenschlager et al. 2011). Actual 
therapy only symptomatically affects motor parkinsonism, though. Therapies affecting non-
motor symptomatology, and above all protective or restorative treatments are unmet needs in 
PD. In order to reach these needs, recently, experiments with cell based therapies to rescue or 
replace dopamine-secreting cells, or with cells able to secrete paracrine factors modulating brain 
tissue repair were initiated (Fillmore, Holloway et al. 2005, Hall, Li et al. 2007, Parish and Arenas 
2007, Laguna Goya, Tyers et al. 2008, Meyer, Maisel et al. 2010). In this review, these 
experimental stem cell based therapeutic strategies will be discussed. As the application of 
embryonic stem cells and induced pluripotent stem cells comes with an unacceptable risk of 
tumor induction (Fujikawa, Oh et al. 2005, Hentze, Graichen et al. 2007, Lee, Tang et al. 2009, 
Ben-David, Benvenisty et al. 2010), this review will only cover experiments dealing with 
expanded, whether or not genetically modified, autologous or allogenic bone marrow-derived 
and/or neural progenitor stem cells. 
 
Adult stem cells (ASC) 
Adult stem cells comprise mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and 
ectodermal stem cells (ESCs). The majority of the cited preclinical and clinical studies use 
expanded and/or induced mesenchymal stem cells. Re-implanted adult autologous stem cells, 
easily harvested out of the iliac crest and whether or not expanded, as a rule, will migrate 
towards diseased tissue, a phenomenon called homing (Sadan, Bahat-Stromza et al. 2009, de 
Munter and Wolters 2013). Those stem cells have the potency to modulate immune responses 
(Aggarwal and Pittenger 2005, Zappia, Casazza et al. 2005) and to both transdifferentiate into 
target cells in order to replace damaged cells (Tropel, Platet et al. 2006, Barzilay, Kan et al. 2008, 
Ye, Zeng et al. 2011, Zeng, Wang et al. 2011), and secrete paracrine (trophic) factors relevant for 
cell protection and cell repair by the inhibition of apoptotic pathways (Gnecchi, Zhang et al. 2008, 
Xu, Chen et al. 2008, Jager, Hernigou et al. 2010). So, even before differentiation (Tondreau, 
Lagneaux et al. 2004, Croft and Przyborski 2009), mesenchymal stem cells, might express brain-
derived neurotrophic factor (BNDF), glial cell-derived neurotrophic factor (GDNF) and stromal-
derived factor (SDF-1α). BDNF is shown to have a neuroprotective effect on cultured rodent 
neurons via the Pl3kinase/Akt pathway by inhibiting neural death initiated by trophic factor 
withdrawal or by the exposure to nitric oxide (Wilkins, Kemp et al. 2009). GDNF provides neural 
protection against proteasome inhibitor-induced dopamine neuron degeneration (Du, Li et al. 
2008), although its biological effect on the clearance of mature formed α-synuclein aggregation 
could not be observed, probably due to its short duration of administration (Du, Li et al. 2008).  
SDF-1α, in low doses, promotes dopamine release from 6-OHDA-exposed PC12 cells (cell line 
derived from a pheochromocytoma), presumably by preservation and enhanced survival of these 
cells, as these phenomena are blocked by administration of anti-SDF-1α antibodies (Wang, 
Yasuhara et al. 2010). A high concentration of SDF-1α, however, rather enhances apoptosis 
(Geeraerts, Deiva et al. 2006). SDF-1α acts through CXCR4 (chemokine receptor type 4) resulting 
in a down regulation of caspase-3 and an activation of the PI3/Akt pathway (Shyu, Lin et al. 2008). 
SDF-1α also enhances the survival of neural progenitor cells through the receptors CXCR7 and 
CXCR4 by up regulation of the ERK1/2 (Mitogen-Activated Protein kinase 3) endocytotic signaling 
pathway (Zhu, Xu et al. 2012).  
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The route of administration (intra-vasal, intraparenchymal) during the re-implantation of the 
stem cells seems to have a major impact on the specific trans-differentiation and/or secretion 
patterns of them, as the actual environment influences the further developments of these cells. 
However, by inducing stem cells before re-implantation it is also possible to induce these 
developments already in vitro. Indeed, by exposing these cells to trophic factors, including 
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) (Delcroix, Curtis et al. 
2010), by transducing them with a viral vector, and/or by binding them to pharmacologically 
active microcarriers, containing trophic factors such as NT-3 (Neurotrophin-3) (Delcroix, Garbayo 
et al. 2011), it is possible to further differentiate the stem cells, prior to the re-administration to 
the target organs (Bjorklund, Kirik et al. 2000, Blits, Kitay et al. 2005). So, in vitro, adult stem cells 
may be predisposed to differentiate into dopamine producing cells (Barzilay, Kan et al. 2008, 
Chen, He et al. 2009), thus offering a potential alternative for dopamine substitution therapies, 
or into cells secreting neuroprotective and/or neurorestorative trophic factors, thus protecting 
for dopaminergic cell death respectively stimulating neuro-restoration (Kim, Park et al. 2009). 
Due to the lung trap (Fischer, Harting et al. 2009) and the blood–brain-barrier (Stamatovic, Keep 
et al. 2008, Jackson, Golding et al. 2010), intravasal application of stem cells for disorders of the 
central nervous system is suggested less effective as compared to intracerebral administration 
(Zhang, Zhou et al. 2009, Ye, Zeng et al. 2011).  
 
Preclinical experience with ASC in motor parkinsonism 
In experimental animals, motor parkinsonism (but not PD) might be induced by intra-nigral 6-
hydroxydopamine (6-OHDA) as well as by subcutaneous carbobenzoxy-leuleu-leucinal (MG-132) 
and/or subcutaneous or intravasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Duty 
and Jenner 2011, Garea-Rodriguez, Schlumbohm et al. 2012). MPTP models have the advantage 
that the lesions are induced through a less invasive (subcutaneous or intravasal) route of 
administration as compared with the stereotactic surgical approach when applying 6-OHDA. To 
optimally investigate neural protection, the non-human primate MPTP model seems to be 
preferred (Duty and Jenner 2011). Tables 1 and 2 present the results of preclinical interventions 
using cell-based strategies in the 6-OHDA, MPTP and the proteasome inhibitor MG-132 animal 
models. In all the presented animal studies immune suppression was used to prevent rejection 
of the cells. However, the use of immune suppression may influence not only the behavior of the 
Stem Cells (Guo, Zeng et al. 2007) but also the severity of the lesions in animal models (Palladini, 
Caronti et al. 1996, Ibarra, Correa et al. 2003). As might be appreciated, in the studies reviewed 
in Tables 1 and 2, the following stem cells were used: 
– Expanded bone marrow-derived mesenchymal cells (of the mesodermal lineage) of rat 
(Bouchez, Sensebe et al. 2008, Park, Lee et al. 2008, Wang, Yasuhara et al. 2010, 
Danielyan, Schafer et al. 2011, Delcroix, Garbayo et al. 2011), mouse (Chao, He et al. 
2009) or human origin (Levy, Bahat-Stroomza et al. 2008, Sadan, Bahat-Stromza et al. 
2009, Blandini, Cova et al. 2010, Cova, Armentero et al. 2010); 
– Expanded and enriched, or epigenetically induced bone marrow-derived mesenchymal 
stem cells (Bouchez, Sensebe et al. 2008, Levy, Bahat-Stroomza et al. 2008, Sadan, 
Bahat-Stromza et al. 2009, Delcroix, Garbayo et al. 2011), enabling functional 
development before actual transplantation; 
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– Expanded neural stem cells of the ectodermal lineage, derived from the subventricular 
zone of the rat (Zhu, Ma et al. 2009) or from a cultivated fetal human cell line (Bjugstad, 
Teng et al. 2008, Ramos-Moreno, Castillo et al. 2012). 
But for three studies with intravenous (Chao, He et al. 2009, Wang, Yasuhara et al. 2010) and/or 
intranasal (Danielyan, Schafer et al. 2011) application, all stem cells are applied intranigral and/or 
intra-striatal. Outcome measures comprised motor behavior (rotational behavior) as well as 
histological/ histochemical measures. The main findings on the rotational motor behavior 
showed a significant reduction of turns/minute. But for 4/7 studies (Bouchez, Sensebe et al. 
2008, Blandini, Cova et al. 2010, Wang, Yasuhara et al. 2010, Danielyan, Schafer et al. 2011), in 
all studies with expanded MSCs (Courtine, Bunge et al. 2007, Blandini, Cova et al. 2010, 
Danielyan, Schafer et al. 2011), as well in all studies with expanded and enriched or epigenetically 
induced MSCs (Bouchez, Sensebe et al. 2008, Levy, Bahat-Stroomza et al. 2008, Sadan, Bahat-
Stromza et al. 2009, Delcroix, Garbayo et al. 2011), and expanded neural stem cells (Zhu, Ma et 
al. 2009, Ramos-Moreno, Castillo et al. 2012), this reduction was established.  
 
Table 1  
Placebo-controlled stem cell applications in rodent animal models of parkinsonism  






















14/35 days 1.No intervention  
   (n=6) 
2.Intrastriatal saline  
   (n=7) 
3.Intrastriatal 1.8x105  
     rMSCs (n=7) 
4.Intrastriatal 1.8x105 
    riMSCs (n=7) 
 
• Rotational behaviour (turns/min) 
1.No-intervention group:  23.8±2.1 
2.Control saline treated group: 25.1±1.7 
3.rMSC-treated group: 14.1±3.3* 
4.Enriched riMSC-treated  group: 10.8±1.7* 
• TH-positive neurons 
1.No-intervention group: 
    24.2±6.7% 
4.Enriched riMSC-treated  
    group: 52.5±8.2%* 
 









      
1.Intravenous saline 
    (n=7) 
2.Intravenous 107  
    fibroblasts (n=6) 
3.Intravenous 107  
    rMSCs (n=6) 
• Amphetamine induced Rotational behaviour 
1.Control saline treated  
    group: 8.5±3.5 
2.Fibroblast-treated group: 8.2.1±3.3 
3.rMSC-treated group: 1.2±0.7 turns/min* 
• Cylinder test 
1.Control saline treated  
    group: 64.7±17.3% 
2.Fibroblast-treated group: 60.2.1±16.1% 
3.rMSC-treated group: 29.3±13.7%* 
• Preservation of TH+ cells: 








7.9/110-136 days   1.Intranasal saline    
    day 7 and 9 (n=7) 
2.Intranasal 5x105MSC   
   day 7 and 9 (n=9) 
3.Intranasal saline  
day 7 and 9 (n=10)  
4.Intranasal 5x105MSC  
    day 7 and 9 (n=12) 
 
• Stepping ratio (contralateral/ipsilateral):  
2 MSC(0.7)**>1 saline(0.1) 
• Amphetamine-induced rotational behaviour: 
4 MSC*<3 saline group 
• Histology 4 MSC 24% MSCs survived in CNS 
for at least 4.5 months. 
• TH+ survival 2*>1 and  4*>3 


























5/28 days 1.Intrastriatal saline  
   (n=9) 
2.Intrastriatal 1x105  
     hMSCs (n=8) 
 
• Apomorphine-induced Rotational behaviour: 
1.No effect 
2.Reduced rotational behaviour* 
• Apoptosis decreased in hMSCs treated group 
(2<1) 








      
SHAM unilateral lesion 
1.Intrastriatal saline 
2.Intrastriatal 3.2x104  
    hMSCs (n=6-10) 
3.Intrastriatal 1.8x105  
    hMSCs (n=6-10) 
6-OHDA unilateral lesion 
1.Intrastriatal saline 
2.Intrastriatal 3.2x104  
    hMSCs (n=6-10) 
3.Intrastriatal 1.8x105  
    hMSCs (n=6-10) 
• Dose-dependent neuro-rescue effects 
(hMSCs vs saline) in unilateral 6-OHDA 
lesioned, but not SHAM lesioned rats with: 
a).Reduction*/**ongoing toxin-induced 
degeneration of dopaminergic terminals 
b).Enhanced neuro-genesis*/**(neural 
progenitor cells) in the periventricular zone 









14/64 days   1.Intrastriatal saline   
   (n=6) 
2.Intrastriatal 1.5x105  
    rMSCs (n=6) 
3.Intrastriatal 1.5x105  
    riMSCs+P (n=6) 
4.Intrastriatal 1.5x105  
    riMSCs+P+NT3(n=6) 
• Rotational behaviour (turns/min): 
1.saline group 18.5  
2.rMSCs group 17.5 
3.riMSCs+P group 8.5* 
4.riMSCs+P+NT3 group 3.0* 










35/125 days 1.Intrastriatal saline  
   (n=7) 
2.Intrastriatal 5x105  
   hMSCs (n=7) 
3.Intrastriatal 5x105  
   neural hiMSCs (n=7) 
• Rotational behaviour (turns/min/post-lesional 
100%): 
1.saline group: 88%  
2.hMSCs group: 90% 
3.hiMSCs+P group: 42%* 
 
Sadan, Bahat-







   
1.Intrastriatal saline  
   (n=10) 
2.Intrastriatal 1.5x105  
   4.5x105 hMSCs  
   (n=21) 
3.Intrastriatal 1.5x105  
   4.5x105 hMSCs  (n=21) 
• D-Amphetamine-induced Rotational 
behaviour increase: 
1.Saline grp 4.74±1.07  
2.hMSCs grp 2.86±0.54  
3.hiMSCs grp 2.16±0.37* 
• TH+cells (treated vs untreated site: 
hMSCs(2)> and hiMSCs(3)*> 






35/155 days 1.No intervention  
   (n=13) 
2.Intranigral 5x104  
     rNSCs (n=20) 
3. Intrastriatal 5x104  
    rNSCs (n=5) 
• Rotational behaviour 
1.No intervention group 233.9±70.43 
2.rNSCs SNc group 189.3±63.24*** 
3.rNSCs Intrastriatal group 169.3±47.28* 
• TH+cells in the SNc: 2>1 
• EGFP-labeled NSCs identified as TH+cells in 2 
and 3 
Ramos-Moreno, 






45/165 days   1.Intrastriatal saline   
   (n=15) 
2.Intrastriatal 3x105  
    hNSCs (n=17) 
3.Intrastriatal 3x105  
    hiNSCs Bcl-XL  
    expression (n=21) 
• D-amphetamine-induced rotational 
behaviour: 
1.saline grp 18 turns/m / 2.hNSCs grp 17 
turns/m / 3.hiNSCs grp 3 turns/m*** 
• Apomorphine-induced rotational behaviour: 
1.saline grp 6.5 turns/m / 2.hNSCs grp 2 
turns/m** / 3.hiNSCs grp 2.5 turns/m** 
• Paw mobility test: 3** > 2* > 1 
Abbreviations: 6-OHDA 6-hydroxydopamine, ASCs Adult stem cells, MSCs Mesenchymal stem cells, NSCs Neural stem cells, h human, r rat, I induced or 
transduced, EGFP Enhanced Green Fluorescent Protein, BDNF Brain-Derived Neurotrophic Factor, GDNF Glial cell Derived Neurotrophic Factor, m minute, NT-3 
Neurotrophine-3, P Pharmacologically active microcarriers, Bcl-XLL anti-apoptotic granulocyte-colony stimulating factor enhancing the expression of key genes 




The administration of expanded, not-induced stem cells in these studies varied widely in relation 
to the onset of the toxin-induced motor parkinsonism. Stem cells were applied within 2 hours 
(Sadan, Bahat-Stromza et al. 2009, Wang, Yasuhara et al. 2010), within 5 to 14 days (Blandini, 
Cova et al. 2010, Cova, Armentero et al. 2010), or 30 days after the lesion (Bjugstad, Teng et al. 
2008, Levy, Bahat-Stroomza et al. 2008, Chao, He et al. 2009, Zhu, Ma et al. 2009, Ramos-
Moreno, Castillo et al. 2012). Overlooking the effects in these studies on rotational behavior, the 
period in between application and lesioning seems to influence the clinical outcome: the earlier 
the application, the better the resulting clinical effects. Remarkably, after intra-vasal 
administration of ASCs, whether applied in the acute phase (Wang, Yasuhara et al. 2010)or 3 
weeks after lesioning (Wang, Yasuhara et al. 2010), only a few ASCs (about 2%) could be detected 
in the nigral substance, the majority was trapped in the lungs. Nevertheless, also in these 
experiments, a significant beneficial effect on motor behavior could be established (Wang, 
Yasuhara et al. 2010). Here, it seems relevant to mention that after intrastriatal (intracaudate) 
application in the non-human primate MPTP model, 1% of the implanted stem cells could be 
identified at the injection site, whereas over 80% was found to be migrated to and along the 
impaired nigrostriatal pathways (Bjugstad, Teng et al. 2008). As for the histological 
/histochemical findings, after intracerebral stem cell application, in all experiments, more striatal 
TH-positive neurons were seen in the treated as compared to the non-treated, control lesioned 
animals, suggesting ASC-induced increased neuronal plasticity (neurorescue) with increased 
modulation of cell survival (and an increased striatal dopamine level), enhanced neurogenesis 
(progenitor cells in the subventricular zone), and a decreased modulation of inflammation, gliosis 
and death-signaling (Bouchez, Sensebe et al. 2008, Park, Lee et al. 2008, Sadan, Bahat-Stromza 
et al. 2009, Zhu, Ma et al. 2009, Cova, Armentero et al. 2010, Park, Bang et al. 2011). The same 
preservation of TH-positive cells was also observed after intravenous (Wang, Yasuhara et al. 
2010) and intranasal MSC application (Danielyan, Schafer et al. 2011).  
 
Table 2 
 Placebo-controlled stem cell applications in animal models of parkinsonism  












*p<0.05  **p<0.01  
***p<0.001 











    saline (n=24) 
2. Intraperitoneal  
    MPTP+IV saline 
    (n=24) 
3.Intraperitoneal  
    MPTP+IV 105  
      mMSCs (n=24) 
• SN TH+ cells: 3**>2 
• SN microglial cells: 3*<2 









1 day after last 




    saline (n=10) 
2. Intraperitoneal  
    MPTP+3-NP(n=8) 
3.Intraperitoneal  
    MPTP+3-NP and IV  
    106 hiMSCs in 200µl  
    (n=8) 
 
• Group 2 and 3: 48% loss of nigral cells 
• Group 3 compared to group 2: 
a.2% of hiMSCs in SN and 4% in the Striatum 
b.Motor behaviour improved* during 10 days 
• c.Increased modulation of cell survival* and 
decreased modulation of death-signaling** 
pathways, with 20% cell survival** 
d.Decreased modulation of inflammation**and 





Table 2  
continued  














*p<0.05  **p<0.01  
***p<0.001 





hiNSCs 4 and/or 6 
months after 
last MPTP inj/4 
(n=3) and 7 
(n=4) months  
  
Bilateral intrastriatal and 
unilateral intranigral 
implantation of each 106 
hiNSCs 
 
• >80% of hiNSCs immigrated along the impaired 
nigrostriatal pathway 
• <1% of 2x106hiNSCs implanted within the 















1.MG-132 lesioned  
   rats  
2.MG-132 lesioned   
   rats treated during 3  
   weeks with weekly  
   intravasal applied 
   106 hMSCs 
 
• 1.7% hMSCs detected in the nigral substance 
• Survival of nigral and striatal TH= cells after 
hMSCs 
• Increased striatal dopamine level* after hMSCs 
• Reduction* in microglia activation after hMSCs 
 
Abbreviations: ASCs Adult stem cells, IV intravenous, MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MSCs Mesenchymal stem cells, NSCs Neural stem 




Clinical experience with ASC in motor, parkinsonism  
As of yet, only three studies were reported, dealing with the effects of, intracerebral or intravasal 
applied, allogenic or autologous adult stem cells in patients suffering motor parkinsonism in PD, 
multiple system atrophy (MSA) or progressive supranuclear palsy (PSP) (Lee, Kim et al. 2008, 
Venkataramana, Kumar et al. 2010, Venkataramana, Pal et al. 2012).  
 
The results are summarized in Table 3. In most but not all PD patients, the subventricular 
application of both, allogenic and autologous bone marrow-derived mesenchymal stem cells did 
improve clinical scores of motor behavior, as expressed in a significant decrease of UPDRS scores 
in ON and OFF conditions. Interestingly, these effects did appear faster and more outspoken the 
earlier these interventions were applied, mimicking the results in preclinical experiments. 
Magnetic Resonance tractography of degenerated dopaminergic projections did show significant 
improvements in those patients.  
 
In MSA and PSP patients, compared to placebo treated patients, in some patients, a temporary 
improvement (Bjugstad, Teng et al. 2008) or reduced deterioration in motor and cognitive 
functions (Bjugstad, Teng et al. 2008) witnessed a reduction in natural progressive deterioration 
with subventricular or intravasal ASC implantations. This reduced disease progression in these 
patients was also found reflected in MRI (Magnetic Resonance Imaging)- and FDG PET 
(fluorodeoxyglucose positron emission tomography)- imaging, showing less atrophy and less 




Table 3  
























3, 6, 12 1.PD patients with bilat. 
subventr. application of 
2x106MSCs /kg weight  
in 2ml (n=8) 
 
2.MSA+PSP patients with 
bilat.subventr.application of 2x106 
MSCs/kg weight  
in 2ml (n=4) 
     
 
UPDRS in ON/OFF: 
a. In PD: permanently improved*compared with baseline 
during both ON (18%:51.2 vs 62.3) and OFF (31.2%: 59.5 
vs 86.5). Effect stronger in PD with disease duration < 5yrs 
(ON 45.5% OFF 56.7%) as compared to PD with a duration 
> 10yrs (ON 6.3% OFF 12.4%) 
b. Some MSA/PSP temporarily improved. The effect was not 
correlated with disease severity and duration. MR 
tractography: 
   -PD patients,after implantation,did show a  
    trend of steadily improvement in tracto- 
    graphical images in genu and peduncles 
   -MSA/PSP showed further reduction of  
    tractographical images after implantation. 
 
Venkataramana 










      
   
PD patients (n=7) with an UPDRS 
ON/OFF score 50.6/65.0 and a 
mean disease duration of 14.7yr 
treated with 106 MSCs/kg 
bodyweight in the subventricular 
zone 
 
UPDRS in ON/OFF: 
a. In 3/7 patients there was a stable improvement of 
ON/OFF scores of 38% respect.22.9% with unchanged 
anti-parkinsonian medication 
b. In 3/7 patients after treatment, only marginal clinical 
effects were observed 
c. Anti-parkinsonian medication significantly reduced in 2 
patients 
 









8,10,12   
Patients with cognitive intact MSA-
C (with UMSARS scores between 
30 to 50) 
 
1.IV or IA Placebo (n=17) 
 
2.MSCs (4x106) IV or IA (n=14) 
 
UMSARS score: 
a. MSCs-treated patients showed a reduced* increase of 
UMSARS score compared to placebo treated patients 
b. Intra-arterial (IA) application of MSCs was complicated 
with some MRI-detectable ischemic lesions 
 
The cognitive functions significantly* worsened in placebo 
but not in MSCs-treated patients 
 
MRI and FDG PET showed significantly* increased gray 
cerebral cortical areas respect. more decreased cortical and 
cerebellar glucose metabolism in placebo-treated, as 
compared to MSCs-treated patients 
 
Abbreviations: MSCs Mesenchymal stem cells, MSA Multiple system atrophy, MSA-C Multiple system atrophy, cerebellar type, PSP Progressive supranuclear 





PD is a chronic progressive, diffuse α-synucleinopathic disease of the central nervous system in 
which (symptomatic) therapeutic strategies aim to compensate for the striatal dopamine 
deficiency in order to mainly decrease motor symptomatology. As of yet, protective/repairing 
therapeutic strategies in PD are an unmet need. Generally speaking, stem cells, and specifically 
adult stem cells, pending their environment after re-implantation or pending their in-vitro 
induction, are supposed to not only differentiate into functional (neuronal) cells, including 
dopamine producing neurons, but to also easily expand and thus to deliver enough cells for 
transplantation. Although differentiation and proliferation of bone marrow-derived stem cells 
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are jeopardized by aging and chronic diseases including diabetes (Dimmeler and Leri 2008), renal 
failure (Li, Kubo et al. 2010) and ALS (Amyotrophic lateral sclerosis) (Koh, Baik et al. 2012), in PD 
patients, up to the 15th passage, ASCs are fully comparable to those of healthy age-matched 
individuals regarding phenotype, morphology and capacity to multi-differentiate (Zhang, Wang 
et al. 2008), and are also able to inhibit T-lymphocyte proliferation induced by mitogens. Next to 
the multi-differentiated proliferative capacity, adult stem cells, and especially expanded and 
induced ASC’s, may secrete an array of trophic factors. As a matter of fact they may specialize to 
express mainly such factors by induction in vitro through exposure to trophic factors (including 
epidermal growth factor EGF and basic fibroblast growth factor bFGF), by transduction with a 
viral vector and/or by binding these ASCs to pharmacologically active microcarriers, containing 
trophic factors such as NT-3 prior to the application.  
When adding epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-
free medium, in order to expand and induce human ASCs, the secretion of neurotrophic factors 
such as BDNF (normally neglectable) will increase to 125 ± 12 pg/day/106 ASCs (Somoza, Juri et 
al. 2010). Thus, induced ASCs will function as a vehicle for adequate delivery of neurotrophic 
factors (BDNF and GDNF) when transplanted in the central nervous system (Sadan, Bahat-
Stromza et al. 2009, Somoza, Juri et al. 2010). It is suggested that ASC-produced neurotrophic 
factors such as GDNF and BDNF enhance neuro-protection with an increased modulation of cell 
survival and a decreased modulation of inflammation, gliosis and death signaling.  
These trophic factors thus stimulate neurorescue by better protection of α-synucleinopathic 
jeopardized neurons, including DA producing neurons. This effect was also reported in a MPTP 
animal model in which allogenic neural stem cells were applied unilateral (Ourednik, Ourednik 
et al. 2002). The jeopardized DA producing neurons were rescued and this effect was also 
observed in the opposite side of the SN in which no stem cells were applied (Ourednik, Ourednik 
et al. 2002). So, in PD patients, autologous ASCs, and especially expanded and/or induced ASCs, 
due to their capacity to increase neuroplasticity, theoretically not only offer an increased 
neuroprotection, but also an increased neuro-repair in PD patients resulting in a slowing down 
of natural progression in this debilitating disease. In preclinical studies, the stimulated secretion 
of GDNF and BDNF by ASCs is found to result in a higher number of striatal TH-positive neurons 
in the rat lesioned striatum as compared to placebo-treated rats, accompanied with a higher 
striatal dopamine level and decreased rotational behavior (Blandini, Cova et al. 2010, Somoza, 
Juri et al. 2010). Other ASC produced trophic factors, such as basic fibroblast growth factor bFGF 
and epidermal growth factor EGF, seem to be more relevant for neurorestoration (synthesis of 
extracellular matrix). In rodents, the intranigral application of (adenovirus mediated) glial cell 
line derived neurotrophic factor (GDNF), one week before the ipsilateral nigral 6-OHDA lesioning, 
did rescue 70% of the nigral TH-positive cells as compared to 30% in the not-pretreated, lesioned 
(control) animals, resulting in a significantly reduced rotational behavior: 5.4 ± 15.2 turns/15-
minutes versus 40.8 ± 25 turns/15-minutes (p < 0.05) (Chen, Liu et al. 2003). Note however that 
each intracerebral needle-induced manipulation per se might initiate the secretion of the same 
neurotrophic factors and/or cytokines mimicking a clinical effect, which may confound the 
results of a placebo treatment (Perry, Bell et al. 1995, McCluskey, Campbell et al. 2008).  
In the preclinical studies, reviewed above, two studies were performed in which ASCs were 
locally applied within 2 hours after the application of a 6-OHDA unilateral lesion in rodents 
(Sadan, Bahat-Stromza et al. 2009, Wang, Yasuhara et al. 2010). Both studies, reported a 
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significant improvement in rotational behavior and in survival of TH positive neurons within 4–6 
weeks. In the studies applying ASCs, and especially expanded noninduced ASCs, later on, in a 
more chronic phase of a lesion, no significant reduction in rotational behavior could be 
established (Croft and Przyborski 2009). In translation, the clinical effects of implantation of 
expanded MSCs in PD patients might profit their application in an early phase of their disease.  
Indeed, in PD patients, the clinical effects of stem cell application seem to relate with disease 
duration (Bjugstad, Teng et al. 2008).  
Finally, as ASCs are large cells, unable to cross the blood–brain barrier (Stamatovic, Keep et al. 
2008), intracerebral application seems to be superior to intravasal application, as only 1-2% of 
thus applied cells will reach the central nervous system (Park, Lee et al. 2008).  
Intranasal administration of MSCs, however, might offer an alternative, as this way of application 
in unilateral 6-OHDA-lesioned rodents did result in both, a significantly improved motor behavior 
and a significant decrease in inflammatory cytokines (suggesting a strong cell protective effect 
by inhibiting inflammation cascades) with 24% of the cells surviving for at least 4.5 month in the 




– ASCs are capable of migration to the lesioned cells/organs throughout the body, a 
phenomenon, which is called homing. 
– ASCs are easily to harvest out of the iliac crest. Their number might be increased by 
expanding them, and their functions might be developed prior to re-application by 
inducing them. Unlike ASCs in patients with other chronic diseases, in PD patients those 
cells are not impaired. 
– Expanded and/or induced ASCs may stabilize motor (and non-motor) parkinsonism in 
patients suffering PD and may be also Parkinson-plus syndromes, by increasing neural 
plasticity rather than by differentiating into neurons. Early in the disease, ASCs will 
promote neuro-rescue/neuroprotection by increasing immune modulation and 
reducing inflammation), especially when expanded (undifferentiated) ASCs are 
administered. Later in the disease, they mainly will promote neuro-restoration, 
especially when induced (differentiated) ASCs are given. 
– Neurotrophic factors such as BDNF and GDNF (mainly interfering with destructive 
pathways) play a major role in neuroprotection, whereas other growth factors such as 
EGF and bFGF (promoting synthesis of extracellular matrix) are more important in 
neurorepair. The best time to start with ASCs administration is in the very early phase 






2.4. Stem cell grafting in parkinsonism – Why, how, and when 
 
de Munter JPJM,Melamed E,Wolters ECh (2013)Parkinsonism Relat Disord 20.S1:67-70 
 
Abstract 
Parkinson’s disease is a devastating, progressive neurodegenerative disorder that affects the 
central and peripheral nervous systems. Although recent advancements have led to a better 
understanding of the disorder, there is currently no long-term disease-modifying strategy. 
Recently, preclinical data have identified the significant effects of pluripotent stem cell grafting 
in 6-OHDA and MPTP animal models of motor parkinsonism; there have also been some clinical 
data in patients with motor parkinsonism.  
Pluripotent stem cells can nestle in affected organs and can differentiate into a variety of cells, 
including neural (dopamine producing) cells. Depending on the environment into which they are 
grafted, these stem cells can also influence immune responses by regulating the activity of B-
cells, T-cells, and NK-cells. Pluripotent stem cells can also produce chemotrophins, including 
BDNF (brain-derived neurotrophic factor), GDNF (glial-derived neurotrophic factor), NGF (nerve 
growth factor), TGF-b (transforming growth factor-b), IGF-1 (insulin-like growth factor 1), NT-3 
(neurotrophin 3), and SCF-1 (stem cell factor 1). Influencing these trophic factors can influence 
plasticity. This article explores the potential of pluripotent stem cells in the treatment of PD. We 
will explore the utilization of pluripotent stem cells in the immune-modulation of B-cells, T-cells 
and NK-cells, the trans-differentiation of pluripotent stems cells into DA-cells, and the secretion 
of trophic factors and its relation to plasticity. We will also cover how best to conduct a clinical 
trial, which stem cells can be safely used in patients, what are the methods of induction before 
application, and how to re-apply stem cells in patients by intravasal, intrathecal or intracerebral 
methods. Finally, we will describe how to objectively record the clinical results. 
 
Parkinson’s Disease and parkinsonism 
Parkinson’s disease (PD) is the most common chronic progressive neurodegenerative movement 
disorder, and it affects at least 5 million people aged 50 years or older worldwide. This number 
is expected to double over the next 20 years. Individuals with PD are also more likely to have a 
shortened life span because PD has a twofold higher mortality rate compared to individuals of 
the same age without PD mainly due to pneumonia, which shortens the average life expectancy 
by 10 years. The clinical hallmark of idiopathic PD is a complex of bradykinesia, hypokinesia, 
rigidity, and the loss of postural reflexes. These clinical manifestations are also found in other 
forms of parkinsonism, including genetic, iatrogenic, and toxic parkinsonism. However, they can 
also be seen in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). PD was 
historically considered an abiotrophic disorder that exclusively affected the dopaminergic motor 
neurons, and clinically expressed motor dysfunction as the result of striatal dopaminergic 
denervation. However, the current understanding is that PD is the result of a varied pathology 
that may affect nearly every part of the nervous system. Numerous genes that have been 
identified in familial parkinsonism have provided significant clues into both the genetic and 
environmental risks. The neurodegeneration that is seen in PD is characterized by a-
synucleinopathy; it starts in the peripheral nervous system and lower brainstem, and it 
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progressively extends through the upper brainstem and neocortex. Therefore some patients may 
first present with a range of non-motor symptoms, including disturbances of the autonomic 
nervous system affecting olfaction, sleep and mood, and subtle cognitive deterioration. Recent 
research also suggests that more aggressive neurodegeneration and cellular dysfunction, which 
occur in the substantia nigra, may precede the formation of Lewy pathology (Milber, Noorigian 
et al. 2012), indicating that Lewy pathology-associated neurodegeneration may not be the 
primary pathologic phenomenon occurring in Parkinson’s disease. Although not yet complete, 
this greater understanding of the mechanisms underlying the neuronal dysfunction of PD has 
resulted in new therapies, such as antioxidant administration to reduce oxidative stress, trophic 
factor administration to promote neuronal survival, and anti-inflammatory medications to 
counteract any inflammatory attack. PD is clinically diagnosed at the onset of motor symptoms 
that develop as the result of the striatal dopaminergic denervation caused by degeneration of 
the dopaminergic neurons in the pars compacta of the substantia nigra. Treatment of PD is based 
on the conservative pulsatile (oral) or continuous (transdermal, subcutaneous, and/or 
intrajejunal) supplementation of the striatal dopamine deficiency with dopaminomimetics to 
restore striatal dopaminergic denervation. Therapy affects only symptomatic motor 
parkinsonism and PD-related non-motor symptomatology. However, protective and restorative 
treatments are still unmet needs. Recently, experiments with cell-based therapies have been 
initiated to rescue or replace dopaminergic cells with stem cells through trans-differentiation, 
immunomodulation, and stimulation of neural plasticity with stem cell-secreted paracrine 
factors (Meyer, Maisel et al. 2010). 
 
Stem cells 
Which stem cells to apply? 
Umbilical cord-derived and bone marrow-derived stem cells may qualify for grafting in humans 
as efficiently as embryonic stem cells; however, only autologous stem cells (ASCs) qualify as 
treatment options in PD (de Munter and Wolters 2013). ASCs are harvested easily, they are safe, 
and they can differentiate into neural cells under certain conditions. The ASCs in PD, unlike those 
in other chronic diseases such as diabetes mellitus, are fully functional and comparable with the 
healthy cells in quantity, quality, plasticity, and immune response (Zhang, Wang et al. 2008). 
From a clinical translational perspective, there are no impassible regulatory hurdles associated 
with non-manipulated autologous stem cells. Mesenchymal stem cells (MSCs) and the more 
common hematopoietic stem cells (HSCs) also seem to be effective (Cabanes, Bonilla et al. 2007) 
in the treatment of PD. Both cell types can be expanded and stored for a long period of time by 
using cryopreservation. This does not affect plasticity (Veeraputhiran, Theus et al. 2010). 
 
Harvesting  
Harvesting ASCs is easy and can be safely performed through bone marrow biopsy. Usually, bone 
marrow aspirate is filtered after extraction and processed by gradient centrifugation. The 
number of ASCs in centrifuged bone marrow aspirate is low. Additionally, the percentage of 
MSCs usually does not exceed 1% of the level of HSCs, and this is 0.01% of the total number of 
mononuclear cells.  
However, adequate doses for intravascular application in human neurological ischemic disorders 
should contain at least 1.0–3.0×107 bone marrow-derived mononuclear cells (with 1.0–3.0×105 
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HSCs and 1.0–3.0×103 MSCs) per kilogram body weight (Yang, Strong et al. 2011). In summary, 
bone marrow aspirate contains sufficient quantities of ASCs to apply to the patient. In vitro 
expansion with cryopreservation is not needed in the case of a once-only autologous treatment. 
 
Expansion  
Today, both MSCs and HSCs can be cultured and expanded to achieve sufficient numbers of cells 
for frequent autologous re-applications or allogenic applications by using small volumes of bone 
marrow aspirate. Although expansion is a common practice in regenerative medicine, expanding 
in vitro ASCs is still an object of major concern because of the limited replicative capacity, which 
is known as the “Hayflick limit”. This limit is presumably the result of chromosomal telomere 
shortening after each cell division in bone marrow-derived and adipose tissue-derived stem cells 
(Ferreira, Irioda et al. 2012). Additionally in early cell passages, aneuploidies were the most 
common findings, reflecting the uncertainties about the safety of ASCs cultivation. The age of 
the donor also limits the expansion of ASCs (Stenderup, Justesen et al. 2003). In summary, there 
are still major concerns regarding the long-term effect of expanded cells in vivo. However, the 
risk of inducing malignancies cannot be ruled out. 
 
Preservation  
Cryopreservation is also an option to optimally exploit adult stem cells. Cryopreservation with 
dimethyl sulfoxide (DMSO) prevents degeneration of the adult stem cells and enables safe 
storage for decades (Veeraputhiran, Theus et al. 2010). However, DMSO is toxic, but it is 
necessary to prevent the formation of ice crystals within the frozen cells. With the use of the 
appropriate protocols, DMSO can be washed out safely, thereby reducing the adverse effects 
accompanying transplantation of frozen bone marrow-derived stem cells. In summary, 
preservation could be a safe option to store ASCs for future use to avoid repeated bone marrow 
punctures over time. Preservation can also help avoid the use of aged and less effective stem 
cells. 
 
Immunosuppressive drugs  
The main advantage of using autologous ASCs is the fact that there is no need to suppress the 
immune system to enable the cells to perform their tasks. Immunosuppression is necessary with 
embryonic stem cells, umbilical cord-derived stem cells, and allogenic stem cells. 
Immunosuppressive drugs can have a negative impact on the survival, differentiation, and 
plasticity of allogenic ASCs, and should be avoided if possible (Guo, Zeng et al. 2007). 
 
Induction  
There are protocols available to induce stem cells into a desirable genetic expression profile prior 
to administration (Somoza, Juri et al. 2010). However, this reprogramming is not without risk, 
and it complicates the availability from a regulatory perspective. The main risk is the increased 
chance for tumor formation; thus, the application of induced pluriform stem cells does not seem 
advantageous (Lee, Tang et al. 2009). There is a similar risk with embryonic stem cells. Both 




How to apply stem cells? 
Stem cells may be administered for the treatment of central nervous system (CNS) disorders in 
four ways: intracerebrally, intrathecally/ intraventricularly, intranasally, or intravascularly. 
Intracerebral application of stem cells involves applying stem cells directly to the injured or 
disease-affected tissue. Intrathecal/intraventricular application of stem cells involves applying 
stem cells directly into the cerebral spinal fluid. Intranasal application of stem cells involves 
applying stem cells into the brain via the olfactory epithelium and fila olfactoria. Finally, 
intravascular application involves applying stem cells into the blood vessels. Adult stem cells, and 
especially MSCs, are capable of migration toward injured or damaged tissue by a process called 
homing. Stromal cell derived factor 1 (SDF-1) presumably acts as a chemotactic factor, attracting 
MSCs towards an injured site (Wragg, Mellad et al. 2008). However, treating diseases of the CNS 
may require directed application because the blood–brain barrier may hamper CNS penetration 
of the stem cells. One of the major challenges to the use of stem cells may be ensuring that the 
highest number of stem cells reaches the lesion (de Munter, Lee et al. 2013). 
 
Intravascular/Intravenous administration  
For the intravascular administration of stem cells to be successful, the stem cells must be able to 
cross the liver and lung capillary networks and the blood–brain barrier (BBB) and eventually 
reach the brain. In normal situations, cells are not able to pass through the BBB; however, there 
is evidence that the BBB becomes leaky in the case of acute lesions and inflammations of CNS 
tissues (Engelhardt and Sorokin 2009). The intra-arterial route is more beneficial than the 
intravenous route because the stem cells do not need to cross the liver and lung capillary 
networks. Only 2% of intravascular applied stem cells were reported to penetrate into the 
substantia nigra (Wang, Yasuhara et al. 2010). 
 
Intranasal/intrathecal administration  
Intranasal administration and intrathecal administration of stem cells are more effective because 
the blood–brain barrier and the capillary networks of the lung and liver can be avoided. 
Intranasal administration may allow CNS penetration through the olfactory epithelium and the 
fila olfactoria. Intrathecal application will also bypass the blood–cerebrospinal fluid (CSF) barrier 
which, compared to the BBB, is easier for stem cells to cross (Redzic 2011). In CSF, stem cells are 
also forced to express a neural lineage direction (Ye, Zeng et al. 2011). Trophic factors can also 
pass through CNS without any problems. When in contact with CSF, stem cells produce 
neuroprotective factors such as BDNF and GDNF; however, when the cells are in contact with 
serum they mainly produce endothelial growth factors (Kinnaird, Stabile et al. 2004). 
 
Intracerebral administration  
Finally, stem cells may also be applied directly into the cerebral nigrostriatal regions through 
stereotactic brain surgery. Ipsilateral grafted stem cells and/or paracrine factors produced by 
those cells will also reach the contralateral nigrostriatal regions (Ourednik, Ourednik et al. 2002). 
 
When to apply stem cells? 
A recent comprehensive meta-analysis (de Munter, Lee et al. 2013) illustrated the beneficial 
effects of stem cell application in 10 published preclinical studies with ASCs that were expanded, 
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but not induced in three different models of parkinsonism (6-OHDA, MPTP and MG-132 induced 
lesioning). ASCs were applied intravascularly or directly into the nigral striatum. The time of 
application related to the onset of the lesion, and this varied from 0 to 30 days after lesioning. 
Five out of 6 studies in which the ASCs were applied within 14 days after lesioning reported 
significant improvements both in rotational behavior and the preservation of TH+ cells when 
compared to the vehicle groups. Three out of 4 studies in which the ASCs were applied 14 days 
or more after the lesioning also reported significant, but less impressive improvements in 
rotational behavior and/or in the preservation of TH+ cells compared to the vehicle groups. 
Behavioral effects in the early-treated animals (40–80%) exceeded those in the later-treated 
animals (2–43%). These findings suggest that early intervention with stem cells induces more 
clinical effects compared to later interventions. Currently, only a few studies in patients with 
parkinsonism treated with ASCs have been published. Clinical results reported from intracerebral 
(Venkataramana, Kumar et al. 2010, Venkataramana, Pal et al. 2012) or intravascular (Lee, Lee 
et al. 2012) application of autologous (Venkataramana, Kumar et al. 2010, Lee, Lee et al. 2012) 
or allogenic stem cells without immune suppression (Venkataramana, Pal et al. 2012), in PD 
(Venkataramana, Kumar et al. 2010, Venkataramana, Pal et al. 2012) and/or MSA patients (Lee, 
Lee et al. 2012) did not draw any conclusions, but the improvements that were described were 
encouraging, if modest. It is likely that the effects were modest because stem cells were applied 
in late, advanced parkinsonism. 
 
How to interpret the effects in animal models of parkinsonism? 
The reported significant effects, especially after early grafting, in animal models and in humans 
with parkinsonism (although the results from end-stage MSA patients are still controversial) 
might be reached by trans-differentiation of the applied stem cells and by immunomodulation 
of these cells; they can also be reached by stimulation of neural plasticity by stem cell-secreted 
paracrine factors that modulate brain tissue repair (Meyer, Maisel et al. 2010). 
 
Trans-differentiation 
It is not likely that intravascular grafted stem cells pass the BBB. Less than 2% of these stem cells 
were found to penetrate the CNS in an acutely injured brain (Wang, Yasuhara et al. 2010). After 
intracerebral grafting, these numbers may be significantly higher. In vitro, ASCs are capable of 
transdifferentiating into dopamine-producing neurons (Tatard, D'Ippolito et al. 2007). However, 
it is not known if the phenotype of the reproduced neurons is similar to the originally lost DA 
producing cells. It is also still unknown if trans-differentiation is possible in living animal models 
or in humans. Grafted cells in PD patients are vulnerable for transmissible degradation, and 
therefore those cells might not bring definite stable improvements (Olanow and Brundin 2013). 
 
Immunomodulation 
Epidemiological studies indicate that anti-inflammatory medication use in PD patients provides 
some protection, which supports the concept that microglial activation is an important 
component of disease progression. While the evidence supports a role for the innate activation 
of microglia by a-synuclein, more recent work has revealed a role for their up-regulation through 
the adaptive immune system. It is also supported by the presence of CD8+ and CD4+ T-cells in 




Neurotrophic factors promote neuroplasticity with cell protection and cell repair (Zhou and Shine 
2003). Preclinical animal studies reported beneficial effects in behavior and in surviving TH+ cells 
after ASC grafting.  
Increased GDNF and BDNF levels seem to be responsible for these effects (Somoza, Juri et al. 
2010). In one study, GDNF was measured and found to be significantly higher in the ASC-treated 
group compared to the placebo-treated group; this suggests a direct relationship between 
improved clinical outcome, more preserved TH+ cells, and the increased expression of GDNF 
(Blandini, Cova et al. 2010). In another preclinical study with epigenetically induced ASCs, the 
stimulated secretion of GNDF and BNDF resulted in a higher number of surviving striatal TH+ 
neurons in the lesioned rat striatum compared to placebo-treated rats. This was accompanied 
by a higher striatal dopamine level and a decreased rotational behavior, illustrating the 
suggested paracrine effect of ASCs (Somoza, Juri et al. 2010). Spared TH+ cells contralateral to 
the applied intranigral ASCs argue for a paracrine mechanism (Blandini, Cova et al. 2010).  
Finally, the intranigral application of GDNF in rodents one week prior to ipsilateral nigral 6-OHDA 
lesioning rescued 70% of the nigral TH+ cells compared to a loss of 70% of these cells in the non-
pretreated, lesion-control animals. This resulted in a significantly reduced rotational behavior 
(Chen, Liu et al. 2003). In vitro, the genetic expression profile can be programmed to boost 
BDNF/GDNF production following cultivation of stem cells in enriched medium (Somoza, Juri et 
al. 2010). Although the stimulation of neurotrophic factor production in vitro and in vivo seems 
promising, so far all translational clinical trials with these factors in PD patients were 
disappointing. The trials were prematurely terminated due to adverse events and a lack of 
significant improvement, potentially due to an adenovirus-induced immune response (Dass, 
Olanow et al. 2006). 
 
Conclusions 
There is an unmet need in parkinsonism for protective and restorative therapies. Hopefully, adult 
stem cells will inhibit disease progression by secreting neurotrophic factors and by stimulating 
neuroplasticity. Even if they are successful, age and concomitant diseases, including diabetes or 
renal failure, may influence the quality of the adult stem cells, thereby limiting their use. Further 
research is essential to further develop this promising field of cell-based therapies.  
 
In summary:  
– ASCs (both HSCs and MSCs) are the optimal cells to graft because both are safe and 
promote neuroplasticity, but unlike induced pluripotent stem cells and embryonic stem 
cells they do not induce the development of malignancies.  
– The observed clinical effects are induced rather by the production of neurotrophic 
factors than by trans-differentiation.  
– Intranasal and intrathecal administration seems to be the best route of administration.  
– Expanding MSCs and HSCs is possible but might induce chromosomal aberrations.  
– Cryopreservation of stem cells is safe and cell banking may be a good strategy for 
overcoming the effects of aging and chronic diseases, such as renal failure and diabetes.  
– Translated from preclinical studies, the strongest clinical effect is reached when 





Bone marrow-derived stem cells in acute vascular ischemia 
 
Introduction chapter 3 
Chapter 3 is based on the first experiments with a transplantation of a fresh bone marrow-
derived human stem cell preparation, based on a buffy-coat procedure, in animals with an 
hindlimb ischemia. This buffy-coat procedure is based on centrifugation.  
As erythrocytes, lymphocytes, stem cells and plasma with platelets have different weights, they 
will be separated in different layers using centrifugation. The white layer contains lymphocytes 
and stem cells, the red layer contains erythrocytes, and the lucent layer consists of plasm and 
proteins. In the animals with the induced vascular occlusion, only the white layer containing 
mesenchymal and hematopoietic stem cells (both having angiogenetic potentials) is injected 
intra-arterial and intra-muscular.  
The purpose of this experiment was to test the effect of these stem cells on micro-angiogenesis 
in rats with an acute occlusion of a main limb artery, and to compare this effect with those in 
animals with an identical occlusion without any intervention.   
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3.1. Efficacy of Different Doses of Human Autologous Adult Bone 
Marrow Stem Cell Transplantation on Angiogenesis in an 
Immune Deficient Rat Model with Hind Limb Ischemia. 
 
Beugels J, De Munter JPJM, Van der Hulst R, Kramer BW, Wolters ECh (2019);  J Stem 
Cell Res Dev Ther S1002 dx.doi.org/10.24966/SRDT-2060/S1002 
 
Background: Stem cell transplantation has been implied to facilitate angiogenesis by direct 
paracrine effects on signaling pathways. There are many different sources, types, dosages and 
routes of administration of stem cells under investigation. In this study we tested the 
concomitant intramuscular and intravenous administration of human mesenchymal and 
hematopoietic stem cells from bone marrow aspirates in three different dosages in order to 
establish an optimal dose for angiogenesis. For this purpose a nude T cell deficient rat model 
with hind limb ischemia was used as a model for angiogenesis which did not warrant 
immunosuppressive drugs. 
Methods and Results: Seven days after a surgical occlusion of the A. iliaca externa in the right 
hind limb, a baseline Digital Subtraction Angiography (DSA) was performed, and animals were 
intra arterially and intramuscularly injected with low, medium or high concentrations of human 
mesenchymal stem cells or with a saline 0.9%solution (vehicle). At day 35, DSA was repeated, 
and the images of both registrations were compared between the different concentration groups 
and the vehicle group. DSA clearly demonstrated the presence of occlusions, resulting in 
moderate to severe ischemia 7 days after ligation. Comparing Mean Gray Values at day 35 DSA 
versus day 7 DSA, the difference did show a natural decrease in the Vehicle-treated group, 
whereas low- and medium human mesenchymal stem cell doses established a significant 
increase. High dose had a tendency to decreased values resulting in muscle damage and further 
occlusions. A dose response could not be detected. 
Conclusion: This study showed that the centrifuged human bone marrow suspension containing 
low and medium concentrations of mesenchymal and hematopoietic stem cells significantly 
improved the hind limb ischemia as compared to vehicle-treated group in T-cell deficient rats, 
and that this effect is almost lost with higher doses, may be due to hyper viscosity.  
 
Introduction 
Angiogenesis is essential for the function of most organs. The angiogenesis after organ injury or 
transplantation is key to the survival, regeneration and functioning of the affected organ. Stem 
cell trans-plantation was established to induce promotion of repair of ischemic tissue partially 
through angiogenesis which has been shown in models of hind limb ischemia for example 
(Tateishi-Yuyama, Matsubara et al. 2002). Stem cell therapies differ with respect to the origin of 
the cells, cell numbers and route of application (Fadini, Agostini et al. 2010, Scheubel, Holtz et 
al. 2010, Klepanec, Mistrik et al. 2012, Wang, Li et al. 2014). Studies were for example performed 
with unfractionated bone marrow cells, endothelial progenitor cells and/or peripheral blood 
mononuclear cells which make comparison very difficult (Fadini, Agostini et al. 2010). In addition, 
the different cell types have different properties and functions. A recent meta-analysis could not 
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identify an approach that is clinically established neither with respect to cell type, dose route of 
application (Fadini, Agostini et al. 2010, Abdul Wahid, Ismail et al. 2018). Mesenchymal stem cells 
offer a unique combination of anti-inflammatory and regenerative effects whereas endothelial 
stem cells may directly promote angiogenesis (Ponemone, Gupta et al. 2017). In animals with 
subacute ligated femoral arteries, neo-angiogenesis with restoration of the blood flow to the 
ischemic limb was reported to develop after injection of different kinds of stem cells 
(Schatteman, Hanlon et al. 2000, Hirata, Li et al. 2003, Pesce, Orlandi et al. 2003, Kinnaird, Stabile 
et al. 2004, Kinnaird, Stabile et al. 2004, Urbich and Dimmeler 2004, Lian, Zhang et al. 2010, 
Lawall, Bramlage et al. 2011). These findings are considered to be the effect of both cell presence 
and the paracrine secretion of growth factors and cytokines. The role of the various cell types of 
the transplants (mesenchymal cells, hematopoietic cells, etc.), however, remains unclear, 
although after transplantation, both the number of circulating endothelial progenitor cells 
increases (Takahashi, Kalka et al. 1999, Shintani, Murohara et al. 2001). Some cells of the 
transplant were found to be incorporated into newly formed collaterals in ischemic areas 
(Asahara, Masuda et al. 1999, Takahashi, Kalka et al. 1999). However, the intra-arterial versus 
the intramuscular route was found to be equivalent which raises questions about the 
mechanisms since no direct initial contact of the transplanted cells with the injured tissue was 
apparently necessary (Klepanec, Mistrik et al. 2012, Abdul Wahid, Ismail et al. 2018). Although a 
systemic effect may be suspected, there was however a dose dependency in response (Klepanec, 
Mistrik et al. 2012). 
 We asked in this study whether we can determine an optimal dose for the administration of 
unfractionated human bone marrow derived cells, containing a mixture of mesenchymal, 
hematopoietic stem cells and angiotrophic factors after centrifugation, in an immunodeficient 
animal model in order to promote angiogenesis after hind limb ischemia. We combined intra-
arterial with intramuscular administration of human cells to test for enhanced revascularization 
after 35 days in a dose dependent manner. 
 
Methods 
The animal experiments were executed after animal approval was obtained. We chose an 
immunodeficient animal model which does not mandate the concomitant administration of 
immunosuppressive drugs in order to avoid confounding. After clinical examination, 35 female 
animals were anesthetized and the right A. iliaca externa was proximally occluded to establish a 
right hind limb ischemia. Rats were anesthetized with isoflurane, and the right hind limb was 
shaved with an electric clipper, and disinfect-ed with ethanol. The animals then were 
subcutaneously injected with tramadol 2mg/kg Body Weight (BW) for analgesia. After an incision 
in the right hind limb, the A. iliaca externa was exposed and proximally occluded with Vycril 5-0. 
Subcutaneous tissue was then sutured with Vycril 3-0 and the skin was closed with Michel 
clamps. After the occlusion, the animals were kept one week in their cages for recovery before 
digital subtraction angiography. Seven days after the occlusion, the animals were again 
anesthetized with isoflurane and then the ventral region of the neck was clipped and disinfected 
with ethanol. The animals received Tramadol 2mg/kg BW subcutaneously for analgesia. First, a 
conventional X-Ray was performed to document the anatomic locations for further analysis. 
Secondly, the Arteria Carotis Communis Sinistra (ACCS - left common carotid artery) was 
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prepared and a catheter (1270.02 Umbilical Catheter, Vygon, 2,5 French 30 cm) was inserted into 
the ACCS and guided into the aorta, with the catheter tip ending directly in front of the 
bifurcation of the A. iliaca interna. Finally, a Digital Subtraction Angiography (DSA) was 
performed with a GE OEC 7700 X-ray device and using 0.3 to 0.5 ml of Ultravist® in a fast bolus 
to visualize the vessels of the rats. The complete DSA procedures were repeated at day 35 after 
the occlusion with the difference that the catheters were then inserted directly in the abdominal 
aorta. The DSA device (GE, OEC 7700) settings were 2 images per second at 1,1-1,2 mA and 52- 
54mV. The analysis of the angiography was performed using ImageJ® software. 
 
Cell Preparation 
Six healthy volunteers were recruited for iliac crest-bone marrow collection, after giving written 
informed consents. Bone marrow samples were processed under Good Manufacturing Practice 
(GMP) conditions by centrifugation according to standard operating protocols to obtain the buffy 
coat (internal product name ASCT01). The samples were analysed to assess the total number of 
viable CD34+ cells. Within 48 hours after the bone marrow procurement, the samples were 
administered to the rats. During the whole procedure, bone marrow cells were kept between 2-
8 degrees Celsius, which ensured a cellular viability greater than 95% (data not shown). Directly 
before administration to the rats, bone marrow cell suspensions were care-fully resuspended 
and adjusted with sodium chloride 0.9% (vehicle) solution to the needed concentrations. Table 
1 gives for each group the mean number of administrated viable CD34+ cells per kg. Study drugs 
(bone marrow cell suspension and vehicle) were injected both intra-arterial (through the DSA 
catheter over a period of 10 min) and intramuscular through syringes, warmed in the water bath 
at 37°C prior to injection. The ratio of cells injected intraarterially and intra-muscularly was 2:1. 
Cell concentrations for intra-arterial injections are given in table 1. 
 
 
Table 1  
Overview mean number of CD34+ Cells per treatment group. 
Concentration group Mean number of viable CD34+ Cells 
administered intra-arterially (I.A.) and 
intra-muscularly (I.M.) per animal 
Total number of rats 
Low Concentration I.A.:  327,600 CD34+ Cells/kg 
I.M.: 163,800 CD34+ Cells/kg 
 
7 
Medium Concentration I.A.:  688,800 CD34+ Cells/kg 
I.M.: 344,400 CD34+ Cells/kg 
 
6 
High Concentration I.A.:  1,308,000 CD34+ Cells/kg 
I.M.:    654,800 CD34+ Cells/kg 
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The primary outcome of this study was the change in the vascular density of the blood vessels as 
an indicator of angiogenesis in the ischemic limbs after treatment with various doses of bone 
marrow cells versus treatment with the vehicle. Therefore, Regions of Interest (ROI) were set by 
conventional X-ray from the head of the femur to the distal end of the fibula of both the vascular 
occluded right and the intact left hind limbs of the individual rats. In these regions, the Mean 
Gray Value (MGV) was visualized in the digital images taken during the subtraction angiography 
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(DSA) at day 7 and day 35 (MGV-7 and MGV-35). MGV was calculated using the pixel calculator 
of the ImageJ® Software. 
The effect of the unilateral ligation of the (right) iliac artery was studied by comparing MGV-7 of 
both legs. Then, the effect of the vehicle on vascularization in the right hind limb after ligation 
was studied by comparing Vehicle MGV-7 and MGV-35 calculations in the right hind limb. The 
effect of bone marrow cells on the vascularization in the ischemic legs was studied by comparing 
their MGV-7 and MGV-35 calculations in the ligated right hind limbs with the vehicle MGVs.  
 
Statistical Analysis 
The changes in MGV for the different bone marrow cells treated groups were tested to the 
changes in the MGV for the Vehicle group using Analysis of Variance (ANOVA).The individual 
changes between the MGV at day 35 and day 7 for every group were tested within the group 
using a pair wise T-test. At last, the positive changes in the MGV ratio’s for the occluded legs are 
grouped as 1. No changes or negative changes are grouped as 0. With a Chi-square non-
parametric test the bone marrow treated group was compared with the Vehicle group and tested 
for significance. Statistical significance was assumed with p<0.05 levels. 
 
Results 
The surgery was successfully performed in all animals. There was no difference in body weight 
between the different treatment groups and the vehicle group before the surgery (data not 
shown).In the treatment group treated with the high bone marrow cell dose, two animals died 
during the application of this dose, and another one had to be sacrificed during follow-up. During 
the follow-up of the treated animals, all remaining animals showed an uncomplicated and 
expected body weight development (data not shown). During the study the limb temperatures 
were measured. The temperature of the limb was stable over time (data not shown). The MGV-
7 and MGV-35 for both vascular occluded right and in-tact left legs were calculated for each 
animal. There was a significant decrease in MGV-7 in the occluded right legs as compared with 
the intact left legs in MGV-7 (Figure 1a), which showed about 40% loss of calculated vascular 
density as compared to the left MGV. During the follow-up, vehicle-treated animals showed 
significant progression up to roughly 60 % of the MGV at day 35 (Figure 1b) which is in line with 
results in immunocompetent animal models (Kinnaird, Stabile et al. 2004) 
 
At day 35, a significant increase of vascular density was found in all other bone marrow cells 
treated groups compared to the vehicle treated group (Figure 1b) except in the high dose group. 
To set these changes into proportion to each other, figure 1c presents the percentages of change 
in MGV at day 35 for the occluded leg for the different ASCT01 and vehicle treated groups. Low 
and medium dose of unfractionated bone marrow cells improved mean gray values significantly 
which high dose treatment did not. The proportional improvement was highest in the low dose 
bone marrow cells group. We then asked the question whether there was a correlation between 





Figure 1. Overview MGV-7 and MGV-35 values in the ischemic right hind leg (left) and in the intact left hind leg. (1a): MGV in intact left leg 
for Vehicle, low dose, medium dose and high dose group. (1b): MGV in occluded right leg for vehicle, low dose, medium dose and high dose 
group. Significance compared to MGV-7 with ANOVA marked with *p<0.01. (1c): Percentage of change between the MGV at day 7 and 35 
for the occluded leg and the different groups. (*1) Deterioration of the limb ischemia in vehicle treated animals (Pair wise T-Test p = 0.003); 
(*2) Difference after low dose cell therapy to the vehicle treated group (ANOVA p < 0.001); (*3) Difference after medium dose cell therapy 
to the vehicle treated group  (AOVA p<0.01). No improvement after high dose therapy. 
 
Figure 2. The dose-response graph describes the relationship between the total number of CD34+ cells in low and medium dose ASCT01 
and the improvement on day 35 in Mean Gray Value (MGV). The values are weighted by dividing the expected value by the measured value 

































Absolute number of administered CD34+ Cells on a log-scale
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Figure 2 represents the dose response curve which showed no clear correlation between the 
absolute number of CD34+ cells administered intra-arterially and intramuscularly and the 
absolute change in MGV at day 35 compared with day 7. The concomitant application of cells 
intraarterially and intramuscularly into the affected limb was done to optimize the re-
vascularisation. Angiographical data, as obtained during this study, illustrated that the newly 
formed vessels were still very small. A representative study is shown in figure 3.  
 
 
Figure 3. Example of a set of angiographic images of a with human bone marrow cells (ASCT01) treated T cell deficient rat. The left image 
is taken at day 7 (before treatment) and the right image is taken at day 35 after the treatment with low dose of human bone marrow cells. 
Despite concomitant application of cells intramuscularly and intravenously, the newly formed vessels are very small 
Discussion 
We used for our study a T cell deficient rat model in order to avoid confounding effects of 
immunosuppressive drugs. The critical limb ischemia did deteriorate in the vehicle group, which 
is in line with the natural course of the disease. In order to promote the effects of the 
unfractionated bone marrow preparation we tested the combined intra-arterial/intramuscular 
treatment with human bone marrow-de-rived stem cells in the ischemic leg, at day 35 in a dose 
dependent manner. We found no dose dependency but a profound clinical improvement after 
the lower and medium cell concentrations with a significant increase of vascular density, if 
compared with the reduced vascular density at day 7. This significant repair of vascular density, 
though, was not seen in the animals treated with higher bone marrow cell concentrations. 
Treating the ligated legs with these high doses, on the contrary, had a non-significant tendency 
to further loss of vascular density as compared to the MGV-7 situation was established.  
We tested in 5 animals the highest possible cell concentration of bone marrow cells which 
resulted in the death of 2 out of 5 rats during administration of this preparation. Although in 
general, bone marrow cell treatment was well tolerated in the low and medium dose groups, in 
the higher dose groups there were some difficulties with the intra-arterial administration, due 
to the high viscosity of the solutions, probably resulting in physical obstruction in these vessels 
despite the rather long infusion period.  
Angiographical data illustrated that the newly perfused vessels were still very small (Figure 3). 
This could indicate that our intra-arterial and intramuscular approach did not generate an 
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expedition of the underlying angiogenesis. The process of angiogenesis is starting up slowly, 
making the clinical improvements initially difficult to detect. Therefore, a longer follow up period 
after treatment would probably result in more and longer blood vessels formation and diameter 
in the treatment groups. This is most likely not possible in the placebo group due to the natural 
deterioration of the hind limb occlusion.  
Our approach of intra-arterial plus intramuscular administration was very different from 
currently clinically tested intramuscular or intra-arterial approaches (Ponemone, Gupta et al. 
2017, Abdul Wahid, Ismail et al. 2018). We chose the combined approach to bring the cells to 
the circulation and allow access from the endothelial side for cell to cell interaction and secretion 
of paracrine factors (Kinnaird, Stabile et al. 2004, Sahoo, Klychko et al. 2011). In addition, the 
allogenic cells have a short half-life irrespective of the immunosuppression of the animals 
(Schiattarella, Perrino et al. 2014). The chosen xenograft model, in which T-cell deficient rats 
were treated with human bone marrow stem cells without any further immune suppression, is 
useful in order to avoid the confounding effects of immunosuppression (Amann, Luedemann et 
al. 2009). It has the advantages, such as better animal treatment conditions, and better 
mimicking the human clinical situation when compared with studies were immune suppressive 
drugs were used. 
It would be interesting to also assess the effect of individual treatments (intra-arterial and intra-
muscular administration) to clarify the contribution of each route of stem cells administration. 
Since clinical trials have shown equipoise between the two administration routes, we did not 
include these groups in order to reduce the number of experimental animals. 
 We faced serious limitation due to the high viscosity which makes this approach less promising 
(Fadini, Agostini et al. 2010). Our study has additional limitations with respect to the time period 
of follow up and the mode of administration.  
The approach to test cell-based or cell-derived preparations in T-cell deficient rats is however 
possible and allows the assessment of cell-based or cell-derived preparations without additional 
drugs administration since the quest for the best cell preparation is still ongoing (Schiattarella, 
Perrino et al. 2014). The different properties of the cell mixture of bone marrow versus 
mesenchymal stromal cells offer opportunities in particular with respect to immunomodulation 
and/or regeneration (Aurora and Olson 2014). Despite the evolving evidence for clinical 
effectiveness of autologous bone marrow derived treatment (Ponemone, Gupta et al. 2017), the 
preparation of bone marrow and the selection of subgroups of cells from bone marrow warrants 
further studies (Fadini, Agostini et al. 2010).  
 
Conclusion 
This study reports that T cell deficient rats can be used as a model for angiogenesis after critical 
limb ischemia. We used the immunosuppressed animals to test centrifuged human bone marrow 
suspension containing mesenchymal and hematopoietic stem cells which significantly improved 
hind limb perfusion in T cell deficient rats. This study did show that the centrifuged human bone 
marrow suspension containing low and medium doses of bone marrow cells significantly 
improved the hind limb ischemia as compared to vehicle-treated group in T-cell deficient rats, 






Bone marrow-derived stem cells in acute neurodegenerative 
processes 
 
Introduction chapter 4 
Chapter 4 focus on two experiments performed with a minimal manipulated stem cell 
preparation derived from human bone marrow in acute preclinical models for a traumatic 
neurodegenerative disorder. As animal models for traumatic brain injury are quite complex, we 
chose for models displaying traumatic spinal cord injuries (SCI). The stem cell preparation was 
manufactured under good manufacturing practice (GMP). After permission of the ethic 
committee of Maastricht university medical center (MUMC+) and the university Maastricht, bone 
marrow collection was performed in healthy volunteers. Conform the results of the preclinical 
studies (chapter 2), in these experiments, we avoided any co-medication with immune 
suppressive medication, as this medication might present a major confounder masking the 
results of neuroprotection and induces also a negative effect on the plasticity/viability of stem 
cells. The first part of this chapter (4.1.) presents the experiments in T-cell deficient rats with a 
balloon compressed spinal cord injury, the second part (4.2.) the experiments in normal immune 
competent rats with a drop-weight-induced spinal lesion. Results were compared with those 
found in placebo-treated as well as (mimicking human SCI treatment) in methylprednisolone-
treated SCI-rats. These experiments were designed for the confirmation of the hypothesized 
decrease of the spinal cord lesion-induced secondary inflammation. Special attention was given 
to apply fresh stem cell preparations in a very limited time window, within 24 hours after the 
animal lesioning (Figure 1).  
 
 
Figure 1. Overview of the activities in time to align the human donors to the treated animals in real-time 
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4.1. Standardized human bone marrow-derived stem cells 
infusion improves survival and recovery in a rat model of 
spinal cord injury 
 
De Munter JP, Beugels J, De Munter S, Janssen L, Cillero-Pastor B, Moskvin O, Brook G, 
Pavlov D, Strekalova T, Kramer BW, Wolters ECh (2019) J Neurol Sci 402:16-29. 
 
Abstract 
Spinal cord injury (SCI) is an incurable disorder with an unmet need of an effective treatment. 
Recently, autologous human bone marrow-derived stem cells have shown to promote functional 
improvement, due to their anti-inflammatory and regenerative/apocrine properties. In this 
study, the primary objective was to test whether a single intrathecal injection with a 100μL 
suspension of 400,000 fresh human bone marrow-derived CD34+ and an equal number of CD105+ 
stem cells (Neuro-Cells(NC)), one day after balloon-compression of the spinal cord, improves  
motor function and reduces secondary damage in immune-deficient rats. During the first 5 
weeks after this intervention, NC significantly improved locomotor recovery and induced less 
injury-associated adverse events compared to vehicle-treated rats. Histological analysis showed 
that NC reduced astrogliosis, and apoptosis early after administration (day4), but not at a later 
stage (day56) after SCI. Proteomic studies (at day56) pointed to the release of paracrine factors 
and identified proteins involved in regenerative processes. As stem cells seem to reach their 
effects in acute lesions by mainly suppressing (secondary) inflammation , it is thus realistic to 
expect a lower magnitude of their eventual beneficial effect in T-cell deficient rats, a fact 
reinforcing the robustness of Neuro-Cells efficacy. Taken together, this study indicates that an 
intrathecal instillation of Neuro-Cells holds great promise as a neuro-regenerative intervention 
in a clinical setting with acute SCI patients. 
 
Introduction  
The prevalence of spinal cord injury (SCI) worldwide is estimated at 2.5 million cases and the 
financial burden per case is calculated to be between 200,000 and 260,000 Euros/year (DeVivo 
1997). Pending severity of the injury, SCIs may cause an (in)complete loss of sensory, motor, and 
vegetative functions under the level of the spinal cord involved: in legs (paraplegia) or in arms 
and in legs (tetraplegia). Traditionally, in 60% of the cases, traumatic spinal cord injury is caused 
by falls and by motor vehicle accidents (Norenberg, Smith et al. 2004), but recently more and 
more combat-wounded soldiers are affected (Schoenfeld, Laughlin et al. 2013). Due to the lack 
of disease-modifying interventions, life expectancy in SCI patients is impaired (Strauss, Devivo et 
al. 2006) and the quality of their lives is poor (McKinley, Meade et al. 2004, Gupta, Bathen et al. 
2010). As a small functional improvement in SCI patients might come with a major increase in 
quality of life and daily independency, recently, much attention is given to control and reduce 
collateral damage of neural tissue by inhibiting the posttraumatic inflammatory cascades 
(Donnelly and Popovich 2008, Alexander and Popovich 2009, Silva, Sousa et al. 2014, Lawrence 
2018). Less than 10% of functional long-tract connections is needed to enable locomotion (Blight 
1983). Although this level of connectivity often remains after the injury, axons might become 
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non-functional because of collateral damage resulting in neuro-degeneration at a later stage 
(Bunge, Puckett et al. 1993). Therefore, prevention of secondary damage in the acute phase of 
spinal cord injury is of utmost importance, which offers the opportunity of functional 
improvement by disease-modifying interventions (McDonald and Sadowsky 2002, Silva, Sousa et 
al. 2014). Until the recent past, steroids were applied for this purpose (Bracken 2002), although 
widespread use has stopped due to limited effects and severe adverse effects (Suberviola, 
Gonzalez-Castro et al. 2008, Botelho, Daniel et al. 2009).  
In SCI, a therapeutic intervention combining both anti-inflammatory and regenerative properties 
is an unmet need. Hypothetically, stem cells may be such an intervention, as one of the 
characteristics of adult stem cells (both hematopoietic and mesenchymal stem cells) is the ability 
to both inhibit inflammation and to mediate regeneration by increasing neuroplasticity in 
neurodegenerative processes (Schwarting, Litwak et al. 2008, Antonic, Sena et al. 2013, 
Akyurekli, Le et al. 2015, Chen, Jia et al. 2015, Neirinckx, Agirman et al. 2015, Assinck, Duncan et 
al. 2017, Nejati-Koshki, Mortazavi et al. 2017, Lawrence 2018, Jin, Medress et al. 2019).  
Recent studies suggested that not only the site of the lesion, but also the timing of the 
administration of stem cells after the lesion are crucial for their beneficial effects in the context 
of the evolving post-traumatic inflammatory response (Donnelly and Popovich 2008, Wragg, 
Mellad et al. 2008, Alexander and Popovich 2009, de Munter and Wolters 2013, Wagey 2014, 
Assinck, Duncan et al. 2017, Nejati-Koshki, Mortazavi et al. 2017, Jin, Medress et al. 2019). Dose 
and number of cells administrated appear to be of less importance (Caplan 2017).  
The objective of this study was to investigate whether a single intrathecal administration with 
‘Neuro-Cells’ (a not substantial manipulated low immunogenic, fresh human bone marrow-
derived stem cell preparation, depleted of erythrocytes and the majority of the lymphocytes 
according to the manufacturing standard operating procedures of Neuroplast BV) provided a 
better survival and functional recovery in T-cell deficient rats after spinal cord injury. In this 
study, a moderate grade SCI was applied in rats by a moderate balloon compression of a spinal 
thoracic (Th 9) segment. Unfortunately, treatment of these animals with autologous stem cells 
or with a low-immunogenic rat stem cell preparation (following the manufacturing procedure of 
Neuro-Cells) is not realistic due to the limited volume of rat bone marrow, and the invasiveness 
of the cell collection procedure itself in rats.  
Thus, T-cell deficient rats were selected to avoid both rejection of human stem cells and the use 
of immune suppressive drugs. Immune suppressive drugs are considered major confounders as 
they not only interfere with stem cells but also offer a cell protective effect to local neurons 
(Palladini, Caronti et al. 1996, Ibarra, Correa et al. 2003, Diaz-Ruiz, Vergara et al. 2004, Guo, Zeng 
et al. 2007). They can substantially influence the outcome in experimental studies after the 
effects of stem cell interventions in favour of the vehicle treated animals. Therefore, these drugs 
dampen neuro-inflammation following acute spinal cord injury and thus final damage, with 
consequent less sensorimotor and neurovegetative symptoms (Potas, Zheng et al. 2006). In 
comparison to normal, immune competent rats, the higher liability to infections may also have 
a significant effect on survival of the experimental animals (Potas, Zheng et al. 2006).  
We hypothesized that infusion with Neuro-Cells 24h after SCI will improve locomotor recovery 
by reducing secondary damage. Functional behavioral recovery was monitored weekly using the 
Basso, Beattie, Bresnahan (BBB) open field test (Basso, Beattie et al. 1995). Histological studies 
were performed 4- and 56-days post-surgery to determine the number of apoptotic cells, 
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reactive astrocytes, and microglia infiltration in both vehicle and Neuro-Cells-treated animals. 
Moreover, we used mass-spectrometry technology to screen for and identify peptides in each 
site relative to the spinal lesion (rostral, lesion, caudal) obtained in vivo. We hypothesized that 
Neuro-Cells changes the composition of local peptides by down regulation of pro-inflammatory 
proteins as compared to the vehicle treated animals. This effect is expected to be the strongest 
in the lesion site as compared to the rostral and caudal sites.  
 
Methods  
Animals and experimental design  
Adult male T-cell deficient A-thymic RH-Foxn1rnu (260–310g) purchased from Harlan (Harlan 
laboratories, The Netherlands) were housed in pairs during the acclimatization period, for post-
operative care and throughout the rest of the experiments. Rats were maintained in an isolated 
part of the animal facility apart from immune competent animals and under standard housing 
conditions (12h light/dark cycle, lights on at 8:00a.m., humidity 40–60%, temperature 22 ± 1°C) 
with ad libitum access to food and water. The Animal Care and Use Committee of the University 
of Maastricht reviewed and approved all animal surgeries, procedures, and post-operational care 
(permit number DEC2013-013). Laboratory personnel managed animals following the National 
Institute of Health Guide for the Care and Use of Laboratory Animals. A total number of 62 rats 
underwent surgical procedures for inclusion in this study (Fig.1).  
 
 
Figure 1. Experimental design. At day 0 (d0), spinal cord injury (SCI) or a sham lesion was induced in T-cell deficient rats. Rats were injected 
intrathecal with vehicle or Neuro-Cells, caudal to the lesion at day 1. Immunohistochemistry (IHC) was performed at day 4 and day 56 after 
administration. Proteomic studies were performed at day 56. Throughout the study, Basso-Beattie-Bresnahan (BBB) measurements for 
assessing locomotor behaviour (Basso, Beattie et al. 1995) were performed on a weekly base. 
 
Spinal cord balloon compression 
After a subcutaneous injection of buprenorphine (0.05mg/kg), animals were anaesthetized (3–
4% Isoflurane) and maintained (1.5–2.5% Isoflurane, Sigma-Aldrich) in anaesthesia with a stable 
body temperature of 37°C. Having removed the spinal processes T10–T11 after a 2-cm midline 
incision at T10-L1, a small hole (1.5mm diameter) was drilled in the vertebral arch T10, using a 
surgical microscope (Vanicky, Urdzikova et al. 2001). After opening the periosteal membrane in 
order to allow direct visualization of the spinal cord with intact dura mater, a groove was drilled 
in the midline on the dorsal surface of the vertebral T11 lamina. Then, an epidural inserted 
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French Fogarty catheter (Baxter Healthcare Corporation, Irvine, CA) filled with saline and 
connected to an airtight 50μL Hamilton syringe type 1705, cranially for 1 cm, was guided through 
this groove, thus positioning the center of the balloon at T8–T9. In case of SCI-lesioning, but not 
in sham-lesioning, the balloon was then rapidly inflated with 15μL saline and held in situ during 
5 min before deflating and removal of the catheter, closing the wound and terminating 
anaesthesia. Post-operative care included subcutaneous application of buprenorphine 
0.05mg/kg during 4 days to relief the pain.  
 
Neuro-Cells 
Neuro-Cells (NC) is the working name (patent WO2015/059300A1) of a fresh, standardized 
human bone marrow derived stem cells containing product, that is produced under good 
manufacturing practices (GMPs) without expansion and/or labelling (or other major 
manipulation) of the stem cells. Neuro-Cells comprises of hematopoietic stem cells and their 
progenitors (HSCs), mesenchymal stem cells and their progenitors (MSCs) and other 
mononuclear cells. Four healthy male volunteer donors were recruited with informed consent 
for collection of 50–75mL bone marrow from their iliac crest under local anaesthesia, following 
standard operating procedures. Neuro-Cells was depleted from erythrocytes by Ficoll (GE 
Healthcare, Chicago, Ill.) density gradient centrifugation (at 400g, at room temperature) and the 
number of lymphocytes was substantially reduced (Table1) by positive selection between 95 and 
97% and resuspending the remaining cells in Ringer lactate.  
MSCs and HSCs were characterized by flow cytometry (Miltenyi, Germany). The group of MSCs 
was identified by being positive for CD73, or CD90, or CD105 and negative for CD34 and CD45 
and CD14 (Dominici, Le Blanc et al. 2006).  
 
Table 1 
Characterization of cell population in Neuro-Cells 
Cell population in Neuro-Cells Mean absolute number of cells 
injected in each animal (in 100µL) 
Total nucleated cells 1.2 x 107 
HSC: total CD34+ cells 4.0 x 105 
MSC: CD271+ cells 7.8 x 104 ± 2.6 x 104 
MSC: CD133+ cells 1.5 x 104 ± 0.5 x 104 
MSC: CD90+ cells 3.7 x 103 ± 1.3 x 103 
MSC: CD105+ cells 3.5 x 105 ± 2.0 x 105 
MSC: CD73+ cells 4.5 x 103 ± 2.1 x 103 
 
 
HSCs were positive for CD34, and CD38. Every Neuro-Cells batch fulfilled the GMP release criteria 
of at least 4 million HSCs and an equal number of MSCs suspended in 10mL Ringer-lactate for 
intrathecal application.  
As for the intra-donor variation, the intrathecal treatment of the SCI-rats was calibrated to 
4.0×105 CD34+ cells in vials of 100μL. However, due to the fresh nature of the cells and the 
calibration based on the number of CD34+cells, the individual number of MSCs will differ per 




Intrathecal infusion  
At day 1 post-surgery, we subcutaneously injected the rats with 0.05mg/kg buprenorphine (AST 
Farma B.V., The Netherlands) and further anaesthetized them with isoflurane (induction phase 
with 3–4% isoflurane and maintenance phase with 1.5–2.5% isoflurane), keeping the rats' body 
temperature at 37°C using heating pads.  
The wound of the first operation was reopened in order to visualize the dura. Then the dura was 
punctured and, after collection of a drop of cerebrospinal fluid (CSF), a syringe, either filled with 
Neuro-Cells or vehicle (Veh.;Ringer lactate), was connected and emptied, caudally of the lesion, 
through a microliter pump over a time period of 5min. We infused SCI-treated rats with 100μL 
Neuro-Cells or 100μL vehicle.  
Post-operative treatment and care were identical to those after the lesioning. Local pressure at 
the puncture hole and applying some drops of the animal's blood on the puncture hole 
prevented for CSF leakage.  
 
Post-operative care 
Animals' wellbeing, general health condition, urodynamic and body weights were assessed twice 
per day until day 35. The bladder was emptied manually twice a day until the rats were able to 
spontaneously empty their bladder again, usually within 14 days after the lesion. During the 
period of manual bladder emptying, the urine was routinely checked for bacteria growth using a 
urine dipstick.  
 
Functional evaluation  
Rats were assessed for locomotor behavior with the Basso-Beattie Bresnahan (BBB) open field 
test (Basso, Beattie et al. 1995). Locomotor recovery was tested pre-SCI (baseline) and at days 1, 
7, 14, 21, 28 and 35 post-lesion. At post-surgery day 1, SCI-lesioned rats had to display a flaccid 
paraplegia (BBB score 0) before the application of Neuro-Cells or vehicle. Based on the 
established natural recovery, SCI-lesioned animals were also excluded when scoring was below 
4 (protracted recovery) and/or above 8 (partial lesion) at day 7 (Vanicky, Urdzikova et al. 2001). 
The exclusion parameters of animals were established before the execution of the experiment. 
Open field locomotor function was assessed by two independent researchers, evaluating video 
tapes not aware of the treatment. 
 
 Immunohistochemical analyses 
At days 4 and 56, four rats out of the NC- and Veh.-treated SCI animals and three out of the NC- 
and Veh.-treated Sham animals were anaesthetized with isoflurane (induction phase with 3–4% 
isoflurane and maintenance phase with 1.5–2.5% isoflurane) and sacrificed by transcardial 
perfusion with Ringer lactate (Baxter, pH 7.4). The spinal cord tissue of the entire affected area 
was positioned into cryomolds in a longitudinal orientation and embedded in optimal cutting 
temperature compound (OCT, VWR, The Netherlands; for rats sacrificed 4 days post SCI) or 
porcine gelatin (10%, Sigma Aldrich; for rats sacrificed 56 days post SCI). Subsequently, the spinal 
cord tissue was snap frozen in liquid nitrogen and stored at −80 °C until further processing.  
To assess the presence of human-derived transplanted cells, as well as astrogliosis, inflammation 
and apoptosis of the infused cells, serial longitudinal cryosections of the spinal cord (10 μm) were 
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cut through the areas of interest: the rostral part of the lesion (RO), the center of the lesion (CE), 
and the caudal part of the lesion (CA), using a cryostat (Leica Biosystems), and then stored at −20 
°C until further processing.  
To identify human stem cells transplanted into the rat spinal cord at day 4 after infusion caudally 
to the lesion, antibodies directed against human mitochondrial (MAB1273C3, 1:100, clone 113–
1, Millipore) were used. To study the early- and late-effects of Neuro-Cells in inflammation, 
astrogliosis and apoptosis, sections were incubated overnight at 4 °C with the following primary 
antibodies: rabbit anti-CD68 (Abcam, 1:500, ab125212), rabbit anti-GFAP (Abcam; 1:500, 
ab7260), and rabbit anti-cleaved caspase-3 (Cell signalling, 1:500, [Asp175]1331311 9661). 
Sections were washed with 1× PBS and incubated with secondary antibodies [(donkey anti-rabbit 
Alexa 488 (Invitrogen, 1:100) or donkey anti-mouse Alexa 488 (Invitrogen, 1:100))] in 0,1% 
blocking buffer for 1 h at room temperature. Cell nuclei were stained for 10 min with 4′,6-
diamidino-2-phenylindole (DAPI, Thermofisher).  
For quantitation, two sections per rat were visualized with a confocal microscope (DSU, 
Olympus® BX51W1; 20× objective) and StereoInvestigator software (MicroBrightField, Williston, 
VT) and ImageJ programs (NIH, Bethesda, MD) were used for analysis. Image J was used to 
calculate the area of each anatomical region (rostral, lesion and caudal) and integrated mean 
density. The corrected total cell fluorescence (CTCF) of GFAP+ and CD68+ was calculated as 
integrated density – (area of selected region x mean fluorescent intensity of background 
reading).  
For the CA and RO sites of the lesion, fluorescence intensity was measured at the outer surface 
of the spinal cord and at the middle part of the section 2 points at each part of the lesion 
(Appendix S1, Fig. 1). For the CE part, fluorescence intensity was measured at the border of the 
center lesion. The average values of fluorescence intensities from 2 images were used as the 
reference for comparisons within each group. Serum of the rats sacrificed at day 4 was taken for 
ELISA testing to determine the concentration of interleukins and compare the concentrations of 
the vehicle and Neuro-Cells treated SCI-lesioned animals with the sham lesioned animals. To 
study the concentrations of IL-1β, IL-6 and TNFα in a blood plasma, rat enzyme-linked 
immunosorbent assay (ELISA) was performed using Rat Interleukin 1 beta (Rt IL-1β) ELISA kit 
(ThermoFisher Scientific, Waltham, MA, USA), IL-6 Rat ELISA Kit (ThermoFisher Scientific, 
Waltham, MA, USA) and TNFα (Rt TNFα) Rat ELISA Kit (ThermoFisher Scientific, Waltham, MA, 
USA) according to the manufacturer's instructions. The microwell absorbance was measured at 
450 nm with Promega microplate reader for all cytokines (Promega, Madison, WI, USA). 
 
Statistical analysis 
Analyses were performed using statistical package SPSS 17.0 for Windows XP. Data were 
normally distributed as determined by Shapiro-Wilk tests for normality and we therefore 
performed parametrical statistical analyses on datasets. We performed a two-way ANOVA (with 
‘group’ as the predicting factor and ‘lesion site’ as the moderating factor) to assess the data 
obtained from the histology study. If a group effect, level on spinal cord effect or an interaction 
effect (group x lesion site) was significant a post hoc Fishers Least Significant Difference (LSD) 
test was performed, after determining equality of variances using Levene's test (which was the 
case unless stated otherwise).  
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Repeated measures ANOVA was used to analyse the BBB score and the bladder recovery function 
over the different days with within-subjects factor “testing day”, and “group” as fixed between-
subject factors. Huynh-Feldt correction was used to correct for violations of sphericity. Rat 
survival as a function of treatment was determined as Kaplan-Meier estimates, and differences 
in the survival curves were evaluated with this method. There were no censored data. A p value 





For proteomic studies in NC-treated and Veh-treated rats, sacrificed at day 56, ammonium 
bicarbonate, dithiothreitol, iodoacetamide and trifluoroacetic acid (ULC grade) were purchased 
from Sigma-Aldrich, urea from GE Healthcare, the enzyme mix trypsin/lysC (mass spec grade) 
from Promega, and water, acetonitrile, formic acid, all ULC grade, from Biosolve. 
 
Sample preparation 
Gelatin was removed from the spinal cords by 3 washes in warm (30–35 °C) 50mM Ammonium 
bicarbonate (ABC). After washing, 5M Urea in 50mM ABC was added to the spinal cord tissues. 
Tissue disruption and lysis was performed by three freeze-thaw cycles using a warm water bath 
and liquid nitrogen. During 45 min, the lysate then was reduced with 20mM Dithiothreitol (DTT) 
before being alkylated with 40mM Iodoacetamide (IAM) for another 45 min in the darkness. The 
alkylation was terminated by 20mM DTT to consume any excess IAM.  
Digestion was performed with a mixture of LysC and Trypsin, which was added at a ratio of 1:25 
(enzyme to protein). After two hours of digestion at 37 °C in a water bath, the lysate was diluted 
with 50mM ABC to 1M Urea and further digested at 37 °C overnight. The digestion was 
terminated by addition of formic acid (FA) to a total of 1%. Biognosys iRT's were added to each 
peptide sample according to manufacturer's instructions (required for the DIA analysis using 
Spectronaut X software, Biognosys Inc., Beverly, MA, USA). 
 
Liquid chromatography – Mass spectrometry 
Peptide separation was performed on a Thermo Scientific (Dionex) Ultimate 3000 Rapid 
Separation UHPLC system equipped with an Acclaim PepMap C18 analytical column (2 μm, 100 
Å, 75 μm×150 mm). Peptide samples were first desalted on an online installed C18 trapping 
column. Desalted peptides were then separated on the analytical column with a 90 min linear 
gradient from 5% to 35% Acetonitrile (ACN) with 0.1% FA at 300 nL/min flow rate.  
The UHPLC system was coupled to a Q Exactive HF mass spectrometer (ThermoScientific). DDA 
settings were as follows. Full MS scan between 375 and 1500 m/z at resolution of 120,000 
followed by MS/MS scans of the top 15 most intense ions at a resolution of 15,000. The HRM 
DIA (data-independent acquisition) method consisted of a survey full MS scan at 120,000 






For protein identification the DDA spectra were analysed with Proteome Discoverer (PD) version 
2.1.1.21. Within the PD software, the search engine Sequest was used with the SwissProt Human 
(Homo sapiens (TaxID=9606) (v2016-11-30)) and Rat (Rattus norvegicus (TaxID=10,116)) (v2016-
11-30) databases and the Biognosys iRT peptide sequences (supplied by Biognosys). The 
database search was performed with the following settings: enzyme was trypsin, a maximum of 
2 missed cleavages, minimum peptide length of 6, precursor mass tolerance of 10 ppm, fragment 
mass tolerance of 0.02 Da, dynamic modifications of methionine oxidation and protein N-
terminus acetylation, static modification of cysteine carbamidomethylation. The DDA 
measurements were used to create a spectral library using spectral library generation in 
Spectronaut 9 (Bruderer, Bernhardt et al. 2015) (Biognosys). Only identifications with FDR of 
maximum 1% at peptide and protein level were taken into account for spectral library 
generation. For protein quantitation, the DIA data were analysed with Spectronaut 9, with the 
manufacturer's recommended default settings. 
 
Differential abundance testing 
Within each site of the lesion (RO, CE, CA), differential protein abundance between Neuro-Cells- 
and vehicle-treated conditions was tested using Spectonaut's built-in algorithm. Abundance data 
for proteins found differentially abundant with q-value below 0.05 was submitted to 
downstream functional analysis. 
 
Representations of biological functionality 
The following complementary knowledge-based classifications of protein functionality were 
used in combination, to create biological interpretation of the detected lists of differentially 
abundant proteins: i) Gene Ontology (including Biological Process and Cellular Component 
branches of the hierarchy) were adopted from GSEA website of Broad Institute (Subramanian, 
Tamayo et al. 2005) ii) regulons, generated by collecting the known transcription-target 
relationships from HTRIdb (Bovolenta, Acencio et al. 2012) and CellNet (Cahan, Li et al. 2014) 
and iii) Reactome pathways (Fabregat, Sidiropoulos et al. 2016). For all the functionality 
representations, members of the gene ID-based categories were remapped to protein IDs with 
Bioconductor's biomaRt package (Durinck, Spellman et al. 2009). The sets of protein IDs were 
restricted to proteins actually detected in the experiment (at any lesion site and condition). 
 
Protein set enrichment analysis 
Functionality enrichment tests with lists of responsive proteins (Subramanian, Tamayo et al. 
2005) in context of the 3 functionality representations described above, were performed with 
goseq package (Young, Wakefield et al. 2010) using Wallenius approximation and correction for 




To identify response patterns at a general level rather than individual functional categories, we 
generated protein-sharing networks. For this purpose, we collected respective category-protein 
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relationships (e.g. Reactome pathways) and restricted them to proteins that were called 
responsive to Neuro-Cells in at least one of the three sites. Subsequently, for each pair of the 
categories (network nodes), the number of shared proteins was recorded and used to map to 
the width of the edge connecting those two nodes. The analysis was performed with a 
combination of R programming language (R core team, 2014) and Cytoscape network analysis 




During the quarantine period, 66 rats were randomized into two groups: group 1 (N=49) for SCI-
lesioning, and group 2 (N=17) for sham-lesioning. Before this lesioning, though, one animal 
belonging to group 2 was lost because of intercurrent health problems, and during the SCI-
lesioning another one (out of group 1), because of anaesthesia related death. The 48 surviving 
SCI-lesioned animals in group 1 were further randomized in 24 rats for treatment with Neuro-
Cells (SCI-NC animals) and 24 rats for treatment with the vehicle (SCI-Veh animals). The 16-
surviving sham-lesioned rats were randomized into 7 animals for a treatment with Neuro-Cells 








All SCI-lesioned animals had a BBB score of 0 points before the application of their treatment. 
Day 4 of the study, 4 SCI-NC and 4 SCI-Veh as well as 3 Sham-NC and 3 Sham-Veh. animals were 
sacrificed for immunohistochemistry. Within the first week after the SCI-lesioning, 13 animals 
had to be excluded from the experimental design: 2 SCI-NC animals (due to direct perilesional 
surgical complications and shock) and 3 SCI-Veh animals (due to direct post-lesional convulsions, 
shock, and artificial-induced bladder rupture). Conform the protocol, another 4 SCI-NC rats had 
to be excluded because of a BBB-score at day 7 < 4 (probably because of a histological confirmed 
increase of the SCI-lesion due to the intrathecal injection of the viscous Neuro-Cells preparation), 
and 4 SCI-Veh rats because of a BBB-score > 8 (probably because of an impartial SCI lesion). 
During the study, 1 SCI-NC rat and 5 SCI-Veh animals reached a humane endpoint due to SCI-
surgery-induced complications. The 9 Sham-Veh and 7 Sham-NC treated animals, during the 
study, did not suffer any surgery-related complication, nor did they reach any humane endpoint. 
So, in the end 13 SCI-NC, 8 SCI-Veh, 6 Sham-Veh, and 4 Sham-NC treated rats completed the 
study and were sacrificed at day 56. An overview of the study is displayed in Fig. 2. 
 
Survival 
There were no mortalities in the 16 sham-lesioned animals. In the SCI-lesioned animals, apart 
from the 5 peri-lesional direct SCI-surgery related deaths, during the 56 days following lesioning, 
5 out of 13 Vehicle-treated animals reached a humane endpoint, due to development of ascites 
(n=3; day4, day5, day6), kidney failure (n=1; day18) and severe body weight loss (n=1; day38). In 
Neuro-Cells treated rats only 1 out of 14 animals reached a humane endpoint at day 10 post-
surgery, due to severe body weight loss (Fig. 2). The SCI-lesioned rats treated with Neuro-Cells 
appear to survive longer, as group differences reached significance (p ≤ 0.05). A plot of the 
survival function is shown in Fig. 3. 
 
 
Figure 3 Kaplan-Meier estimates of postoperative survival (adverse events reaching human end point) stratified by treatment with either 




Adverse events, general health conditions, body weight and urodynamic functions 
There were no serious health problems in the 16 sham-lesioned animals. During the 56 days 
following lesioning, 5 out of 13 vehicle treated animals reached serious adverse events (SAEs) 
with a humane endpoint, due to development of ascites (n=3; day4, day5, day6), kidney failure 
(n=1; day18) and severe body weight loss (n=1;day38). In Neuro-Cells treated rats only 1 out of 
14 animals reached such SAE at day 10 post-surgery, due to severe body weight loss (Fig. 2). The 
SCI-lesioned rats treated with Neuro-Cells appear to suffer significant less SAEs (p≤0.05). A plot 
of the survival function is shown in Fig. 3.  
Apart from these SAEs, surviving animals, suffered a higher incidence in the NC-treated group 
(p=0.12) of a temporary cystitis, favourably reacting to a treatment with Baycal. All surviving 
animals, after a modest loss of body weight during the first week after surgery, did gain body 
weight during the following weeks of the study period. Animals that underwent spinal cord injury 
and that were treated with Neuro-Cells did not differ in body weight compared to vehicle-treated 
group at day 1 and day 35 post-surgery (S5, Table 4). Sham-lesioned animals, whether treated 
with Neuro-Cells or Vehicle, did not suffer any adverse event, loss of body weight, or any loss of 
urodynamic functions. Regarding the SCI-related loss of urodynamic functions, after surgery, all 
animals needed assistance with bladder voiding. Measuring manually expelled urine, NC-
treatment did not affect the recovery of bladder control throughout a 14 days observation period 
(repeated measurement ANOVA, p=0.916) as compared to the Vehicle-treated animals. 
 
BBB Score 
On day 1, the sham-lesioned groups received almost normal BBB scores, whereas both the SCI-
treated groups scored the lowest possible (0 points), demonstrating the validity of this rat model 
of SCI. The scores increased in both SCI-vehicle and SCI-Neuro-Cells groups over time (repeated 
measure ANOVA, F (6,114)=2.72,        p < 0.032). However, by 14 days and 35 days post-surgery, 
there was a statistically significant difference in BBB scores between the Neuro-Cells- and 
vehicle-treated rats (p < 0.01; p < 0.008 respectively; Fig. 4). These results indicated that Neuro-
Cells induced functional improvement after SCI in rats. 
 
ELISA-serum 
The concentration of serum interleukin-1β, 6 and TNF-α were measured by ELISA. Fig. 5 
compared the mean differences between the vehicle respectively Neuro-Cells treated SCI-
lesioned animals with the vehicle and Neuro-Cells treated sham lesioned animals. 
 
Immunohistochemistry 
The survival of human transplanted stem cells was evaluated 3 days post-implantation of Neuro-
Cells. Human positive cells were found partially attached to the spinal cord surface, which were 





Figure 4 Effects of Neuro-Cells and vehicle (placebo) on locomotor function in rats after SCI-surgery and sham SCI-surgery. The first BBB 
evaluation took place at day 0, before surgery. At that time, no statistically significant differences in BBB scores were found between NC 
and Veh treated SCI-rats, whereas the BBB scores in the sham-operated rats during the whole study were different from SCI-operated rats 
(p<0.001). During the whole study, BBB scores in NC-treated SCI-rats were higher as those in Veh-treated SCI-rats, differences reaching 
significance at day 14 and 35 (*p<0.01). 
 
Figure 5 Differences in serum concentration between the Veh.- and NC-treated SCI-lesioned and sham-lesioned animals at day 4. At that 
time, there was a significant increase of serum Interleukin-1β and serum TNF-α in the Veh.-treated SCI-lesioned animals compared to the 
Veh.- and NC-treated sham-lesioned animals, but not for the NC-treated groups (*p<0.05). The serum Interleukin-6 was lower in the NC-
treated SCI-lesioned animals as compared to the Veh.-treated SCI-lesioned animals but both were significantly higher as compared to their 
sham-lesioned counterpart. 
 
Figure 6 Presence of human cells at CA (and less in CE) in NC-treated SCI rats detected by human mitochondrial epitopes, displayed in 
representative images at CA, 3 days after the treatment. A) DAPI, B) Human mt, C) Overlay. Scale bars represent 50 µm. 
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Early effects (day 4) on post-injury cellular responses 
Monocytes and macrophages are key players of the inflammatory modulation and of the 
resolution of inflammation after SCI (Shechter, London et al. 2009, London, Cohen et al. 2013). 
In comparison to sham lesioned, vehicle or NC-treated animals, we observed a significant effect 
at the SCI-induced lesion site (F(1,42)=56.02, p < 0.001) in CD68+ expression at day 4, with an 
increase at the central part of the lesion. Post hoc analysis showed that the CD68+ expression 
was significantly increased (p < 0.008) at the CA in the Neuro-Cells-treated rats compared to 
vehicle-treated rats (Fig. 7B). No differences were found in the CD68+ expression at the RO 
between the two treated groups (Fig. 7B). SCI-induced astrogliosis is an important process in glial 
scar tissue formation, as reactive astrocytes increase their expression of GFAP. In order to assess 
astrogliosis in SCI rats (vehicle vs. Neuro-Cells) 4 days post-injury, we examined the GFAP 
expression at the RO, CE and CA site of the lesion, in relation to those in the sham lesioned, 
vehicle or NC-treated animals (Figs. 6C and 7D). Analysis showed a significant main effect of the 
SCI-induced lesion site in GFAP expression (F(1,42)=29.05, p < 0.001) with an increase in GFAP+ 
expression at the central part of the lesion. There was also a significant main effect of the group 
(F (1,42)=4.61, p <0.038), as Neuro-Cells treated rats had an overall lower number of GFAP+ 
expression as compared to the vehicle-treated group of rats. Post hoc analysis revealed a 
significant decrease in GFAP+ expression at the CE in the Neuro-Cells-treated rats (p < 0.042; Fig. 
7D) when compared to vehicle-treated rats.  
No differences were found in the GFAP+ expression between the Neuro-Cells and vehicle-treated 
groups at the RO or the CA site of the lesion (Fig. 7D). Components of the caspase-3 apoptotic 
pathway are activated after traumatic SCI in rats and occur early in neurons at the injury site and 
hours to days later in oligodendroglia adjacent to and distant from the injury site (Springer, Azbill 
et al. 1999, Soini, Kahlos et al. 2005).  
To examine the effects of vehicle and Neuro-Cells on apoptotic cell death after SCI, we quantified 
the expression of cleaved caspase-3+ at day 4 post-injury in relation to those in sham-lesioned, 
vehicle or NC-treated rats (Fig. 7E and F). We found a significant effect in the SCI-lesion site (F(1, 
42)=9.30, p < 0.001), namely an increased number of cleaved caspase-3+ cells at the lesion site 
and a significant main group effect (F (1, 42)=6.13, p < 0.017).  
Interestingly, a significant interaction effect (F(1, 42)=4.45, p < 0.018) was observed, suggesting 
that the pattern of cleaved caspase-3+ expression differs along the sites of the lesion depending 
on the group (vehicle versus Neuro-Cells). Post hoc analysis revealed a significant decrease in 
cleaved caspase-3+ cells in rats treated with Neuro-Cells at the CA (p < 0.003; Fig. 7E and F) and 
at the CE (p < 0.012), suggesting a decreased apoptosis in both segments. The number of cleaved 
caspase-3+ cells did not differ between Neuro-Cells and vehicle-treated rats at the RO site of the 
lesion (Fig. 7E and F).  
 
Late effects (day 56) on cellular responses 
At day 56, we found a significant effect of the SCI-lesion site (F(1,40)=54.72, p < 0.001) with a 
significant increase in CD68+ expression at the CE site but no significant differences were 
observed between Neuro-Cells- and vehicle-treated rats at the RO, CE and CA sites (Fig. 8A and 
B). A significant main effect of the lesion site (F(1,41)=6.56, p < 0.003) with an increase in GFAP+ 
expression was also found at the CE site (Fig. 8C). Post hoc analysis revealed no differences in 
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GFAP+ expression between Neuro-Cells- and vehicle-treated rats at any site of the lesion (Fig. 
8D). A significant main effect of the lesion site (F(1, 42)=8.67, p < 0.001) was found in the number 
of cleaved caspase-3+ cells but post hoc comparisons between Neuro-Cells and vehicle-treated 
rats did not reach significance, suggesting that the number of cells that are undergoing apoptosis 
was not different between both groups 56 days post-injury (Fig. 8E and F). 
 
 
Figure 7 CD68+, GFAP+ and cleaved caspase-3+ cells in Veh.- and NC-treated rats across the RO, CE and CA sites (Lesion=CE) relative to the 
lesion at day 4 postinjury. Panels show representative examples of fluorescent labeling of CD68+ (A), GFAP+ (C) and caspase-3+ cells (E). For 
the caspase-3+ cells we quantify the total number of positive cells (E). Magnification bar represents 50 μm. The effects of NC in CD68+, 
GFAP+ and caspase-3+ at the RO, CE and CA sites are shown (B, D, F).The data are expressed as mean ± SEM. n=7–8 sections per animal in 
each group. *: significant, p≤0.05. 
 
Proteomic studies 
Differential protein expression 
We quantified 573 protein abundances in SCI rats that were injected with Neuro-Cells and in SCI 
rats that were injected with vehicle at day 56 after administration. For this purpose, we used 
tissues from the three different anatomical sites of the lesion: i) rostral (RO), ii) center (CE), and 
iii) caudal (CA). We compared the functional analyses of the differentially abundant proteins with 
alternative functional classifications to assess the biological functionality relevant to the Neuro-
Cells effects (see Methods).  
80 
 
The most relevant representations appeared to be Regulons, Gene Ontology Cellular Component 
and Reactome pathways taken in a gene-sharing network context. 
 
 
Figure 8 CD68+, GFAP+ and cleaved caspase-3+ cells in Veh.- and NC-treated rats across the RO, CE and CA sites (Lesion=CE) relative to the 
lesion at day 56 postinjury. Panels show representative examples of fluorescent labeling of CD68+ (A), GFAP+ (C) and caspase-3+ cells (E). 
For the caspase-3+ cells we quantify the total number of positive cells (E). Magnification bar represents 50 μm. The effects of NC in CD68+, 
GFAP+ and caspase-3+ at the RO, CE and CA sites are shown (B, D, F). The Data are expressed as mean ± SEM. n=7–8 sections per animal in 
each group. *: significant, p < 0.05. 
 
Network of the functional responses: Reactome pathways 
Analysis of the sets of proteins that significantly changed their abundance in response to Neuro-
Cells (with q-value below 0.05) in context of Reactome pathways, and limiting the search to 
pathways affected in either direction with p < 0.001, revealed 17 responsive pathways at RO, 33 
at CE and 17 at CA. The total number of pathways that responded in any direction at any of the 
3 levels of the lesion was 60.  
In order to reveal more general functional patterns that transcend categories of individual 
pathways, we constructed a protein-sharing urine network. Out of 60 responsive pathways, 55 
(~92%) shared the underlying responsive proteins with at least one another pathway.  
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Overall, all the 55 pathways were found in 3 densely connected clusters and 2 outlier clusters of 
2–3 pathways (Fig. 9). While those clusters were identified on the basis of connectivity only, 
irrespective to the sign of response of their members to Neuro-Cells, subsequent visualization of 
the directions of the effect of Neuro-Cells on expression of the 55 pathways at every level of the 
lesion revealed that the highly connected clusters also showed a trend to consistent sign of 
response at a particular level, despite the much less consistent responses at pathway (and 
especially – individual protein) levels between the site of the lesion.  
Hence, by generalizing the considered biological entity from protein to pathway and then to 
network of pathways, we found a progressively more consistent response to Neuro-Cells-treated 
rats at the different levels.  
In particular, the first cluster from the left was enriched in glycosylation, extracellular matrix, 
scavenger receptors, keratan and collagen metabolism related proteins. This cluster showed a 
clear trend to be impaired at the RO and CE sites, and to be upregulated at the CA site, although 
this last trend was no longer present after multiple testing correction.  
The second cluster, in the middle of the network, was enriched in generally defined functional 
pattern of ion movements across membrane (including such categories as cardiac construction, 
ion homeostasis, ion transport, reduction of cytosolic Ca2+ levels, ion transport-by-type-
ATPases) and semaphorins.  
This middle cluster had a trend to be upregulated by Neuro-Cells at all the 3 sites of the lesion. 
The right smallest cluster of 10 pathways was not connected in as dense manner as the major 2 
clusters, and the response pattern of the pathways comprising it, was more site dependent.  
Interestingly, “metabolism of carbohydrates” operated as a link between the two highly 
connected clusters with opposite trend of response to Neuro-Cells. “Extracellular matrix 
organization” also provided some protein-sharing links between the two clusters. 
 
Insights on the upstream transcriptional regulatory events from proteomics 
Besides functional summarization of the observed protein-level changes, we also leveraged the 
known transcription factor – target gene relationships to gain preliminary insights on the possible 
upstream gene regulatory events mediating the observed responses to Neuro-Cells. While 
transcriptome data is required to draw this level of conclusions more directly and accurately and 
post-transcriptional and post-translational events alter the gene expression-based signatures. 
We used backward projection of the en masse protein level changes, in order to map them to 
known sets of transcription factor targets to identify the responsible upstream transcriptional 
regulators.  
With this approach, 33 regulons were identified to be upregulated in Neuro-Cells injected rats 
compared to vehicle-treated SCI rats at the CE, 17 regulons at the RO and 21 regulons at the CA 
respectively (S3, Table 2). When we examined the functions of the candidate regulons of the 3 
areas, we found that the regulons identified at the CA and CE level had an identical reported 
function. In those regions 13 upregulated regulons involved in differentiation could be identified, 
though none at RO. These CA and CE situated regulons play a role in spinal cord motor neuron 
differentiation (LMO4), neuron differentiation (NLX2–2, RUNX2), astrocyte differentiation 
(NKX2–2, PAX6) and oligodendrocyte differentiation (OLIG1, OLIG2, SOX10). GOCC analysis 
revealed that in the actin cytoskeleton and actin filament the regulons identified at the CE were 
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mainly located in the plasma membrane, whereas the regulons identified at the CA and at the 
RO were in the mitochondrial membrane (Table 3, S4). 
 
Figure 9. Protein-sharing network of the 55 
responsive Reactome pathways that share proteins 
assigned to them. Significance of the pathway 
enrichment among proteins overexpressed with 
Neuro-Cells is mapped to red color, while pathway 
enrichment among lower expressed proteins is 
mapped to blue color. A, Rostral part of the lesion; B, 
Central part of the lesion; C, Caudal part of the lesion; 
D, Color map showing the range of -log10(FDR) 
values. Numerical pathway IDs: 1, Platelet 
activation, signaling and aggregation; 2, Respiratory 
electron transport, ATP synthesis by chemiosmotic 
coupling, and heat production by uncoupling 
proteins; 3, Advanced glycosylation end product 
receptor signaling; 4, Binding and Uptake of Ligands 
by Scavenger Receptors; 5,Cardiac conduction; 6, 
Chondroitin sulfate/dermatan sulfate metabolism; 7, 
Collagen biosynthesis and modifying enzymes; 8, 
Collagen formation; 9, Complex I biogenesis; 10, 
COPII (Coat Protein 2) Mediated Vesicle Transport; 
11, Cristae formation; 12, CS/DS degradation; 13, 
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d); 
14, Defective CHST6 causes MCDC1; 15, Defective 
ST3GAL3 causes MCT12 and EIEE15; 16, Diseases 
associated with glycosaminoglycan metabolism; 17, 
Diseases of glycosylation; 18, ECM proteoglycans; 
19, Extracellular matrix organization; 20, Formation 
of ATP by chemiosmotic coupling; 21, G alpha 
(12/13) signaling events; 22, Gluconeogenesis; 23, 
Glucose metabolism; 24, Glycolysis; 25, 
Glycosaminoglycan metabolism; 26, Hemostasis; 27, 
HuR (ELAVL1) binds and stabilizes mRNA; 28, Integrin 
cell surface interactions; 29, Ion homeostasis; 30, Ion 
transport by P-type ATPases; 31, Keratan 
sulfate/keratin metabolism; 32, Keratan sulfate 
biosynthesis; 33, Keratan sulfate degradation; 34, 
Metabolism of carbohydrates; 35, Metabolism of fat-
soluble vitamins; 36, Metabolism of RNA; 37, 
Metallothioneins bind metals; 38, Netrin-1 signaling; 
39, Neurotransmitter receptors and postsynaptic 
signal transmission; 40, Neutrophil degranulation; 
41, RA biosynthesis pathway; 42, Recycling pathway 
of L1 R-HSA-437239; 43, Reduction of cytosolic Ca++ 
levels; 44, Respiratory electron transport; 45, 
Response to metal ions; 46, Retinoid metabolism and 
transport; 47, Retrograde transport at the Trans-
Golgi-Network; 48, Scavenging by Class A Receptors; 
49, Sema4D in semaphorin signaling; 50, Sema4D 
induced cell migration and growth-cone collapse; 51, 
Semaphorin interactions; 52, Smooth Muscle 
Contraction; 53, SRP-dependent cotranslational 
protein targeting to membrane; 54, Transport of 
Mature mRNA derived from an Intron-Containing 







A large body of literature provides evidence for the beneficial effects of cell-based therapies in 
patients with SCI (Tetzlaff, Okon et al. 2011). Many studies have investigated the effects of stem 
cells as a potential treatment for SCI, however most of the studies failed to demonstrate safety 
and substantial functional improvement, after the use of manipulated stem cells (Yoon, Shim et 
al. 2007). Manipulation of stem cells before administration leads to proliferation and/or to 
differentiation in a disease-free signalling environment that is not relevant to the initial aim of 
the transplantation. Without exposure to signalling proteins in the direct disease environment, 
active labelling and/or expanding will change the phenotype and function of the stem cells and 
will bring these cells into the next stage of differentiation in which they are able to expand and/or 
to exert only basic functions. The latter, however, is key to the working mechanism in 
neurodegenerative disorders (Caplan 2017). mesenchymal stem cells (MSCs) and hematopoietic 
stem cells (HSCs) are not able to pass the blood-brain and central nervous system (CNS)-CSF 
barrier and after intrathecal application float in the CSF (Stamatovic, Keep et al. 2008, Jackson, 
Golding et al. 2010, Wood, O'Loughlin et al. 2011). However, signalling proteins are able to freely 
trespass these barriers and thus interact with these cells (Yanez-Mo, Siljander et al. 2015, 
Bavisotti, Scalia et al. 2019). We have developed therefore a standardized bone marrow fraction 
of not- or marginally manipulated MSCs and HSCs (Neuro-Cells), which can be intrathecally 
injected into the disease environment. By depleting the erythrocytes and the majority of the 
lymphocytes of the original bone marrow-derived stem cell preparation, Neuro-Cells is suitable 
to be injected straight into the cerebrospinal fluid without eliciting an inflammatory reaction 
(rejection) (Lossinsky and Shivers 2004, Assmus, Tonn et al. 2010). The advantage of Neuro-Cells 
over similar products is the fact that the HSCs and MSCs are not labelled or expanded, but are 
kept in their original state until intrathecally administered, allowing the exposure to the disease 
specific signalling environment and thus activating the release of paracrine factors by the stem 
cells to better control the neuron hostile environment (Kinnaird, Stabile et al. 2004, Gnecchi, 
Zhang et al. 2008, Hsiao, Asgari et al. 2012, Dostert, Mesure et al. 2017). Both bone-marrow- and 
adipose-tissue-derived stem cells seem to improve motor dysfunction, though the exact 
mechanisms remain unclear. In this study, the human bone-marrow derived stem cells (Neuro-
Cells) offer the advantage that they were not labelled nor expanded when infused directly into 
the cerebrospinal fluid in SCI-treated rats, they interact with the disease specific signalling 
environment (Ren, Han et al. 2014, Zhang, Li et al. 2014, Rani, Ryan et al. 2015, Zhang, Yeo et al. 
2016, Harting, Srivastava et al. 2018, Ruppert, Nguyen et al. 2018). We speculate that the 
beneficial effects of Neuro-Cells during the first days after its intervention in acute SCI might be 
induced by its anti-inflammatory properties, as evidenced by histological findings and differences 
in serum interleukin concentrations at day 4 of the study. 56 Days after this intervention, 
histological analysis did not reveal any signs of anti-inflammatory properties anymore, though 
proteomics then provided enough insights in regulons and pathways to suggest that the 
improvement in locomotor activity at that time was rather associated with neurogenesis and 
axonal regeneration. Further research, though, is needed to indeed get proof of stem cell-
exerted dedicated apocrine effects (maybe through extracellular vesicles), induced by the 
specific pathological environment. Several studies have shown that the therapeutic activity of 
MSCs is mainly mediated by MSC-secreted factors, suggesting the possible involvement of 
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extracellular vesicles (EVs) as important players mediating the therapeutic effects of cells being 
used as therapeutics (such as MSCs and endothelial cells) via regenerative and anti-inflammatory 
modes of action (Rani, Ryan et al. 2015, Zhang, Yeo et al. 2016, Harting, Srivastava et al. 2018, 
Ruppert, Nguyen et al. 2018). For instance, MSC-EVs were found to exert immune-suppressive 
effects, by enforcing M2 macrophage polarization and stimulating T-cell induction (Zhang, Li et 
al. 2014). 
 
Early-onset effects of Neuro-Cells in SCI 
Treatment with Neuro-Cells 24 h after surgery did not induce serious side effects or mortality in 
SCI-lesioned and sham-lesioned rats. Apart from a higher incidence of a temporary Baycal-
responsive cystitis in the NC-treated animals (P < 0.12), their ‘well-being’, body weight, and 
bladder control recovery during the entire study was comparable to that in Vehicle-treated rats 
(S5, Table 2, and S6, Fig. 3). Importantly, not only SCI-related survival (serious adverse events 
leading to human end points) reached significance, NC-treated animals also reached (significant) 
better BBB scores. Considering the histological analyses, rats treated with Neuro-Cells initially 
showed a significant reduction in GFAP+ expression at CE, indicative for a lower number of 
reactive astrocytes. These glial cells are, among others, one of the key players in scar tissue 
formation following an insult to the spinal cord. Previously, it has been suggested that the 
improved motor function is associated with a reduction in astrogliosis (Ren, Han et al. 2014). This 
question, though, is beyond the scope of the current study. Furthermore, we showed that an 
early intervention with Neuro-Cells significantly increased the CD68+ cells, caudal of the lesion, 
5 days after the acute injury. Several studies testing cell-based therapies in SCI have reported a 
decrease in inflammation, however it must be noted that different markers have been used to 
assess inflammation in SCI rats. In our study, we used CD68, which is frequently used as a marker 
for microglia and peripheral-derived macrophages, two cell types that are morphologically 
indistinguishable from each other. The primary role of microglia/macrophages is to remove 
tissue and cellular debris, thereby enabling the resolution of inflammation and tissue repair 
(London, Cohen et al. 2013). Since blood-derived macrophages enter the site of injury after 
approximately 3 days, we speculate that our results mainly reflect the activation, and possibly 
the proliferation of resident microglia at the lesion and caudal site of the lesion following SCI and 
the rapid injection of viscous Neuro-Cells (Popovich and Hickey 2001). The residual presence of 
human macrophages in Neuro-Cells may be another factor explaining the increased CD68+ cells 
caudal to the lesion site in the rats treated with the xenotransplant. The anti-CD68 antibody used 
for immunostaining was specific for rat as well as for human proteins, thus possibly reflecting an 
immune reaction to the xenotransplant. It has also been reported that subpopulations of HSCs 
and MSCs do express CD68, which could explain the increased expression of CD68+ we observed 
caudal to the lesion and the lesion itself. Over time, due to migration and differentiation, the 
number of the CD68+ cells will eventually increase at all levels.  
Interestingly, we found significantly less apoptotic cells in the same anatomical regions (central 
and caudal part of the SCI-induced lesion) in the Neuro-Cells-treated SCI rats compared to the 
vehicle-treated rats. We found that 4 days after infusion with Neuro-Cells, rats in those parts of 
the lesion had significantly less caspase-3+ cells. The latter is in line with a recent study indicating 
that transplantation of bone-marrow stem cells in SCI mice downregulated the caspase-3+ cells 
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after SCI (Gashmardi, Hosseini et al. 2017). Importantly, cells that stained positive for the human 
mitochondria antibody were detected at CA and only few at CE in NC-treated rats, 4 days after 
administration (Fig. 6). These results may suggest that Neuro-Cells migrated from the intrathecal 
space to the lesion and are able to integrate into the spinal cord tissue. Since only a few positive 
cells were detected at the lesion, these data also may suggest that the majority of the Neuro-
Cells remained in the intrathecal space. Urdzikova et al. studying the immunomodulatory effects 
of human-derived MSCs administered in immune-competent rats with SCI have reported similar 
observations (Urdzikova, Ruzicka et al. 2014). 
 
Late-onset effects of Neuro-Cells in SCI 
Neuro-Cells continued to improve motor recovery during the 35 days post-injury observation. 
No effects though were found in GFAP+, CD68+ cells as well as the number of cleaved caspase-3+ 
cells in Neuro-Cells-treated as compared to vehicle-treated T-cell deficient SCI rats at any site of 
the lesion, at 56 days after administration. We speculate that the recovery has already happened 
during the study period resulting in no detectable difference in GFAP and CD68 positive cells. 
Moreover, it appears that Neuro-Cells-treated SCI rats had a higher number of cleaved caspase-
3+ cells at the lesion 57 days postinjury, which may be explained by a recently demonstrated role 
of caspase-3 in mediating the differentiation of HSCs (Fujita, Crane et al. 2008, Janzen, Fleming 
et al. 2008). Since Neuro-Cells also contains HSCs, we speculate that HSCs pass on their 
immunomodulatory effect to resident cells. However, it must be noted that small changes in long 
tracts can result in a significant improvement of locomotor functions and are not always related 
to the extent of the lesion (Blight 1983). The regulation of spinal cord injury is possibly a function 
of complex pathway interactions of cellular and biochemical reactions to trauma-induced 
primary and secondary inflammatory processes and a dense scar formation. Protein expression 
profiling in SCI rats injected with Neuro-Cells 56 days after treatment clearly demonstrated a 
distinct spatial localization at the rostral and caudal sites of the lesion, which is in agreement 
with literature (Cizkova, Le Marrec-Croq et al. 2014, Devaux, Cizkova et al. 2016). Our clustering 
analysis revealed upregulated regulons at the lesion that are involved in positive regulation of 
differentiation (e.g. astrocyte differentiation, neuron differentiation). Our analysis took into 
account the spatial distribution of proteins between Neuro-Cells- and vehicle-treated rats. To a 
certain extent, the same pattern was observed at CA but not at RO. Among the regulons that are 
significantly upregulated at CA are the LMO4, which is involved in ATP signalling that promotes 
neuron survival after hypoxia (Chen, Schock et al. 2007), and Olig1 and Olig2, which are linked to 
the development and maturation of oligodendrocytes (Lu, Sun et al. 2002, Cheng, Wang et al. 
2007). Both for CA and CE, NKX2.2, a regulon that has a critically important role in the 
differentiation of adult oligodendrocyte progenitor cells (OPCs) into remyelinating 
oligodendrocytes was significantly upregulated (Fancy, Zhao et al. 2004). Moreover, 
upregulation of HIF1A in the lesion itself is linked to regeneration of lost or damaged tissue in 
mammals that have a repair response (Zhang, Strehin et al. 2015). Interestingly, in CE and CA, 
regulons of human origin could be identified (e.g. UBE2L3, ANXA7, ENO1, MYH11, HNRNPA0, 
TPD52), regulons which role is still obscure, thus providing a novel protein list through which NC 
might exert its recovery effects.  
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This result may support previous evidence, suggesting that MSCs rapidly pass on their effect to 
resident cells, which may substantially mediate the NC-induced immunomodulatory and 
regenerative effects (Eggenhofer, Luk et al. 2014). 
SCI regulation might be the result of complex cellular and biochemical pathway interactions 
during primary and secondary inflammatory processes and scar formation. In the context of 
reactome pathways, we found a cluster enriched in glycosylation, keratan and collagen 
metabolism related proteins that appeared to be downregulated at the caudal site of the lesion 
and at the lesion but upregulated at the rostral site of the lesion. It has been reported, that 
increased N-glycosylation correlates in vivo with increased astrogliosis (Nourse, Prieto et al. 
2014).  
Down regulation of glycosylation in Neuro-Cells treated rats may be responsible for the reduced 
astrogliosis we observed at all sites of the lesion. Interestingly, inhibition of collagen matrix 
formation in spinal cord lesions have also been associated with axonal regeneration and motor 
function recovery (Klapka and Muller 2006).  
An upregulation in ion movements across membrane (for instance the Ion transport by 
Ptype_ATPases) and semaphorins was identified at all three sites of the lesion. P-type ATPases is 
a protein family that plays an important role in the ATP-dependent flipping of phospholipids 
across the cell membranes, a biological process that is vital in vesicle trafficking. Semaphorins 
are expressed in the adult nervous system and have been implicated in controlling axon guidance 
(Tran, Kolodkin et al. 2007, Pasterkamp and Giger 2009, Yoshida 2012). However, contrary to 
netrins, the role of semaphorins in regeneration has not been studied extensively.  
At the lesion, Netrin-1 and L1CAM related proteins are found to be significantly upregulated. In 
a rat model of nerve injury, Ke et al. have shown that overexpression of Netrin-1 in bone-
marrow-derived MSCs improves functional recovery (Ke, Li et al. 2015).  
The LICAM immunoglobulin family has been involved in the promotion of regenerative axon 
sprouting and functional improvement after CNS injury as well as neuronal migration and 
synapse formation (Maness and Schachner 2007, Li, Wu et al. 2008, Barry, Gu et al. 2010). The 
significant upregulation of platelet activation observed at the rostral site of the lesion has 
previously shown to be associated with inflammation, angiogenesis, and tissue regeneration. 
Platelets-derived microparticles were found to trigger endogenous stem cell repair mechanisms 
after middle cerebral artery occlusion in rats (Shan, Li et al. 2013).  
Our proteomic analysis revealed both a signal of plasma-membrane and extracellular space 
restructuring processes at the lesion and unfolded another two ion transport gene sets at all 
three sites of the lesion (S7, Table 5), suggesting a paracrine effect of Neuro-Cells in SCI rats.  
Several studies have shown that the therapeutic activity of MSCs is mainly mediated by MSC-
secreted factors, suggesting the possible involvement of extracellular vesicles (EVs) as important 
players mediating the therapeutic effects of cells being used as therapeutics (such as MSCs and 
endothelial cells) via anti-inflammatory and apocrine modes of action (Zhang, Li et al. 2014, Rani, 
Ryan et al. 2015, Dostert, Mesure et al. 2017, Harting, Srivastava et al. 2018)). For instance, MSC-
EVs were found to exert immune-suppressive effects, by enforcing M2 macrophage polarization 
and stimulating T-cell induction (Ruppert, Nguyen et al. 2018). Extracellular vesicles (EVs), which 
include micro-vesicles, play an important role in intercellular communication both under 
physiological as well as pathophysiological conditions (Dignat-George and Boulanger 2011, 
87 
 
Raposo and Stoorvogel 2013). EVs are carriers of active molecules regulating in a paracrine or 
endocrine manner the recipient cells (Thery 2011, Yanez-Mo, Siljander et al. 2015).  
Taken together, in this particular experimental setting, Neuro-Cells did induce a beneficial effect 
over Vehicle in the treatment of acute balloon compression–induced immune-deficient SCI-rats, 
significantly reducing SCI-related mortality and improving locomotor recovery. The advantage of 
applying low-immunogenic stem cells into T-cell derived immune-deficient rats is the prevention 
for rejection of the graft and/or host-versus-graft disease, without the co-application of 
immunosuppressive drugs, which may interfere with stem cell activities (Palladini, Caronti et al. 
1996, Ibarra, Correa et al. 2003). Therefore, the significant acceleration of the natural, 
spontaneous recovery after SCI-lesioning in these rats, as shown in this research project, indeed, 
might be interpreted as a main effect of the stem cell transplant.  
The disadvantage in those immune-deficient rats, though, is that due to the reduced secondary 
posttraumatic inflammation in these animals, final balloon compression-induced damage with 
consequent sensorimotor and neuro-vegetative symptoms is significantly less when compared 
to immune-competent rats.  
As stem cells are supposed to reach their effects in acute lesions by suppressing (secondary) 
inflammation, it is thus realistic to expect a lower magnitude of their eventual beneficial effect 
in SCI-lesioned T-cell deficient rats. Another disadvantage is that those animals, indeed, 
especially after an intervention with inflammation-reducing stem cells, are more prone to 
infections (Potas, Zheng et al. 2006). Most probably, this trend (p < 0.12) to a higher frequency 
of bladder infections in our NC-treated SCI-lesioned rats (as compared to the placebo-treated 
rats) might be explained in this way. 
 
Conclusion 
Our study provided the first proof of concept that Neuro-Cells improved the survival and 
accelerated natural motor recovery after SCI. The effects of Neuro-Cells on pathological 
processes related to acute SCI are multiple. We speculate that an intrathecal injection of Neuro-
Cells in spinal cord-injured rats, after some days, improved motor function initially, but not later 
on, in combination with a decrease of interleukins concentrations confirmed by histological 
established reduction of astrogliosis and apoptosis.  
The continued motor recovery may suggest that Neuro-Cells exert their effects on a dual role: 1) 
at an early stage via their anti-inflammatory properties and 2) resulting at a later stage in a 
modulation of the injury environment. Overall, by targeting multiple mechanistic pathways, the 
infused Neuro-Cells may induce or pass on certain aspects of their regenerative properties, 
providing plausible biological mechanisms involved in the regenerative process. Therefore, this 
treatment holds great promise as a neuro-regenerative treatment including functional recovery 
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Abstract 
Background: Spinal cord injury (SCI) is a highly debilitating pathology without curative treatment. 
One of the most promising disease modifying strategies consists in the implantation of stem cells 
to reduce inflammation and promote neural regeneration. In the present study we tested a new 
human bone marrow-derived stromal cell preparation (bmSC) as a therapy of SCI. 
Methods: Spinal cord contusion injury was induced in adult male rats at thoracic level T9/T10 
using the Infinite Horizon impactor. One hour after lesion the animals were treated with a sub-
occipital injection of human bmSC into the cisterna magna. No immune suppression was used. 
One dose of bmSC consisted, on average, of 2.3 million non-manipulated cells in 100 μL 
suspension, which was processed out of fresh human bone marrow from the iliac crest of healthy 
volunteers. Treatment efficacy was compared with intraperitoneal injections of 
methylprednisolone (MP) or saline. The recovery of motor functions was assessed during a 
surveillance period of nine weeks. Adverse events as well as general health, weight and 
urodynamic functions were monitored daily. After this time, the animals were perfused, and the 
spinal cord tissue was investigated histologically. 
Results: Rats treated with bmSC did not reject the human implants and showed no sign of 
sickness behavior or neuropathic pain. Compared to MP treatment, animals displayed better 
recovery of their SCI-induced motor deficits. There were no significant differences in the 
recovery of bladder control between groups. Histological analysis at ten weeks after SCI revealed 
no differences in tissue sparing and astrogliosis, however, bmSC treatment was accompanied 
with reduced axonal degeneration in the dorsal ascending fiber tracts, lower Iba1-
immunoreactivity (IR) close to the lesion site and reduced apoptosis in the ventral grey matter. 
Neuroinflammation, as evidenced by CD68-IR, was significantly reduced in the MP-treated 
group. 
Conclusions: Human bmSC, which were prepared by negative selection without expansion in 
culture, have neuroprotective properties after SCI. Given the effect size on motor function, 
implantation in the acute phase was not sufficient to induce spinal cord repair. Due to their 
immune modulatory properties, allogeneic implants of bmSC can be used in combinatorial 
therapies of SCI. 
 
Background 
In spinal cord injury (SCI) cellular degeneration and the disruption of connections between the 
brain and the body cause paralysis and the loss of sensory and autonomic functions. Worldwide, 
the incidence of SCI ranges from 13 to 163 per million people per year, depending on the country 
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(Kang, Ding et al. 2018). Over two thirds are due to trauma (falls, traffic and sport-related 
accidents, gun shots) and the rest to non-traumatic SCI (spinal stenosis, tumours, vascular 
ischemia). In addition to the devastating loss of quality of life to the patients, SCI causes a large 
economic burden on their families and society. Although rehabilitation therapy has continuously 
improved since the 1950s, there is no curative treatment of SCI (Gupta, Bathen et al. 2010, Kang, 
Ding et al. 2018). Spinal cord injury triggers local and systemic secondary mechanisms resulting 
in a chronic inflammatory state, which is mainly responsible for extensive cell death (Donnelly 
and Popovich 2008). These mechanisms are addressed with one available pharmacological 
treatment, namely the application of a high dose of methylprednisolone (MP) within the first 
hours after the injury. Following three independent clinical trials in the 1980s and 1990s 
(National Acute SCI Studies; (Bracken, Shepard et al. 1998)) MP became a standard intervention 
(Falavigna, Quadros et al. 2018). However, subsequent clinical experience showed that it is often 
ineffective and causes severe side effects such as higher incidence of sepsis, gastrointestinal 
haemorrhage or pulmonary embolism (Hugenholtz, Cass et al. 2002). Thus, new therapies of SCI 
are highly desired.  A promising strategy to cure neurodegenerative pathologies is based on the 
application of stem cells (Tetzlaff, Okon et al. 2011, Shende and Subedi 2017, Tsintou, 
Dalamagkas et al. 2020). Such attempts where at first directed at cell replacement (Whittemore 
1999), and with neural stem cells this continues to be an objective (Lu, Wang et al. 2012). With 
non-neuronal stem cells, on the other hand, the main rationale consists in modulating the 
inflammatory response (Tetzlaff, Okon et al. 2011, de Munter, Beugels et al. 2019). Paracrine 
factors and extracellular vesicles that are released from mesenchymal stem cells (MSC) are 
expected to prevent secondary degeneration and to support regenerative remodeling after SCI 
(Zhang, Chopp et al. 2015, Shende and Subedi 2017, Romanelli, Bieler et al. 2019). An easily 
accessible source of this type of cells is the bone marrow, which contains hematopoietic and 
mesenchymal stem cells. Different from induced pluripotent stem cells (Nagoshi, Tsuji et al. 
2019), bone marrow-derived stromal cells (bmSC) pose no risk of tumor formation. We have 
developed a novel procedure to prepare fresh human bmSC with low immunogenicity 
(Neuroplast BV, patent WO2015/059300A1). This preparation is based on the depletion of 
erythrocytes and lymphocytes from bone marrow extracts without substantial manipulation or 
cultivation of the isolated cells. The objective of the present study was to assess the safety and 
therapeutic benefits of acute intrathecal injection of the novel bmSC preparation in SCI-lesioned 
rats and to compare it with acute intraperitoneal injection of MP. So far, one study has been 
published with these bmSC as a treatment of SCI (de Munter, Beugels et al. 2019). In these 
experiments, cell suspensions were injected into the spinal cord of immune compromised rats 
after a balloon compression injury. This treatment was associated with an improvement in the 
recovery of motor function at two and five weeks after SCI but not at one, three and four weeks. 
While serum levels of IL-1β and TNF-α were reduced, treatment had no consistent effect on 
neuro-inflammation in the spinal cord. Based on the outcome, the present investigation has 
implemented the following design:  
1) We have tested the bmSC in immune competent animals. Previously, T-cell deficient rats were 
used in order to avoid a possible immunological rejection to the human implants. Since one 
expected mechanism of action consists in the suppression of inflammation, the use of immune 
competent rats was considered necessary.  
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2) As suggested by the EMA, stem cell treatment was compared with MP. Despite its limited 
efficacy, MP is still the only FDA-approved pharmacological treatment of SCI (Bracken, Shepard 
et al. 1998, Falavigna, Quadros et al. 2018), and any new intervention should therefore be 
compared with this standard.  
3) A different SCI model was chosen. While the balloon compression used before is a validated 
model to investigate physiological consequences of SCI, a much larger number of human SCI 
cases (about half of all; (Shende and Subedi 2017)) are represented by the contusion injury 
model.  
4) Rats were monitored up to nine weeks after SCI to assess the long-term effects of implanted 
bmSC, which may be observed in the chronic stage.  
5) Additional outcome measures in the present study included tests of motor function (Rotarod), 
autonomic function (bladder control), neuropathic pain (tactile allodynia) and a more extensive 




The ethics committee for Animal Care of the Hospital Nacional de Parapléjicos reviewed 
experimental protocol, surgical procedures and post-operational care (163CEEA/2017), which 
were subsequently approved by the Consejería de Agricultura y Ganadería de Castilla-la Mancha 
(ref. 210498, following EU directive 2010/63/EU). During the acclimatization period, six to eight 
week old male Wistar rats (Rattus norwegicus; mean weight 304g +/- 14g, raised in the animal 
facility of the hospital), were kept in pairs under standard housing conditions (12 hrs light/dark 
cycle, humidity 40–60%, temperature 22 °C) with ad libitum access to food and water. Following 
surgery, animals were kept in separate cages. A total of 26 animals entered the study (Fig. 1). 
 
Figure 1. Experimental plan and treatment groups. Animals that received spinal cord contusion injury were pseudo-randomly assigned to 
four groups. Rats with intraperitoneal and intrathecal (cisterna magna) saline injections were planned to be evaluated as one control group 
unless behavioral evaluation showed statistical differences between them. One animal was lost due to bleeding during spinal cord surgery, 
two animals had to be excluded from the study because open field evaluation revealed an incomplete lesion (BBB at 2 dpo) and two rats 





In an exploratory experiment to determine the least invasive way of implanting the stem cells 
(intrathecal injection in the spinals cord vs. cisterna magna), additional 10 rats had been 
operated and their motor recovery was followed over a period of 3 weeks. 
 
Spinal cord contusion injury 
To induce anaesthesia the rats were exposed to 5% isoflurane/95% oxygen in a plexiglass 
chamber. During surgery, anaesthetic was reduced to 2,5% isoflurane/oxygen breathed via an 
inhalation mask of a vaporizer (flow rate 0.4 L/min; Medical Supplies and Services). Fifteen 
minutes before surgery, rats were weighed and received the analgesic buprenorfine 0,05 mg/kg 
(Buprex 0.03 mg/mL). After induction of anaesthesia, the fur on the back was shaved. The 
animals were then taped to the operating table, their body temperature being maintained on a 
heat pad with a rectal thermometer probe. Corneal dehydration was prevented with ophthalmic 
ointment (Lubrithal). Surgery was performed with the help of an operating microscope (Leica). 
After skin incision and dissection of the muscle layers covering the vertebrae, serrate muscles 
were spread with a retractor (Reda 19621-07), and the spinal cord was exposed by laminectomy 
of vertebrae T9-T11 without damaging the dura mater (small rongeur FST 16021-14, scalpel with 
round blade, two round forceps mid-size, one forceps with teeth, sterilized cotton-tips, gelatin 
sponge). To suspend the spinal cord for applying the contusion injury, the dorsal spinal processes 
T7 and T12 were fixed with the clamps of the impactor device (Infinite Horizon, IH). The impactor 
rod was positioned centrally at T9/T10 over the spinal cord mid- line, and the contusion was 
applied, using a force of 2 N, calibrated before every experiment, and zero dwell time. We 
checked the procedure visually (hematoma) and by monitoring the IH displacement/time and 
force/time plots. In two cases, where the impactor rod hit a bone, the laminectomy was 
extended and the contusion injury repeated. Following this procedure, the rats were released 
from the IH clamps. The wound was covered with subcutaneous fat tissue from the same animal. 
Overlying muscles were re-apposed and sutured, and the skin was closed with a non-interrupted 
intradermal suture (resorbable thread 4.0) and disinfected with iodine. Animals were then 
disconnected from anaesthesia and received 2 x 2.5 mL isotonic saline s.c. and antibiotic 
treatment marbofloxacin 5 mg/kg (Marbocyl 10 mg/mL, s.c.). 
 
Postoperative treatment and care 
Following surgery, rats were housed individually to prevent biting at skin sutures. Throughout 
the study, we performed daily overall health assessments, including inspection of the an imal’s 
well-being, body weight, urodynamic assessments and routine checks to detect urinary tract 
infections. For the first three days animals received two daily s.c. injections of buprenorfine 0.05 
mg/kg for pain relief. Subcutaneous injections of 5 mg/kg marbofloxacin were given at the day 
of surgery, at two- and four-days post operation (dpo). Postsurgical care also included food 
pellets soaked in water and a water bottle with longer tube. The bladders were checked twice 
daily and voided manually until the rats were urinating spontaneously. The volume of retained 
urine was recorded. In case of urinary infection, the animals were treated with marbofloxacin 5 
mg/kg s.c. every 48 hrs until the urine was clear and without blood. Euthanasia at the end of the 





Animals were pseudo-randomly assigned to four experimental groups, which all received the 
same SCI but differed in the treatment procedure (Fig. 1). Group 1 received five NaCl i.p. 
injections, the first immediately after SCI and subsequently every 8 h; group 2 received one 100 
μL NaCl injection into the cisterna magna at 1–2 h after SCI; group 3 was treated with five MP 
injections i.p., one after SCI and subsequently every 8 h; group 4 was treated with one 100 μL 
bmSC injection into the cisterna magna at 1–2 h after SCI. Rats were assigned random identifiers, 
which were written with permanent marker on their tails. During the following 9 weeks of 
behavioral evaluation, care takers and investigators were blinded regarding the experimental 
condition of the individual animals. To keep the number of experimental animals low, the control 
groups (NaCl i.p. and per cisterna magna) were planned to be joined in one statistical group 
unless significant differences were found in the behavioral tests. 
 
Preparation of bmSC 
Bone marrow-derived cells for SCI treatment were prepared at the Neuroplast facility, Geleen, 
Netherlands, under GMP conditions. The cells were not expanded by cultivation (Neuro-Cells, 
patent WO2015/059300A1). Recruitment of volunteers for bone marrow collection, procedures 
and documentation were approved by the ethics committee of Maastricht University Medical 
Center (METC 13–2-032). From two donors (BM31, BM33) 50 mL bone marrow was collected. 
Clotting was prevented by EDTA adjuvants. The fresh bone marrow was immediately processed, 
using automated Ficoll density gradient centrifugation to remove the erythrocytes and reactive 
proteins. Subsequently, B-cells (CD20+), T-cells (CD3+), monocytes (CD14+) and natural killer cells 
(CD56+) were removed using antibody-based cell sorting with magnetic beads (negative 
selection; CliniMacs Plus, Miltenyi Biotec GmbH). The viability and cell type composition of each 
batch was analysed with flow cytometry (CD34, CD271, CD90, CD105, CD73). For the present 
study, cells were cryoprotected with DMSO, frozen in liquid nitrogen, shipped on dry ice to 
Toledo, Spain, and then stored in liquid nitrogen until use. Cell viability was again determined 
after thawing, i.e. immediately before application in vivo (cytometry, propidium iodide 
exclusion). On average, cisterna magna injections contained 2.3 +/− 0.5 × 106 viable cells. 
 
Intrathecal infusion of bmSC, injections of MP or vehicle 
For cisterna magna injections of bmSC or saline, 1.5 h after SCI, animals were re-anesthetized 
with ketamine 50 mg/kg (Ketolar 50 mg/mL. i.p.) combined with xylacine 5 mg/kg (Sedaxylan 20 
mg/mL, i.p.) and one i.p. injection of atropine 0.04 mg/kg. The head and neck of anesthetized 
rats were shaved, and the animals were positioned in a stereotactic frame (Kopf) with the neck 
flexed to 70° at the atlanto-occipital joint. Ophthalmic ointment was applied, and the skin was 
superficially disinfected with 70% ethanol. Simultaneously, the bmSC were prepared for 
injection: For the treatment of two rats, one batch containing 1mL of frozen cell suspension was 
thawed in a 37 °C water bath, spun down, washed with saline, centrifuged and resuspended in 
210 μL saline. From this, 10 μL was removed for cytometric counting of cell numbers and 
determination of cell viability. The remaining 200 μL cell suspension was kept on ice until the 
rats were ready for receiving the injections. The setup for slow injection into the cisterna magna 
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consisted of an electric syringe pump and a sterile 1mL plastic syringe connected to a Fogarty 
arterial embolectomy catheter 0.67 mm, fixed to the stereotactic device. A steel canula 23G 
0.6mm was used to penetrate the atlantooccipital membrane before inserting the catheter. 
When the anesthetized rat was in place, the atlantooccipital membrane was accessed by midline 
anterior-posterior incisions of skin and muscles, which were separated and fixed laterally. 
Syringe and catheter, previously flushed with sterile saline, were loaded with cell suspension 
(bmSC treatment) or saline (vehicle treatment) and placed in the holder of the microliter pump. 
Under microscopic control, the membrane was then punctured and access to the cisterna magna 
confirmed by observing the appearance of clear cerebrospinal fluid. The catheter was inserted 
and its content slowly infused (100 μL/3 min) before retracting the catheter. Finally, the muscle 
and skin were sutured, wiped with Betadine, and the animal was placed in its cage, receiving 
postoperative care as described for SCI. Rats belonging to the MP group received in total five i.p. 
injections of 30 mg/kg MP, given at 1 h after SCI and subsequently one every 8 h. Lyophilized MP 
was reconstituted to 20mg/mL just prior to injection and kept at 4 °C for the remaining 
applications. Rats belonging to the second control group were treated with the same volume of 
saline, 150 μL/100 g, injected i.p. at the same times. 
 
Evaluation of locomotor functions in the open field 
Recovery of limb movements was evaluated using the Basso/Beattie/Bresnahan (BBB) locomotor 
function test (Basso, Beattie et al. 1995) for five minutes/rat in an open field. The BBB scale 
ranges from 0 (no hind limb movement) to 21 (normal movements, coordinated gait with parallel 
paw placement). Scores from 0-7 indicate the return of isolated movements in the three joints 
(hip, knee and ankle). Scores from 8 to 13 indicate the return of paw placement and coordinated 
movements with the forelimbs. Scores from 14 to 21 show the return of toe clearance during 
stepping, predominant paw position, trunk stability, and tail position. Motor scores were 
measured pre-SCI (baseline), at 2 dpo, 4 dpo, and once per week for the next nine weeks after 
lesioning. At the beginning, we established a criterion of BBB < 2 at 2dpo for inclusion in the 
study because a higher score was considered to indicate incomplete SCI. Scoring was performed 
by two independent investigators who were blinded with respect to the treatment of the 
individual animal. Following independent assessment, both investigators discussed their reasons 
and independently awarded their score. 
 
Rotarod locomotor function test 
The Rotarod test (Mann and Chesselet 2015), which required the rats to maintain their body on 
a rotating rod, was performed according the instruction manual of the manufacturer (Ugo Basile 
SRL, Gemonio, Italy). In four training sessions of 5 minutes each, which were administered two 
and one days before SCI surgery, all rats learned this task at a constant speed of 5 rpm of the 
rotating rod. Since balancing on the rotating bar cannot be performed by a rat with completely 
paralyzed hind legs, the first testing was performed at 4 dpo, subsequently at 7dpo and then 
once per week. In the test runs, the rotation speed was accelerated from 5 rpm to 15 rpm over 
a period of 3 minutes. Readout in this assay was the time that the rats were able to stay on the 
rotating rod before falling off (mean of two repetitions, separated by a break of ≥ 15 min). Data 
obtained from rats that refused to hold on to the bar were included in the evaluation because 
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we lacked an independent criterion to distinguish between voluntary refusal and inability to 
perform the task. 
 
Von Frey test of mechanical allodynia/hyperalgesia 
Before SCI and at the end of the 9-week observation period, tactile allodynia/hyperalgesia was 
tested manually using a kit of von Frey filaments with a range of different diameters. For this, 
rats were placed individually in small cages with a wire mesh bottom. To deliver a constant force, 
a filament with specific diameter was pressed perpendicularly to the plantar surface of the hind 
paw until it buckled and held for 2–5 s. A response was considered positive when the animal 
exhibited any nocifensive behaviour such as brisk withdrawal or licking of the paw (Deuis, 
Dvorakova et al. 2017). Both hind paws were stimulated from below, and the paw withdrawal 
threshold determined using the simplified up-down method (Bonin, Bories et al. 2014). 
 
Tissue preparation and histological staining 
Ten weeks after SCI the rats were sacrificed with an overdose of sodium pentobarbital followed 
by transcardial perfusion with phosphate buffered saline (PBS) and 4% paraformaldehyde/PBS. 
Spinal cords were prepared, post-fixed for 1 h, then transferred to PBS and stored at 4 °C. For 
histological processing, 18mm long spinal cord segments that included the lesion site were 
dissected, dehydrated, embedded in paraffin and cut in 3 μm transverse sections using a Leica 
RM2265 microtome.  
Sections separated by 250 μm were mounted on polylysinecoated glass slides (Superfrost Plus) 
and stored at 4 °C. To assess the extension of the lesion, the complete series of spinal cord 
sections of all rats were rehydrated, stained with hematoxylin/eosin (H&E), dehydrated again 
and cover slipped with Histomount (Merck). 
 
Immunohistochemistry 
Prior to immunohistochemical staining, rehydrated sections were incubated for 30 min at 90 °C 
(water bath) in 10mM Na citrate/0.05% Tween 20, pH 6.0, for antigen retrieval. Standard 
procedure included blocking 1 h at RT with 5% normal goat serum/0.05% Tween 20 in Tris-
buffered saline (TBS-T), incubation with primary antibodies for 12 h at 4 °C in a humidified 
chamber and 2 h incubation with fluorescence-labeled secondary antibodies at RT. Nuclei were 
stained with 10 μg/mL Hoechst-33342 for 15 min at RT. Sections were cover slipped with 
Mowiol/DAPCO or ImmuMount (Thermoscientific). We used the following primary antibodies, 
usually in a double staining protocol in the dilutions indicated in parenthesis: Rabbit anti-GFAP, 
polyclonal (Sigma G9269; 1/500), rabbit anti-caspase-3/activated (Calbiochem PC679; 1/200), rat 
anti-MBP, polyclonal (Abcam ab7349; 1/1000), mouse anti-Smi32, monoclonal (Palex 23R-100; 
1/2000), mouse anti-β (III) tubulin, monoclonal (Chemicon CBL412; 1/100), mouse anti-CD68, 
monoclonal (Serotec MCA341R; 1/200), mouse anti-NeuN, monoclonal (Millipore MAB377; 
1/200), guinea pig anti-Iba1, polyclonal (Synaptic systems 234,004; 1/500), mouse antihuman 
mitochondria, monoclonal, fluorescence-labeled with Cy3 (Millipore MAB1273C3; 1/200). 
Secondary antibodies were labeled with fluorescent dyes: Goat antiguinea pig IgG, Alexa-488 
(Invitrogen A11073; 1/500), goat anti-rabbit IgG, TRITC (Sigma T5268; 1/500), goat anti-mouse 
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IgG, Alexa-594 (Invitrogen A11005; 1/500), goat anti-mouse IgG, Alexa-488 (Jackson 115–
545,003; 1/500), and goat anti-rat IgG, Alexa-488 (1/500). 
 
Microscopy and image analysis 
Sections stained with H&E were photographed with a stereology microscope (Olympus BX61) 
using 4x and 10x objectives. For quantitative evaluation we determined the maximal anterior-
posterior extension of the tissue lesion and the tissue loss in the lesion center of each rat. The 
latter was calculated by comparing the remaining tissue area in transverse spinal cord sections 
to corresponding sections of a rat without SCI. Immunohistochemical staining was evaluated 
using a Leica epifluorescence microscope. Following visual inspection, objectives and exposure 
times were selected to account for different signal intensities obtained with different antibodies. 
Exposure conditions were held constant for quantitative evaluation with GFAP (5x objective), 
CD68 (10x), Iba1, Smi32, MBP (20x) and activated caspase-3 (40x). Photographs were analyzed 
using Fuji Image-J, applying the same brightness/contrast adjustments and threshold values for 
each marker. The intensity of GFAP-immunoreactivity (IR) was measured as integrated density 
in regions of interest (ROI) in the glial scar around the lesion center; Iba-1: in the white matter in 
sections anterior and posterior of the lesion and in the lesion center; Smi32 and CD68: in the 
dorsal columns and in the ventrolateral white matter in sections anterior and posterior of the 
lesion. Signal intensities were normalized to values found in spinal cord sections from non-
injured rats. For evaluation of apoptosis we counted cell nuclei that were IR for activated 
caspase-3 and expressed data as percentage of all nuclei in the ROI, which were located in dorsal 
and ventral grey matter, anterior and posterior of the lesion center (supplementary Fig. S1). 
 
Statistical analysis 
Unless stated otherwise in the figure legends, data are presented as mean values +/− standard 
error of the mean (SEM). Non-parametric data are represented in a box and whiskers graph. The 
statistical analysis of weight and behavioral data (changes in time, effect of treatment), 
performed with GraphPad Prism v5 software, consisted of two-factor ANOVA, followed by post-
hoc Tukey tests. For histological data, the differences among means were analyzed with unpaired 
Student’s t-test, considering p < 0.05 as statistically significant. 
 
Results 
Effect of bmSC implantation on the general health status, body weight and autonomic 
functions.  
The general health condition of the animals was not compromised. No adverse effects such as 
sickness behavior or tissue reaction to the bmSC were observed. Unexpectedly, one (bmSC-
treated) rat was found dead after 29 dpo and one (MP treated) after 50 dpo. Pathological 
inspection of these animals did not show any significant abnormality. In five cases, biting at hind 
limbs occurred, but no animal had to be sacrificed due to sickness behavior or urinary infection. 
Following SCI surgery, body weight in all rats typically fell by 10–15% during the first 4 days and 
subsequently recovered with an average weight gain of about 8% per week during the first 5 
weeks of the study and then slowing declining to 2% per week (Fig. 2a).  
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Treatment was found to have a significant effect on relative change in body weight in bmSC-
treated rats versus the control groups (interaction effect time x group, repeated measure 
ANOVA, F (7,56) = 8.83, p < 0.001). Post-hoc testing revealed that bmSC-treated rats initially lost 
significantly more weight than MP and vehicle-treated controls, but that they later on gained 
significantly more body weight compared to those groups (3 weeks after surgery: p = 0.042; 4 
weeks: p = 0.018; 5 weeks: p < 0.01). After SCI, animals needed assistance with bladder voiding, 
and all rats recovered autonomic bladder control within 2 weeks. Based on the volume of 
manually expelled urine, we found that the interventions with bmSC and MP did not significantly 
affect the return of spontaneous bladder control (Fig. 2b).  
 
 
Figure 2 Health status after SCI. No adverse events were attributed to bmSC treatment. a Changes of body weight following SCI: Initially, 
stem cell treated rats lost more body weight while at a later stage (starting at 14 dpo) they gained more weight compared to MP- and 
vehicle-treated animals. Data were normalized to the body weight before surgery (mean +/− SEM; two factor ANOVA, post hoc Tukey test, 
* p < 0.05, ** p < 0.01). b Recovery of the spontaneous micturition reflex: Displayed is the time after SCI [days] that passed until the animals 
no longer required manual voiding of the bladder by the experimenter (median, 25%/95% and range). There were no significant differences 
between treatment groups (H-test). c Testing of mechanical nociception (von Frey, reduced threshold of paw withdrawal response) at nine 
weeks after SCI showed no hyperalgesia/allodynia in bmSC implanted animals, while this occurred in 1/5 rats treated with MP and 3/9 rats 
that had received NaCl injections. Treatments following SCI are designated as: control - injections of 0.8% saline solution; MP - of methyl 
prednisolone; bmSC - of human bone marrow-derived stem cells. 
 
The response to tactile stimulation of the hind paws was tested manually with von Frey hairs 
before SCI surgery and after 9 weeks at the end of the study. Confirming the observations on 
overall health, none of the bmSC treated animals showed mechanical allodynia/hyperalgesia 
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(lowered threshold of the paw withdrawal response). This was, however, the case in three 
animals of the NaCl control group and one rat of the MP treatment group (Fig. 2c). 
 
Tissue damage caused by the SCI 
At the end of the study, the spinal cords of all animals were investigated with histology. 
Hematoxylin/eosin staining of transverse sections revealed extensive tissue damage caused by 
the contusion injury (Fig. 3). At the lesion center, more than half of the tissue was destroyed in 
all cases. Cavitation occurred, and to a large extent the remaining tissue contained non-neuronal 
scar, necrotic tissue and infiltration of inflammatory cells (Fig. 3a-f). Ependymal cells, identified 
morphologically, appeared to have proliferated. There were no quantitative differences between 
the treatment groups regarding the tissue loss in the center of the lesion (Fig. 3g). The anterior-
posterior extension of the damage, which comprised all sections with pathological tissue 
alterations, was on average 4.7mm (SD = 1.5 mm; Fig. 3h) without significant differences 
between treatment groups (t-tests, p > 0.05). The lesion centers, characterized by a fluid-filled 
cavity and scar formation, had an average size of 1.4mm (SD = 1.1 mm) also without significant 
effect of treatment. 
 
 
Figure 3 Treatment with bmSC and MP did not affect tissue degeneration. Lesion size and extent of tissue degeneration were evaluated in 
H&E-stained spinal cord sections at 10 weeks after SCI. a-f Panels show representative tissue sections 0.9 cm anterior of the lesion site (a-
c) and at the lesion center (d-f); treatment groups were: a,d injection of saline; b,e methylprednisolone; and c,f human bmSC; same 
magnification in all photographs. g Relative tissue loss in the center of the lesion (normalized to spinal cord sections without lesion). h 
Anterior to posterior extension of lesion size as identified in H&E-stained spinal cord sections. Bars show means and SEM, n= 5-7 animals, 
differences between treatment groups were not significant. 
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Recovery of sensory-motor functions 
At 2 dpo, 23 successfully operated animals scored < 2 in the BBB locomotor function scale (none 
or only slight movements of one or two joints; mean score of both hind legs), demonstrating a 
reasonable degree of reliability of the SCI rat model in our hands. Scoring differences between 
two blinded independent investigators were low (0–1), and in case of differences, the mean 
score of the two evaluators was recorded. Due to spontaneous recovery, time significantly 
affected motor function in all treatment groups (Fig. 4; p < 0.001), and a significant interaction 
effect was found between the groups and the treatment over time (repeated measure ANOVA, 
F (7, 56) = 5.75, p < 0.001). Importantly, rats treated with bmSC had significantly better motor 
function (BBB scores) compared to MP-treated rats at 4 days (p = 0.015),  7 days (p = 0.029), 2 
weeks (p =0.008), 3 weeks (p = 0.005), 4 weeks (p = 0.009) and 5 weeks (p = 0.015) after surgery 
(Fig. 4). After this time, mean score differences between bmSC and MP treatment remained in 
the same order of magnitude (ΔBBB was 4.5 at week 5 and 3.9 at week 9). These results indicate 
that the bmSC implantation resulted in better motor improvement than standard MP therapy. 
The effect was noted already at 4 dpo and reached highly significant levels during 5 weeks of 
recovery. Differences in recovery between bmSC and NaCl treatment, however, were smaller 
(ΔBBB was 0.8 at week 5 and 1.5 at week 9) and did not reach significance. 
 
 
Figure 4 Injection of bmSC caused better recovery of motor function than MP treatment. Mean BBB scores (± SEM) of the three treatment 
groups. All rats had BBB = 21 before SCI, and the first evaluation occurred two days after surgery. As indicated in Fig. 1, only animals with 
BBB < 2 at 2 dpo (SCI considered as complete) were included in the evaluation. Following a two-factor ANOVA that revealed effects of 
treatment and time after SCI, post hoc Tukey test showed significant differences between bmSC and MP treatment (* p < 0.05, ** p < 
0.01) and between NaCl and MP treatment (♯ p < 0.05). 
  
In addition to evaluation in the open field, rats were subjected to the Rotarod test. At 4 dpo none 
of the animals that met the inclusion criterion (BBB < 2) was able use their hindlimbs to maintain 
balance on the rotating bar. Spontaneous recovery caused a significant increase in Rotarod score 
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during the first 4 weeks in all experimental groups (supplementary Fig. S2). After 4 weeks, motor 
performance in this test did not improve further and in the saline treated animals actually 
deteriorated thereafter. Several rats refused the task as they did not grasp the bar with their 
fore paws. Their low score contributed to a very high variability. Thus, although bmSC treated 
animals had higher mean scores throughout the period of evaluation than both control groups, 
these differences were not significant. 
 
Figure 5 Astrogliosis was not affected by bmSC and MP treatment. Evaluation of GFAP-IR in spinal cord tissue ten weeks after SCI. a-b 
Overview of scar formation around the lesion center in a typical example; nuclear labeling with Hoechst-33342 (a) was combined with 
GFAP (b) immunostaining; 5x objective, scale bar 0.5mm in a. c Reactive astrocytes in the gey matter outside of the lesion center. d-f Higher 
magnification of GFAP-IR close to the lesion site in SCI rats with control treatment (d), MP injections (e), bmSC implants (f), and g in the 
white matter of an animal without SCI; 20x objective, images d-g with the same times of exposure, scale bar 100 μm in g. h Quantification 
of GFAP-IR (integrated density) near the lesion site revealed no significant differences between SCI treatment groups (t-tests, p > 0.5). Data 
were normalized to GFAP-IR in the white matter of rats without lesion (statistical difference not indicated); bars show means and SEM, n 
= 5–6 rats/group. 
Effect of bmSC and MP treatment on the astrocytic scar 
Astrocytes were visualized with GFAP-IHC in spinal cord sections containing the lesion site and 
in anterior and posterior sections without tissue alterations. This showed a dramatic increase of 
GFAP staining around the lesion center (Fig. 5a-g), indicating a persistent astrocytic scar in the 
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chronic stage at 10 weeks after SCI. Treatment conditions had no significant effect on the GFAP-
IR neither in white matter outside the lesion area nor in the center of SCI (Fig. 5h). 
 
Effect of bmSC and MP treatment on microglial and macrophages 
Microglia and macrophages were stained with antibodies against Iba1, again using sections 
including the lesion site, anterior and posterior of this region (Fig. 6a-g). In the white matter of 
spinal cord sections outside of the area directly affected by the SCI we found cells with typical 
microglia morphology. Their Iba1 expression was 2- to 5-fold stronger compared to the white 
matter of rats without SCI. In the lesion center, Iba1-IR increased about 10-fold in animals treated 
with saline or MP but only 4-fold in animals that had received bmSC implants (Fig. 6h). Compared 
to the control treatment (NaCl injections) the effect of bmSC was significant (t-test, p < 0.05), 
indicating that the injected cells might have reduced activation of microglia or macrophages.  
 
Effect of bmSC and MP treatment on axon pathology 
Non-phosphorylated neurofilaments are associated with their disassembled state in neuronal 
cell somata. In mature axons, in contrast, neurofilaments are heavily phosphorylated. Since this 
depends on myelin signals, the presence of non-phosphorylated neurofilaments in fiber tracts is 
indicative of demyelination and axonal damage (Trapp, Peterson et al. 1998, Yuan, Rao et al. 
2012).  
 
Figure 6 Injection of bmSC reduced activation of microglia/macrophages. Evaluation of Iba1-IR in spinal cord tissue ten weeks after SCI. a-
c Microglia in spinal cord white matter 0.5–0.7 cm anterior of the lesion center. d-f Microglia and macrophages in sections containing the 
lesion center; representative examples from rats treated with saline (a, d), MP (b, e) and bmSC (c, f). g Microglia in the white matter of an 
animal without SCI; 20 objective, scale bar 100 μm valid for all photographs. h Quantification of Iba1-IR in the white matter ca. 0.8 cm 
anterior to and within the area close to the lesion center. Here, Iba1 expression was significantly lower after bmSC treatment compared to 
control treatment (t-test,* p < 0.5). Data were normalized to Iba1-IR in the white matter of rats without lesion (statistical difference not 
indicated); bars show means and SEM, n = 5–6 rats/group  
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We investigated this using the monoclonal antibody Smi32, which labels non-phosphorylated 
neurofilament-M and -H (Lee, Otvos et al. 1988). Immune staining was observed in the white 
matter tracts of all SCI animals but not of non-injured rats. In the ascending dorsal colums the 




Figure 7 The presence of non-phosphorylated filaments as an indicator of axonal damage. Ten weeks after SCI immune staining with Smi32 
antibody (red) was combined with myelin basic protein-IR (green) and Hoechst-33342 nuclear staining (blue). a-f Overview of transverse 
spinal cord sections at intervals of approximately 3.2mm from 8mm anterior to 8mm posterior of the lesion site; 5x objective,  scale bar in 
a. Note the presence of Smi32-binding in the ascending dorsal columns anterior but not posterior of the lesion site and in white matter 
tracts in all sections.  
g Non-phosphorylated neurofilament in ascending fiber tracts anterior of the site of injury, 20x objective. h-i Higher magnification of 
Smi32-IR in white matter (h) and motor neurons in the ventral horn (i), 40x objective, scale bar in i. No Smi32 staining was observed in the 
white matter of animals without SCI (see Fig. 8). 
 
 
In contrast, it was absent in the dorsal area of sections containing the lesion site, where all fiber 
tracts had completely degenerated, and also in the dorsal columns below the lesion, where these 
axons were not affected by the SCI (Fig. 7a-h). In ventrolateral fiber tracts, non-phosphorylated 
neurofilament was found in all spinal cord sections of lesioned rats. Smi32-IR was also visible in 
the somata of nerve cells, most strongly in the ventral horns (Fig. 7i). This could also be observed 
in tissue of non-injured animals and is not pathological. Quantification of the Smi32-IR revealed 
a significant effect of bmSC treatment in the dorsal columns anterior of the lesion site, where 
the ascending somatosensory axons were affected by the SCI (Fig. 8a-d, i).  
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Stem cell treatment reduced the amount of axonal damage compared to saline treatment (t-
test, p < 0.05). The strong expression of non-phosphorylated neurofilaments in ventral and 
lateral fiber tracts was not significantly different between treatments (Fig. 8e-h, i). 
 
 
Figure 8 Treatment with bmSC reduced axonal damage in ascending fiber tracts anterior of the lesion site. Staining with Smi32 (red) was 
combined with Iba1 (green) in spinal cord tissue ten weeks after SCI. a-h Smi32 IR in the dorsal columns (a-d) and ventrolateral white 
matter (e-h) of a rat without SCI (a, e), and of SCI animals treated with saline (b, f), MP (c, g) and bmSC injections (d, h); 20 objective, scale 
bar in a. Note the absence of non-phosphorylated neurofilament in control samples without SCI in a and e. i Quantification of Smi32-IR in 
the ascending dorsal columns anterior and posterior of the lesion site (dc ant, dc post), the ventrolateral white matter (v&l) and 
corresponding regions without SCI (no Smi32-IR, marked x). Bars show means and SEM, n = 5–6 rats/group. Treatment with bmSC was 
associated with reduced Smi32-IR in the anterior dorsal columns compared to saline treatment (t-test * p < 0.05), while MP had no effect 
and differences in dc post and vl were not significant. 
Effect of bmSC and MP treatment on neuroinflammation 
To a large degree the devastating effects of SCI are due to a persistent neuroinflammatory 
response, one of its hallmarks being the lysosomal antigen CD68 (ED1), which is present in 
activated microglia and macrophages (McKay, Brooks et al. 2007). We found that activation of 
these myeloid cells was still very strong at 10 weeks after SCI (Fig. 9a, b). The histological 
distribution of CD68 IR throughout the white matter resembled that of axonal damage. Chronic 
neuroinflammation was observed in fiber tracts distal of the lesion, such as ascending 
somatosensory fibers anterior and the descending corticocpinal tract posterior of T9/T10 (Fig. 
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9c, d). Activated microglia and macrophages were also present in the lesion center and in ventral 
and lateral white matter tracts (Fig. 9e, f). Quantification of CD68-IR revealed that it was lower 
in MP treated animals than after NaCl treatment, while no significant effects were found after 
bmSC injection (Fig. 9g-k). 
 
Effect of bmSC and MP treatment on apoptosis 
Apoptosis was evaluated using an antibody against activated caspase-3, which at 10 weeks after 
SCI was clearly identified in cell nuclei (supplementary Fig. S1, Fig 10a-h). While some apoptotic 
cells were also detected in the grey matter of rats without SCI (up to 7% of all nuclei), the 
percentage was much higher (15% – 20%) in the rats with spinal cord contusion. Treatment with 
bmSC significantly reduced apoptosis in the ventral horn (Fig. 10i). 
 
 
Figure 9 Injections of MP mitigated SCI-induced neuroinflammation. Microglia activation and macrophage infiltration ten weeks after SCI 
were evaluated with immune staining of CD68 (ED1). a-b Overview of transverse spinal cord sections 0.8 cm anterior of the lesion site and 
at its center. CD68 (green) was combined with Hoechst-33342 nuclear staining (blue), 5x objective, scale bar in b. Note very strong CD68-
IR everywhere in the white matter as well as its absence in the scar tissue (b). c-f Examples of activated microglia/macrophages in 
ascending fiber tracts in the dorsal columns anterior of the lesion site (c), in corticospinal tract posterior of the lesion center (d; marked 
with dotted ellipse in c and d), in the lesion center (e), and anterior ventrolateral white matter (f). g-j Examples of CD68-IR in dorsal columns 
of rats without SCI and after SCI treatments; 10x objective, scale bar in g. k Quantification of CD68-IR in the dorsal columns (dc) and 
ventrolateral white matter (vl) anterior and posterior of the lesion site and corresponding regions without SCI (no CD68-IR). Bars show 
means and SEM, n = 5 rats/group. As indicated (t-test * p < 0.05) treatment with MP was associated with reduced CD68-IR compared to 





Figure 10 Injection of bmSC reduced apoptosis in the ventral horn. Ten weeks after SCI, cellular apoptosis was evaluated using activated 
caspase-3 as a marker. a-h Representative ROI containing apoptotic nuclei in the ventral horns of non-injured animals (a, b), after 
SCI/treatment with saline (c, d), with MP (e, f) and with bmSC (g, h). Immune staining of activated caspase-3 (red, all panels) was combined 
with Hoechst-33342 nuclear staining (blue, b, d, f, h, double exposure); 40x objective, scale bar in h. i Quantification of apoptosis in the 
grey matter is expressed as the percentage of activated caspase-3 IR nuclei of all nuclei. Bars show means and SEM, n = 5 rats/group; 
statistical evaluation with ANOVA, post-hoc Tukey tests. More apoptosis was observed after SCI when rats were treated with saline (♯ p < 
0.05, ♯♯ p < 0.01). This increase in number of apoptotic cells failed to be significant after MP treatment and in the ventral horn also after 







The therapeutic benefit of human bmSC as a treatment of SCI was compared to high dose MP 
injections in adult rats. Within two hours after T9/T10 spinal cord contusion one dose of a 
dedicated human bmSC preparation (Neuroplast BV) was injected into the cisterna magna. These 
allogeneic implants were not rejected and significantly improved the recovery of motor functions 
compared to MP treatment. The mean BBB score of bmSC treated rats after nine weeks was 
10.8, compared to 6.8 after MP interventions. Differences between bmSC and saline injections 
(score of 9.3) were smaller and did not reach significance (Figs. 2,4). On the histological level 
(Figs. 3,5-10), bmSC treatment was beneficial with respect to axonal degeneration and apoptosis, 
compared to both control groups, while MP only had an anti-inflammatory effect. To date, more 
than 25 studies have been published using bone marrow-derived stem cells to treat SCI in rats  
(Shende and Subedi 2017, Mukhamedshina, Shulman et al. 2019, Romanelli, Bieler et al. 2019, 
Zhao, Zhou et al. 2019). In the past, the cells were usually expanded before use and their 
phenotype was not characterized. For the present study, we prepared human bmSC solely by 
removing immune cells from the bone marrow extract and did not cultivate them before 
implantation. Based on characterization with flow cytometry the injected cell suspension 
contained about 8% stem cells with a roughly equal proportion of hematopoietic and 
mesenchymal cells. How effective was this treatment in comparison with previous approaches? 
Even with standardized methods of evaluating motor function (BBB, rotarod) it is difficult to 
compare the outcomes reported by different laboratories (cf. BBB-scores of SCI control groups 
in (de Munter, Beugels et al. 2019, Mukhamedshina, Shulman et al. 2019, Maqueda and 
Rodriguez 2020)). With this caveat we may conclude that the therapeutic benefit of the new 
human bmSC preparation in rats was similar to what has been achieved using autologous cells. 
In the rat SCI model of severe contusion injury, no stem cell treatment has so far succeeded in 
repairing the tissue loss in the lesion center. Despite this, a benefit on functional recovery is 
observed justifying clinical trials (Shende and Subedi 2017, Srivastava, Agrahari et al. 2019). 
 
Steroid treatment and limitations of the present study 
Many publications on SCI treatment with MP report small to moderate improvement of motor 
recovery in the first weeks compared to placebo treatment. These are attributed to a reduction 
of inflammation, oxidative stress and neuronal apoptosis (Lu, Niu et al. 2016). However, an 
absence of therapeutic benefit or even negative effects were also found (Lankhorst, ter Laak et 
al. 2000). In monkeys, MP inhibited the SCI-induced proliferation of ependymal stem cells in the 
spinal cord (Ye, Qin et al. 2018). A meta-analysis of animal experiments concluded that 
“beneficial effects of MP administration were obtained in 34% of the studies, no effects in 58%, 
and mixed results in 8%. The results were inconsistent both among and within species, even when 
attempts were made to detect any patterns in the results through subgroup analyses” (Akhtar, 
Pippin et al. 2009). Due to its privileged role as the only FDA-approved pharmacological 
intervention in human SCI patients, MP is nonetheless often included in pre-clinical research. 
Following consultation with the EMA, we treated our rats with five intraperitoneal injections of 
30 mg/kg MP with the first dose immediately after surgery and the following over 24 hours, 
similar to the NASCIS II trial (Bracken, Shepard et al. 1998). Compared to saline injections, this 
106 
 
treatment significantly attenuated inflammation as shown with CD68 staining ten weeks after 
SCI (Fig. 9). Unexpectedly, it reduced motor recovery of the rats (Fig. 4). Ethical principles in 
animal experimentation demand the largest possible reduction in the number of animals. Based 
on expected effect size and variance we planned eight rats for the treatment and six for the three 
different control groups. While a highly significant benefit of bmSC compared to MP treatment 
was reached (Fig. 4) and differences with all control groups were significant on the histological 
level (Figs. 6-10), this design was underpowered to demonstrate a functional benefit of bmSC 
compared to saline treatment. Additional tests with the Rotarod assay indicated a positive 
influence of bmSC on motor recovery compared to both control groups, however these data did 
not reach significance because of their high variability (Supplementary Fig. S2). This was primarily 
caused by the fact that 1/2 to 1/3 of the rats, irrespective of treatment, did not try to hold on to 
the rotating bar, although all animals had successfully been trained to do the task prior to SCI. 
Increasing body weight of the animals appeared to make the task more difficult during the study. 
 
In a future clinical application, the bmSC are intended to be extracted from the same person who 
suffered the SCI and will receive the treatment. The time between bmSC preparation and 
injection shall not exceed 48 hrs (Neuroplast, patent WO2015/059300A1). Deviating from this 
procedure we tested the human cells in rats. Since it was not possible to implant the cells 
immediately after their preparation, bmSC were cryopreserved and resuspended for 
implantation, and this reduced their viability. Of all nucleated cells in the bmSC preparation 3.3 
% were hematopoietic stem cells (CD34), 3.8 % mesenchymal stem cells (CD271, CD90, CD105, 
CD73) and the rest were non-identified stroma cells also including dead cells. 
Despite these limitations, the implants were not rejected, the treated animals showed no 
sickness behavior and a better recovery of body weight than control groups (Fig. 2). We attribute 
this success to the properties of the human bmSC as modulators of innate immunity. 
  
The advantages of bmSC implants as a therapy of SCI  
Today, stem cell-based therapies are among the most promising experimental strategies to treat 
neurodegenerative pathologies including SCI. As an advantage to other sources, such as 
embryonic and induced pluripotent stem cells (iPCS), adult stem cells are easily isolated from 
blood, bone marrow or adipose tissue. In contrast to iPSC (Gazdic, Volarevic et al. 2018, Nagoshi, 
Tsuji et al. 2019) they do not require genetic reprogramming and pose no risk of tumor 
formation. Several attempts using bmSC in rodents have achieved significant improvements in 
motor functions, which were in the same order of magnitude as in the present study (Tetzlaff, 
Okon et al. 2011, Shende and Subedi 2017).  
Despite the inherent difficulties to publish negative results, some failures to reach functional 
improvement have also come to light (Hofstetter, Schwarz et al. 2002, Ankeny, McTigue et al. 
2004, Tetzlaff, Okon et al. 2011), and this raises the question as to the best conditions for bmSC 
treatment of SCI.  
Three considerations deserve particular attention: preparation of the bmSC, mode and time of 
application. 
1)  Following standard extraction of bone marrow from the ilicac crest of human donors, we are 
using a novel procedure to prepare bmSC, which is based exclusively on the elimination of 
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macrophages and lymphocytes without manipulation or expansion in vitro. This procedure 
allows implantation within 48 hrs after harvesting of the cells. In most of the previous studies 
bmSC were expanded to large numbers before use (Tetzlaff, Okon et al. 2011, Shende and 
Subedi 2017) and this, unfortunately, reduces their growth potential (Hayflick limit 
(Schellenberg, Lin et al. 2011)) as well as their anti-inflammatory properties (Li, Ding et al. 
2012). It also leads to the accumulation of stochastic mutations, such that the risk of 
malignant transformation cannot be ruled out (Wagner 2012). A major advantage of our 
approach is to avoid negative changes associated with long term cultivation. 
2)  Cell implants that are intended for the therapy of CNS pathologies first need to reach their 
target tissues. While contusion SCI initially disrupts the blood-spinal cord barrier, this is 
restored by endogenous repair processes. Therefore, systemic applications of cells, such as 
by intravenous injection (Cizkova, Rosocha et al. 2006, Vaquero, Zurita et al. 2006), may have 
only a limited time window, which in rodents lasts about one week for the gray matter 
(Donnelly and Popovich 2008). Since we intend to explore treatment in the chronic phase in 
the future, we chose infusion into the cerebrospinal fluid (CSF). Stem cell injections into the 
CSF were shown to be more effective than into the blood circulation (Vaquero, Zurita et al. 
2006, Paul, Samdani et al. 2009, Shin, Kim et al. 2013), and in the majority of clinical studies 
cells were transplanted via lumbar puncture (Hofstetter, Schwarz et al. 2002, Shende and 
Subedi 2017). In rats we accessed the subarachnoid space via the cisterna magna (Shin, Kim 
et al. 2013), implying that the injected cells had to migrate toward the area of injury in the 
spinal cord. While the mechanisms of this are not well understood, homing to damaged areas 
has been shown to be a property of bmSC even when injected into the blood stream (Cizkova, 
Rosocha et al. 2006). We considered the alternative to inject the cells directly below the dura 
mater of the spinal cord, as was done previously after dorsal column transection (Lu, Jones 
et al. 2005) and compression injury (de Munter, Beugels et al. 2019). However, in preparatory 
experiments we found that spinal cord injection per se caused additional damage. This 
application may be more effective for interventions in the chronic phase, when cells can be 
implanted into the cavity within the spinal cord that has formed by then (Lu, Wang et al. 
2012). 
3)  Thus, the time of intervention is another crucial parameter when considering stem cell 
therapy of SCI. By far the most animal experiments have been carried out in the acute phase, 
and with bmSC this seems to be justified because their main benefit is expected to be 
neuroprotection by modulating the immediate inflammatory response (Donnelly and 
Popovich 2008, de Munter, Shafarevich et al. 2019, de Munter, Beugels et al. 2019). Our 
histological evaluation indicates that the acute intervention, while not reducing gross tissue 
damage (Fig. 3), did have lasting cytoprotective effects as shown with a reduction in axonal 
damage (Fig. 8) and apoptosis (Fig. 10) ten weeks later. Since immune suppression on 
macrophages was larger after MP treatment (Fig. 9), we hypothesize that the bmSC elicited 
additional neurotrophic effects. These will be explored in future SCI experiments using 
intervention in the chronic state. In a delayed treatment protocol with intraspinal 
administration into the lesion cavity the integration of grafted cells promises to be better 
because the release of toxic compounds, lytic enzymes and free radicals of the early phase 




The putative mode of action of bmSC after SCI 
This raises the question regarding the mechanisms by which the injected bmSC were effective in 
our experiments. Increasing evidence suggests that extracellular vehicles (EVs) are important 
players in mediating the therapeutic effects of therapeutically applied stem cells (Rani, Ryan et 
al. 2015, Ruppert, Nguyen et al. 2018, Romanelli, Bieler et al. 2019, Zhao, Zhou et al. 2019). 
Exosomes from mesenchymal stem cells exert immune-suppressive effects by enforcing M2 
macrophage polarization, inhibiting complement activation (Zhao, Zhou et al. 2019) and 
indirectly driving regulatory T cell induction (Zhang, Chopp et al. 2015). In addition, classical 
mechanisms of paracrine release of cytokines and growth factors are likely to be involved 
(Neuhuber, Timothy Himes et al. 2005, Gnecchi, Danieli et al. 2016), although attempts at 
isolating these factors so far have failed to replace stem cells with a pure pharmacological 
intervention. Stem cell-conditioned media which contain EVs as well as paracrine factors can be 
effective, although repeated delivery may be required (Rani, Ryan et al. 2015, Romanelli, Bieler 
et al. 2019).  
It is believed that beneficial effects of bmSC are derived rather from the mesenchymal and not 
the hematopoietic stem cell fraction (Shende and Subedi 2017), and this view is linked to the 
expectation that the cells integrate and differentiate in the tissue (Gnecchi, Danieli et al. 2016). 
Our bmSC preparation contained less than 5 % mesenchymal stem cell. We have reason to 
believe that hematopoietic stem cells and remaining stromal cells (not expressing CD34, CD271, 
CD90, CD105, CD73) also released modulators that positively influenced recovery after SCI.  
Although the injected bmSC reduced Iba1 staining, their effect on CD68 did not reach 
significance. The fact that cell treatment improved motor recovery much better than MP, while 
the latter did reduce the number of CD68 positive macrophages, also indicates that bmSC may 
have acted on other than myeloid cells.  
The formation of fibrotic and glial scar is a major impediment to axonal regeneration after spinal 
cord injury. While reports with bmSC have claimed to reduce this (Shende and Subedi 2017, de 
Munter, Beugels et al. 2019, Romanelli, Bieler et al. 2019), we did not see differences in scar 
formation or lesion size between different groups. Either there was a transient effect, not visible 
ten weeks after SCI, or the damage caused by 200 Kdyn (2N) contusion injury was too large to 
put any scar reducing effects in evidence.  
Were there continuing effects in the chronic stage? The behavioral data show that almost all 
improvement in sensory-motor performance of the rats occurred within the first three weeks 
and that the therapeutic benefit of bmSC treatment also occurred in this period (Fig. 4). Using a 
specific antibody against human mitochondrial proteins (Millipore MAB1273C3, validated in 
vitro) we searched for the presence of human cells in the spinal cords of all rats. At ten weeks 
after SCI we were not able to detect the implants. Although the absence of an IR signal is certainly 
not conclusive, it is more likely that the implanted bmSC were only effective in the acute and 
subacute phase after SCI.  
Differences observed after ten weeks on the histological level, such as lower microglial activation 
and reduced axonal damage may be the result of better recovery in the subacute phase. This 
must certainly be the case for the lingering anti-inflammatory effect of acute MP injections. It is 
intriguing, though, that we observed a high level of apoptosis and a significant effect of bmSC on 
this phenomenon even at ten weeks after lesion. Double IHC with antibodies against activated 
caspase-3/Iba1 and activated caspase-3/NeuN indicated that the apoptotic nuclei did not belong 
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to microglia or neurons (data not shown). Previous studies found continuing apoptosis of 
oligodendrocytes in the chronic phase after SCI (Beattie, Farooqui et al. 2000). Other groups (Lu, 
Jones et al. 2005, Cizkova, Rosocha et al. 2006) were able to locate injected bmSC infiltrating the 
lesion site. In several cases, cells were found to have differentiated into oligodendrocytes, 
whereas the expression of neural markers was rare. Following the most thorough analysis of 
cellular transplantation therapies for SCI, Tetzlaff and colleagues (Tetzlaff, Okon et al. 2011) 
concluded that remyelination of demyelinated axons may be the most realistic therapeutic 
objective. 
Conclusions for improving SCI therapy based on bmSC implants 
Using acute intervention with bmSC we were able to improve the natural recovery process within 
the first 10 weeks after lesion compared with corticosteroid treatment without adverse effects 
due to a possible immunological rejection. By reaching these objectives, the results of this study 
confirmed the beneficial effects of stem cells that were obtained earlier using immune-
compromised rats and balloon compression SCI (de Munter, Beugels et al. 2019). In this and 
many other studies implanted stem cells could not be identified in the tissue when this was 
attempted in the chronic stages after SCI. Their failure to survive may be attributed to a hostile 
microenvironment created by the lesion (Khazaei, Ahuja et al. 2020). It is therefore an objective 
to modify the tissue response such that implanted cells remain functional. Since the bmSC 
themselves modulate the innate immune system (Ruppert, Nguyen et al. 2018, de Munter, 
Shafarevich et al. 2019, Zhao, Zhou et al. 2019), we suggest that a combination of 
pharmacological/cell-based therapies should complement the signals released from the bmSC 
by activating different molecular targets. 
In the past, even the most promising results of preclinical studies with rodents could not be 
translated to clinical therapies of SCI or any other neuro-degenerative disease. Depending on the 
physiological question and the risk of treatment, additional studies with non-human primates 
may therefore be necessary before a clinical trial is justified (Tsintou, Dalamagkas et al. 2020). 
Since large mammals are expensive, sample sizes are usually small. Such experiments are 
ethically justified only to the extent that the animal models are more predictive for clinical 
interventions than experiments with rodents.  
A recent comparative study with bmSC injections after SCI in 115 rats and 17 pigs arrived at 
similar results in both species (Mukhamedshina, Shulman et al. 2019). The present results 
demonstrate that our bmSC preparation had benefits and no negative side effects even when 
implanted in a different species and with a considerable percentage of non-viable cells due to 
one freezing/thawing cycle before implantation. In a clinical trial, bmSC would be prepared from 
the same patient, implanted without cryopreservation and within 48 hrs after injury.  
Since the potential risk for the patient is minimal we do not see the necessity of an intermediate 
study with large mammals or non-human primates, especially since differences in the motor 
systems between different primate species are also not negligible (Lemon and Griffiths 2005). 
Exaggerated promises are a recurrent phenomenon in SCI research.  
Our conclusion, while optimistic, is more modest: The intrathecal transplantation of human bone 
marrow-derived cells prepared via negative selection and without cultivation will contribute to 








Additional file 1 Fig. S1. Evaluation of cellular apoptosis. Spinal cord sections were processed with double IHC against activated caspase-
3/NeuN (neurons) and activated caspase-3/Iba1 (microglía/macrophages) and combined with DAPI nuclear staining. a Drawing of spinal 
cord and transverse sections indicating the ROIs for evaluation in the grey matter (40 x objective). b Low power photograph of the dorsal 
horn of a rat with SCI, demonstrating the distribution of apoptotic nuclei (pink). Annotation indicates outline of grey matter, ROI,counted 
cell nuclei and scale bar=100 μm. 
 
 
Additional file 2 Fig. S2. Motor recovery as revealed with the Rotarod test. Motor performance in the rotarod stepping test is expressed in 
the amount of time [sec] that the animals maintained themselves on the rotating bar (mean ± SEM); SCI + bmSC: treatment with human 
bone marrow-derived stem cells; SCI + MP: injections of methyl prednisolone; SCI control: injections of NaCl. Before SCI, all animals reached 
the maximum time of 300 s. The first evaluation was performed at 4 dpo. Differences between groups were not significant. Rats that did 





Bone marrow-derived stem cells in chronic neuro-degenerative 
processes 
 
Introduction chapter 5 
Chapter 5 displays the results of the experiments performed with a transplantation of a minimal 
manipulated stem cell preparation derived from human bone marrow in animal models for 
chronic neurodegenerative processes. We aimed for testing human stem cells in Parkinson’s 
disease (PD). Although available alpha-synuclein models as well as mutated forms of the LRRK2 
gene recapitulate most of the symptoms of PD, undisputable representative animal models able 
to reproduce this multisystem pathological condition are not available. So, we chose to work 
with transgenic FUS and SOD mice, representative for the familial form of amyotrophic lateral 
sclerosis (ALS). The familial form of amyotrophic lateral sclerosis occurs in 10% of all the ALS 
cases. The other 90% are the sporadic forms of ALS in which the causes are unknown. 
Figure 1 gives an overview of the mutations in familial forms and the preclinical models in use to 
test interventions for ALS (Alrafiah 2018). 
ALS is traditionally considered a pure motor neuron disease with progressive loss of upper and 
lower motor neurons. Results of interventions with Neuro-Cells in transgenic FUS and SOD mice 
are displayed in chapter 5.1. 
As of now, it is more and more recognized to be a multisystem disorder. Many patients suffering 
ALS also exhibit mild cognitive impairment and a subset have severe impairment with features 
of frontotemporal dementia (FTLD). FTLD is considered a presenile dementia. The current 
classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and 
FTLD-FUS. Transgenic FUS mice thus have a genotype with at least two phenotypes: ALS and 
FTLD. 
Frontotemporal lobar degeneration is the result of damage to neurons in parts of the brain called 
the frontal and temporal regions. Gradually, this damage causes difficulties in thinking and 
behaviours normally controlled by these parts of the brain. These group of disorders causes 
unusual behaviours, emotional problems, and severe loss of thinking abilities, and are 
responsible for the majority of dementia cases under the age of 60 years.  
 
ALS and FTLD are both found to correlate with reductions to endoplasmic reticulum - 
mitochondria associations linked to the activation of glycogen synthase kinase-3β (GSK-3β). This 
kinase is also strongly associated with ALS/FTD (Stoica, Paillusson et al. 2016). 
 
We were able to also investigate the effect of Neuro-Cells in transgenic FUS mice, which 
exhibited (subtle) FTLD-like signs and symptoms, as a rule some weeks before the onset of the 






Figure 1. Pathogenesis of C9OR72-, TARDBP-, SOD1-, and FUS-associated ALS. A: Chromosome 9 hexanucleotide repeat72 (C9ORF72) 2 
mutation acts through a gain-of-function (GOF) mechanism. GGGGCC[G4C2] is translocated to the cytosol and then either translated to 
form aggregates of poly-(GP) dipeptide-repeat proteins (DPR) or misfolded to form aggregates of ubiquitinated (U) RNA foci associated 
with TDP43 or FUS proteins, which both mediate neuronal toxicity. B: transactive response DNA-binding protein (TARDBP) mutation acts 
through both loss of function (LOF) and GOF mechanisms. Normal TDP43 function is lost due to mutant (mt) TDP43 proteins inhibiting 
normal TDP43 from binding to pre-mRNA. C: superoxide dismutase 1 (SOD1) mutation acts through a GOF mechanism. Mutant SOD1 
dimers in the cytosol accumulate as SOD1 inclusions within mitochondria and Lewy-body-like hyaline (LBLH) inclusions in the cytosol where 
they can trigger mitochondrial reactive oxygen species (ROS) generation later, causing mitochondrial destruction. D: fused in sarcoma 
(FUS) mutation acts through both LOF and GOF mechanisms. Mutant FUS proteins cause LOF by inhibiting normal FUS from binding to pre-







5.1. Neuro-Cells therapy improves motor outcomes and 
suppresses inflammation during experimental syndrome of 
amyotrophic lateral sclerosis in mice 
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Abstract 
Aims: Mutations in DNA/RNA-binding factor (fused-in-sarcoma) FUS and superoxide dismutase-
1 (SOD-1) cause amyotrophic lateral sclerosis (ALS). They were reproduced in SOD-1-G93A (SOD-
1) and new FUS[1-359]-transgenic (FUS-tg) mice, where inflammation contributes to disease 
progression. The effects of standard disease therapy and anti-inflammatory treatments were 
investigated using these mutants. 
Methods: FUS-tg mice or controls received either vehicle, or standard ALS treatment riluzole (8 
mg/kg/day), or anti-inflammatory drug a selective blocker of cyclooxygenase-2 celecoxib (30 
mg/kg/day) for six weeks, or a single intracerebroventricular (i.c.v.) infusion of Neuro-Cells (a 
preparation of 1.39 × 106 mesenchymal and hemopoietic human stem cells, containing 5 × 105 
of CD34+ cells), which showed anti-inflammatory properties. SOD-1 mice received i.c.v.-
administration of Neuro-Cells or vehicle. 
Results: All FUS-tg-treated animals displayed less marked reductions in weight gain, food/water 
intake, and motor deficits than FUS-tg-vehicle-treated mice. Neuro-Cell treated mutants had 
reduced muscle atrophy and lumbar motor neuron degeneration. This group but not celecoxib-
FUS-tg-treated mice had ameliorated motor performance and lumbar expression of microglial 
activation marker, ionized calcium-binding adapter molecule-1 (Iba-1), and glycogen-synthase-
kinase-3ß (GSK-3ß). The Neuro-Cells-treated-SOD-1 mice showed better motor functions than 
vehicle-treated-SOD-1 group. 
Conclusion: The neuropathology in FUS-tg mice is sensitive to standard ALS treatments and 
Neuro-Cells infusion. The latter improves motor outcomes in two ALS models possibly by 
suppressing microglial activation. 
Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive 
degeneration of lower motor neurons, as well as neurons in the cortex and brainstem, which 
leads to paralysis and premature death (Al-Chalabi, Hardiman et al. 2016). The aetiology of ALS 
remains unclear both in sporadic cases (90%) and in the familial forms of ALS (Blair, Williams et 
al. 2010, Al-Chalabi, Hardiman et al. 2016). Among the known genetic causes that give rise to 
ALS, the mutation of the fused in sarcoma protein (FUS) is the second most frequent among the 
familial forms of ALS (Blair, Williams et al. 2010, Freischmidt, Muller et al. 2015, Lutz 2018).  
Mutations of FUS gene were thought to cause synaptic dysfunction and pathological protein 
aggregation (Sabatelli, Moncada et al. 2013), which were felt to be key events leading to 
neuronal degeneration (Marrone, Drexler et al. 2019). However, the most recent studies have 
revealed that the expression of mutant FUS leads to stress-mediated induction of chaperones, 
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decreased expression of ion channels and transporters essential for synaptic function, and 
reduced synaptic activity without the loss of nuclear FUS or its cytoplasmic aggregation (Lopez-
Erauskin, Tadokoro et al. 2018).  
The nuclear effects of FUS also seem to result in impairment of the function of paraspeckles, 
granules in the nuclear interchromatin space that are assembled on a scaffold long noncoding 
RNA (lncRNA) NEAT1 (Fox and Lamond 2010, Shelkovnikova, Peters et al. 2013, Shelkovnikova, 
Kukharsky et al. 2018). This results in aberrant microRNA biogenesis, apoptotic processes, 
oxidative stress, and mitochondrial dysfunction contributing to neurodegenerative processes 
(Shelkovnikova, Peters et al. 2013, Shelkovnikova, Kukharsky et al. 2018). Indeed, the latest 
studies using human fibroblast cell lines expressing mutant FUS from ALS patients and post 
mortem tissue have identified the accumulation of dysfunctional paraspeckles associated with 
abnormal NEAT1 expression as an important feature of FUS-associated ALS pathology (An, Skelt 
et al. 2019).  NEAT1 was recently reported to promote inflammation via stimulating interleukin-
1β production and pyroptosis and activating macrophages.(Huang-Fu, Cheng et al. 2018, Zhang, 
Cao et al. 2019). Regardless of whether the disease is associated with FUS gene mutations or 
related to other factors, its pathological mechanisms are associated with neuroinflammation 
(Blair, Williams et al. 2010, Al-Chalabi, Hardiman et al. 2016, Morello, Spampinato et al. 2017, 
Lutz 2018). In particular, the activation of microglia and astrocytes is considered to be a hallmark 
of the disease and is accompanied by elevated pro-inflammatory cytokine concentrations in the 
brain, blood, and cerebrospinal fluid (Mishra, Vijayalakshmi et al. 2017, Morello, Spampinato et 
al. 2017, Crisafulli, Brajkovic et al. 2018). For example, a recent clinical study reported high blood 
concentrations of pro-inflammatory cytokines and related proteins in ALS patients, including 
interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor (TNF), and 
TNF receptor-1 (Hu, Cao et al. 2017). It has been suggested that microglial inflammatory 
processes might be a key early event that contribute to neurodegeneration and play a dynamic 
role in the pathogenesis of the disease (Morello, Spampinato et al. 2017, Crisafulli, Brajkovic et 
al. 2018). Cerebrospinal fluid from ALS patients induces  marked microglial activation, and 
upregulation of the pro-inflammatory cytokines and factors including IL-6, TNF, cyclooxygenase-
2 (COX-2), and prostaglandin E2 (PGE2), accompanied by a downregulation of trophic factors 
(Mishra, Vijayalakshmi et al. 2017, Shruthi, Sumitha et al. 2017). Despite the evidence that the 
level of inflammation is critical in ALS, clinical studies with compounds that target inflammatory 
mechanisms and associated cascades, including the TNF inhibitor thalidomide, non-steroid anti-
inflammatory drugs (NSAIDs), a selective COX-2 inhibitor celecoxib, corticosteroids, 
cyclophosphamide, cyclosporine, cytochrome C inhibitors, and caspase-reducing drugs have all 
failed to induce significant improvement of the ALS pathology (Gordon, Moore et al. 2007, Calvo, 
Moglia et al. 2010, Collins and Bowser 2017).19-21 Thus, while the therapeutic niche for anti-
inflammatory treatment of the ALS is strongly implicated by clinical and preclinical studies, 
current literature lacks any clear examples of positive results. In the present study, we sought to 
test the effects of a stem cell therapy “Neuro-Cells” with anti-inflammatory actions (de Munter 
and Wolters 2013, de Munter, Beugels et al. 2019) on experimental models of ALS in mice. 
Therefore, we have employed a FUS[1-359]-tg mouse model (Shelkovnikova, Peters et al. 2013) 
according to the guidelines set by Ludolph et al, 2010, for ALS preclinical studies (Ludolph, 
Bendotti et al. 2010) that have recommended the use of other ALS models apart from the SOD-
1 mouse “gold standard” (Gurney, Pu et al. 1994). The pattern of pathology in FUS[1-359]-tg line 
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recapitulates key features of human ALS, including motor neuron degeneration and microgliosis 
in the brainstem and spinal cord, muscle atrophy, paralysis, microglial activation, and elevated 
levels of pro-inflammatory cytokines in the CNS and blood (Shelkovnikova, Peters et al. 2013, 
Lysikova, Kukharsky et al. 2019). The model permits the impact of therapy on ALS-related 
changes to be evaluated including basic physiological and motor functions, as well as evaluation 
of the expression of pro-inflammatory and degeneration markers such as Iba-1, GSK-3ß, IL-1ß, 
and IL-6 in the lumbar spinal cord and blood levels of IL-1ß and IL-6. In the FUS model, the effect 
of the standard therapies has not been studied. We therefore chose to compare them to Neuro-
Cells. In addition, we examined the effects of Neuro-Cells administration on motor function in 
the SOD-1 mouse line, a well-established model of ALS (G93A line;25). Here, we gave in both 
models a single intracerebroventricular (i.c.v.) infusion of a preparation of nonmanipulated 
human stem cells “Neuro-Cells” obtained from bone marrow, which are a combination of both 
mesenchymal stem cells (MSCs) and hemopoietic stem cells (HSCs). As both MSCs and HSCs have 
been shown to have the ability to differentiate into a spectrum of adult cell populations, many 
studies have sought to examine either the combined or individual contributions to repair in vivo 
in models of injury and potentially capitalize on the relationship between the two cell 
populations that is known to exist (Fitzsimmons, Mazurek et al. 2018, Andrzejewska, Jablonska 
et al. 2019). As for instance, MSCs were shown to act as a feeder layer maintaining HSCs in an 
undifferentiated state. If HSCs are allowed to differentiate during their expansion, it increases 
the process of cell aging and death (Kim, Yoo et al. 2008). In spinal injury models, the engraftment 
of CD34+ human HSCs produces neurons efficiently in the regenerating chicken embryo spinal 
cord (Sigurjonsson, Perreault et al. 2005) and the use of MSCs to form guiding strands in the 
injured spinal cord promotes recovery (Hofstetter, Schwarz et al. 2002). A direct comparison has 
been made between human mononuclear cell preparations (a mixture of HSCs and MSCs) and 
culture-expanded MSCs transplanted into a spinal cord injury model in rats without differences 
with regard to graft efficiency, spinal cord tissue sparing, or glial scar reduction (Samdani, Paul 
et al. 2009). In view of these results, we found that an injection of a mixture of MSC and HSC, to 
maximize the potential benefit of these populations, had an anti-inflammatory effect (de 
Munter, Beugels et al. 2019). The intrathecal administration of the MSC/HSC preparation, 
containing 4 × 105 of CD34+ cells into rats that had been subjected to a spinal cord injury, was 
shown to improve functional outcomes and decrease peripheral concentrations of pro-
inflammatory cytokines (TNF, IL-1ß, and IL-6) in the cerebrospinal fluid (de Munter, Beugels et 
al. 2019). Previous studies have reported beneficial effects of stem cell therapy in animal models 
of ALS (Uccelli, Milanese et al. 2012, Boido, Piras et al. 2014, Agarwala and Tamplin 2018); the 
majority of these studies employed manipulated MCSs,(Uccelli, Milanese et al. 2012, Oh, Moon 
et al. 2015, Mazzini, Vescovi et al. 2016, Gorabi, Kiaie et al. 2019), while the use of unmanipulated 
stem cells and preparations containing HSCs and MSCs has been shown to increase the 
therapeutic activity of stem cell therapy (Li and Wu 2011, Caplan 2015, Yousefi, Lavi Arab et al. 
2019). Thus, we hypothesized that this treatment might also ameliorate ALS-like pathology 
owing to the anti-inflammatory effects of Neuro-Cells. Here, we sought compare the effects of 
Neuro-Cells to the current anti-ALS therapy riluzole (Miller, Mitchell et al. 2012) and the classic 





Material and methods 
Details on animals and all experimental procedures can be found in Data S1. 
 
Animals and human endpoint 
FUS-tg, SOD-1 male mice and their wild-type littermates (WT) were provided by the FDA-certified 
IPAC RAS facilities and Charles River provider, respectively (http://www.ipac.ac.ru/index.html 
and http://www.spf-animals.ru/about/ providers /animals). Mice were single housed under 
standard conditions and reversed lighting. Experimental procedures were set up in accordance 
with a Directive 2010/63/EU and approved by the local veterinarian Committee for Bioethics of 
IPAC RAS (N19-16.06.2017) and MSMU (22/10/17-MSMU-35). Bone marrow collection from 
healthy volunteers was done under GMP license (Neuroplast BV Farmatec The Netherlands) and 
approved by Ethical Committee of MUMC, Maastricht University (iCell1 METC MUMC and iCell2 
METC Zuyderland Zuid). All efforts were undertaken to ensure compliance with above-
mentioned regulations concerning human endpoint in animal research. 
 
Study design 
Experimental designs were based on reported patterns of pathology in employed models. ALS 
pathology in 12-week-old FUS-tg mutants is characterized by rapid, progressive motor neuron 
degeneration within 2 weeks (Shelkovnikova, Peters et al. 2013), while SOD-1 mouse line (G93A 
mutants) has more gradually developing ALS pathology displaying its first signs by the age of 
about 16 weeks 25 progressing to the human endpoint within 4-6 weeks (Browne and Abbott 
2016, Rodriguez-Cueto, Santos-Garcia et al. 2018). We devoted our efforts to ensure compliance 
with above-mentioned observations concerning human endpoint in animal research. At the age 
of 7-8 weeks, FUS-tg animals and wild-type (WT) controls were studied in a cat-walk, grip test, 
weighed (data not shown), and assigned to groups. At the age of nine weeks, FUS-tg and WT 
mice received (a) regular tap water, or (b) riluzole (Ril; 8 mg/kg/day, via drinking water), or (c) or 
celecoxib (Cel, 30 mg/kg/day) via food pellets, or (d) single i.c.v. administration of Neuro-Cells 
(NC, 500,000-CD34+ in 10 μL of Ringer Lactate buffer), or (d) i.c.v. administration of Ringer Lactate 
buffer (Figure 1A). Doses of pharmaca were selected as described previously (Pompl, Ho et al. 
2003, Li, Sung et al. 2013, Costa-Nunes, Cline et al. 2015); see below). Stereotaxic surgery was 
adapted from previously reported procedure (Strekalova, Wotjak et al. 2001). During the 
following six weeks, all mice were weekly weighed and studied in the rotarod, pole, and wire 
tests for motor function, dosing with pharmaca was continued. As post-surgery physiological 
parameters of wild-type mice that received either tap water or i.c.v. vehicle injection were 
similar (Figure S1), these two groups were merged into a vehicle-treated (Veh) group for 
subsequent analysis. On Week 6, at the age of fifteen weeks, mice were investigated for food 
and water intake and then sacrificed 24 hours thereafter. Mice were either perfused with NaCl 
or 4%-paraformaldehyde; muscle gastrocnemius, blood, and spinal cord were harvested for 
weighing, Western blot, ELISA assays, and histology. Since Neuro-Cells-treated animals showed 
greater functional improvement than other groups, these mice and mutants subjected to the 
i.c.v. vehicle infusion were studied in all in vitro assays including muscle atrophy and motor 
neuron counts in the lumbar part of the spinal cord. The concentrations of IL-1ß and IL-6 in blood 
serum and protein expression of IL-1ß, IL-6, Iba-1, and GSK-3ß in the lumbar part of the spinal 
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cord of mice treated with either vehicle, Neuro-Cells, or celecoxib were measured by ELISA and 
Western blot assays. Pharmaca outline and genotype were double blind for all experimenters. 
Numbers of animals used are indicated in Figure legends. In additional experiment, SOD-1 male 
mice (G93A line) at age 12 weeks were subjected to the i.c.v. infusion of the Neuro-Cells from 
the batch used in FUS-tg animals (SOD-1-NC group, n = 7) or to the i.c.v. vehicle administration 
(SOD-1-Veh group, n = 5; Figure 1B).  Mice were weekly weighed and tested for motor functions 
for nine weeks as in a previous study and sacrificed at age of 21 weeks, at the onset of ALS-like 
syndrome in this model (Gurney, Pu et al. 1994, Li, Sung et al. 2013, Browne and Abbott 2016, 
Rodriguez-Cueto, Santos-Garcia et al. 2018) 
 
 
Figure 1. Experiment design of the study on (A) FUS-tg mice and (B) SOD-1 mice 
 
Functional readouts 
Weekly measured body weights of mice were normalized to their baseline values recorded at 
week 1 (Figure 1). Body weights during weeks 1-6 and weight gain between these weeks were 
normalized to the mean values of wild-type mice treated with vehicle (WT-Veh). On the 6th 
week, 24-hour food intake and 12-hour water intake were evaluated as described elsewhere 




Mice were allowed to grip a horizontal wire (diameter 0.3 cm, height above the surface 60 cm) 
for 180s. The latency of falling and the number and percent of mice with falling events (latency 
< 20s) were recorded as described elsewhere (Veniaminova, Oplatchikova et al. 2019). 
 
Pole test 
Mice were placed on a top of the vertical bar (diameter 1.1 cm, height 60 cm) and allowed to 
climb down to a horizontal surface. The latency of descending the bar and the number and 
percent of mice with sliding events (latency to descend < 50s) were scored as described 
elsewhere (Veniaminova, Oplatchikova et al. 2019). 
 
Rotarod 
Mice were placed on constantly rotting rod of rotarod (Columbus Instruments, Columbus, OH, 
USA; speed 10 rpm) for 600s. Latency to fall and the number and percent of mice with falling 
events (latency < 200s) were registered in three runs as described elsewhere (Veniaminova, 
Oplatchikova et al. 2019). 
 
Administration of drugs 
In the study with FUS-tg mice, potential effects of Neuro-Cells were compared to effects of 
celecoxib, NSAID, and a COX-2 inhibitor, that was used as a classic anti-inflammatory compound 
(Goldenberg 1999, Pompl, Ho et al. 2003, Maciel, Silva et al. 2013), and of riluzole (2-amino-6-
trifluoromethoxy-benzothiazole), a standard ALS treatment that can slow down the fatal disease 
progress by 2-3 months (Miller, Mitchell et al. 2012) and frequently serves as a reference drug in 
translational studies with ALS (Li, Sung et al. 2013, Rodriguez-Cueto, Santos-Garcia et al. 2018).  
Riluzole tablets (Sandoz, Almere, Netherlands) were crushed and dissolved in tap water, and its 
concentration was adjusted to the dosage of 8 mg/kg/day and daily water intake in CD1 mice (Li, 
Sung et al. 2013, Rodriguez-Cueto, Santos-Garcia et al. 2018). Celecoxib-containing food pellets 
were produced as described elsewhere (Costa-Nunes, Cline et al. 2015), and drug concentration 
was adjusted to the dosage of 30 mg/kg/day and daily diet consumption. 
 
Generation, properties, and intracerebroventricular infusion of Neuro-Cells 
Neuro-Cells, a preparation of human bone marrow-derived HSCs and MSCs, was provided by 
Neuroplast BV (Maastricht, Netherlands). The Neuro-Cell preparation comprised 1.39 × 106 MSCs 
and HSCs, containing 5 × 105 CD34+ cells in 10 μL. The expression profile of MSC markers was 
overlapping; in the total cell preparation 85.6% were CD105+, 13% were CD90+, 7% were CD271+, 
and 4% were CD73+ in single FACs staining. Prior to infusion, cells were resuspended and checked 
for vitality (see Data S1 and Table S2). Animals were anesthetized by halothane (Halothane TM; 
Willy Rusch, Boblingen, Germany) and immobilized in a stereotaxic frame (World Precision 
Instruments, Sarasota, TX, USA) for unilateral i.c.v. infusion via a hole made in a scull of mice as 
described elsewhere (Strekalova, Wotjak et al. 2001). All preparations of Neuro-Cells were from 
the same stock sample. They were arranged ex temporo; after thawing, cell counting was 
performed using the “Countess II FL Automated Cell Counter” (Thermo Fisher Scientific 
AMQAF1000, Toronto, ON, Canada) showing 62%-68% cell vitality (see Data S1).  
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Subsequent flow cytometry was done, and HSC numbers were adjusted for injection. Pilot 
studies carried out to determine the distribution of infused Neuro-Cells and optimize the 
protocols for the i.c.v. administration, suggested their presence in the brain and peripheral 
organs 12 and 24 hours after injection (100,000 or 250,000 cells were infused to lateral ventricles 
in 12 mice; see Data S1). Immunohistochemical study of Neuro-Cells-treated mice with human 
antimitochondrial antibodies was carried out as described elsewhere (Donders, Vanheusden et 
al. 2015) and revealed a positive signal in their ventricles, brain tissue, lungs, and spleen, 
suggesting a wide distribution of Neuro-Cells in the cerebrospinal fluid and persistent vitality (see 
Data S1; Figures S1 and S2). These findings are consistent with the results of the pilot study with 
i.c.v. infusion of bone marrow-derived mouse stem cells obtained from mutants expressing 
green fluorescent protein (GFP) (see Data S1; Figure S3,S5). These experiments showed that i.c.v. 
administration of Neuro-Cells to mice at the concentrations 100,000-500,000 is well tolerated. 
 
Blood and tissue collection 
Mice were terminally anesthetized by sodium pentobarbitone and from about a half of them, 
blood, both gastrocnemius muscles and lumbar parts of the spinal cord were collected as 
described elsewhere (Howland, Liu et al. 2002). Another half was perfused with 4% 
paraformaldehyde; the lumbar parts of spinal cords and muscle gastrocnemius were dissected 
as described elsewhere (Howland, Liu et al. 2002). 
 
Scoring for muscle atrophy 
Muscle gastrocnemius was fixed, sectioned, and stained for hematoxylin and eosin. Scoring for 
atrophy was performed by three independent pathologists, blinded to sample identity using a 
light microscope (Axiovision 4.3, Zeiss, Berlin, Germany); ranking histograms were generated 
ranging samples were from 1 to 11 from “moderate” (1) to “severe” (11) atrophy. 
 
Motor neuron counting 
Briefly, cross sections were carried out at 50-μm cuts encompassing L3-L5 with 250 μm interval 
and stained with thionine NISSL. Counts were performed by two observers blinded to sample 
identity using a Zeiss Axoplan2 system (Zeiss, Berlin, Germany). 
 
ELISA of plasma cytokines 
Mouse enzyme-linked immunosorbent assay (ELISA) was performed using MOUSE IL-1β and IL-
6 ELISA MAX™ Deluxe Sets (BioLegend, San Diego, CA, USA) according to the manufacturer's 
instructions; protein concentrations were measured using the BCA protein assay kit (Pierce, 
Rockford, IL, USA) as described elsewhere (Couch, Anthony et al. 2013). 
 
Western blot and protein isolation 
Western blot analysis on spinal cord samples and quantification of protein concentration were 
performed as described elsewhere (58; see Table S3). Relative expression of proteins was 
calculated in fold changes from levels of β-tubulin as described elsewhere (Gorlova, Pavlov et al. 
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GraphPad Prism 6.00 software (San Diego, CA, USA) was used; dependently on groups, multiple 
group comparisons were analysed using one-way, two-way, and repeated-measures ANOVA 
followed by the Tukey's test. Mann-Whitney test was used for two-group comparisons. 
Qualitative data were analyzed by Fisher's exact test. The level of significance was P < .05. The 




Physiological parameters in FUS-tg mice treated with riluzole, celecoxib, or Neuro-Cells 
 
Body weight, food, and liquid intake 
Repeated-measures ANOVA and post hoc Tukey's tests revealed significant increases in body 
weight normalized to the basal values in WT-Veh, WT-Ril, and WT-Cel mice from week 1 to week 
6 (F3,29=7.86, P=.023; Figure 2A). FUS-tg-Veh mice displayed a significant decrease in this measure 
(F3,29=12.76, P =.0147). No significant changes in this parameter were found in FUS-tg mice that 
received either treatment (P>.05) indicating partial rescue effects of all applied treatments on 
FUS-tg mice. Two-way ANOVA and post hoc Tukey's test revealed a significant effect of genotype 
on body weight, normalized to the means of control mice at each week of study, at third to sixth 
weeks (P<.05, two-way ANOVA). This parameter was significantly lower in FUS-tg-Veh mice on 
the third to sixth weeks than in WT-Veh group (P=.031, P=.026, P=.018 and P=.001, respectively; 
Tukey's test, Figure S5). Such decreases were found in FUS-tg-Ril mice on the sixth week (P=.043) 
and in FUS-tg-Cel group, on the fifth and sixth weeks (P=.025 and P=.019, respectively), but not 
in FUS-tg-NC animals. ANOVA showed significant effects of genotype and treatment for body 
weight gain (F1,10=27.98, P<.0001, and F3,10=3.499, P=.0182), but not for their interaction 
(F3,10=0.7239, P=.53499). There was a significant decrease in body weight gain in FUS-tg- Veh, 
FUS-tg-Ril, and FUS-tg-Cel groups, but not in FUS-tg-NC animals, in comparison with controls 
(F2,15=4.6, P=.012; F2,7=18.39, P=.0068; F2,8=9.27, P<.005; F2,19=1.06, P=.599; respectively, Tukey's 
test, Figure 2B). FUS-tg-NC did not differ significantly from FUS-tg-Veh animals in this measure 
(F2,11=2.59, P=.1827). At Week 6, ANOVA showed significant effects of genotype and treatment 
for body weight (F1,10=27.98, P <.0001, and F3,10=3.499, P=.0182), but not for their interaction 
(F3,10=0.7239, P=.53499).  FUS-tg-Veh animals showed a significant decrease in body weight in 
comparison with WT-Veh group (F2,15=34.72, P=.015, Figure 2C) that was not observed in FUS-tg-
treated groups (P>.05).  ANOVA revealed significant genotype effect for liquid intake (F1,57=11.78, 
P=.0011), but not treatment and a tendency to significance in their interaction (F3,57=0.6534, 
P=.5841 and F3,57=2.404, P=.0769). There was significant genotype effect for food intake 
(F1,71=10.58, P=.0018), but not treatment effect, nor their interaction (F3,71=1.192, P=.3189, and 
F3,71=1.136, P=.3404).  
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In comparison with WT-Veh group, both parameters were significantly decreased in FUS-tg-Veh 
mice (food intake: F2,29=10, P=.0018, liquid intake: F3,29=11.78, P=.0011; Tukey's test; Figure 
2D,E), but not in mutants that received either treatment (P>.05). Together, in a course of the 
development of ALS pathology, FUS-tg-Veh mice showed a decline in physiological readouts, 






Figure 2. Effects of riluzole, celecoxib, and Neuro-Cells on Physiological parameters of FUS-tg mice. A, There was a significant increase in 
body weight in the WT groups, but not in the FUS-tg-Veh mice (*P < .05 vs basal values; see the text). FUS-tg mice-NC group showed a 
significant weight gain. B, In comparison with controls, there was significantly lower weight gain in FUS-tg mice except FUS-tg-NC, (*P < 
.05 vs WTVeh group); no such changes were found in the FUS-tg-NC group (P > .05). C, At Week 6, there was a significant reduction of body 
weight in FUS-tg-Veh group in comparison with wild-type controls (*P < .05); no such changes were found in mutants that received other 
treatments (P > .05). In comparison with WT-Veh group, FUS-tg-Veh group displayed a significant decrease in (D) liquid intake and (E) food 
intake (*P < .05), but not other FUS-tg groups. Each WT-group was comprised of 8 animals; 7-11 mice were used in FUS-tg groups (FUS-




No significant group differences were found in motor tests till sixth week of the study, on week 
1-5 (P>.05; data not shown). At sixth week, in the wire test, the number of animals that has fallen 
from the wire was significantly higher in FUS-tg-Veh group than in controls (P=.018, Fisher's test; 
Figure 3A), that was not the case for groups of mutants subjected to either treatment (P>.05). In 
addition, this measure was significantly lower in FUS-tg-NC mice than in FUS-tg-Veh mice 
(P=.0028, Fisher's test). ANOVA showed significant effects of genotype and treatment for the 
latency to fall (F1,89=24.52, P<.0001 and F3,89=2.867, P=.0410), but not for their interaction 
(F3,89=1.126, P=.3431) and a significant decrease of this parameter in FUS-tg-Veh mice in 




Figure 3. Motor parameters in FUS-tg mice and effects of riluzole, celecoxib, or Neuro-Cells. In comparison with WT-Veh mice, FUS-tg-Veh 
group showed a significant (A) increase in the number of mice with falling events and (B) decrease in the latency to fall in the wire test, 
that was not found in FUS-tg animals that received either treatment (P>.05). FUS-tg-NC mice had a significantly lower number of mice with 
falling events. In the pole test, in comparison with controls, FUS-tg-Veh, FUS-tg-Ril, FUS-tg-Cel, but not in FUS-tg-NC had a significantly (C) 
higher number of mice with sliding events and (D) decrease in the latency to descend. The latter group had a significantly fewer mice with 
sliding events than the FUS-tg-Veh group. In the rotarod, in comparison with WT-Veh animals, FUS-tg-Veh mice, but not mutant mice that 
received either treatment, had (E) higher number of mice with falling events and (F) a significant decrease in the latency to fall. FUS-tg-NC 
mice had a significantly fewer number of animals displaying falling in comparison with the FUS-tg-Veh group; this group and riluzole-
treated FUS-tg mice did not show changes in the latency to fall in comparison with the WT-Veh mice (*P < .05 vs WT-Veh group, #P < .05 
vs FUStg-Veh group; left panels: exact Fisher's test, right panels: two-way ANOVA and Tukey's test). Each WT-group was comprised of 10 
animals; 7-15 mice were used in FUS-tg groups (FUS-Veh, n = 15; FUS-Ril, n = 10, FUS-Cel, n = 7, FUS-NC, n = 9). 
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No such differences were observed in FUS-tg mice that received either treatment (P>.05). In the 
pole test, in comparison with WT-Veh animals, the number of animals with sliding events was 
significantly higher in FUStg-Veh, FUS-tg-Ril, and FUS-tg-Cel groups (P=.0023, P=.018, and P=.001, 
respectively; Fisher's test; Figure 3C), but not in the FUStg-NC group (P=.38). This measure was 
significantly smaller in the latter group than in FUS-tg-Veh group (P=.0012; Figure 3D).  
There were significant showed significant effects of genotype for the latency to descend 
(F1,77=29.03, P<.0001, two-way ANOVA), but not for treatment and their interaction (F3,77=1.471, 
P=.2289, and F3,77=0.1812, P=.9089). This measure was significantly shorter in FUS-tg-Veh and 
FUS-tg-Cel animals than in controls (P=.025 and P=.032¸ respectively; Tukey's test; Figure 3F) 
suggesting sliding of these mice and motor deficits. No such changes were shown for FUS-tg-Ril 
and FUS-tg-NC animals (P=.32 and P=.55, respectively).  
The number of animals falling off the rotarod test was significantly higher in FUS-tg-Veh group 
than in WT-Veh controls (P=.029, Fisher's test; Figure 3E). No such differences were observed in 
mutants from the treatment groups (P>.05); this parameter was significantly lower in FUS-tg-NC 
mice than in FUS-tg-Veh group (P=.0015). ANOVA showed significant effects of genotype for the 
latency to fall in this test (F1,99=14.36, P=.0003), but not for treatment and their interaction 
(F3,99=1.431, P=.2383, and F3,99=1.048, P=.3747). A significant decrease in this measure was found 
in FUS-tg Veh group as compared to WT-Veh group (F3,29=7.28, P=.023 Tukey's test; Figure 3F), 
but not in the groups mutants that received either treatment (P>.05).  
Thus, all treatments prevented the occurrence of significant motor decline in FUS-tg mice in 
comparison with controls, whereas only the Neuro-Cells infusion resulted in a significant 
improvement in motor performance in comparison with vehicle-treated mutants. While housing 
on celecoxib-containing food pellets resulted in a non-significant decrease of body weight in a 
control group, this factor has unlikely interfered with the evaluation of ALS syndrome in 
celecoxib-treated mutants, since no differences in behavioural and physiological parameters 
were found between naïve and celecoxib-treated controls. 
 
Histological hallmarks of ALS syndrome in FUS-tg mice and effects of Neuro-Cells 
There was a significant difference group difference in mass of the left and right muscle 
gastrocnemius (F3,29=11.30, P=.004, and F3,29=12.35, P<.001, respectively, one-way ANOVA). In 
comparison with WT-Veh group, FUS-tg-Veh and FUS-tg-Ril mice, but not FUS-tg-NC animals, 
showed a significant decrease in these measures (P=.004 and P=.008, P=.002 and P=.0016, 
P=.273 and P=.3165, respectively, Tukey's test; Figure 4A,B). Because FUS-tg-Ril mice showed a 
loss of muscle mass similar to that of FUS-tg-Veh animals, further assessment of muscle atrophy 
using a histological assay was carried out FUS-tg-NC mice that were compared against FUS-tg-
Veh animals. Histological analysis revealed significant atrophy of muscle gastrocnemius in FUS-
tg-Veh mice (Figure 4C-E). FUS-tg-NC group had significantly lower scores of muscle 
degeneration than FUS-tg-Veh mice (U=9.6, P=.037, Mann-Whitney). Thus, muscle atrophy in 
mutants was partly rescued by Neuro-Cells infusion. Next, we examined the effects of Neuro-
Cells administration on the motor neuron degeneration at a time corresponding to the onset of 
the ALS syndrome and the muscle atrophy, as mentioned above. At this time, there was a 
significant loss (40%-60%) of motor neurons in the FUS-tg mutants. FUS-tg-NC group displayed 
improved motor scores in comparison with other groups as well as higher muscle mass as 
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compared to Ril-treated mutants. Thus, motor neuron counts in the lumbar L3-L5 mouse spinal 
cord were studied in FUS-tg mice treated with either vehicle or Neuro-Cells. We found that the 
number of motor neurons in the lumbar parts of the spinal cord of FUS-tg-NC animals was 




Figure 4. Histological hallmarks of ALS-like syndrome in FUS-tg mice treated with Neuro-Cells. In comparison with WT-Veh, FUS-tg-Veh, 
FUS-tg-Veh and FUS-tg-Ril showed a significant decrease in the mass of muscles gastrocnemius of (A) left and (B) right limbs (*P<.05 vs 
WT-Veh group) that was not observed for FUS-tg-NC group (P>.05; 6-10 mice were used: WT-Veh, n=10, FUS-Veh, n=10; FUS-tg-Ril, n=8, 
FUS-tg-NC, n=6). C, A score of atrophy between (D) moderate and (E) severe cases (extreme histological examples in mice from FUS-tg-NC 
(n=5) and FUS-tg-Veh (n=6) groups) revealed significantly lower scores for FUS-tg-NC than FUS-tg-Veh mice (P*<.05, Mann-Whitney). F, 
The number of motor neurons was significantly higher in FUS-tg-NC of FUS-tg-Veh mice (P*<.05, Mann-Whitney, 6 mice per group were 
used). H,G, Photomicrographs exemplifying the range of motor neuron number in the ventral horn of the lumbar cord in FUStg-NC of FUS-
tg-Veh mice in lumbar parts of the spinal cord, respectively. Scale bar=20 μm. 
 
Pro-inflammatory changes and altered activities of GSK-3 in FUS-tg mice: effects of 
celecoxib and Neuro-Cells 
There were significant group differences in serum concentrations of IL-1β and IL-6 (F=10.62 
P<.001, and F=11.74, P<.001, one-way ANOVA, respectively). In comparison with WT-Veh mice, 
these measures were significantly elevated in FUS-tg-Veh group (P=.012 and P=.035, 
respectively; Tukey's test; Figure 5A,B). No such increases in IL-6 were found for FUS-tg-Cel and 
FUS-tg-NC groups (P = .29 and P=.22, respectively). These groups showed a significant decrease 
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in this measure in comparison with the FUS-tg-Veh mice (P=.01 and P=.025, respectively). In 
comparison with FUS-tg-Veh group, serum levels of IL-1β were significantly lower in FUS-tg-Cel 
mice and non-significantly lower in FUS-tg-NC mice (P=.042 and P=.065, respectively; Figure 5A); 
no other significant differences were found. Significant group differences in protein levels were 
found for GSK-3β, IL-1β, and Iba-1 (F=4.992, P=.0035; F=6.784, P=.0006; and F=5.605, P=.0018) 
but not GSK-3α (F=1.359, P=.272). In comparison with WT-Veh mice, expression of GSK-3β, IL-
1β, and Iba-1, but not GSK-3α was significantly elevated in FUS-tg-Veh animals (P=.026, P=.013, 
P=.041, and P=.14, respectively, Tukey's test; Figure 5C-F; for original Western blot images used 
for quantification see Figure S6).  
 
 
Figure 5. Effects of celecoxib and Neuro-Cells on the expression of molecular markers of inflammation and GSK-3 in FUS-tg mice. A, In 
comparison with controls, animals from FUS-tg-Veh and FUS-tg-NC groups displayed increased serum concentrations of IL-1β; FUS-tg-Cel 
group displayed reduced values of this measure in comparison with FUS-tg-Veh mice. B, In comparison with controls, FUS-tg-Veh, but not 
FUS-tg-Cel and FUS-tg-NC, had elevated serum IL-6. Two later groups had significantly lower serum IL-6 concentrations than FUS-tg-Veh 
group. In comparison with WT-Veh mice, there were significantly elevated protein levels of (C) GSK-3β, (E) IL-1β and (F) Iba-1 in spinal 
cords of FUS-tg-Veh animals; but not in FUS-tg-Cel and FUS-tg-NC groups. D, No significant differences were found in the protein levels of 
GSK-3α (P>.05). FUS-tg-NC group showed significantly lower values of protein expression of GSK-3β, IL-1β, and Iba-1 than FUS-tg-Veh 
mice. FUS-tg-Cel group showed a significant decrease of IL-1β expression in comparison to FUS-Veh group. (*P<.05 vs WT-Veh group, 
#P<.05 vs FUS-tg-Veh group: one-way ANOVA and Tukey's test). 5-9 mice per group were used: 6 mice in WT-Veh group, 5 mice in WT-Cel 




All increased parameters were significantly lower in FUS-tg-NC mice than in the latter group 
(P=.0027, P=.011, and P=.036, respectively); similar decreases were found in FUS-tg-Cel group 
for IL-1β, but not for GSK-3β and Iba-1 (P=.017, P=.181, and P=.785, respectively). Thus, both 
administration of celecoxib and Neuro-Cells decreased, but only the latter treatment has 
significantly lowered expression of markers of microglial activation Iba-1 and GSK-3β in the spinal 
cord. 
 
Effects of administration of Neuro-Cells infusion in SOD-1 mice 
There were no significant differences in body weight between SOD-1-Veh and SOD-1-NC groups 
during weeks 1-9 (P>.05; Mann-Whitney test). The number of mice fallen from the wire was 
significantly lower, and the latency to fall was significantly longer in SOD-1-NC than in SOD-1-Veh 
groups (P=.028, Fisher test; and U=4.5, P=.003; Figure 6A,B). No other group differences were 




Figure 6. Effects of Neuro-Cells infusion in SOD-1 mice. A, There were significantly fewer numbers of mice displaying the falling in the wire 
test in SOD-1-NC mice than in SOD-1-Veh mutants. B, The latency to fall in the wire test was significantly longer in SOD-1-NC mice than in 
SOD-1-Veh. C, D, There was nonsignificant trend to higher muscle weight in SOD-1-NC than in SOD-1-Veh group for left and right muscles 
gastrocnemius, respectively, and for (E,F) higher liquid and food intake in SOD-1-NC mice than in SOD-1-Veh animals (*P<.05 vs SOD-1-Veh 
group). 5 mice were used in SOD-1-Veh group, and 7 mice were used in SOD-1-NC group  
There was a trend to higher muscle weight in SOD-1-NC animals in comparison with SOD-1-Veh 
mice for left and right muscles gastrocnemius (U=6.5, P=.081, and U=7, P=.10, respectively; 
Figure 6C,D) and an optical trend to higher liquid and food intake in SOD-1-NC mice (U=7, P=.10, 
U=3.6, P=.16; Figure 6E,F). Thus, Neuro-Cells infusion to SOD-1 mutants resulted in overall 




Our study supports the hypothesis that the new stem cell preparation Neuro-Cells ameliorates 
an experimental ALS syndrome. A single i.c.v. infusion of Neuro-Cells into FUS-tg mutants 
counteracted the development of neurodegenerative changes, muscle atrophy, motor deficits, 
and general physical decline and was associated with a decrease in inflammatory markers. These 
findings are in accordance with recently published results demonstrating beneficial functional 
and anti-inflammatory action of Neuro-Cells in a rat model of spinal cord injury (de Munter, 
Beugels et al. 2019). The effects of Neuro-Cells in FUS-tg mice were compared against standard 
therapies with riluzole and classic anti-inflammatory drug celecoxib. These standard treatments 
partially ameliorated ALS pathology, but these improvements were less marked than the effects 
of Neuro-Cells. The administration of Neuro-Cells, but not celecoxib, normalized the expression 
of Iba-1, a marker of microglial activation and GSK-3ß expression in the spinal cord. While the 
administration of celecoxib altered cytokine expression in the mutants in a similar manner as 
Neuro-Cells, it did not alter the expression of Iba-1 and GSK-3ß in the mutants. The findings 
concerning Iba-1 and GSK-3ß expression support the view that there is a critical role for microglial 
activation and inflammation in ALS (Hu, Cao et al. 2017, Mishra, Vijayalakshmi et al. 2017, 
Morello, Spampinato et al. 2017, Shruthi, Sumitha et al. 2017, Crisafulli, Brajkovic et al. 2018). 
The upregulation of GSK-3ß cascade is known to be functionally associated with pro-
inflammatory changes and microglial activation, which is a well-established marker of ALS 
histopathology, and the FUS-ALS forms in particular (Stoica, Paillusson et al. 2016, Duda, 
Wisniewski et al. 2018). GSK-3ß activities are inversely related to neurotrophin expression, and 
its downregulation is another recognized molecular feature of human ALS (Mishra, Vijayalakshmi 
et al. 2017, Shruthi, Sumitha et al. 2017, Sumitha, Manjunatha et al. 2019). GSK-3ß is also 
implicated in the mechanisms of microglial activation during neurodegeneration (Luca, Calandra 
et al. 2018). Thus, present study suggests that microglial activation and increased GSK-3ß 
activities could be targets for ALS therapy, as they were normalized by the administration of the 
stem cell therapy. It is a generally held view that the anti-inflammatory effects of stem cells are 
considered to be attributable to the paracrine activity of anti-inflammatory cytokines and growth 
factors, as well as the release of extracellular vesicles containing anti-inflammatory and anti-
apoptotic proteins (de Munter and Wolters 2013, Spees, Lee et al. 2016, Dostert, Mesure et al. 
2017). These processes are likely to act on RNA-dependent and RNA-independent elements of 
FUS related pathology (Shelkovnikova, Robinson et al. 2014, An, Skelt et al. 2019, Marrone, 
Drexler et al. 2019).  Transplanted bone marrow derived stem cells were shown to secrete such 
anti-inflammatory cytokines and growth factors, as IL-10, vascular endothelial growth factor 
(VEGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), brain-derived 
neurotrophic factor (BDNF), neuronal growth factor (NGF), and others (Redondo-Castro, 
Cunningham et al. 2017, Kshitiz, Ellison et al. 2019). This secretion was shown to be condition-
dependent, and in particular, the presence of inflammation was found to stimulate the release 
of the anti-inflammatory molecules (Redondo-Castro, Cunningham et al. 2017). Given that FUS 
protein is considered to be functionally related with insulin/IGF-signaling pathway (Therrien, 
Rouleau et al. 2016), an important element of which is BDNF, a ligand of TrkB receptor (Cline, 
Steinbusch et al. 2012), which regulates the mechanisms of cellular stress (Hoell, Larsson et al. 
2011, Sama, Ward et al. 2013), it can be suggested that paracrine secretion of Neuro-Cells 
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cytokines and growth factors may underlie the anti-inflammatory and antidegenerative changes 
observed in the FUS-tg mice. In addition, FUS protein can regulate the serine-threonine protein 
kinase (Ak strain transforming, Akt) and forkhead box O1 (FOXO) proteins (Gorlova, Pavlov et al. 
2019), further elements of GSK-3β cascade that can explain the reported changes in GSK-3β 
expression in the FUS-tg model. Moreover, paracrine secretion by stem cells of trophic factors 
can ameliorate decreased vascular network density in lumbar spinal cords, a recently 
demonstrated disease mechanism in employed here FUS-tg mice, which is sensitive to a therapy 
with angiogenetic/growth factors (Crivello, Hogg et al. 2019). Thus, it might be speculated that 
the effects of the stem cells might be due to paracrine activities and the release of neurotrophins 
and anti-inflammatory cytokines that classical drug therapy cannot provide (de Munter and 
Wolters 2013). We found that the physiological parameters and performance of FUS-tg mice 
treated with Neuro-Cells compared to mutants receiving other therapies were better preserved. 
In particular, celecoxib-treated mutant mice exhibited limited amelioration of the functional 
endpoints and no changes in the Iba-1 or GSK-3ß expression. These data may go some way to 
explain the reported failures of using anti-inflammatory drugs during ALS (Gordon, Moore et al. 
2007, Calvo, Moglia et al. 2010, Collins and Bowser 2017). Nevertheless, standard ALS and anti-
inflammatory treatment induced partial ameliorative effects on the ALS-related abnormalities 
that validates the FUS-tg line as a model of ALS. To verify results obtained on FUS-tg mice, we 
performed the i.c.v. infusion of Neuro-Cells in SOD-1 mutants, the classic ALS model. The results 
indicated that there were improved motor functions under these conditions following Neuro-
Cells administration. Together, our data provide evidence of the disease-counteracting and anti-
inflammatory effects of Neuro-Cells in two experimental models of ALS and are in line with 
previously published reports on effectiveness of stem cell therapy during this disease (Ruiz-
Lopez, Guardiola et al. 2016, Agarwala and Tamplin 2018), as well as with previous findings with 
this preparation applied in a spinal cord injury model (de Munter, Beugels et al. 2019). They also 
highlight the importance of compliance in preclinical ALS studies with the internationally 
accepted guidelines (Ludolph, Bendotti et al. 2010) to more accurately approximate the 
usefulness of novel therapeutics (see Data S1), including stem cells and thus provide a better 
basis for clinical trials. 
 
Conclusions 
Our study provides the first evidence for greater efficacy of Neuro-Cells as a therapeutic option 
capable of counteracting the progression of ALS-like pathology and accompanying inflammatory 
changes in comparison with the standard pharmacological references. As discussed above, it is 
very likely that both MSCs and HSCs types of cells contribute to the effect seen in the study. 
While beneficial effects of HSCs are likely to be due to their well characterized roles in 
neuropoiesis and production of trophic factors, MSCs, besides their crucial function in the 
regulation of HSCs functions, might ameliorate angiogenesis and vascular density and exert anti-
inflammatory effects. Further research is needed to define the mechanisms of anti-inflammatory 
action and other effects of Neuro-Cells on hallmarks of ALS syndrome. Yet, at this stage, stem 






Animals and housing 
Mouse colony of FUS-tg mice and their wild type littermates (WT) was bred in the FDA-certified 
SPF facilities of IPAC; generation of FUS-tg mice is described below. SOD-1 mutant mice were 
obtained from Charles River provider (see main text). Starting from two weeks prior to the 
experiment, six-weeks-old male mice were single-housed under standard conditions (12 hrs 
light/dark cycle, lights on at 21:00, humidity 50–60%, temperature 22±1°C) with food and water 
ad libitum. All efforts were undertaken to minimize the potential discomfort of experimental 
animals.  
 
Generation of FUS-tg mice  
Generation of FUS-tg mice was performed as described elsewhere (Schelkovnikova et al., 2013). 
Briefly, a fragment of human FUS [1–359] cDNA including 9 bp of 5′-UTR was cloned into Thy-1 
promoter plasmid 323-pTSC21k. A gel-purified fragment obtained by digestion of the resulting 
plasmid DNA with NotI was used for microinjection of mouse oocytes. Transgenic animals were 
identified by PCR analysis of DNA from ear biopsies by the presence of 255-bp product (primers 
5′-TCTTTGTGCAAGGCCTGGGT-3′ and 5′-AGAAGCAAGACCTCT-GCAGAG-3′). The original 
transgenic line on C57Bl6/CBA genetic background was backcrossed with CD1 wild type mice for 
several (>7) generations. 
 
Characteristics of human marrow stem cells  
“Neuro-Cells” is a standardized preparation of fresh, unmanipulated human bone marrow-
derived stem cells, which is produced under regulations of good manufacturing practices (GMPs) 
without expansion and/or labeling (de Munter et al., 2019; patent WO2015/059300A1). Neuro-
Cells comprise mesenchymal stem cells and their progenitors (MSCs), hematopoietic stem cells 
and their progenitors (HSCs), and other mononuclear cells (Table 1). 
 
Table 1  
Characterization of cell populations in ''Neuro-Cells" preparation 
Cell populations in Neuro-Cells Absolute number of cells injected per mouse in 10  µl 
Total number of nucleated cells  1.39 x 106/10  µl 
CD34+ cells 5.00 x 105/10  µl 
Other mononucleated cells 8.9 x 105/10 µl 
The proportion of MSCs expressing CD markers in overlapping manner (in total cell preparation, defined by single 
staining assay): 
MSC: CD271+ cells (7%) 
MSC: CD90+ cells (13%) 
MSC: CD105+ cells (85.9%) 




Production of human marrow stem cells  
For production of Neuro-Cells, healthy volunteer donors with informed consent were recruited 
for collection of 50-75 mL of bone marrow from their iliac crest under local anesthesia following 
standard operating procedures. Briefly, mononuclear cells were isolated by Ficoll density 
gradient centrifugation (1.077 g/ml; Sigma, Munich, Germany) at 400×g for 35 minutes. The 
mononuclear cells were re-suspended in the culture medium composed of DMEM (GIBCO, 
Rockville, MD, USA) with low glucose concentration and 10% fetal bovine serum (FBS; Hyclone, 
Logan, UT, USA). The mononuclear cells were plated at 1×106 cells/25 cm2 in culture flasks and 
the cultures were incubated at 37°C in 5% CO2 in the air and 95% humidity. The medium was 
exchanged after 48 hours and then every 3 to 4 days. When the cultures reached approximately 
90% of confluence, human marrow stem cells (“Neuro-Cells”) were passaged with 0.25% trypsin 
(GIBCO) and re-plated into passage culture at a density of 5000 to 10,000 cells/cm2. Cells at 
passages 3 and 4 were used for transplantation. Upon harvest, the cells were isolated by 
treatment with 0.25% trypsin. The cells were then washed four times and re-suspended in PBS 
at a density of 100,000 cells/μl. Viability of the cells was assessed using a 0.4% Trypan Blue dye 
(Sigma, Berlin, Germany) exclusion method prior to and following transplantation. The cells were 
analyzed for their immunophenotype by flow cytometry (Beckman Coulter, Fullerton, CA, USA). 
Fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin-conjugated antibodies specific 
for human CD14, CD19, CD45, CD34, CD73, CD90, CD105, and HLA-DR tested for flow cytometry 
application. The percentage of positive cells was determined based on fluorescence emission of 
the nonspecific FITC/phycoerythrin isotypic antibody controls. A preparation of Neuro-Cells was 
aliquoted, deeply frozen and stored at -80 C° until the use.  A standard thawing procedure was 
applied on the day of the administration of Neuro-Cells (see below). Cells were re-suspended in 
Ringer Lactate buffer; their vitality was evaluated as described above and concentration in buffer 
was adjusted to 500,000 CD34+ in 10 µl for i.c.v. injections; vials were kept in +4C°. Table 1 
presents an overview of the number of cells injected per a mouse. 
 
Thawing of Neuro-Cells preparations 
For all experiments with i.c.v. administration of Neuro-Cells, preparations from the same stock 
sample were arranged ex temporo. The standard thawing procedure is described in Table 2.  
 
Vitality assessment of Neuro-Cells preparations after thawing 
After thawing, сell counting was performed using the "Countess II FL Automated Cell Counter" 
(Thermo Fisher Scientific AMQAF1000, Toronto, ON, Canada) according to the manufacturer's 
protocol. Three batches of cells (Set 1, Set 2. And Set 3) from the same bone marrow extraction 
were used in the study.  
We checked viability of Neuro-Cells samples used in the study and ensured high vitality 
percentages in samples, that were ranging from 62 to 68% Subsequent flow cytometry was done 











Standard thawing procedure for Neuro-Cells 
Step 1 
1 50ml sterile Ringer Lactate solution is used 
pre-warm at 37°C water bath 
Step 2 
1  To thaw frozen Neuro-Cells, cryovials are placed in a water bath at 37°C until only a small  sliver of ice 
is  present; caution is paid to prevent cryovial cap from submerging in the water. 
2 A -  Cryovials are transferred  to  the laminar flow hood 
- all vials are wiped with 70% IPA before opening the cap using a 70% IPA soaked tissue 
 B  each thawed cell type is transferred into an individual 15ml tube containing 5ml pre-warmed thawing 
buffer  
 C - cryovials are rinsed twice with fresh pre-warmed thawing buffer  
- pooled cells are mixed by gently pipetting up/down  twice 
 D Suspension is centrifuged under 300g for 5 min 
 E - supernatant  is completely aspirated  
- the cell pellet are handled carefully  
- pellet is resuspended into the thawing buffer for washing 
 F For washing, pellet is centrifuged under 300g for 5 min  
 G supernatant  is completely aspirated  
- pellet is resuspended into the thawing buffer for washing 
- cells are pooled where applicable 
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Pilot study to define conditions of i.c.v. infusion of Neuro-Cells with stereotaxic surgery  
A pilot study was conducted to define optimal conditions of the i.c.v. infusion of Neuro-Cells to 
mice with stereotaxic surgery.  Following conditions of Neuro-Cell administration were tested in 
a pilot study on 12 CD1 mice: (1) 50, 000 cells for 5 min in 10 ul (n=1), (2) 50, 000 cells for 10 min 
in 10 ul (n=1), (3) 150, 000 cells for 10 min in 10 ul (n=1), (4) 250, 000 cells for 10 min in 10 ul 
(n=2), (5) 500, 000 cells for 10 min in 10 ul (n=2), (6) Ringer Lactate buffer, 10 ul (n=2), (7) no 
injection (n=1). (8) Additionally, the administration of 10, 000 stem cells obtained from bone 
marrow of a mutant mouse expressing green fluorescent protein (GFP) (Kovinva et al., 2019) for 
10 min in 10 ul (n=2) was carried out in order to compare a diffusion of human stem cell 
preparation against mouse stem cell preparation. Mice were killed 24 h after injection using 
halothane. Brain, liver, lungs, spleen were collected and stained for anti-mitochondrial human 
antigen from experimental sets 1-7, as previously described (Donders et al., 2015). Briefly, mice 
were deeply anesthetized by isoflurane inhalation and perfused transcardially with Ringer lactate 
(pH 7.4) and 4%-parapharmaldehyde (Sigma-Aldrich) in 30% PBS-sucrose (Merck Chemicals N.V., 
Overijse, Belgium).  Brains, lungs, lymph nodes, spleen were dissected, positioned into fixative 
solution for 24 h.  Subsequently, tissues were snap frozen in the gas phase of liquid nitrogen and 
stored at -80°C until further processing. Cryosections (10 µm) were cut and stored at -20°C until 
further processing. Staining for human mitochondria, a marker for cells of human origin in mouse 
tissue, was performed. Tissue slices were obtained with a Leica CM3050 S cryostat (Leica, Groot-
Bijgaarden, Belgium). The protocol of immunostaining with anti-human mitochondria was 
previously validated to detect injected cells in a rat study using double staining for C68-positive 
cells (Donders et al., 2015).  Slides were washed with Tris-buffered saline (VWR) containing 0.5% 
Tween-20 (Merck Chemicals) (TBS-T), blocked with 10% normal goat serum (Dako, Heverlee, 
Belgium) in TBS-T for 45 min and subsequently incubated overnight with mouse anti-human 
mitochondria antibody (1:800 in TBS-T; clone 113-1; Millipore, Merck Chemicals, Frankfurt, 
Germany). Control stainings were performed by omitting the primary antibodies. Brain tissue 
was counterstained with 0.1% cresyl violet. Lungs and spleen were counter stained with 
haematoxylin. Sections were dehydrated and sealed with Entellan mounting medium (Millipore) 
and imaged and immediately analyzed using a Nikon Eclipse 80i microscope and processed with 
NIS Elements BR 4.0 software (Nikon Instruments BeLux, Brussels, Belgium). Material from mice 
treated with GFP-containing stem cells (set 8) was visualized using a fluorescent microscope. 
Results from these assays are presented below. 
 
Western Blot  
Tissue samples were treated with lysis buffer containing 20 mM of Tris-HCl (pH 7.5), 450 mM of 
NaCl, 1%-solution of Triton X-100, 1 mM of EDTA, 1 mM of NaF, 1 mM of Na3VO4, and protease 
inhibitor (Roche Diagnostics, Indianapolis, IN, USA); 50 μl of buffer per 1 g of tissue was used. 
Samples were then centrifuged at 16 000 rpm for 20 min at 4°C; supernatant was collected and 
stored until use at -20°C. 25 μg of protein from each sample was mixed with 35 μl of Laemmli 
buffer. A sample of identical volume, comprising of 26 μl of Laemmli buffer, 5 μl of Page Ruler, 
and 4 μl of Magic Mark (Sigma, Munich, Germany) was used as a reference. For electrophoresis, 
samples were diluted in a solution containing MiliQ H2O, 1.5 M of Tris Buffer (pH 8.8), 30%-
solution of Acrylamide, 10%-solution of SDS Temed, and 10%-solution of ammonium persulfate 
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(APS). For the next step, a solution containing MiliQ H2O, 0.5 M of Tris Buffer (pH 8.8), 30%-
solution of Acrylamide, 10%-solution of SDS Temed, 10%-solution of APS and gel (Sigma, Munich, 
Germany) was used. The percentage of gel-containing solution was adjusted to the weight of the 
protein of interest and was 20% for proteins of the size of 4–40 kDa, 12.5% for proteins of the 
size of 40–70 kDa, 10% for proteins of the size of 70–100, and 7.5% for proteins over 100 kDa. A 
buffer containing 25 mM of Tris Base buffer, 192 mM of Glycine (Sigma, Mannheim, Germany), 
10%-solution of SDS and MiliQ H2O (pH 8.3) was used for gel electrophoresis which was carried 
out under the constant voltages of 80 V and 130 V.  
 
Polyvinylidene difluoride (PVDF) membrane (9 x 6 cm, EMD Millipore, Billerica, MA, USA) was 
consequently incubated in a 99%-methanol solution for 1 min (Brocacef, Amsterdam, the 
Netherlands), a MiliQ H2O for 5 min, and a transfer buffer for 15 min. The latter contained 25 
mM of Tris Base, 192 mM of glycine, 20%-solution of methanol, and  MiliQ H2O (pH 8.3). For the 
next step, blot “transfer sandwich” was composed of buffer-soaked sponge, consisting of two 
buffer-soaked Whatman filter papers, gel, activated membrane, and ice-cold transfer buffer; a 
constant current of 300 mA was used for 2 h 30 min. 
 
The membrane was treated with 5%-dry milk solution ofTBST, containing 50 mM Tris-HCl  
(pH=8.2), 150 mM NaCl, 0.05%-solution Tween 20 (Sigma, Munich, Germany) for 1 h at the room 
temperature and subsequently incubated with primary antibodies (Table 3) at 4°C overnight, 
followed by incubation with respective horseradish peroxidase-conjugated secondary (HRP) 
antibodies (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at the room temperature on a roller. The 
membrane was washed in TBST three times, 5 min each time, and then placed on the plastic 
cover. Then, Western BrightTM ECL kit (Advansta Inc, Menlo Park, CA, USA) was used. Relative 
optical density of immunoreactive protein bands was examined using ImageJ software (NIH, 
Bethesda, MD, USA). Results were normalized to the relative intensity of the β-tubulin band that 
was selected as a reference protein as described elsewhere (Gorlova et al., 2019). Blots were 
stripped by incubation with Restore Western Blot Stripping Buffer (Thermo Scientific, Rockford, 
















Primary antibodies used in the Western blot assay 
Antibody Dilution 
Anti-β-tubulin (Abcam, Cambridge, MA, USA)  #ab8227 1:700 
Anti-GSK-3β (Cell Signaling Technology, Beverly, MA, USA) #9832   1:800 
Anti-GSK-3α (Cell Signaling Technology, Beverly, MA, USA) #4337 1:900 
Anti-IL-1β (Cell Signaling Technology, Beverly, MA, USA) #12242 1:700 
Anti-Iba1 (Abcam, Cambridge, MA, USA) ab5076 1:500 
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To normalize the data, the relative expression value of each protein of interest was expressed as 
a percent of the concentration of β-tubulin (the reference protein). The choice of a reference 
protein was based on the previous observations where its expression was found to vary 
moderately across various experimental conditions, as well as the linear representation of the 
intensity of its signal (Gorlova et al., 2019; Pavlov et al., 2019). 
 
Determination of protein concentration  
Protein concentration was quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA) 
as described elsewhere (Gorlova et al., 2019; Pavlov et al., 2019). The working reagent was 
prepared in accordance with manufacturer instructions. 25µl of each standard or sample 
preparations were pipetted into a microplate well; 200µl of the working reagent was added to 
each well and mixed thoroughly on a plate shaker for 30 seconds; assay was run in duplicates. 
The covered plate was incubated at 37°C for 30 minutes and cooled to room temperature for 10 
min. The absorbance was measured at 562 nm in a Biotek Microplate Reader 
(Biotek Instruments, Winooski, VT, USA). Ascent Software Program (Winooski, VT, USA) coupled 
to the microplate reader was used to calculate protein values based comparing optical densities 
with the standard curve. The standard curve was generated by plotting the average blank-
corrected 562 nm measurements for each BSA standard vs. its concentration in µg/ml.  
 
Study compliance with general and proof of concept study requirements specific to ALS 
The presented study is in compliance with the requirements for any proof of concept (you sure?) 
and preclinical studies (Ludolph et al., 2010) including the statement of a genetic background 
and key read-outs, breeding protocols, animal livestock and gender, number of animals per 
group/subgroup, treatment efficacy. Pharmaca outline was double blind for all experimentators. 
To examine the onset of clinical traits we examined weight loss, grip strength, wire hanging and 
rotorod test. Histology was applied for positive outcomes and included motor neuron counts in 
groups of 5-6 mice. Methods and statistics are described elsewhere. Subsequently, we compared 
our results with previously published literature. A sentence regarding any possible conflict of 
interests, including the sources of financing and tested treatment is provided.  The following 
prerequisites for the conduct of a preclinical animal study with a therapeutic aim present:  
1) Recognition of the validity of the model in terms of the ‘genetic validity’ of hereditary/familial 
form of the FUS-tg condition, and the importance of genetic background that is supported by 
extensive literature on the employed mouse model.  
2) The use two different mouse models of ALS, FUS-tg and SOD-1 AG 93 mice.  
3) Validity of the characterization of FUS-tg model is supported by compre-      hensiveness of 
undertaken phenotyping. We used classic tests for motor behaviour in mice and classic 
histological markers of muscular and neuronal degeneration, accompanied by molecular 
readouts that are well known signs of the disease in a clinic.  
4) Our study is a ‘proof of concept’ study as it investigates the role of pathogenetic mechanisms 
of neuroinflammation that are therapeutically relevant with the ALS that is clearly different from 
a ‘preclinical drug testing’ pre-clinical trial. 
5) It is clearly stated that the intervention is meant to be ‘disease-modifying’.  




Figure S1. Identification of i.c.v.-infused Neuro-Cells in the parenchyma surrounding lateral ventricles of the mouse brain. After 24 
hours, mice treated with 250, 000 Neuro-Cells in 10ul of Ringer-lactate buffer could be detected with anti-mitochondrial human antigen 
within the brain parenchyma of experimental CD1 mice (left: control, vehicle-treated mice, right: Neuro-Cells-injected mice). Anti-human 
mitochondrial positive staining was observed in regions that were adjacent to the lateral ventricles (red arrows) that were not present in 
the control. Scale bar = 20um and the tissue was counterstained with cresyl violet. 
 
 
Figure S2. Neuro-Cells were detectable in peripheral organs of experimental CD1 mice after the i.c.v.-infusion: anti-human 
mitochondria staining in the lung. Mice treated with 50 000 or 250 000 Neuro-cells in 10ul exhibited positive staining for the anti-
mitochondrial human antigen in the lung (red arrows), spleen and liver (data not shown). Thus, 24 h post-administration, injected Neuro-
cells had managed to leave the brain and enter peripheral organs. It remains unclear how cells injected into the CSF manage to find there 
way into peripheral organs so rapidly. Scale bar = 20um and the tissue was counter stained with haematoxylin.  
  
 
Figure S3. Identification of stem cells derived from GFP mice in the brain parenchyma after their i.c.v. infusion to experimental CD1 
mice. To understand how syngeneic stems cells traffic after an i.c.v. injection we injected mouse GFP-expressing bone-marrow-derived 
stem cells into the CSF. At 24 hours, GFP-positive cells (Kovina et al., 2019) could be detected in the brain parenchyma with a distribution 
that was similar to that obtained following the administration of Xenogeneic Neuro-Cells. Scale bar = 50um and the tissue was 
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Figure S4. Body weight 1 week after surgery and i.c.v. treatment: lack of effects.  Body weights evaluated after one week in wild type 
controls and FUs-tg mice that received either i.c.v. administration of Neuro-Cells or vehicle did not differ from body weights of non-operated 
animals that were housed with tap water (F2,24=0.38, p=0.94, two-way ANOVA, post-hoc Tukey’s test).  This rules out the possibility of a 
potential negative impact of surgery on animals’ physical state. Based on this finding, control and FUS-tg mice that received either vehicle 
treatment, were merged according to their genotypes for the subsequent analysis. WT – wild type mice; FUS – FUS-tg mice; Veh – housing 
on tap water; Veh-icv – infusion of vehicle in i.c.v.; NC-icv – infusion of Neuro-Cells to i.c.v. 
 
 


























































Figure S5. Body weight at Weeks 1-6 of the experiment. Two-way ANOVA and post-hoc Tukey’s test revealed a significant effect of 
genotype on body weight, normalized to the means of control mice, at week 3 (F3,29=12.94, p=0.012, two-way ANOVA), week 4 (F3,29=28.11, 
p=0.002, two-way ANOVA), week 5 (F3,29=16.17, p<0.001, two-way ANOVA) week 6 (F3,29=19.35, p > 0.001, two-way ANOVA). In addition, 
there was a significant effect of riluzole treatment at week 6 (F1,12=14.26, p=0.039, two-way ANOVA), celecoxib treatment at week 5 
(F1,14=8.13, p=0.017, two-way ANOVA) and week 6 (F1,14=5.63, p<0.001, two-way ANOVA), and Neuro-Cells  treatment at week 4 
(F1,13=12.85, p=0.033, two-way ANOVA), week 5 (F1,13=21.88, p=0.024, two-way ANOVA) and week 6 (F1,13=11.63, p=0.002, two-way 
ANOVA). Post-hoc analysis revealed a significant decrease in body weight in FUS-tg-Veh group at the week 3 (p=0.031, Tukey's test), week 
4 (p=0.026, Tukey's test), week 5 (p=0.018, Tukey's test) and week 6 (p=0.001, Tukey's test), in comparison with wild type control mice. 
FUS-tg mice treated with riluzole showed a significant weight loss at week 6 (p=0.043, Tukey's test), and FUS-tg mice treated with celecoxib 
had this effect at weeks 5 and 6 (p=0.025 and p=0.019, respectively, Tukey's test) in comparison with wild type control mice.*p<0.05 vs. 
WT-Veh group. Thus, all treatments delayed a decrease of body weight in FUS-tg mice in comparison with controls, and infusion of Neuro-







Figure 6. Effects of administration of celecoxib and Neuro-Cells to FUS-tg mice on expression of molecular markers of inflammation 
and GSK-3. Following examination of Western Blot bands we found significantly elevated protein levels of (A) GSK-3β, (B) IL-1β and (C) IL-
1β  and (D) Iba-1 in spinal cords of FUS-tg-Veh animals in comparison with WT-Veh mice that was not found in FUS-tg-Cel and FUS-tg-NC 
groups (p>0.05). (D) No significant differences were found in the protein levels of GSK-3α (p>0.05). Animals from FUS-tg-NC group showed 
significantly lower values of protein expression of GSK-3β, IL-1β and Iba-1 than FUS-tg mice treated with vehicle. Mice from FUS-tg-Cel 
group showed a significant decrease of protein expression of IL-1β in comparison with FUS-Veh group. β-tubulin was used as a loading 
control in the Western blot assay, the expression of all proteins is normalized to β-tubulin expression (*p<0.05, vs.WT-Veh group, #p<0.05, 





5.2. Molecular and behavioral abnormalities in the FUS-tg mice 
mimic frontotemporal lobar degeneration: effects of old and 
new anti-inflammatory therapies 
 
Johannes de Munter, Diana Babaevskaya, Erik Wolters, Dmitry Pavlov, Ekaterina 
Lysikova, Allan Kalueff, Anna Gorlova, Margarita Oplatchikova, Igor А.  Pomytkin, Andrey 
Proshin, Aleksei Umriukhin, Klaus-Peter Lesch, Tatyana Strekalova; J Cellular and 




Genetic mutations in FUS, a DNA/RNA-binding protein, are associated with inherited forms of 
frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A novel 
transgenic FUS[1-359]-tg mouse line recapitulates core hallmarks of human ALS in the spinal 
cord, including neuroinflammation and neurodegeneration, ensuing muscle atrophy and 
paralysis, as well as brain pathomorphological signs of FTLD. However, a question whether 
FUS[1-359]-tg mouse displays behavioural and brain pro-inflammatory changes characteristic for 
the FTLD syndrome was not addressed. Here, we studied emotional, social and cognitive 
behaviours, brain markers of inflammation and plasticity of pre-symptomatic FUS[1-359]-tg male 
mice, a potential FTLD model.  
 
These animals displayed aberrant behaviours and altered brain expression of inflammatory 
markers and related pathways that are reminiscent to the FTLD-like syndrome. FTLD-related 
behavioural and molecular Journal of Cellular and Molecular Medicine features were studied in 
the pre-symptomatic FUS[1-359]-tg mice that received standard or new ALS treatments, which 
have been reported to counteract the ALS-like syndrome in the mutants. We used anti-ALS drug 
riluzole (8 mg/kg/d), or anti-inflammatory drug, a selective blocker of cyclooxygenase-2 
(celecoxib, 30 mg/kg/d) for 3 weeks, or a single intracerebroventricular (i.c.v.) infusion of human 
stem cells (Neuro-Cells, 500 000-CD34+), which showed anti-inflammatory properties. Signs of 
elevated anxiety, depressive-like behaviour, cognitive deficits and abnormal social behaviour 
were less marked in FUS-tg–treated animals. Applied treatments have normalized protein 
expression of interleukin-1β (IL-1β) in the prefrontal cortex and the hippocampus, and of Iba-1 
and GSK-3β in the hippocampus. Thus, the pre-symptomatic FUS[1-359]-tg mice demonstrate 




Genetic mutations in FUS, which is DNA/RNA-binding protein, can cause frontotemporal lobar 
degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)(Ito and Suzuki 2011). FTLD is a 
debilitating disease, often accompanying ALS and involving atrophy of the frontal/temporal 
139 
 
lobes and affecting emotional, social and cognitive functions (DeLoach, Cozart et al. 2015). Until 
recently the contribution of FUS to the FTLD/ALS pathology remains poorly understood. The 
available FTLD models based on the FUS mutation often report somewhat non-specific 
behavioural deficits and limited brain pathology with a late onset (Shiihashi, Ito et al. 2017), or 
the very rapid development of physiological and motor ALS-like pathology (Kasey, Hemangini et 
al. 2016), and, for this reason, it has been argued that further refinement is required (Nolan, 
Talbot et al. 2016). The construction of the FUS[1-359]-tg mice, expressing truncated human 
FUS[1-359], has been shown to exhibit many of the hallmark characteristics of ALS 
(Shelkovnikova, Peters et al. 2013), and FTDL-like changes during the pre-symptomatic stage 
(Lysikova, Kukharsky et al. 2019). This model provides a promising tool to explore the temporal 
contribution of FUS mutations on molecular and behavioural outcome. Meanwhile, hitherto the 
FTDL-like behavioural features and the accompanying molecular changes have not been 
investigated. Here were addressed this outstanding issue by studying the impact of therapy used 
in the clinic and new anti-inflammatory therapies on emotional, cognitive and social 
abnormalities in FUS-tg animals. These therapies have been shown to reduce the ALS-like 
pathology in these mutants (de Munter, Shafarevich et al. 2019). 
 
Methodology 
Animals, study design, methodology and statistical analysis are described in a Appendix S1 (see 
also Figure S1). At the age of eight weeks, which is considered to be the beginning of adulthood, 
the FUS[1-359]-tg (FUS-tg) male mutants display no signs of neurodegeneration in the CNS 
(Figure S3), nor any motor deficits (Shelkovnikova, Peters et al. 2013, de Munter, Shafarevich et 
al.2020). For this reasons we selected mice of this age for both Study 1 and Study 2. FUS-tg mice 
used here showed no deficits in motor tests (not shown).  
 
Over the course of 5 days, wild-type (WT) and FUS-tg mice of average age of 9 weeks were 
investigated for (a) time spent in the open arms of the O-maze, (b) sucrose preference, (c) the 
duration of immobility in the tail suspension test, (d) number of rears in the novel cage test, (e) 
displacement of pellets in the marble test, and (f) the duration of attacks and tail rattling in the 
resident-intruder test (Strekalova and Steinbusch 2010). The FTLD syndrome is well documented 
to be associated with pathological changes in the limbic system, including the hippocampus and 
prefrontal cortex and underlie emotional, social and cognitive abnormalities (Nolan, Talbot et al. 
2016). These two structures play pivotal roles in the regulation of social, anxiety- and depressive-
like behaviours, as well as exploration and cognitive tasks in the mouse models employed here 
(Strekalova and Steinbusch 2010) and, hence, were studied for potential molecular changes 
(Figure S1A). Therefore, mice were killed and the hippocampus and the prefrontal cortex 
collected for RNA isolation/cDNA synthesis and RT-PCR assay of FTDL-related pro-inflammatory 
markers: tumour necrosis factor (TNF), cyclooxygenase-1 (COX-1), interleukin-1β (IL-1β) and 
cytokine expression regulatory molecules implicated in the ALS pathology, matrix-
metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1)(DeLoach, 




Then, per os administration of the commonly used ALS treatment riluzole (8 mg/kg/d), oranti-
inflammatorycyclooxygenase-2 blocker celecoxib (30 mg/kg/d), or vehicle, to FUS-tg and WT 
mice of average age of 9 weeks was started; or they received an intracerebroventricular (i.c.v.) 
infusion of Neuro-Cells (1.39 × 106 mesenchymal and haemopoietic human stem cells containing 
5 × 105 of CD34+ cells) or Ringer-solution (de Munter, Shafarevich et al. 2019, de Munter, Beugels 
et al. 2019), for details on Neuro-Cells preparation, see Appendix S1 and Tables S3 and S4). Two 
weeks later, over a period of 5 days, mice were behaviourally scored for (a) time spent in lit box 
in the dark/light test, (b) new object recognition index, (c) the duration of immobility in the tail 
suspension test, and (d) duration of following, number of attacks and of tail rattling in the 
resident-intruder test (Couch, Trofimov et al. 2016). A different battery of tests was employed in 
the second set of animals with the aim of providing an extended behavioural characterization of 
new FUS-tg line (Figure S1B). To compare molecular changes of mutants in brains to the reported 
changes in the spinal cord, mice were killed at age of 15 weeks, and the hippocampus and the 
prefrontal cortex were dissected for Western blots for IL-1β, Iba-1, glycogen-synthase-kinase-3 
(GSK-3)-β and GSK-3α (de Munter, Shafarevich et al. 2019, de Munter, Beugels et al. 2019). For 
experimental details, see Appendix S1 and Table S2). Data were treated by unpaired two-tailed 
t test, or one- or two-way ANOVA followed by Tukey's test, for two or multiple group 
comparisons, respectively. Repeated measures were analysed by two-way ANOVA for repeated 
measures followed by Sidak post hoc test. 
 
Results and Discussion  
For full statistical results see Supplementary Tables.  
 
Pre-symptomatic FUS-tg mice display aberrant behaviours and pro-inflammatory 
changes.  
FUS-tg mice spent less time in open arms of the elevated O-maze and exhibited a reduced latency 
to immobility in the tail suspension test, decreased sucrose preference, reduced duration of 
attacks (P < .05 vs controls, unpaired t test; Figure 1A-D), and the duration of tail rattling was 
unchanged (P >.5; Figure 1E; Table S5A). A lack of group differences in general locomotion in the 
O-maze rules out a possibility of non-specific confounds in behavioural analysis of two genotypes 
(Figure S3). Two-way ANOVA for repeated measures revealed significant time x genotype 
interaction and genotype effect in the number of rears in the novel cage test (P < .05; Table S5B). 
Sidak post hoc test for multiple comparisons showed significant increase of this measure in FUS-
tg mice on the 4th min (P < .05 vs WT mice; Figure 1F) and trends to such changes on minutes 2, 
3 and 5 (P > .05, Table S5B). In comparison with controls, mutants exhibited unchanged activity 
on the 1st min of scoring (P > .5, t test; Table S5C) and significantly higher number of rearings 
averaged over the 2nd-5th min of the test (P < .05, t test), thus, showing disrupted novelty 
adaptation (Figure 1F). 
There were significant time and genotype effects, as well as significant time x genotype 
interaction the in number of pellets displaced during the marble test (P < .05, t wo-way ANOVA 
for repeated measures; Table S5D). FUS-tg mice displaced fewer pellets during all time periods 
of the test, except for 0-15 minutes, suggesting deficient hippocampus-dependent performance 






Figure 1. FTLD-like changes in FUS-tg mice in (A-G) behavioural parameters and (H-O) molecular markers; *P < .05: FUS-tg (n = 9-15) vs 
WT (n = 8-14) groups, unpaired t test and repeated ANOVA and Tukey's test (see the text). 
Signs of helplessness, anhedonia, anxiety-like features, cognitive and social abnormalities in FUS-
tg animals are characteristic of other FTDL paradigms, that is progranulin-deficient mice (Yin, 
Dumont et al. 2010), ΔNLS-FUS mice (Shiihashi, Ito et al. 2017), and TDP-43-tg mice (Alfieri, Silva 
et al. 2016). The current study suggests the most prominent FDTL-related deficits of the FUS-tg 
mice are the classic tests of emotionality, social and hippocampus-dependent performance. In 
comparison with other FTLD rodent models based on the FUS mutation, the findings reported 
here in the FUS-tg mice suggest that no hyperactivity or other non-specific behavioural 
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alternations are present, but, typical for this disease, features of anxiety, apathy, cognitive and 
social deficits are observed (Shiihashi, Ito et al.2017, Nolan, Talbot et al.2016, Lysikova, 
Kukharsky et al.2019). Hippocampal concentrations of TNF and COX-1 mRNA were elevated in 
the FUS-tg mice (P<.05 vs controls; unpaired t test; Figure 1H-M, Table S6). The Timp1/Mmp9 
ratio was augmented in the prefrontal cortex (P<.05, t test; Figure 1J-K), and no other group 
differences were present (P>.5, t test). Together, these data provide evidence of pro-
inflammatory changes within the brain of the FUS-tg mice that a characteristic for FTDL-
syndrome (Filiano, Martens et al. 2013) and aberrant Timp1/Mmp9 ratio, a factor of ALS 
pathology (DeLoach, Cozart et al. 2015),  cytokine expression (Schoser and Blottner 1999) and 
neuronal plasticity (Ethell and Ethell 2007, Trofimov, Strekalova et al. 2017). 
 
Ameliorative effects of standard ALS treatments and ”Neuro-cells” on the behavioural 
and molecular changes in the FUS-tg mice.  
Concerning the duration of immobility, there were no significant effects of genotype, treatment, 
or their interaction (P>.5, two-way ANOVA, Table S7), but FUS-tg-Veh displayed elevated 
immobility scores (P<.05, vs WT-Veh group, Tukey's test; Figure 2A), that were not observed in 
the treated mutants (P>.05, Tukey's test). In comparison with FUS-tg-Veh mice, this behaviour 
was decreased in FUS-tg-NC, but not FUS-tg-Ril and FUS-tg-Cel animals (P<.05 and P>.5, 
respectively; Tukey's test). For the time spent in the lit box, there were no significant effects of 
treatment, a genotype x treatment interaction (P>.5, two-way ANOVA), but there was an impact 
of genotype (P<.05, two-way ANOVA). In comparison with respective wild-type controls, FUS-tg-
Veh animals, but not treated mutants exhibited a shortened duration of time spent in the lit box 
(P<.05 and P>.5, respectively, Tukey's test; Figure 2B, Table S7), which was increased in FUS-tg-
NC vs FUS-tg-Veh animals (P<.05, Tukey's test). No other group differences were found. There 
were no group differences in the object exploration (P>.5, two-way ANOVA and Tukey's test; not 
shown). A significant genotype x treatment interaction and effects of genotype (P<.05, two-way 
ANOVA), not of treatment (P>.5, two-way ANOVA), were found for the preference for the new 
object. All mutants except FUS-tg-NC animals had decreased scores for this measure (P<.05 and 
P>.05, vs WT groups, respectively, Tukey's test; Figure 2D, Table S7). A significant genotype x 
treatment interaction was revealed for the duration of ‘following’ (P<.05 and P>.5, respectively, 
two-way ANOVA), but not for numbers of attacks and tail rattling (P>.5, Tukey's test; Figure 2E,F, 
Table S7). There was a significant genotype effect on the duration of following and number of 
attacks, but no significant treatment group differences (P>.05, two-way ANOVA). We found a 
significant treatment effect on the duration of following (P<.05, two-way ANOVA), which was 
increased in FUS-tg-Veh and FUS-tg-Cel mice (P<.05, Tukey's test vs respective control groups; 
Figure 2D, Table S7), and FUS-tg-Cel group showed its decrease vs FUS-tg-Veh group (P<.05, 
Tukey's test). No other group differences were found. Thus, treatments ameliorated the 
behavioural end-points in the FUS-tg mice, where their effects on the measures of anxiety and 
aggression were particularly profound, suggesting their importance in the evaluation of FDTL-
like features in this mouse line. Hippocampal concentrations of IL-1β, Iba-1, GSK-3β and GSK-3α 
were different between the groups (P<.05; one-way ANOVA, Figure 2G-J, Figure S4A; Table S8A). 
FUS-tg-Veh animals exhibited increased expression of all molecules except GSK-3α (P<.05 and 
P>.05, vs WT-Veh; respectively; Tukey's test). In FUS-tg-NC mice, concentrations of IL-1β and 
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GSK-3β were lower than in the FUS-tg-Veh group (P<.05, Tukey's test). In the prefrontal cortex, 
levels of IL-1β, Iba-1 and GSK-3β were different between the groups (P<.05), but not for GSK-3α 
(P>.05 and P>.05, respectively, Tukey's test). FUS-tg-Veh animals displayed elevated expression 
of the target molecules (P<.05, vs WT-Veh), except GSK-3α (P>.05, Tukey's test; Figure 2K-N, 
Figure S4B, Table S8B). Concentrations of IL-1β were found to be decreased in FUS-tg-NC vs FUS-
tg-Veh mice (P<.05, Tukey's test). No other group differences were found. In summary, FUS-tg 
mutants displayed up-regulated protein expression for the inflammatory markers and for GSK-
3, which was reminiscent of the changes observed in the spinal cord (Kasey, Hemangini et al. 
2016) and were sensitive to the treatments. Thus, behavioural and molecular abnormalities of 
FUS-tg mice were overly reduced by the use of Riluzole, celecoxib or Neuro-Cells, which often 
exerted greater effects. 
 
 
Figure 2.  Ameliorative effects of standard ALS treatments and Neuro-Cells in FUS-tg mice on (A-F) behaviours and (G-N) expression of 
FTLD/ALS-related molecular markers;*P<.05, vs respective WT-group (n = 6-12), #P<.05, vs FUS-tg-Veh group (n = 7-14); ANOVA and 




Together, the pre-symptomatic FUS[1-359]-tg mice demonstrate behavioural changes that are 
reminiscent of the FTLD-syndrome abnormalities, and they are attenuated by all the treatments. 
Hence, FUS[1-359]-tg mutant mice can be exploited as a new paradigm of the FTLD to address 




MATERIALS AND METHODS 
 
Animals and housing conditions  
A colony of FUS-transgenic mice (FUS-tg) and their wild type littermates (WT) was bred and 
housed in the FDA-certified SPF facilities of the IPAC Center of Pre-clinical Trials. Male mice of 
both genotypes, 10-weeks-old at the start of the experiment, were single housed in standard 
plastic cages (27x22x15) and maintained on a 12-hour light/dark cycle (lights on at 21:00), under 
controllable laboratory conditions (22±1°C, 55% humidity, room temperature 22-24ºC), food and 
water were available ad libitum. Housing conditions and all experimental procedures were set 
up in accordance with a Directive 2010/63/EU of 22 September 2010 and carried out under 
approval of the Committee for Bioethics (N19-16.06.2017) of IPAC RAS. Bone marrow collection 
from healthy volunteers was carried out under GMP license (Neuroplast BV Farmatec The 
Netherlands) and approved by Ethical Committee of MUMC, Maastricht University  (iCell1 METC 
MUMC and iCell2 METC Zuyderland Zuid). All efforts were undertaken to minimize the potential 
discomfort of experimental animals.  
 
Production of FUS Transgenic Mice  
A generation of FUS-tg mice was performed as describe elsewhere (Schelkovnikova et al., 2013). 
Briefly, a fragment of human FUS[1–359] cDNA including 9 bp of 5′-UTR was cloned into Thy-1 
promoter plasmid 323-pTSC21k. A gel-purified fragment obtained by digestion of the resulting 
plasmid DNA with NotI was used for microinjection of mouse oocytes. Transgenic animals were 
identified by PCR analysis of DNA from ear biopsies by the presence of 255-bp product (primers 
5′-TCTTTGTGCAAGGCCTGGGT-3′ and 5′-AGAAGCAAGACCTCTGCAGAG-3′). Initially produced 
transgenic line on C57Bl6/CBA genetic background was backcrossed with CD1 wild type mice by 
seven or more generations. 
 
Study design 
In Study 1, FUS-tg mice at the age of 9 weeks corresponding to a pre-symptomatic stage of the 
ALS model alone with wild type littermates, were studied for motor functions in the Cat-walk, 
Wire test, Grip-test, Pole test and Rotarod model with 1-hour inter-test interval as described 
elsewhere (Veniaminova et al., 2020; de Munter et al., 2020; see below) to verify the absence of 
any motor deficits during three days prior the experiment (Fig.1A, data now shown). These mice 
were investigated in the tests for emotionality, social behaviour and hippocampus-dependent 
performance thereafter. On Day 1, mice were studied in the elevated O-maze test for anxiety-
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like behaviour, on Day 2, they were studied in the sucrose preference test for a sensitivity to 
reward, on Day 3, mice were scored for novelty exploration in the novel cage test and despair 
behaviour in the tail suspension test, on Day 4, mice were investigated for hippocampus-
dependent performance of food pellet displacement behaviour in the marble test and on Day 5, 
parameters of social interaction were scored in the resident-intruder test  (see below). Seventy 
two hours after the last test mutant animals were were perfused with NaCl, anaesthetized and 
killed, alone with respective wild type controls (see below) and brains were harvested and 
dissected to the hippocampus and the prefrontal cortex for a subsequent molecular analysis with 
RT PCR (see below). Twelve animals in average were used per group; numbers of animals used 
is indicated in Figure legends.  
 
In Study 2, FUS-tg mice at the same age as in the Study 1 were tested for motor functions as 
described above; no motor deficits were found in mutants (data not shown). FUS-tg and WT mice 
were treated with (1) regular tap water, or (2) riluzole (8 mg/kg/day, via drinking water), or (3) 
or celecoxib (30mg/kg/day) via diet pellets, or (4) single stereotaxic i.c.v. infusion of Neuro-Cells 
(NC, 500,000-CD34+ in 10 ul of Ringer Lactate buffer), or (5) stereotaxic i.c.v. infusion of Ringer 
Lactate buffer (Fig.1B; de Munter et al., 2020). Doses of pharmaca and stereotaxic surgery were 
carried out as described elsewhere (de Munter et al., 2020; see below). Ten animals in average 
were used per group; numbers of animals used is indicated in Figure legends.  
 
During the following two weeks, all mice were weekly weighed and investigated in the rotarod, 
pole and wire tests for motor functions, dosing with drugs was continued. As post-surgery 
physiological parameters of wild type mice that received either tap water or i.c.v. vehicle 
injection were similar (data not shown), these two groups were merged into a vehicle-treated 
group for subsequent group comparisons. On the third week, mice were investigated for 
emotional, social and cognitive behaviors. At this point of study, no signs of motor deficits in 
were found in FUS-tg groups (data not shown). For the sake of a more complete characterization 
of this new line of FUS-tg mice, we have chosen to employ a battery of behavioural models 
similar to Study 1, although with an extended scope of behavioral responses, while providing a 
sufficient consistency in the analysis of behaviour between the two studies. On Day 1, mice were 
scored for anxiety-like behavior in the dark/light test, on Days 2 and 3, mice new object 
recognition index was assessed, on Day 4, mice were studied in the tail suspension test, and on 
Day 5, the resident-intruder test was performed (see below). To verify whether brain molecular 
changes in mutants match those previously reported for spinal cord in symptomatic FUS-tg 
animals, mice were killed at their symptomatic age of fifteen weeks, given in average age of the 
onset of the ALS-like syndrome of 14 weeks (Shelkovnikova et al., 2013; de Munter et al., 2020). 
Dosing of pharmaca was continued for the remaining three weeks and was interrupted 48 h prior 
a sacrifice. Mice were anaesthetized, perfused with NaCl and killed, brains were isolated, the 
hippocampus and the prefrontal cortex were dissected as described above, for Western blot 
assay. Brain protein expression of target proteins was measured by Western blot assay in mice 
treated with either vehicle, Neuro-Cells or celecoxib, since distinct expression changes in the 
lumbar parts of spinal cord previously showed in these groups for selected markers of 
inflammation and cellular distress (de Munter et al., 2020). Pharmaca outline and genotype were 






Behavioural testing  
The person performing the experiments was blind for the genotype and treatment until the end 
of the behavioral tests. Experiments were carried out in the same rooms by the same persons 
between 09:00 and 17:00 h. Animals were allowed to adapt to experimental room for at least 1 
h before testing. All experiments were recorded on videotape and scored manually and by the 
means of ViewPoint software (ViewPoint SA, Lissieu, France).  
 
Rotarod 
Mice were placed on constantly rotting rod of rotarod (Columbus Instruments, Columbus, OH, 
USA; speed 10 rpm) for 600s. Latency to fall and the number and percent of mice with falling 
events (latency<200s) were registered in three runs as described elsewhere (Veniaminova et al., 
2020; de Munter et al., 2020).  
 
Wire test 
Mice were allowed to grip a horizontal wire (diameter 0.3 cm, height above the surface 60 cm) 
for 180s. The latency of falling and the number and percent of mice with falling events 




Mice were placed on a top of the vertical bar (diameter 1.1 cm, height 60 cm) and allowed to 
climb down to a horizontal surface. The latency of descending the bar and the number and 
percent of mice with sliding events (latency to descend<50s) were scored as described elsewhere 
(Veniaminova et al., 2020; de Munter et al., 2020).  
 
Grip test 
The grip strength meter (Bioseb, Vitrolles, France) was positioned horizontally and mice were 
held by the tail and lowered towards the apparatus. The mouse was allowed to grab the metal 
grid bar and are then pulled backwards in the horizontal plane with minimal force sufficient to 
make it losing a grip. The measurement was accomplished using a sensor and was expressed in 
units as described elsewhere (de Munter et al., 2020). 
 
Figure 3 Experiment design of study on (A) naïve FUS-tg mice and (B) FUS-tg mice treated with standard ALS 




CatWalk XT (Noldus, Wageningen, Netherlands) was employed for refined quantitative 
assessment of motor functions in experimental groups of mice. In the current study, the duration 
of right and left hindlimb swing was measured in baseline conditions and after the onset of the 
treatment as described elsewhere (de Munter et al., 2020). These measures were defined as the 
most sensitive and reliable parameters of motor functions in the FUS-tg mice in pilot experiments 
(Lysikova and Ninkina, unpublished results). 
 
O-maze test 
The apparatus (Open Science, Moscow, Russia), which consisted of a circular path (runway width 
5.5cm, diameter 46cm), was placed 50cm above the floor. Two opposing arms were protected 
by walls (height 10cm), and the illumination strength was 25 lx. Anxiety-like behavior was 
assessed using previously validated parameters as described elsewhere (Couch et al., 2016; 
Costa-Nunes et al., 2020). Mice were placed in one of the closed arm compartments of the maze. 
Total duration of time spent in the open arms of the maze was scored as the parameter of 
anxiety-like behavior during 5 min. 
 
Sucrose Preference 
Mice were given 8 hours of free choice between two bottles of either 1% sucrose or standard 
drinking water, as described elsewhere (Strekalova et al., 2004, Couch et al., 2013; Pavlov et al., 
2019). Bottles were weighed before and after conducting the sucrose preference, and 
consumption calculated accordingly. The beginning of the test started with the onset of the dark 
(active) phase of animals’ cycle. To prevent the possible effects of side preference in drinking 
behaviour, the position of the bottles in the cage was switched at 4 hours, halfway through 
testing. No previous food or water deprivation was applied before the test. Other conditions of 
the test were applied as described elsewhere (Strekalova and Steinbusch 2010). Percentage 
preference for sucrose is calculated using the following formula: Sucrose Preference = Volume 
(Sucrose solution)/(Volume (Sucrose solution) + Volume (Water) x 100. 
 
Novel Cage Test 
The 5-min long novel cage test was carried out to assess exploration of a new environment as 
described elsewhere (Strekalova et al., 2004, Couch et al., 2016; Veniaminova et al., 2020). Mice 
were introduced into a standard plastic cage (21 cm x 21 cm x 15 cm) filled with fresh sawdust. 
The number of exploratory rears was counted under red light per each minute, and summed up 
for minutes 2-5 of the test. 
 
Tail suspension test 
Mice were subjected to the tail suspension by being hung by their tails with adhesive tape to a 
rod 50 cm above the floor for 6 min. Animals were tested in a dark room where only the area of 
the modified tail suspension construction was illuminated by a spotlight from the ceiling; the 
lighting intensity on the height of the mouse position was 25 Lux. The total duration of immobility 
was scored according to the protocol that was previously validated with Noldus EthoVision XT 
8.5 (Noldus Information Technology, Wageningen, Netherlands) as described elsewhere 
(Malatynska et al., 2012). In accordance with the commonly accepted criteria of immobility, the 
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immobility behaviour was defined as the absence of any movements of the animals' head and 
body.  
 
Pellet displacement marble test 
All experimental groups were tested for pellet displacement in a marble test as described 
elsewhere (Strekalova et al., 2013; Veniaminova et al., 2017, 2020). A tendency to displace small 
objects, e.g. small stones or food pellets, from a tube inside the cage, is species-specific in mice 
and has been demonstrated to depend on an intact hippocampal formation. Using a paper tube 
(internal diameter 4 cm, length 10 cm), filled with 20 food pellets and placed in the middle of a 
home cage (21 cm × 27 cm × 14 cm), the number of food pellet displaced by each mouse was 
assessed every 15 min during 1 h and 45 min. 
 
Resident-intruder test  
In the resident-intruder test, mice were individually placed in an observation cage (30x60x30 cm) 
for 30 min. Then, each mouse was exposed to a previously group-housed naïve C57BL/6N male 
intruder of similar weight and age for 8 min in the same cage. The duration and the number of 
attack and tail rattling, and the duration of following behavior were scored as described 
elsewhere (Couch et al., 2016; Strekalova et al., 2018; Gorlova et al., 2020; Veniaminova et al., 
2020). 
 
Dark/Light Box Test 
Mice were placed into the black compartment (15х20х25 cm) from where they could visit the lit 
box (30х20х25 cm, Open Science, Moscow, Russia). Time spent by mice in the lit part of the box, 
in which illumination intensity was 25 Lux on the surface of the apparatus, was scored during 5-
min period, as described elsewhere (Costa-Nunes et al., 2013; Strekalova et al., 2018).   
 
Object Recognition Memory test 
Mice were placed in a glass cylinder observation chamber (Ø 25 cm, height 35 cm) that was 
situated on a stand of 1 m high placed by two walls of the lab room. The cylinder was 5cm from 
the edge on two opposite sides and 30 cm from the edge on the other two sides. Using sound-
proof conditions with subtle illumination (5 Lux) animals were allowed to explore two identical 
objects (taste-free and smell-free plastic toys of 6 cm x 3 cm x 2.5 cm) which were located in 
either part of the cylinder or 15 min. Previous experiments (Strekalova et al., 2013) have shown 
that object placed by the edge is explored by C57Bl6 mice in average 50% less than the same 
object at the opposite location that is likely to be owing to their species-specific tegmotaxic traits 
and fear of height.  
 
On the Day 1, animals were allowed to explore two objects placed either close to the walls 
“preferable” zone (the area in 30 cm from edge) or distanced from walls “non-preferable” zone 
(the area in 5 cm from edge) in the observation cylinder. On the Day 2, the test was repeated. 
The object from “non-preferred” zone was replaced with a new object of a similar size (3 cm x 6 
cm x 3 cm) and of exactly the same material. A placement of a new object to “non-preferred” 
area meant to contrast behavioral manifestation of novelty exploration under competing 
motivations of animals of staying by the walls and avoid the height. The duration of exploration 
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of each object was recorded on each day. Preference for the object exploration was calculated 
as a percentage of the duration of exploration of a new object from the total duration of 
exploration of both objects on Day 2: Index of object preference (recognition) = [Object 
exploration /Total exploration of two objects] × 100%. An increased preference in the 
exploration of a new object that has replaced the former one in the “non-preferred” area from 
day 1 to day 2, was taken as an index of recognition (memory) of the former object. 
 
Killing and Tissue Collection 
Mice were terminally anaesthetized with an intraperitoneal injection of sodium pentobarbitone.  
The left ventricle was perfused in situ with 10 mL ice-cold saline; the brain of each mouse was 
dissected and the prefrontal cortex and the hippocampi as described elsewhere (Trofimov et al., 
2017; de Munter et al., 2020) and stored at -80ᵒC until use. 
 
Quantitative RT-PCR (qPCR) 
RNA extraction was performed as previously described from specifically microdissected snap-
frozen hippocampus and prefrontal cortex (Couch et al., 2013, 2016). mRNA was extracted by 
using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA). First strand cDNA 
synthesis was performed using random primers and Superscript III transcriptase (Invitrogen, 
Darmstadt, Germany); 1 μg total RNA was converted into cDNA. Standard curves were generated 
using total cDNA to enable normalization to three housekeeping genes glyceraldehyde-3-
phosphate (GAPDH), TATA-binding-protein (Tbp), and beta-Actin (ActB) that were selected from 
four candidates; beta2-microtubulin was excluded to its less stable expression using BioGazelle 
qBase+ v2.6 software (Biogazelle, Gent, Belgium) and GeNorm algorythm. qPCR was performed 
using the SYBR Green master mix (Bio-Rad Laboratories, Philadelphia, PA, USA) and the CFX96 
Real-time System (Bio-Rad Laboratories, Philadelphia, PA, USA) for IL-1 β, TNF, COX-1, GSK-3 α, 
GSK-3 β, as well as Mmp9 and Timp1.  
 
Details of primers and cycling conditions can be found in Table 1 (AlcorBio, St.Petersburg, Russia). 
Data were calculated as relative-fold changes compared to control mice as described elsewhere 
(Couch et al., 2016, Trofimov et al., 2017). Results of qRT-PCR measurement were expressed as 
Ct values, where Ct is defined as the threshold cycle of PCR at which amplified product was 0.05% 
of normalized maximal signal. We used the comparative Ct method and computed the difference 
between the expression of the gene of interest and the geometric mean of the 3 housekeeping 
genes in each cDNA sample (2-ΔΔ Ct method). Data are given as expression-folds compared to 
the mean expression values in control mice. Results are expressed as relative-fold compared to 
control animals 
The qRT-PCR was performed in a 12 μl reaction volume containing a 10хPCR Buffer (1.2 μl), 25 
mmol MgCl2 (2 μl), 10 mmol dNTPs (1 μl), specific forward and reverse primers at 20 pmol/μl 
concentration (0.5 μl), 10 pmol/μl probe (0.3 μl), cDNA (1 μl), 5 μ/μl Taq DNA polymerase (0.5 
μl) (Beagle, St. Petersburg, Russia), and ddH2O (5 μl). All samples were run in triplicate. Cycling 
was performed at 95C° for 5 min followed by a 50-cycle amplification at 95°C for 5 s, then at the 




Sequences of primers used 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
GAPDH TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC 
Β-actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 
TNF GCCTGTAGCCCACGTCGTA GGCACCACTAGTTGGTTGTCTTTG 
COX-1 GCCTGAGCCCAGATATAGCA TTTCCGGCTAGAGGTGGGTA 
IL-1β AACCTGCTGGTGTGTGACGTTTC CAGCACGAGGCTTTTTTGTTGT 
GSK-3β TCCATTCCTTTGGAATCTGC CAATTCAGCCAACACACAGC 
GSK-3α AATCTTGGCCAGTCTGAGCT TCAGTCCTGGTGAACTGTCC 
Iba-1 GGCAATGGAGATATCGATA AGAATCATTCTCAAGATGGC 
Mmp9 CCTCTGCATGAAGACGACAT GAGGTGCAGTGGGACACATA 
Timp1 CTGGCATAATCTGAGCCCTG GCAAAGTGATCGCTCTGGTAG 
Tbp ACCTTCACCAATGACTCCTATG ATGATGACTGCAATCGC 
 
Western Blot  
Tissue samples were treated with lysis buffer containing 20 mM of Tris-HCl (pH 7.5), 450 mM of 
NaCl, 1%-solution of Triton X-100, 1 mM of EDTA, 1 mM of NaF, 1 mM of Na3VO4, and protease 
inhibitor (Roche Diagnostics, Indianapolis, IN, USA); 50 μl of buffer per 1 g of tissue was used. 
Samples were then centrifuged at 16 000 rpm for 20 min at 4°C; supernatant was collected and 
stored until use at -20°C. 25 μg of protein from each sample was mixed with 35 μl of Laemmli 
buffer. A sample of identical volume, comprising of 26 μl of Laemmli buffer, 5 μl of Page Ruler, 
and 4 μl of Magic Mark (Sigma, Munich, Germany) was used as a reference. For electrophoresis, 
samples were diluted in a solution containing MiliQ H2O, 1.5 M of Tris Buffer (pH 8.8), 30%-
solution of Acrylamide, 10%-solution of SDS Temed, and 10%-solution of ammonium persulfate 
(APS). For the next step, a solution containing MiliQ H2O, 0.5 M of Tris Buffer (pH 8.8), 30%-
solution of Acrylamide, 10%-solution of SDS Temed, 10%-solution of APS and gel (Sigma, Munich, 
Germany) was used. The percentage of gel-containing solution was adjusted to the weight of the 
protein of interest and was 20% for proteins of the size of 4–40 kDa, 12.5% for proteins of the 
size of 40–70 kDa, 10% for proteins of the size of 70–100, and 7.5% for proteins over 100 kDa. A 
buffer containing 25 mM of Tris Base buffer, 192 mM of Glycine (Sigma, Mannheim, Germany), 
10%-solution of SDS and MiliQ H2O (pH 8.3) was used for gel electrophoresis which was carried 
out under the constant voltages of 80 V and 130 V. Polyvinylidene difluoride (PVDF) membrane 
(9 x 6 cm, EMD Millipore, Billerica, MA, USA) was consequently incubated in a 99%-methanol 
solution for 1 min (Brocacef, Amsterdam, the Netherlands), a MiliQ H2O for 5 min, and a transfer 
buffer for 15 min. The latter contained 25 mM of Tris Base, 192 mM of glycine, 20%-solution of 
methanol, and  MiliQ H2O (pH 8.3). For the next step, blot “transfer sandwich” was composed 
of buffer-soaked sponge, consisting of two buffer-soaked Whatman filter papers, gel, activated 
membrane, and ice-cold transfer buffer; a constant current of 300 mA was used for 2 h 30 min. 
The membrane was treated with 5%-dry milk solution of TBST, containing 50 mM Tris-HCl  
(pH=8.2), 150 mM NaCl, 0.05%-solution Tween 20 (Sigma, Munich, Germany) for 1 h at the room 
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temperature and subsequently incubated with primary antibodies (Table 2) at 4°C overnight, 
followed by incubation with respective horseradish peroxidase-conjugated secondary (HRP) 
antibodies (Sigma-Aldrich, St. Louis, MO, USA) for 2 h at the room temperature on a roller. The 
membrane was washed in TBST three times, 5 min each time, and then placed on the plastic 
cover. Then, Western BrightTM ECL kit (Advansta Inc, Menlo Park, CA, USA) was used. Relative 
optical density of immunoreactive protein bands was examined using ImageJ software (NIH, 
Bethesda, MD, USA). Results were normalized to the relative intensity of the β-tubulin band that 




Primary antibodies used in the Western blot assays 
Antibody Dilution 
Anti-β-tubulin (Abcam, Cambridge, MA, USA)  #ab8227 1:700 
Anti-GSK-3β (Cell Signaling Technology, Beverly, MA, USA) #9832   1:800 
Anti-GSK-3α (Cell Signaling Technology, Beverly, MA, USA) #4337 1:900 
Anti-IL-1β (Cell Signaling Technology, Beverly, MA, USA) #12242 1:700 
Anti-Iba1 (Abcam, Cambridge, MA, USA) ab5076 1:500 
 
 
To normalize the data, the relative expression value of each protein of interest was expressed as 
a percent of the concentration of β-tubulin, which was used as the reference protein. The choice 
of a reference protein was based on the previous observations where its expression was found 
to vary moderately across various experimental conditions, as well as the linear representation 
of the intensity of its signal (Gorlova et al., 2019; Pavlov et al., 2019; de Munter et al., 2020). 
 
Determination of protein concentration  
Protein concentration was quantified using the BCA protein assay kit (Pierce, Rockford, IL, USA) 
as described elsewhere (Gorlova et al., 2019; Pavlov et al., 2019, de Munter et al., 2020). The 
working reagent was prepared in accordance with manufacturer instructions. 25µl of each 
standard or sample preparations were pipetted into a microplate well; 200µl of the working 
reagent was added to each well and mixed thoroughly on a plate shaker for 30 seconds; assay 
was run in duplicates. The covered plate was incubated at 37°C for 30 minutes and cooled to 
room temperature for 10 min. The absorbance was measured at 562 nm in a Biotek Microplate 
Reader (Biotek Instruments, Winooski, VT, USA). Ascent Software Program (Winooski, VT, USA) 
coupled to the microplate reader was used to calculate protein values based comparing optical 
densities with the standard curve. The standard curve was generated by plotting the average 
blank-corrected 562 nm measurements for each BSA standard vs. its concentration in µg/ml.  
 
Administration of drugs 
In the study with FUS-tg mice, potential effects of Neuro-Cells were compared to effects of 
celecoxib, NSAID and a COX-2 inhibitor, that was used as a classic anti-inflammatory compound 
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(Goldenberg et al., 1999; Pompl et al., 2003), and of riluzole (2-amino-6-trifluoromethoxy-
benzothiazole), a standard ALS treatment that can slow down the fatal disease progress by 2-3 
months (Miller et al., 2012) and frequently serves as a reference drug  in translational studies 
with ALS (Li  et al., 2013; Rodríguez-Cueto et al., 2018). Riluzole tablets (Sandoz, Almere, 
Netherlands) were crushed and dissolved in tap water, its concentration was adjusted to the 
dosage of 8 mg/kg/day and daily water intake in CD1 mice (Li  et al., 2013; de Munter et al., 
2020). Celecoxib-containing food pellets were produced as described elsewhere (Costa-Nunes et 
al., 2013; Munter et al., 2020), drug concentration was adjusted to the dosage of 30mg/kg/day 
and daily diet consumption. Intake of solutions and food pellets was measured during the first 
three days of dosing and then weekly as described elsewhere (de Munter et al., 2020). 
 
Characteristics of human marrow stem cells  
“Neuro-Cells” is a standardized preparation of fresh, unmanipulated human bone marrow-
derived stem cells, which was produced under regulations of good manufacturing practices 
(GMPs) without expansion and/or labeling (de Munter et al., 2019; patent WO2015/059300A1) 
and provided by Neuroplast BV (Maastricht, Netherlands). Neuro-Cells comprise mesenchymal 
stem cells and their progenitors (MSCs), hematopoietic stem cells and their progenitors (HSCs), 
and other mononuclear cells (Table 3). The Neuro-Cells preparation comprised 1.39x106 MSCs 
and HSCs, containing 5x105 CD34+ cells in 10 ul. The expression profile of MSC markers is 
overlapping; in the total cell preparation used in this study, 85.6% were CD105+, 13% were CD90+, 











Generation of human marrow stem cells  
For production of Neuro-Cells, healthy volunteer donors with informed consent were recruited 
for collection of 50-75 mL of bone marrow from their iliac crest under local anesthesia following 
standard operating procedures. Briefly, mononuclear cells were isolated by Ficoll density 
gradient centrifugation (1.077 g/ml; Sigma, Munich, Germany) at 400×g for 35 minutes. The 
mononuclear cells were re-suspended in the culture medium composed of DMEM (GIBCO, 
Rockville, MD, USA) with low glucose concentration and 10% fetal bovine serum (FBS; Hyclone, 
Table 3  
Characterization of cell populations in ''Neuro-Cells" preparation 
Cell populations in Neuro-Cells Absolute number of cells injected 
per mouse in 10  µl 
Total number of nucleated cells  1.39 x 106/10  µl 
CD34+ cells 5.00 x 105/10  µl 
Other mononucleated cells 8.9 x 105/10 µl 
The proportion of MSCs expressing CD markers in overlapping manner (in total 
cell preparation, defined by single staining assay): 
MSC: CD271+ cells (7%) 
MSC: CD90+ cells (13%) 
MSC: CD105+ cells (85.9%) 
MSC: CD73+ cells (4%) 
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Logan, UT, USA). The mononuclear cells were plated at 1×106 cells/25 cm2 in culture flasks and 
the cultures were incubated at 37°C in 5% CO2 in the air and 95% humidity. The medium was 
exchanged after 48 hours and then every 3 to 4 days. When the cultures reached approximately 
90% of confluence, human marrow stem cells (“Neuro-Cells”) were passaged with 0.25% trypsin 
(GIBCO) and re-plated into passage culture at a density of 5000 to 10,000 cells/cm2. Cells at 
passages 3 and 4 were used for transplantation. Upon harvest, the cells were isolated by 
treatment with 0.25% trypsin. The cells were then washed four times and re-suspended in PBS 
at a density of 100,000 cells/μl. Viability of the cells was assessed using a 0.4% Trypan Blue dye 
(Sigma, Berlin, Germany) exclusion method prior to and following transplantation. The cells were 
analyzed for their immunophenotype by flow cytometry (Beckman Coulter, Fullerton, CA, USA). 
Fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin-conjugated antibodies specific 
for human CD14, CD19, CD45, CD34, CD73, CD90, CD105, and HLA-DR tested for flow cytometry 
application. The percentage of positive cells was determined based on fluorescence emission of 
the nonspecific FITC/phycoerythrin isotypic antibody controls. A preparation of Neuro-Cells was 




Intracerebroventricular infusion of Neuro-Cells  
After thawing according to a standard procedure (see Table 4), cells were re-suspended in Ringer 
Lactate buffer and studied for vitality. A counting was performed using the "Countess II FL 
Automated Cell Counter" (Thermo Fisher Scientific AMQAF1000, Toronto, ON, Canada) 
according to the manufacturer's protocol. Three batches of Neuro-Cells from the same bone 
marrow extraction were used in the study. The viability measurement of Neuro-Cells samples 
Table 4 
Standard thawing procedure for Neuro-Cells 
Step 1 
1 50ml sterile Ringer Lactate solution is used 
pre-warm at 37°C water bath 
Step 2 
1  To thaw frozen Neuro-Cells, cryovials are placed in a water bath at 37°C until only a small  sliver of ice 
is  present; caution is paid to prevent cryovial cap from submerging in the water. 
2 A -  Cryovials are transferred  to  the laminar flow hood 
- all vials are wiped with 70% IPA before opening the cap using a 70% IPA soaked tissue 
 B  each thawed cell type is transferred into an individual 15ml tube containing 5ml pre-warmed thawing 
buffer  
 C - cryovials are rinsed twice with fresh pre-warmed thawing buffer  
- pooled cells are mixed by gently pipetting up/down  twice 
 D Suspension is centrifuged under 300g for 5 min 
 E - supernatant  is completely aspirated  
- the cell pellet are handled carefully  
- pellet is resuspended into the thawing buffer for washing 
 F For washing, pellet is centrifuged under 300g for 5 min  
 G supernatant  is completely aspirated  
- pellet is resuspended into the thawing buffer for washing 
- cells are pooled where applicable 
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used in the experiment has ensured high vitality percentages in samples, that were ranging from 
62 to 68%. Subsequent flow cytometry was done and HSC numbers were adjusted in injection 
suspension prior the infusion of Neuro-Cells to a mouse brain. Therefore, their concentration in 
buffer was adjusted to 500,000 CD34+ in 10 µl for i.c.v. injections; vials were kept in +4C°. 
Separate preliminary studies were carried out to determine the distribution of infused Neuro-
Cells and optimize the protocols for the i.c.v. administration (de Munter et al., 2020). These 
studies have suggested the presence of Neuro-Cells in the brain and peripheral organs 12 and 24 
h after injection of 100, 000 or 250, 000 cells were infused to lateral ventricles. A positive signal 
in the ventricles, brain tissue, lungs, and spleen was found in Neuro-Cell-treated mice using 
immunohistochemical assay with human anti-mitochondrial antibodies that was carried out as 
described elsewhere (Donders et al., 2015). These results suggested a wide distribution of Neuro-
Cells in the cerebrospinal fluid and their persistent vitality and were consistent with the results 
of the pilot study with i.c.v. infusion of bone marrow-derived mouse stem cells obtained from 
mutants expressing Green Fluorescent Protein (GFP) (de Munter et al., 2020). These experiments 
also showed that i.c.v. administration of Neuro-Cells to mice at the concentrations 100,000 – 
500,000 is well tolerated. Animals were anesthetized by halothane (Halothane TM; Willy Rusch, 
Boblingen, Germany) and immobilized in a stereotaxic frame (World Precision Instruments, 
Sarasota, TX, USA) for unilateral i.c.v. infusion via a hole made in a scull of mice as described 
elsewhere (Strekalova et al., 2001, 2002).  Specifically, after incision of the skin, the periost of 
the skull was removed and the hole was drilled above the left lateral ventricle of the brain (0.5 
mm posterior and 1.0 mm lateral from the midline; coordinates according to Franklin & Paxinos, 
1997). For injection of Neuro-Cells and vehicle, Hamilton syringe (inner diameter: 230.3 µm) was 
carefully lowered into the hole 1.7 mm below the surface of the skull. Following conditions of 
Neuro-Cell administration were employed: 10 ul of Neuro-cells suspension (500, 000 cells) in 
sterile Ringer lactate buffer or buffer alone were infused unilaterally in 10 min. At the end of the 
injection, the holes were sealed with bone wax and the skin was closed with tissue glue 
(Histoacryl, B. Braun Surgical, Melsungen, Germany). After surgery, mice were maintained in a 
warm environment for 3 to 4 h before transferring them back to the animal room. 
 
SUPPLEMENTARY FIGURES AND TABLES WITH STATISTICAL RESULTS 
 
Nissle staining of brains of FUS-tg and wild type control mice 
Nissl staining was performed as described elsewhere (Shelkovnikova et al., 2013). All steps were 
essentially performed as described previously, five FUS[1-359]-tg 8-weeks-old animals per group 
were used, paraffin brain blocks were obtained as described elsewhere (Shelkovnikova et al., 
2014, 2019). To produce paraffin blocks of dissected brains, PFA-fixed hemispheres were 
incubated 2 times for 1 h with 70%-ethanol solution, for 1.5 h with 80%-ethanol solution, for 1 h  
with 95%-ethanol solution, 3 times for 1.5 h, in 100% -ethanol solution, 3 times for 1.5 hour in  
xylene,  for 2 h, in paraffin first wax paraplast Xtra (at 58°C), for 2 h paraffin second wax paraplast 
Xtra (at 58°C) in cassettes (Sigma-Aldrich, St. Louis, MO, USA). Initially, a small amount of molten 
paraffin was dispensed in mold from paraffin reservoir. Tissue was transferred into the mold 
using warm forceps. Subsequently, the mold was placed on a cold plate for paraffin to solidify 
into a thin layer. Hot paraffin was added to the mold from the paraffin dispenser to cover the 
front surface of the plastic cassette. Then paraffin blocks were stored until use at the room 
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temperature. To remove paraffin, sections were incubated 3 times for 5 min with xylene, 2 times 
for 10 min with 100%-ethanol solution, 2 times for 10 min with 95%-ethanol solution, 2 times for 
10 min with 70%-ethanol solution, 2 min for 10 min with 50%-ethanol solution (Sigma-Aldrich, 
St. Louis, MO, USA) and 2 times for 5 min in ice-cold deionized water. 20-µm-thick hemisphere 
sections from paraffin brain blocks were obtained from lateral 3.6 to lateral 0.4 mm along the 
medial-lateral axis ahead of bregma (Paxinos and Franklin, 2001) using a Leica CM 1850 cryostat 
(Leica Microsystems, Wetzlar, Germany) and mounted on gelatin-covered glass with coverslips. 
For Nissle assay, brain sections were randomly selected, dewaxed with xylene (Sigma-Aldrich, St. 
Louis, MO, USA), treated with 95%-ethanol solution (Sigma-Aldrich, St. Louis, MO, USA), stained 
with 0.1% cresyl violet for 15 min (Sigma-Aldrich, St. Louis, MO, USA) and washed with distilled 
water. Images were acquired on a Leica SP8 microscope (Leica Microsystems, Mannheim, 
Germany). 
 
Supplementary Figure 2.  Nissle staining of frontal lobes of (A) the WT mouse and (B) FUS[1-359]-tg mouse at age of 8 weeks. No signs of 
neurodegeneration in FUS[1-359]-tg can be observed; magnification x 200, scale 100 mkm.gg 
General locomotor activity in the elevated O-maze 
We scored total numbers of crossed sections (4x5.5cm) in both arms of the elevated O-maze 
during 5 min to estimate possible changes in locomotion between two genotypes. No significant 
differences were found (df=18, p=0.6091; two-tailed t-test; Suppl. Fig.3). 
 
 
Supplementary Figure 3. A lack of genotype differences in locomotor activity in the O-maze test. There were no significant differences 
between groups in the number of crossed sections in O-maze (p>0.05, t-test), ten animals per group were used. WT – wild type mice, 
FUS-tg - FUS[1-359] mice. Bars are Mean ± SEM. 
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These data show that FUS-tg and wild type control mice had similar response to the testing 
procedure in the O-maze in terms of locomotion. This lack of changes in general locomotion rules 
out a possibility of confounds in behavioral analysis of mice in this test. 
 
Western blot study of protein expression of molecular markers of inflammation and GSK-3 FUS-
tg mice treated with old and new anti-inflammatory therapies  
Western blot assay was carried out to investigate the expression of molecular markers of 
inflammation and GSK-3 in the hippocampus and prefrontal cortex of FUS-tg mice that received 
celecoxib or Neuro-Cells. To normalize the data, the relative expression value of each protein of 
interest was expressed as a percent of the concentration of β-tubulin (see above) as described 
elsewhere (de Munter et al., 2020).  
 
 
Supplementary Figure 4. Effects of standard ALS treatments and Neuro-Cells on behavioural and brain molecular changes in FUS-tg mice. 
(A) Following examination of Western Blot bands in the hippocampus, we found significantly elevated protein levels of IL-1β, Iba-1 and 
GSK-3β in FUS Veh and FUS Cel animals in comparison with WT Veh mice (p<0.05) that was not found in FUS-tg-NC group (p>0.05). FUS-
tg-NC mice had significantly lower expression of these proteins in comparison with other groups of mutants (p<0.05). FUS Cel mice showed 
significantly higher protein concentration of GSK-3α than mice (p<0.05). (B) The analysis of Western Blot bands in the prefrontal cortex  
has revealed a significant increase of protein levels of IL-1β  in GSK-3β in FUS Veh and FUS Cel mice and significant increase of protein 
concentrations of Iba-1 and GSK-3β in FUS Veh  animals in comparison with the WT Veh group (p<0.05). No other group differences were 
found (p>0.05). β-tubulin was used as a loading control in the Western blot assay, the expression of all proteins is normalized to β-tubulin 
expression (*p<0.05, vs. WT Veh group, #p<0.05, vs. FUS Veh group: one-way ANOVA and Tukey’s test),  see the main ms text; bars are 
Mean ± SEM.   
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The choice of a reference protein was based on the previous observations where its expression 
was found to vary moderately across various experimental conditions, as well as the linear 
representation of the intensity of its signal (Gorlova et al., 2019; Pavlov et al., 2019; de Munter 




Summary of statistics  
 
5A. Summary of comparisons between the FUS-tg and WT groups (unpaired t-test) 
Elevated O-maze: 









Duration of attacks 
Resident-Intruder 













5B. Repeated comparisons rearings novel cage test Fus-tg & WT(2way ANOVA,unpaired t-test) 












5C. Summary comparisons WT vs FUS-tg in displaced food pellets marble test (unpaired t-test) 
























Table 5A: Summary of comparisons between the FUS-tg and WT groups in the measures of 
emotionality and social behaviour (two-tailed unpaired t-test). Fig. 1A-E. Welsh’ correction was 
used in the analysis of tail suspension test; significant group differences are in bold; ↑ an 
increase; ↓ a decrease of a parameter vs WT group; bold is significant. 
 
Table 5b: Summary of comparisons in the number of exploratory rearings in the novel cage test 
between the FUS-tg and the WT groups. Two-way ANOVA for repeated measures revealed 
significant time x genotype interaction (F=2.62, p<.05) and genotype effect (F=7.17, p<.05). Fig 
1F. FUS-tg mice showed an increase of this measure on the 4th min in comparison with WT mice 
(Sidak post-hoc test); ↑ an increase; ↓ a decrease of a parameter vs WT group; bold is 
significant. 
 
Table 5C: Summary of comparisons in numbers of displaced food pellets in the marble test 
between the FUS-tg and WT groups. There were significant time and genotype effects, as well as 
significant time x genotype interaction the in number of pellets displaced during the marble test 
(F=18.8, p<.05; F=21.2, p<.05 and F=3.18, p<.05, respectively, two-way ANOVA for repeated 
measures). Fig.1G. WT mice had higher than FUS-tg mice number of displaced pellets at nearly 
all time points of the test (Sidak post-hoc test). ↑ an increase; ↓ a decrease of a parameter vs 









Hippocampus Prefrontal cortex 
TNF t=2.42, df=26, p=0.023↑ t=1.43, df=26, p=0.166 
IL-1β t=0.54, df=28, p=0.593 t=0.36, df=23, p=0.718 
COX-1 t=3.66, df=27, p=0.001↑ t=1.82, df=27, p=0.079 
TIMP1 t=0.98, df=8, p=0.355 t=1.16, df=16, p=0.264 
Mmp9 t=0.34, df=8, p=0.746 t=0.53, df=17, p=0.600 




Table 6: Summary of the FUS-tg and WT group comparisons in brain mRNA concentration of 
molecular factors involved in inflammation, degeneration and plasticity (Fig. 1H-N). There were 
significant group differences in the expression of target molecules in the hippocampus and the 
prefrontal cortex (unpaired two-tail t-test); ↑ an increase; ↓ a decrease of a parameter vs WT 




Table 7: Summary of comparisons between the FUS-tg treated with vehicle, celecoxib, riluzole 
or Neuro-Cells in the measures of emotionality and social behaviour (Fig 2 A-F, two-way ANOVA 
and Tukey test; data for WT group comparisons are not shown).  In the dark/light box, there was 
no significant genotype x treatment interaction in the time spent in the lit box (F(3,55) =1.96, 
p=0.130). ANOVA revealed significant genotype effect for this measure (F(1,55)= 18.84, 
P<0.0001), indicating increased anxiety-like behavior in the FUS-tg. There was no significant 
treatment effect on time spent in the lit box (F(3,55)=0.35, p=0.79). In the tail suspension test, a 
two-way ANOVA did not show a significant genotype x treatment interaction in the duration of 
immobility (F(3,62)=2.09, p=0.11). There was a significant genotype effect for this parameter 
(F(1,62)=13.29, p=0.0005), indicating increased despair behavior in the FUS-tg group. There was 
a significant treatment effect on the duration of immobility (F(3,62)=4.02, p=0.011). In the social 
interaction test, significant genotype x treatment interaction was revealed by a two-way ANOVA 
in the duration of ‘following’ behavior (F(3,60)=9.70, p<0.0001), but not in the number of attacks 
(F(3,53)=0.43, p=0.73) and number of tail rattling events (F(3,53)=1.004, p=0.400). ANOVA 
analysis showed significant genotype effects for the number of attacks (F(1,53)=8.28, p=0.006) 
and duration of following (F(1,60)=39.45, p<0.0001) and significant treatment effects on 
duration of following (F(3,60)=8.76, p<0.0001). Tukey analysis revealed significant group 





Summary of statistics FUS-tg mice treated (two-way ANOVA and Tukey-test) 
Groups Dark/light 
box: time 
























p=0.036↑ p=0.005↓ P<0.01↑ p=0.361 p=0.880 p<0.0001↓ 
WT-Ril vs 
FUS-tg-Ril 
p=0.017↑ p=0.864 P<0.01↑ p=0.997 p=0.993 P=0.058 
WT-Cel vs 
FUS-tg-Cel 
p=0.998 p=0.575 p=0.270 p=0.524 p=0.999 p<0.002↓ 
WT-NC vs 
FUS-tg-NC 
p=0.893 p>0.999 p>0.999 p=0.966 p=0.995 p=0.958 
FUS-tg-Veh 
vs FUS-tg-Ril 
p>0.999 p=0.059 p>0.999 p=0.992 p=0.700 p=0.124 
FUS-tg-Veh 
vs FUS-tg-Cel 
p=0.941 p=0.428 p=0.980 p>0.999 p=0.894 p=0.720 
Fus-tg-Veh vs 
Fus-tg-NC 
p=0.936 p=0.008↑ p=0.160 p=0.869 p=0.670 p<0.0001↑ 
 
Table 8A 
Summary of statistics FUS-tg mice treated (one-way ANOVA/Tukey-test) 
Hippocampus 
Groups IL-1β Iba-1 GSK-3β GSK-3α 
WT-Veh vs FUS-tg-Veh p=0.0001↓ p=0.0209↓ p=0.0001↓ p=0.2003 
WT-Veh vs FUS-tg-Cel p=0.0003↓ p=0.077 p=0.372 p=0.0366↓ 
WT-Veh vs FUS-tg-NC p=0.646 p=0.950 p=0.748 p=0.071 
FUS-tg-Veh vs FUS-tg-Cel p=0.889 p=0.999 p=0.108 p=0.670 
Fus-tg-Veh vs Fus-tg-NC p=0.014↑ p=0.148 p=0.009↑ p=0.915 
 
Table 8A: Summary of group comparisons of brain concentrations of protein factors of 
inflammation and degeneration in the hippocampus of the WT-Veh group and FUS-tg mice 
treated with vehicle, celecoxib or Neuro-Cells (Fig.2 G-J). There were significant group 
differences in protein concentrations of IL-1β, Iba-1 GSK-3β and GSK-3α (F(3,30)=12.37, 
p<0.0001; F (3,30)=4.38, p=0.011; F(3,30)=9.15, p=0.0002; F(3,28)=3.76, p=0.022; one-way 
ANOVA, respectively). Tukey analysis revealed significant group differences in target molecules 




Summary of statistics FUS-tg mice treated (one-way ANOVA/Tukey-test) 
Prefrontal cortex 
Groups IL-1β Iba-1 GSK-3β GSK-3α 
WT-Veh vs FUS-tg-Veh p=0.0005↓ p=0.017↓ p=0.017↓ p=0.799 
WT-Veh vs FUS-tg-Cel p=0.048↓ p=0.230 p=0.113 p=0.319 
WT-Veh vs FUS-tg-NC p=0.697 p=0.092 p=0.164 p=0.990 
FUS-tg-Veh vs FUS-tg-Cel p=0.823 p=0.897 p=0.998 p=0.736 




Table 8B: Summary of group comparisons of brain concentrations of protein factors of 
inflammation and degeneration in the prefrontal cortex of the WT-Veh group and FUS-tg animals 
treated with vehicle, celecoxib or Neuro-Cells (Fig.2K-N). Significant group differences were 
found for protein levels of IL-1β, Iba-1 and GSK-3β (F (3,30)=7.79, p=0.0005; F (3,30)=3.84, 
p=0.019 and F (3,30)=3.966, p=0.017; one-way ANOVA, respectively) but not GSK-3α 
(F(3,30)=1.10, p=0.366, one-way ANOVA). Tukey analysis revealed significant group differences 
in target molecules (in bold); ↑ an increase; ↓ a decrease of a parameter between groups; ns: 







Introduction chapter 6 
Based on literature as well as the outcomes of the preclinical studies as presented before, here 
we propose a multi-pathway effect of stem cells, explaining their action. Due to their necrotizing 
effects, inflammatory processes themselves stimulate a cascade of various secondary processes, 
inducing further inflammation. By their signaling proteins, stem cells play a major role in this 
multi-facetted cascade. Bm-SCs, therefore, can be seen as multitasking ‘drugs’ able to 
simultaneously switch of the various secondary pathways. Classical drugs, though, do not have 
this ability and therefore their effect on inflammatory processes is minimized by leaving several 
of these activated secondary pro-inflammatory pathways untouched. In this chapter, the multi-
pathway approach of stem cells is postulated and justified by the results of all the presented 
preclinical experiments.  
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6.1. Why do anti-inflammatory signals of bone marrow-derived 
stromal cells improve neuro-degenerative conditions where 
anti-inflammatory drugs fail? 
 
de Munter JPJM, Mey J, Strekalova T, Kramer BW, Wolters ECh (2020)     J 
Neural Transm https://doi.org/10.1007/s00702-020-02173-3. 
Abstract  
Neurodegenerative disorders share the final degenerative pathway, the inflammation-induced 
apoptosis and/or necrosis, irrespective of their aetiology, be it of acute and chronic traumatic, 
vascular and idiopathic origin. Although disease-modifying strategies are an unmet need in these 
disorders, lately, (pre)clinical studies suggested favourable effects after an intervention with 
bone marrow-derived stromal cells (bm-SC). Recent interventions with intrathecal 
transplantation of these cells in preclinical rodent models improved the functional outcome and 
reduced the inflammation, but not anti-inflammatory drugs. The benefit of bm-SCs was 
demonstrated in rats with an acute (traumatic spinal cord injury, tSCI) and in mice with a chronic 
(amyotrophic lateral sclerosis (ALS)-like FUS 1-358 or SOD1-G93-A mutation) neurodegenerative 
process. Bm-SCs, were found to modify underlying disease processes, to reduce final clinical SCI-
related outcome, and to slow down ALS-like clinical progression. After double-blind 
interventions with bm-SC transplantations, Vehicle (placebo), and (non)steroidal anti-
inflammatory drugs (Methylprednisolone, Riluzole, Celecoxib), clinical, histological and 
histochemical findings, serum/spinal cytokines, markers for spinal microglial activation inclusive, 
evidenced the cell-to-cell action of bm-SCs in both otherwise healthy and immune-deficient tSCI-
rats, as well as wild-type and FUS/SOD1-transgenic ALS-like mice. The multi-pathway hypothesis 
of the cell-to-cell action of bmSCs, presumably using extracellular vesicles (EVs) as carriers of 
messages in form of RNAs, DNA, proteins and lipids rather than influencing a single inflammatory 
pathway, could be justified by the reported differences of cytokines and other chemokines in the 
serum and spinal tissue. The mode of action of bm-SCs is hypothesized to be associated with its 
dedicated adjusting of the pro-apoptotic glycogen synthase kinase-3β level towards an anti-
apoptotic level whereas their multi-pathway hypothesis seems to be confirmed by the decreased 
levels of the pro-inflammatory interleukin (IL)-1β and tumor necrosing factor (TNF) as well as the 
level of the marker of activated microglia, ionized calcium binding adapter (Iba)-1 level. 
 
Introduction 
Neurodegenerative disorders are becoming increasingly prevalent and are a growing burden on 
the population worldwide. Acute neurodegenerative disorders are caused by trauma or vascular 
problems, leading to apoptosis and inflammation. Though many molecular and genetic causes 
are thought to serve as predisposing or disease-propagating factors, the underlying pathogenesis 
in chronic neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) is in most 
cases still obscure. Recent discoveries in these diseases, though, have demonstrated the 
presence of inflammation propagating substrates, and trials with several potential immune-
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modulating therapies provided increasing evidence that primary induced apoptosis followed by 
secondary inflammation are heavily involved in the pathogenesis not only in acute but also in 
chronic neurodegenerative diseases. Although steroidal and non-steroidal anti-inflammatory 
drugs (N)SAIDs), with their anti-inflammatory effects, as well as various neurotrophic factors, 
with their pro-survival signaling mechanisms, in the past had been proven to be effective in 
attenuating neuronal death in many in vitro and in vivo models of neurodegeneration,  all larger 
phase II/III trials with both N)SAIDs and/or various neurotrophic factors, so far, did bring 
equivocal and/or worse outcomes (Gilgun-Sherki, Melamed et al. 2006, Hernan, Logroscino et 
al. 2006, McGeer and McGeer 2007, Schwartz and Ziv 2008, Schwartz and Shechter 2010, 
Bracken 2012, Ling, Murdoch et al. 2016). Maybe wrong timing of administration, nonselective 
inhibition of COX-2 or Rho-A, sub-optimal dose in target site, or limited penetration to the brain 
through the blood-brain barrier here may have played a role. Differences between rodent 
models and humans aside, perhaps the most confounding factor might be that the point(s) of 
action might be downstream of the pathophysiological process and retrospective in terms of 
neuronal death induction. Neuroprotection via pro-survival signaling also might not adequately 
annihilate the continuing pathological insult or might be too late to reverse the demise of 
compromised neurons (Tang 2017). Unfortunately, monitoring inflammation by identifying 
microglia-produced cytokines as biomarkers to help in the diagnosis, to predict the progression, 
and to target key immune factors in the various neurodegenerative processes is still a challenge. 
The translation of cytokines as a biomarker in clinical practice is further hampered by intra-
individual variation, environmental factors, and genetic background, disease stage, anatomical 
onset of motor neuron impairment (Hu, Cao et al. 2017, McCauley and Baloh 2019, Moreno-
Martinez, Calvo et al. 2019, Moreno-Martinez, de la Torre et al. 2019). Even age and gender, play 
a role, and the different pro- and anti-inflammatory cytokines along the disease progression 
therefore should be further studied to understand its time point activation and its relation to 
other molecular and clinical mediators in neurodegeneration to finally provide a better 
monitoring of disease progression (Moreno-Martinez, Calvo et al. 2019).  
Various genetic and environmental factors underly neurodegeneration, the result from activated 
inflammasomes, responsible for the activation of inflammatory responses removing cell debris, 
wastes and pathogens via phagocytosis. Inflammasomes are key signalling platforms that detect 
pathogenic microorganisms and sterile stressors, and that activate highly pro-inflammatory 
cytokines. In terms of molecular pathogenesis, neurodegenerative disorders share a negative 
contribution of nonneuronal cells (immune cells, glial cells) expressing and activating 
inflammasomes as a significant commonality (Lewis, Manning et al. 2012, Orsini, Oliveira et al. 
2015).  
 
Microglia, the resident immune cells in the CNS, comprise an entire spectrum of phenotypes that 
span the range from deleterious to regulatory to remodeling effects. Although microglial 
activation provides a defense against injury and infection, chronic or excessive activation is 
considered to be detrimental and has been implicated in many neurodegenerative and 
psychiatric disorders (Hammond, Dufort et al. 2019). In response to their environment, microglia 
are able to rapidly change morphology and function (London, Cohen et al. 2013). Gene 
expression analyses led to the identification of homeostatic (state 1 microglia) as well as 
“disease-associated” microglial phenotypes (DAMs) (Keren-Shaul, Spinrad et al. 2017).  
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As DAMs are not associated with the disease etiology, but rather with a general response 
program that is involved in clearance of the protease-resistant misfolded and aggregated 
proteins, one still rather prefers the name “reactive” microglia. Out of the enormous variety of 
reactive microglia, two main types of reactive microglia have been defined: the classically 
activated (cytotoxic) (state 2) microglia that affect neuronal survival and that secrete pro-
inflammatory cytokines, tumour necrosis factor TNF), interleukins-1β and 12 (IL-1β, IL-12), 
interferon-gamma (IFN-ɣ), and nitric oxide inclusive, the so-called interferon response microglia 
(IRMs]; and the alternatively activated (cytoprotective) microglia that express genes involved in 
innate immune response, thus supporting an anti-inflammatory response and preventing 
classical microglial activation, called activated response (state 3) microglia (ARMs).  
ARM-response overlaps with the DAM-response described by Keren-Shaul  (Keren-Shaul, Spinrad 
et al. 2017), but these cells are not necessarily disease associated and might be considered part 
of the normal evolution of microglia in healthy aging. At odds with the original DAM-response 
description is also the heterogeneity in the ARMs. Alternatively activated microglia secrete 
interleukin-4 (IL-4), interleukin-13, or transforming growth factor β (Hammond, Dufort et al. 
2019). Distinct ‘reactive’ microglia signatures can be used to better understand microglia 
function and to identify and manipulate specific subpopulations in health and disease. The 
ionized calcium binding adapter marker (Iba)-1, which is upregulated in reactive microglia (IRM 
and ARM), is often used to identify these cells in general (Sala Frigerio, Wolfs et al. 2019). 
 
In acute neuro-degenerative disorders, the classical activated microglia response (IRM)  is caused 
by primary insult-induced necrosis, whereas in chronic disorders, ongoing activation is elicited 
by a genetic and/or environmental-driven abnormal accumulation of misfolded proteins, 
mitochondrial dysfunction, oxidative stress and/or inflammation, all processes which reinforce 
each other (Lim, Byeon et al. 2007, Ganguly, Chakrabarti et al. 2017). In ALS, as with other 
neurodegenerative diseases, the degeneration is a complex interplay between multiple 
pathogenic cellular mechanisms such as oxidative stress, mitochondrial dysfunction, impaired 
axonal transport, excitotoxicity, protein aggregation, endoplasmic reticulum stress, neuro-
inflammation, abnormal RNA processing, non-neuronal cells and target muscle contribution 
(Mancuso and Navarro 2015).  
Activated cells proliferate and form dense clusters around the cell bodies of injured neurons 
(Ramirez, Poulton et al. 2011).  These classically reactive phenotypes of intrinsic microglia and/or 
monocyte-derived macrophages produce a pro-inflammation signal cascade by the secretion of 
various cytotoxic factors, pro-inflammatory signaling molecules, and the expression of immune 
molecules, TNF and other inflammatory cytokines inclusive. They also increase their expression 
Iba-1. Once classically activated state 2 microglia start to express glycogen synthase kinase-3β 
(GSK-3β), what they normally not do (Tang, Han et al. 2015), thus further promoting both innate 
and adaptive immune responses (Wang, Brown et al. 2011, Beurel, Grieco et al. 2015).  
GSK-3β, though, has an interesting paradoxical effect: a high dose initiates a pro-apoptotic effect 
during mitochondrial-mediated intrinsic apoptosis but in a low dose, it induces an anti-apoptotic 
effect during death receptor-mediated extrinsic apoptosis. Low doses of GSK-3 inhibitors, 
therefore, provide a feasible means to counteract excessive inflammation and induce 
neuroprotective actions in chronic neurodegenerative conditions, among them amyotrophic 
lateral sclerosis (Mazzardo-Martins, Martins et al. 2012).  
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Activation of microglia is a hallmark of brain pathology, and reactive microglia are especially 
thought to be involved in neuroinflammatory responses (Ito, Imai et al. 1998). As a consequence, 
the environment around the damaged neurons becomes toxic, and thus further enhancing the 
degeneration (Subramaniam and Federoff 2017). Once the inciting event has been adequately 
resolved, a lower production of pro-inflammatory cytokines will polarize these cells, switching 
them from state 2 microglia (IRMs) into state 3 microglia (ARMs) that express genes involved in 
innate immune response, facilitating phagocytosis of cell debris and misfolded proteins, 
promoting tissue repair, and supporting neuronal survival by neurotrophic factors (Khalid, Ampie 
et al. 2017). However, when the pathogenic stimulus cannot be adequately cleared, chronic 
inflammation develops with a persistent IRM response that can cause unintended injury to local 
tissues.  
Thus, chronic neurodegeneration is facilitated by the lack of neurotrophic growth factors and by 
the continued production of cytotoxic by-products of a pro-inflammatory response (Hooten, 
Beers et al. 2015). The type, location and connections of the necrotic cell populations are leading 
in the (variable) clinical expression of these neurodegenerative processes.  
 
Anti-inflammatory drug-Interventions in neurodegeneration 
As discussed above, neurodegenerative diseases share strong neuro-inflammatory multi-
pathway components, which are at least in part responsible for the continuing cell death. 
Pharmacological treatments therefore should intend to reduce this inflammatory response. 
Curiously, so far, interventions with anti-inflammatory drugs in patients suffering these disorders 
did not result in successful treatments (Gilgun-Sherki, Melamed et al. 2006, Hernan, Logroscino 
et al. 2006, McGeer and McGeer 2007, Schwartz and Ziv 2008, Schwartz and Shechter 2010, Ling, 
Murdoch et al. 2016). In patients suffering acute neurodegeneration such as spinal cord injuries, 
in which secondary inflammatory processes are mainly responsible for final clinical outcome, 
initially it was suggested that methylprednisolone (MP) did significantly reduce disability, though 
this could not be confirmed in later studies, and side effects appeared to outweigh any beneficial 
effects (Hurlbert 2000, Bracken 2012).  
Also, in patients suffering chronic neurodegenerative disorders, Alzheimer disease, Parkinson 
disease and amyotrophic lateral sclerosis (ALS) inclusive, anti-inflammatory drugs were found to 
be ineffective (Fondell, O'Reilly et al. 2012, Collins and Bowser 2017, Khalid, Ampie et al. 2017, 
Crisafulli, Brajkovic et al. 2018). Activation of microglia and astrocytes with increased levels of 
pro-inflammatory serum and CSF cytokines IL-1β, IL-6, IL-8, TNF and vascular endothelial growth 
factor (VEGF) are considered the hallmark in ALS (Ciervo, Ning et al. 2017, Hu, Cao et al. 2017, 
Morello, Spampinato et al. 2017, Crisafulli, Brajkovic et al. 2018).  
Interventions with corticosteroids and/or other anti-inflammatory drugs such as the COX-2 
inhibitor celecoxib, which causes reduction of the brain levels of inflammatory cytokines TNF and 
IL-1β (Osman, Mubasher et al. 2016), however, were found ineffective in experimental ALS-like 
animals and/or ALS patients (Galbiati, Onesto et al. 2012, Collins and Bowser 2017, Crisafulli, 
Brajkovic et al. 2018). Apart from an eventual, subtle, inconsistent increase of survival time in 
ALS which might be seen in some patients after an intervention with riluzole (Miller, Mitchell et 
al. 2012) and/or edavarone (Yoshino and Kimura 2006), disease-modifying interventions, for 
instance adequate inflammasome-targeted strategies, are still an unmet need in most 
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neurodegenerative disorders (Voet, Srinivasan et al. 2019). Further, growth factors may play a 
potential role in facilitating functional recovery in degenerative neurons (Shruthi, Sumitha et al. 
2017).   
  
BM-Derived Stromal Cell-Interventions in neurodegeneration 
Although interventions with anti-inflammatory drugs in experimental neuro-degenerative 
animal studies have not resulted in successful clinical trials, a more recent approach to treat such 
disorders, in both experimental animals and humans, with implanting bone marrow-derived 
stromal cells (bm-SCs), seems very promising. Such transplants supposedly modulate the 
immune system in both acute  (Deda, Inci et al. 2008, Martinez, Palomo Ruiz et al. 2017, Tsai, 
Liou et al. 2018, Cofano, Boido et al. 2019, Jin, Medress et al. 2019) and chronic (Mazzini, Vescovi 
et al. 2016, Ciervo, Ning et al. 2017, Gashmardi, Hosseini et al. 2017, Sykova, Rychmach et al. 
2017, Cizkova, Cubinkova et al. 2018, Garbuzova-Davis, Haller et al. 2018, Oh, Noh et al. 2018, 
Gugliandolo, Bramanti et al. 2019) neurodegenerative disorders in experimental animals as well 
as in patients. Our own experiments with human bm-SC in experimental animal models of both 
an acute (traumatic spinal cord injury; tSCI) (de Munter, Beugels et al. 2019, Romero-Ramirez, 
Wu et al. 2020) and a chronic neurodegenerative disorder (amyotrophic lateral sclerosis; ALS) 
(de Munter, Shafarevich et al. 2019) were fully in line with these findings. In these studies, fresh 
bm-SCs specimen were manufactured into standardized preparations for intrathecal application, 
in order to bring naïve stem cells into the environment where neuroinflammation and 
degeneration are ongoing. Hereto, these specimens were reduced in volume after positive 
depletion of erythrocytes, monocytes and lymphocytes and negative selection of untouched 
stem cells (Neuro-Cells: patent WO2015/ 059300A1). We explored the effect of an intrathecal 
transplantation with bm-SCs (4x105 CD34+ cells) in both T-cell-deficient and immune competent 
Wistar rats, one day after a traumatic spinal cord injury, resulting in a complete paraplegia (de 
Munter, Beugels et al. 2019, Romero-Ramirez, Wu et al. 2020) Bm-SCs were found to be free of 
side-effects, to significantly protect for SCI-related mortality, and to improve natural motor 
recovery (Basso, Beattie et al. 1995) compared to placebo-treated animals, in the following 
weeks (de Munter, Beugels et al. 2019). When compared to an acute 48 hr intra-peritoneal high-
dose methylpred-nisolone (MP) application (Romero-Ramirez, Wu et al. 2020), bm-SC again 
significantly improved locomotor functions (Basso, Beattie et al. 1995) and restored body weight.  
Bm-SC-treated rats also never evidenced SCI-associated neuropathic pains during testing of 
mechanical nociception (von Frey), as sporadically seen in SCI-rats treated with placebo and/or 
MP. In those experiments, there was no rejection of the transplants, and there were no adverse 
events. The effects of an intrathecal intervention with bm-SCs (5 x105 CD34+ cells) were also 
studied in two different experimental ALS-like mice models. As the aetiology of ALS is still 
unclear, animal models are based on gene mutations which are found in familial cases: Cu-Zn 
superoxide dismutase gene SOD1, C9ORF72, PGRN, TBK1, TARDBP, and FUS genes (Freischmidt, 
Muller et al. 2015, Al-Chalabi, Hardiman et al. 2016, Lutz 2018). Still asymptomatic 10-weeks old 
FUS(1-358) (Shelkovnikova, Peters et al. 2013) and 12-weeks-old SOD1(G93A) mutant mice (de 
Munter, Shafarevich et al. 2019) were treated with bm-SC transplantations before developing a 
progressive loss of motor functions, muscle atrophy and weights loss due to a fast degeneration 
of spinal motor neurons with denervation in the following weeks, thereby representing a 
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relevant preclinical model for amyotrophic lateral sclerosis (ALS). Conform previous studies 
(Uccelli, Milanese et al. 2012, Boido, Piras et al. 2014, Ciervo, Ning et al. 2017), intrathecal bm-
SC transplantations in FUS(1-358) and SOD1(G93A) mutant ALS-like mice were found to 
significantly induce disease-modifying effects; they significantly delayed cachexia, weight loss 
and motor dysfunction, as well as muscle atrophy and the loss of spinal lumbar motor neuron as 
seen in placebo-treated transgenic mice. Interventions with riluzole and/or celecoxib at the same 
(pre-symptomatic) age in these animals, however, failed to slow down the development of these 
ALS-like symptoms in the mutant mice. 
 
Mode-of-action of BM-Derived Stromal Cells 
The mode of action of bone marrow-derived stromal cells was originally postulated to be related 
to cellular integration by leveraging the plasticity of the stromal/stem and progenitor cells for 
the replacement of lost neural tissue. In addition, the mechanism was also considered to relate 
indirectly via cellular interactions which stimulate secretion of neurotrophic factors as well as 
factors affecting the immune response by modulating T- and B-cell activity thereby decreasing 
apoptosis of neural cells and inflammatory responses (Ruppert, Nguyen et al. 2018). 
Mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are the main stem cells 
sourced by bone marrow (Kucia, Reca et al. 2005). Both stem cell types are capable of 
differentiation into spindle neuron-like cells (Koshizuka, Okada et al. 2004, Sigurjonsson, 
Perreault et al. 2005, Ye, Zeng et al. 2011). Further, after harvesting, HSCs differentiate easily in 
pro-inflammatory cells increasing inflammation. These cells, though, can be kept in their naïve 
status when at the same time MSCs were present (Le Blanc and Ringden 2005). As stem cells 
only sparsely pass intact blood-brain-barriers (BBB) and/or CSF-brain barriers, it is most probably 
that eventual effects of bm-SCs are not reached by cell replacement but might rather be 
effectuated by communicators, signaling proteins that freely pass those barriers, though. If given 
intrathecally, the bm-SCs are trapped in the cerebrospinal fluid and disappear within a couple of 
weeks completely (Engelhardt and Sorokin 2009, Redzic 2011, Abramowski, Krasemann et al. 
2016). The bm-SCs are decision making-cells that coordinate their operations with their 
immediate environment (Fischbach, Bluestone et al. 2013, Caplan 2017). They act cell-to-cell 
using all kind of communicators, such as extracellular vesicles (EVs) and soluble factors such as 
cytokines (including chemokines, interferons, interleukins, lymphokines, and tumour necrosis 
factor), growth factors and mitochondria transfer. EVs are small, membrane-bound 
nanoparticles that can be released from most, if not all cells, and that can carry functionally 
active cargo (proteins, nucleic acids) that has been shown to modify the recipient cells physiology 
to react in a paracrine and endocrine manner (Yanez-Mo, Siljander et al. 2015, Zhang, Yeo et al. 
2016, Harting, Srivastava et al. 2018, Ruppert, Nguyen et al. 2018). The EVs-cargo which 
comprises DNA, RNA, protein and lipids reflects the physiological as well as the 
pathophysiological state of a cell (Abels and Breakefield 2016). EVs are emerging as a promising 
tool for therapeutic delivery owing to its favorable intrinsic features of biocompatibility, stability, 
stealth capacity, and the ability to overcome natural barriers (Dostert, Mesure et al. 2017, 
Shahjin, Chand et al. 2019). In other studies, bm-SC-EVs were found to exert immune-suppressive 
effects by enforcing ARM macrophage polarization and stimulating T-cell induction as well as 
producing neurotrophic factors and anti-inflammatory cytokines, as a dedicated reaction of 
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environmental vesicles or cytokines from degenerating, malfunctioning cells (Dostert, Mesure et 
al. 2017, Cizkova, Cubinkova et al. 2018, Harting, Srivastava et al. 2018, Kim, Oh et al. 2018, 
Wang, Pei et al. 2018, Beers and Appel 2019, Shahjin, Chand et al. 2019). This hypothesis, though, 
is still a hypothesis, and recently, the possibility that bm-SCs one way or the other might donate 
healthy mitochondria to neurons that harbour dysfunctional mitochondria has also been raised 
to explain their positive effects (Babenko, Silachev et al. 2015). In order to further address the 
question why immune-modulating bm-SCs strategies are more successful than anti-
inflammatory drugs in human neurodegenerative disorders, we  want to summarize the different 
cytokines and proteins with the relevant pathway and want to discuss a compilation of all 
findings from three preclinical studies, looking after the effects of an intervention with bm-SC in 
in SCI and ALS-like animal models (de Munter, Shafarevich et al. 2019, de Munter, Beugels et al. 
2019, Romero-Ramirez, Wu et al. 2020). The following cytokines and proteins were studied in 
the mentioned preclinical experiments: 
 
TNF: 
Tumour necrosis factor (TNF) is important to maintain immunity and cellular homeostasis and 
creating a balance between cell survival, apoptosis and necroptosis. TNF regulates the 
generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS), and this 
ROS/RNS signaling plays an important role in activating and controling inflammatory conditions 
(Blaser, Dostert et al. 2016). Further TNF initiates the MAPK signaling pathway and the NF-kappa 
B signaling pathway, both involved in apoptosis and necroptosis (Wrzodek, Buchel et al. 2013). 
 
IL-1β: 
Interleukin-1β is a pro-inflammatory cytokine and a mediator of neuronal injury. Experiments 
with Interleukin-1 cause an impaired cerebral blood flow (Murray, Parry-Jones et al. 2015). 
Mechanistically it seems that Interleukin-1β is also correlated with the caspase pathways, thus 
initiating apoptosis (Spinello, Vecile et al. 2019). 
 
IL-6: 
Interleukin-6 is a cytokine that is released by proteolytic cleavage and is involved in the 
regulation of the immune system and inflammation within the central nervous system. IL-6 binds 
to an IL-6 receptor, and then associates with a dimer of the ubiquitously expressed gp130 
receptor subunit, which initiates intra-cellular signaling. Interleukin-6 can bind to the membrane 
of cells (liver and leucocytes) and initiate a classical signaling, which is regenerative and anti-
inflammatory, though the soluble form can bind with a co-protein to nearly all cell types and 
initiate trans signaling, which is inflammatory and pro-apoptotic (Rose-John 2012). IL-6 signaling 
activates downstream signaling pathways such as Janus kinases/signal transducers and 
activators of transcription (Jak/STAT), the phosphatidylinositol 3-kinase cascade and the 
mitogen-activated protein kinase cascade through gp130 homodimer formation (Garbers, 
Hermanns et al. 2012).    
 
Iba-1: 
Iba-1 is a marker of reactive microglia (Imai and Kohsaka 2002). Microglial activation presumably 
involves the FGF2/FGFR1 (fibroblast growth factor and receptor) pathway as can be seen when 
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this pathway is blocked (Zou, Shi et al. 2019). Microglia play an important role in modulating 
inflammation, and especially the polarized (ARM) microglia contribute to a more regenerative 
environment. This was confirmed, as a matter of fact, by the microglia expression of arg1, CD206 
and CCR2 (Roszer 2015) in our experiment (Figure 2). However, activation of microglia might also 
be reached by the modulating effects of Il-6 and TNF (Chu 2013, Schaper and Rose-John 2015). 
 
GSK-3β: 
Glycogen synthase kinase-3 is responsible for maintaining selective intracellular phosphorylation 
of many substrates. This enzyme is involved in all kind of different roles in multiple signaling 
pathways. The upregulation of GSK-3β expression in T-Cells is seen as pathogenic in auto-
immune diseases (Beurel, Kaidanovich-Beilin et al. 2013). Blocking GSK-3 may bring down 
disease-progression in neurodegenerative diseases by decreasing inflammation and apoptosis 
and providing a cell protective environment (Morales-Garcia, Susin et al. 2013). 
 
Figure 1 presents an overview of the time axis of these three studies in which we compared the 
histological effects of bm-SC with the effects reached after matched interventions with placebo 
(vehicle), methyl-prednisolone, Riluzole and/or Celecoxib in SCI-lesioned and ALS-like 
experimental animals, at different timepoints after intrathecal application (1, 2 and 3).The 
findings will be put into perspective of the hypothesis that stem cells are decision-making cells 
and that they adapt to their environment. At the time point marked with the number 1 in the 
red circle (Figure 1), 3 days after the administration of the intrathecal intervention with bm-SCs 
or Vehicle and 4 days after the initial lesioning, histology was performed of the spinal tissue in 
both balloon compression-induced SCI-lesioned and sham-lesioned immune-deficient rats 




Figure 1: overview of the three preclinical studies, looking after the effects of an intervention with the same bm-SCs in acute and chronic 
degenerative diseases, providing the different time points of tissue sampling for histology 
Naïve bm-SCs applied 24 hours after the lesioning straight into the cerebrospinal fluid of a SCI 
injured rat were able to polarize IRMs into ARMs, to decrease astrocytes in the lesion, to protect 
neurons for apoptosis in the lesion and to decrease serum pro-inflammatory interleukins (IL-1β. 
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Il-6 and TNF) when compared to the vehicle treated animals. The focus of the bm-SCs cells was 
to “detox” the cerebrospinal fluid and save precious neurons in an acute neurodegenerative 
condition (de Munter, Beugels et al. 2019). At the time point marked with the number 2 in the 
red circle (Figure 1), 56 days after the administration of the intrathecal intervention with bm-SCs 
or Vehicle and 57 days after the initial balloon compression-induced lesioning in immune-
deficient rats, histology was performed of the spinal tissue (caudal, central and rostral of the 
lesion) and lesion tissue was prepared for proteomics to investigate the up and downregulation 
of different regulons. Findings at this timepoint are displayed in Figure 3. At the time point also 
marked with the number 2 in the red circle (Figure 1), 70 days after the administration of the 
intervention with bm-SCs, Methyl-prednisolone or Vehicle, and 71 days after the initial drop-
weight lesioning of otherwise healthy rats, lesion site, expression of astroglia and western Blot 
Iba-1 in the spinal lesion site were investigated. Findings are displayed in Figure 4.                                                           
Finally, at the time point marked with the number 3 in the red circle (Figure 1), 35 days after the 
application of Vehicle, bm-SCs, Riluzole or Celecoxib in still asymptomatic ALS-like FUS-mutated 
mice, ELISA serum and spinal Western Blot histology were performed (de Munter, Shafarevich 
et al. 2019). Findings are displayed in Figure 5. As shown in figure 2, three days after the 
intervention with the Vehicle, the devastating effects of the SCI lesioning In the Vehicle-treated 
rats were mainly found due to a persistent neuroinflammatory response, as reflected by the 
increased expression of microglia in IRM mode, as well as the increased astrogliosis and 
apoptosis, when compared to the animals treated with bm-SC (de Munter, Beugels et al. 2019). 
The results reached at the various timepoints after the interventions with bm-SCs are 
summarized in Table 1. 
 
 
Figure 2: Expression of microglia (2A), astroglia (2B), and apoptosis (2C) caudal, central and rostral of the SCI lesion, and the quantified 
polarization from IRM to ARM microglia (2D) 3 days after the interventions with bm-SCs or Vehicle in T-cell deficient balloon compression-
induced spinal cord injured rats. (2E) Displays the serum concentration of Interleukin-1β, (2F) the serum Interleukin-6, and (2G) the serum 





56 Days after the interventions, histological studies of the lesioned tissues in the bm-SC and 
Vehicle-treated SCI-lesioned animals did not establish any significant difference in the expression 
of microglia, astrocytes and apoptosis anymore (see figure 3). A comprehensive proteomic 
profile of the lesioned spinal tissue showed various changes in the up- and down-regulation of 
the protein expression when compared with the findings at baseline (vehicle treated animals), 
which were set to 100%. The most important findings were the downregulation of pro-





Figure 3: Expression of microglia (3A), astroglia (3B) and apoptosis (3C) caudal, central, and rostral of the SCI lesion in the spinal cord of 
animals sacrificed 56 days after the intervention with bm-SCs or Vehicle, in T-cell deficient balloon compression-induced spinal cord injured 
rats. In 3D the significant (p<0.05) up- and down-regulated proteins of the analysed lesioned spinal  tissue are presented. Protein expression 
in the injured tissues of the Vehicle-treated animals are displayed in the baseline (de Munter, Beugels et al. 2019). 
 
 
As might be appreciated in Figure 4, 70 days after the intervention with Vehicle, 
Methylprednisolone or bm-SC in drop weight-induced SCI-injured, otherwise healthy rats, the 
absence of any significant difference in histological findings as established 56 days after the 
intervention with bm-SC and Vehicle treated - SCI-lesioned immune-deficient rats, as displayed 
in Figure 3 could be confirmed in immune competent rats. The lesion size in the animals treated 
with bm-SCs was somewhat smaller than in the rats treated with Vehicle and 
Methylprednisolone, but not significantly.  
An interesting finding, though, was the significant lower expression of Iba-1 in the lesion site of 
the animals treated with bm-SCs, but not in the animals treated with Methylprednisolone and/or 
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Vehicle (Romero-Ramirez, Wu et al. 2020) confirming the hypothesis that bm-SCs reach anti-




Figure 4: Lesion size as evaluated with cleaved Caspase-3 (4A), expression of astroglia (4B) and Western blot Iba-1 (4C) in the spinal cord 
tissue (data were normalized to Iba1-IR in the white matter of the not-lesioned (No SCI) rats) in immune competent rats after a drop 
weight-induced SCI lesion, 70 days after an intervention with Methylprednisolone (MP), Vehicle (NaCl) or human stem cells (bm-SCs) 
(Romero-Ramirez, Wu et al. 2020).  
 
In these animals, apoptosis, as evaluated with activated caspase-3, was found significantly 
reduced in the ventral horns as well as axonal pathology in the ascending dorsal columns when 
compared to Vehicle and/or MP-treated rats (Romero-Ramirez, Wu et al. 2020). 
Most straight forward answer to the initial question about the mode-of-action of bm-SCs seems 
to be the multi-pathway approach of bm-SCs in contrast to the single pathway approach of 
(N)SAIDS. An alternative explanation could be the activation of a still not clear pathway more 
upstream of the inflammatory cascades. Bm-SCs might be seen as decision making cells, that 
coordinate their operations with their immediate environment  (Fischbach, Bluestone et al. 
2013, Caplan 2017). Their cell-to-cell communication here may play a major role and future 
research must elucidate the content of stem cells secreted EVs in modulating inflammatory 
environments. 
In summary, bm-SC’s immune-modulating properties, including their paracrine cytokines with 
their polarizing effect on IRMs, attack more and different mechanisms than the individual anti-
inflammatory drugs, as also suggested by our proteomic findings in the SCI-rats (de Munter, 
Beugels et al. 2019). Despite the evidence that inflammation is critical in both SCI and ALS, 
treatment with various anti-inflammatory drugs (including Rho-A, COX-2 and TNF inhibitors, 
steroids, cyclophosphamide, cyclosporine, cytochrome-C inhibitors, and caspase-reducing drugs) 
seems to fail to clinically-significant modify SCI and/or ALS symptomatology and/or pathology in 
humans (Hurlbert 2000, Bracken 2012, Collins and Bowser 2017, Crisafulli, Brajkovic et al. 2018), 
unless the result of insufficient dosage or bioavailability, delayed time points of delivery, and/or 
or the taking-over of the eventually inhibited pathway by other single or down-stream pathways.  
By the way, the bm-SC-induced immunomodulatory and regenerative effects might also be 
mediated when the stem cells quickly pass on their effects to resident cells (Eggenhofer, Luk et 
al. 2014). Figure 6 illustrates the multi-pathway approach of bm-SCs. 
As for the application route of stem cells in patients suffering neurodegenerative disorders, in 




Figure 5 Overview of the ELISA serum IL-1β (5A) and IL-6 (5B) levels,  and the western blot staining of spinal IL-1β (5C), Iba-1 (5D) and GSK-
3β (5E) levels in wild type (WT) and  FUS-tg mice treated with Vehicle, Riluzole, Celecoxib and bm-SCs as established 35 days after these 




Intravenous application ends up with most bm-SCs stuck in lung and liver (Fischer, Harting et al. 
2009), and the number of engrafted bm-SCs in the central nervous system will be minimal due 
to the lack of ability to easily cross the blood-brain barrier by these cells (Cerri, Greco et al. 2015). 
On top of this, repeated intrathecal bm-SC transplantations proved to be safe and feasible, and 
are found most promising for the treatment of patients with neurological diseases (Pan, Deng et 
al. 2019) 
Table 1:  
Summary of the effects of interventions with intrathecal applied bm-SC in experimental animal  models 
for both acute (SCI) and chronic (ALS-like) neurodegenerative disorders. 
Intrathecal application       
24 hr after SCI lesioning 
cytokine TNF ↓ (p < 0.05) in serum and spinal tissue 
cytokines IL-1β  ↓ (p < 0.05) and ↓ IL-6 (trending) 
Iba-1 ↓  (p < 0.05) in serum and spinal tissue  
polarize cytotoxic macrophages 2 (IRMs) into cytoprotective macrophages 3 (ARMs) apoptotic/pro-
inflammatory proteins ↓ (p < 0.05) 
regenerative/differentiating proteins ↑ (p < 0.05) 
 
Intrathecal application in 
still aymptomatic ALS-like 
FUS-tg mice (see Fig. 5) 
cytokine IL-1ß ↓ and IL-6 levels ↓ in serum and spinal tissue (p < 0.05) 
Iba-1 ↓  (p < 0.05) in serum and spinal tissue 




Figure 6 An overview of the interaction of stem cells in the maintenance of a regenerative non-toxic cerebrospinal fluid. The MSCs by cell-
to-cell communication polarize the IRM macrophages into ARM macrophages. The ARM macrophages decrease the pro-inflammatory 
cytokines and enhance the growth factors. ARM macrophages gen-expression for CD206, CCR26 and Arg1. (Abbreviations: ARM: activated 
response microglia, BDNF:Brain-derived neurotrophic factor; EVs: Extracellular vesicles, GSK-β: glycogen synthase kinase-3 beta,HSC: 
hematopoietic stem cell,IGF-1: insulin-like growth factor-1, IFN-γ: Interferon-gamma, IL-1: Interleukin-1,  IL-6: Interleukin-6,  iNOS: 
inducible nitric oxide synthase,  IRM: Interferon Response Microglia,    MSC: mesenchymal stem cell,  NO: nitric oxide,  ROS: reactive oxygen 
species,  TNF: tumor necrose factor, VEGF: vascular endothelial growth factor). 
 
Conclusion 
Evidence is provided for bm-SCs to: 
1. significantly improve survival and accelerate natural motor recovery in rats suffering 
balloon compression and/or weight-induced spinal cord injuries with a complete 
paraplegia in combination with reduced apoptosis, whereas methylprednisolone failed 
to do so; 
2. significantly delay the onset of ALS-like symptoms in pre-symptomatic FUS- and SOD1-
transgenic mice, whereas riluzole and celecoxib failed to do so. 
These effects may be initially reached by bm-SC’s preventing for the neurodegeneration-induced 
inflammatory reaction with sharply increased serum/spinal Il-1β and TNF levels, later on, having 
passed their effects to resident cells, in combination with bringing down the pro-inflammatory 
and pro-apoptotic degeneration-induced effects, as evidenced by their reduction of raised GSK-
3β and the conversion of IRM microglia into ARM microglia. As (N)SAIDs are clinically ineffective 
in these acute and chronic neurodegenerative conditions, bm-SCs here might reach their effects 
by reducing specifically the increased GSK-3β and Iba-1 protein levels in the affected central 
nervous system. It is possible that bm-SCs might reach these effects by acting on other than 
myeloid cells. Finally, the fact that bm-SCs can adapt their activity depending the environment 
where they are in, justifies the manufacturing/processing approach to keep these cells in a naïve 





Conclusions and Summary 
 
Introduction chapter 7 
After displaying the preclinical results and proposing the hypothesis of the decision-making stem 
cells, which detox the hostile cerebrospinal fluid, chapter 7.1 elaborates on this concept. The 
whole process from the first laboratory tests to the proof of concept in the animal experiments 
allowing to test our hypothesis in a clinical trial in patients suffering neurodegenerative 
disorders, will be addressed. The creation of an innovative new clinical bm-SC preparation 
(named Neuro-Cells) for the treatment of neurodegenerative disorders will be explained in this 
chapter. Due to the effect of this new preparation on the final patho-physiological pathway to 
neurodegeneration, necrosis, as shared by both acute and chronic neurodegenerative diseases, 
this new preparation is expected to induce a e disease-modifying rather than symptomatic 
effect. In the end, the questions as defined in chapter 1, will be addressed in detail.  
Finally, chapter 7.2, offers a summary of the preclinical findings as realised in the experimental 
treatment of preclinical acute and chronic neurodegenerative conditions with fresh human stem 
cell transplantations, as well as the proposed multi-pathway action of these stem cells in the 






7.1. Bone marrow-derived stem cells: from bench to bedside 
 
Increasing evidence indicates that inflammation is particularly involved in the pathogenesis of 
neurodegenerative diseases, and even if inflammation is not a primary causative process, its 
presence may contribute to the continued neuronal loss. Accordingly, both neurotrophic factors 
as well as anti-inflammatory agents, steroidal and non-steroidal anti-inflammatory drugs 
inclusive, were hypothesized to prevent and treat neurodegenerative conditions such as 
Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and traumatic 
brain/spinal cord injuries. However, there is always a  confounding factor with hypothesized 
therapeutic interventions:  the interventions might engage downstream of the underlying cause  
and retrospective in terms of final outcomes of the aimed disorder (Tang 2017). Unfortunately, 
clinical trials with anti-inflammatory drugs in neurodegenerative disorders, so far, did bring 
equivocal outcomes (Schwartz and Shechter 2010, Bracken 2012), and some clinical trials even 
resulted in detrimental effects (Ling et al 2016). Although pro-survival signaling mechanisms 
from the brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and 
granulocyte-colony stimulating factor (G-CSF), have all been shown to attenuate motor neuron 
death and prolong survival in ALS-like vitro (Kamei, Tanaka et al. 2007) and in vivo models (Lu, 
Jones et al. 2005, Bouhy, Malgrange et al. 2006, Blurton-Jones, Kitazawa et al. 2009), all the larger 
clinical phase II/III trials failed to show any benefits (Cedarbaum, Stambler et al. 1999, Meininger, 
Bensimon et al. 2004, Gordon, Moore et al. 2007, Fondell, O'Reilly et al. 2012).  
 
Neurodegeneration as many faces and many causes. The causes are still not known for the 
majority of the diseases. The burden of neurodegenerative diseases for the individual patient 
and for the community is high. The number of patients will increase as due to a direct result of 
the improved health care, mean age will increase in the next two decades (Arthur, Calvo et al. 
2016, Longinetti and Fang 2019), and many neurodegenerative diseases, especially 
parkinsonism, ischemic stroke, amyotrophic lateral sclerosis and Alzheimer’s disease are strongly 
related to aging (Wirdefeldt, Adami et al. 2011). Although spinal cord injury and traumatic brain 
injury were mostly seen in younger people, , over the last twenty years the mean age of these 
patients changed from 35 years of age to over 50 years of age (Furlan, Sakakibara et al. 2013). 
As 20 years ago, spinal cord injury was mainly caused by traffic accidents, today we see a shift 
towards falling accidents in and around the residencies of the patients (van den Berg, Castellote 
et al. 2010).  
 
The causes of neurodegenerative diseases may differ, but they share a final common pathway 
by inducing cell death and necrosis. In typical neurodegenerative diseases, this final pathway is 
initiated by activated glycogen synthase kinase 3β (GSK3) signaling damages ER-mitochondria 
associations (Stoica, Paillusson et al. 2016), and targetting this activation, therefore, might be 
regarded a potential therapy of neurodegenerative diseases (Duda, Wisniewski et al. 2018). 
These reduced ER-mitochondria associations are evidenced in FUS (fused-in-sarcoma) and TDP-
43 (transactive response DNA binding protein 43 kDa) transgenic ALS/FTD-like mice. Pathological 
TDP-43 aggregates are also the major component of ubiquitin-positive cytoplasmic inclusions 
found in the brains of patients with frontotemporal lobar degeneration (FTLD) and amyotrophic 
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lateral sclerosis (ALS), and are also found in patients suffering Alzheimer’s disease, Parkinson’s 
disease and other synucleinopathies (Stoica, Paillusson et al. 2016). In these disorders, the 
resulting mitochondriopathy results in reduced ATP levels with cell death and necrosis. As a 
matter of fact, cell death and necrosis in itself are inflammatory stimuli and lead to the activation 
of pro-inflammatory cytokines and microglia with the maintenance of a toxic environment, and, 
as a consequence, ongoing damage of cells and tissue. This secondary inflammation is shared by 
all neurodegenerative disorders. These pro-inflammatory cytokines, nitric oxide species, TNF-α, 
and the interleukins IL-1β and IL-6 inclusive, increase the production of cytotoxic reactive oxygen 
species (ROS) and may lead to abnormal accumulation of misfolded proteins, mitochondrial 
dysfunction, oxidative stress and/or persistent inflammation. These processes not only 
progressively worsen the toxic environment surrounding neural cells but also reinforce each 
other (Lim and Beal 2006; Ganguly et al 2017). Activated microglia, astrocytes and infiltrated T-
helper cells thus regulate cell death and eliminate associated waste materials within the central 
nervous system. The type, location and connections of the necrotic cell populations are leading 
in the variable clinical presentation of these neurodegenerative processes. In acute insults this 
secondary inflammatory process starts within hours after the initial cause and can last up to one 
year, whereas in more chronic insults this process is less severe but persists continuously. Here, 
the cerebrospinal fluid which nourishes the spinal cord and the brain is turned into a toxic 
environment in which inflammatory components actively enhance the death of neural tissue. It 
is not possible to stop, cure or effectively slow down the progress of these acute and chronic 
neurodegenerative diseases up to date. The majority of the actual interventions is focused to the 
intervention of only one inflammatory pathway instead of the multi-pathways leading to 
secondary inflammation. For example, Celecoxib, which fails to bring down ongoing secondary 
inflammatory processes, only interferes with the cyclooxygenase-2 signaling pathway. To stop 
or slow down the secondary inflammation, we need an intervention, which can simultaneously 
act at different inflammatory pathways involved. Only such intervention can stop or slow down 
the secondary inflammation and thereby effectively stop, bring down or delay the progress of 
the neurodegenerative process. An effective treatment to prevent, stop, resolve or to slow-down 
the secondary inflammatory cascades in acute, but not in chronic, neurodegenerative processes 
needs to be available within 24 hours after the CNS insult (Silva, Sousa et al. 2014, Chitnis and 
Weiner 2017).  
 
Stem cells, as mentioned before, can be seen as decision making cells. For example, a high 
concentration of for example interferon-γ can activate the naïve stem cells to inhibit the innate 
immune responses, whereas a low concentration of interferon-γ will activate the same naïve 
stem cells to do the opposite and enhance the innate immune responses (Chan, Tang et al. 2006, 
Corcione, Benvenuto et al. 2006). To assure that the stem cells can adapt to local circumstances, 
we believe that it is crucial not to change in any way the characteristics of these cells before the 
cells are re-implanted in the patient. Stem cells have all kind of receptors, which can be activated 
by specific antibodies. Such a antibody-receptor binding on the surface of the stem cell can 
change the expression of the stem cell (change in polarization of the cell membrane) and by 
changing the expression the same stem cell loses its naïve status (Andrzejewska, Jablonska et al. 
2019). To avoid changing the expression of the stem cells, therefore, a negative selection is used 
to isolate the stem cells. Negative selection means that magnetic beads bound on specific 
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antibodies are used to remove the lymphocytes and other unwanted cells from the bone marrow 
(Schuler, Harasymczuk et al. 2011). The antibody-free stem cells can freely pass through, while 
the other cells are trapped by a magnet and taken out of the sample.  
As both, HSCs and MSCs are pluripotent cells, it was originally postulated that these cells could 
replace destroyed neural tissue. However, two decades later, we know: 
 
– that both HSCs and MSCs can differentiate into spindle formed cells, which 
phenotypically are neurons alike; 
– that both HSCs and MSCs can modulate T- and B-Cells and react depending the 
environment in an inflammatory-stimulating respectively inflammatory-inhibiting 
manner; 
– that both HSCs and MSCs can directly or indirectly secrete paracrine factors, which 
can stimulate repair/regeneration/revascularization; 
– In vitro, isolated HSCs will act pro-inflammatory and initiate aging and cell death. 
Together with MSCs, HSCs stay undifferentiated and inactive;  
– The naïve status of stem cells seems to be important as these cells can make their 
own decision based on the input of the environment; 
– There is no consensus regarding the number of stem cells, needed to initiate an 
effect, as stem cells can activate neighborhood cells to support. The classical 
pharmacokinetics and pharmacodynamics of drugs do not apply to stem cells; 
 
Stem cells can be expanded in the laboratory, but not indefinitely. Besides the fact that culturing 
of the stem cells takes easily 3 to 4 weeks, it is also reported that culturing per se will lead to 
telomere shortening and other chromosomal alterations (Mayshar, Ben-David et al. 2010, 
Ferreira, Irioda et al. 2012). Finally, in case of an acute CNS insult, the expanded cells will first 
become available when the secondary inflammatory cascades are already fully deployed. 
Looking again to the effects of stem cells in preclinical settings (tables presented in Chapter 2) 
time to implant stem cells after an acute lesion is crucial. Indeed, best outcomes were reported 
when the stem cells were applied in the acute stage of the insult.  
 
Evaluation of the preclinical and clinical studies with fresh bone marrow-derived mononuclear 
cells (a mixture of MSCs, HSCs and stomal cells), similar results were reported as in the studies 
with only expanded MSCs and/or HSCs. Another important conclusion in the in chapter 2 
presented reviews was the fact that intrathecal and intraparenchymal cell transplants were 
superior to intra-arterial and intravenously applied cells. In conclusion, expanded allogenic MSCs 
and HSCs applied intrathecally within 24 hours after the onset of an acute neuro-degenerative 
process (a SCI lesion) seemed to be the best choice, based on the literature review presented in 
Chapter 2. Of note, in these studies, cyclosporine was needed to suppress the rejection of the 
cells. Looking back to these (pre)clinical studies, there are still remarks and short comings, which 




− Cyclosporine is a cell protecting drug itself (Palladini, Caronti et al. 1996) and has a 
negative effect on stem cells (Guo, Zeng et al. 2007). 
− In the presented studies the MSCs and HSCs were no longer naïve. The cells were 
exposed to specific antibodies for their selection and programmed to expand to reach 
sufficient numbers of cells. 
− Performing a Ficoll-gradient centrifugation of bone marrow (Hernandez, Cortina et al. 
2007) is a method by which the white layer of cells containing stem cells can be selected 
without using specific magnetic antibodies, but this preparation contains high numbers 
of pro-inflammatory immune cells, T- and B-Lymphocytes, monocytes and natural-killer 
cells inclusive. Erythrocytes, though, are at least depleted. Looking at literature, 
applying stem cells intrathecally (into the immune privileged cerebrospinal fluid) is safe 
but the presence of erythrocytes and lymphocytes have to be avoided (Assmus, Tonn 
et al. 2010, Jones 2014). 
 
The stem cell preparations (bm-SCs) used in the preclinical studies in SCI and ALS-like animal 
models as described in chapters 4 and 5, are based on the removal of lymphocytes out of the 
harvested human bone marrow preparation. by labeling with specific magnetic antibodies 
against respectively T-Cells, B-Cells, NK (natural killer)-Cells and monocytes. These cells are 
unwanted and as much as possible removed by positive selection. The remaining stem cells were 
not labeled (negative selection). From a valorization point, 2 patents for using the waste product 
with negative selected cells (Neuro-Cells©) has been filed and granted.  
The in chapter 3 presented preclinical experiment to test the eventual stem cell-induced 
angiogenesis in an acute ischemic lesion was performed with a gradient centrifuged mixture of 
bone marrow derived HSCs and MSCs, still containing erythrocytes and lymphocytes. This 
preparation was administered directly in the blood vessels and the muscles, where the presence 
of erythrocytes and lymphocytes in the preparation did not matter. HSCs and MSCs were found 
able to stimulate angiogenesis and to decrease ischemia. Before developing clinical experiments, 
of course, the following step is to develop a robust and professional manufacturing under good 
manufacturing practices (GMP) of a stem cells-containing product, as a GMP compliant product 
is mandatory when going into clinical trials to treat patients.  
Literature summarized in chapter 2 suggested positive preclinical and clinical outcomes in 
neurodegenerative processes after an intervention with human bone marrow-derived 
mononucleated cells, containing both HSCs and MSCs.   
The mechanism of action was not completely understood but there was enough evidence to 
assume that the secretion of paracrine factors and or immune regulating proteins were crucial 
in modulating neuro-inflammation. To elaborate on this hypothesis, the first need was to 
reconfirm the improvement of the neurologic outcome in animal models of acute ischemia 
(chapter 3), of spinal cord injury (Chapter 4), of amyotrophic lateral sclerosis and frontotemporal 
lobe degeneration (Chapter 5) after an intervention with a combination of HSCs and MSCs . 
 
Interpretation of the results of the interventions with bone marrow-derived stem cells provided 
further evidence indeed for an improvement of the clinical outcome in rats with an acute 
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occlusion of the hindlimb artery, by enhancing the angiogenesis. This effect was evaluated by 
measuring the density of micro-vessels in the affected limb and to compare the results with 
those found in vehicle treated animals.  
We also tested bm-SCs (Neuro-Cells) in two animal models for spinal cord injury and performed 
a head-to-head comparison between rats treated with bm-SCs (Neuro-Cells), placebo, and a high 
dose of methylprednisolone. Interventions with bm-SCs were found effective in increasing the 
recovery in both acute spinal cord injury animal models, whereas interventions with 
methylprednisolone and placebo failed to do so.  
Finally, in a new FUS-tg model for ALS, we also established a significant bm-SCs-induced 
improvement of clinical and neuropathological hallmarks of ALS, when comparing the effects 
with final outcomes in those animals when treated with placebo, riluzole and the COX-2 inhibitor 
celecoxib. These findings could also be confirmed in another model for ALS, the SOD-1 mutant 
mouse. In the FUS-tg FTLD-like mice, interventions with bm-SCs did significantly prevent for 
increased concentrations of IL-1β and GSK-3β as evidenced in the FUS-tg-Veh group (p<0.05). In 
these animals, behavioral and molecular abnormalities of FUS-tg mice were also found reduced 
after these interventions, to a greater extent as compared to the interventions with riluzole 
and/or celecoxib. 
So, the combination of HSCs and MSCs in human bm-SCs and/or Neuro-Cells was found to 
improve the neurological/vascular condition in various (neuro)degenerative animal models, 
notably without the presence of cyclosporine. In an acute ischemic degenerative environment 
stem cells promoted the formation of micro-vessels, and in both an acute traumatic spinal cord 
and a chronic ALS-like and FTLD-like neurodegenerative environment, Neuro-Cells decreased the 
secondary inflammation process and rescued neural tissue. These experiments arrested the case 
that bm-SCs indeed affect the final common pathway of secondary inflammation in (neuro)-
degenerative processes, most probably by preventing the activation of GSK-3β and the damage 
of ER-mitochondrial associations.  
 
Conclusion: based on the results of the preclinical studies in spinal cord injured rats and ALS-like 
and FTLD-like mice, an intrathecal intervention with Neuro-Cells might be seen as a potential 
intervention for neurodegenerative disorders in which cell death initiates the activation of 
secondary inflammatory cascades. 
In the immune privileged environment of the spinal cord and the brain, bm-SCs simultaneously 
act on several pathways of inflammation, whereas (N)SAIDs and/or riluzole fail to do so. In 
neurodegenerative processes, bm-SCs, the decision makers, were found to bring down or 
prevent for increased GSK-3β levels, IBA-1 (a microglia activator) levels as well as the levels of 
pro-inflammatory cytokines IL-1β and TNF-α. In the typical neurodegenerative processes such as 
AD, PD, ALS, and FTLD, key is the progressive damage of ER-mitochondria associations. By 
affecting ER-mitochondria associations, and thus ATP production, GSK-3β acts as a downstream 
regulatory switch for numerous signaling pathways involved in glycogen metabolism, cell 
development, gene transcription, and protein translation to cytoskeletal organization, cell cycle 
regulation, proliferation, and apoptosis. Based on the outcomes of our preclinical studies, an 
intervention with bm-SCs (Neuro-Cells) in typical neurodegenerative conditions can ‘detox’ the 
cerebrospinal fluid and create a more regenerative climate. Concerning the original questions 
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regarding interventions with stem cell preparations as formulated in chapter 1, the following 




Not-manipulated negatively selected bone marrow-derived HSCs and MSCs, intrathecally 
applied, seems to be a safe and effective treatment in preclinical models of neurodegeneration. 
Generally speaking, clinical interventions with fresh autologous bm-SCs are preferred as the 
patient’s owns stem cells will not activate a host-versus graft or graft-versus-host reaction. 
However, they also have their limitations, which justify the use of allogenic bm-SCs. Based on 
literature these limitations are diabetes, renal failure, aging, and severe ALS, as plasticity is 
decreasing. Also, the number of fresh bm-SCs (50 ml bone marrow contains about 50-60 x 106 
CD34+ cells) is limited, and their half-life is about 72 hours. PM, during aging, the number of bm-




The question which dose of stem cells to apply seems to be irrelevant. After all, the effect of 
cells, with their ability to migrate, replicate, differentiate, and to respond to the 
microenvironment is not strictly dose dependent. In the performed studies the dose was titrated 
on the total number of CD34+ cells. The dose injected intrathecally contained between 400,000 
and 500,000 CD34+ cells and an equal number of MSC positive stained cells. 
 
When to apply? 
Timing is key and taking literature and the outcome of the preclinical studies into account, an 
effective treatment window in acute neurodegenerative processes lies between 24 to 72 hours 
after the initial CNS insult. As for the more chronic neurodegenerative disorders, the best 
strategy also appears to start as early as possible, as the disease itself results in an ongoing 
necrosis of neural cells, assuming that what is dead cannot be replaced with this therapy. Key is 




Indications to apply 
Compiling the anti-inflammatory characteristics of bm-SCs as confirmed in an acute traumatic 
and a chronic degenerative model of neurodegeneration suggests that the bm-SCs are rather 
not-specific disease-modifying drugs. Neurodegeneration in general results in cell death with the 
activation of IRM activated microglia and macrophages in in the central nervous system. Bm-SCs 
provide protection to neural cells, polarize the activated microglia and macrophages and detox 
the cerebrospinal fluid. Therefore, bm-SCs might offer a disease-modifying effect in both acute 
and chronic neurodegenerative disorders, as displayed in figure 1. This figure provides an 







Figure 1 presents in an overview the disease modifying effect of bm-SCs in an acute CNS insult Spinal Cord Injury and two chronic 




7.2. Summary: the patient’s own bone marrow-derived stromal 
cells as disease modifier in (neuro)degenerative disorders 
 
Neurodegenerative disorders share the final degenerative pathway, the cell death-induced 
secondary inflammation with progressive apoptosis and/or necrosis, irrespective of their 
aetiology. In two preclinical models for acute neurodegeneration (balloon-compressed and drop 
weight impact SCI models) and in two preclinical models for chronic neurodegeneration (ALS-like 
FUS 1-358 and SOD1-G93-A mutation), a GMP produced negative selected human bone marrow 
derived stem cell preparation (bm-SCs; Neuro-Cells) was tested for safety and efficacy.  
 
After double-blind interventions with this preparation, with placebo, or with (non)steroidal anti-
inflammatory drugs (methylprednisolone, riluzole, celecoxib), clinical, histological and 
histochemical findings (serum/spinal cytokines and markers for spinal microglial activation 
inclusive) evidenced the cell-to-cell action of bm-SCs in both otherwise healthy and immune-
deficient tSCI-rats, as well as in wild-type and FUS/SOD1-transgenic ALS-like and FUS-transgenic 
FTLD-like mice. All studies yielded significantly better results in bm-SC-treated animals as 
compared to the animals treated with placebo and/or NSAIDs. In SCI-lesioned rats, bm-SCs led 
to faster motor recovery, less apoptotic cells and less astrocytes in the lesion as compared to 
vehicle and methylprednisolone. In ALS-like mice, bm-SCs led to less motor impairment, less 
muscle atrophy and a decreased loss of motor neurons in the spinal cord as compared to vehicle, 
riluzole and celecoxib treated animals. In the FUS-tg FTLD-like mice, after interventions with bm-
SCs (Neuro-Cells), behavioural and molecular abnormalities of FUS-tg mice were also found 
reduced to a greater extent as compared to the interventions with riluzole and/or celecoxib. 
 
The multi-pathway hypothesis of the action of bmSCs, presumably through extracellular vesicles 
(EVs) as messaging carriers of RNA, DNA, proteins and lipids, rather than influencing a single 
inflammatory pathway, could be justified by the established differences of serum and spinal 
tissue levels of cytokines and other chemokines. The mode of action of bm-SCs is hypothesized 
to be associated with its dedicated adjusting of the pro-apoptotic glycogen synthase kinase-3β 
level towards an anti-apoptotic level whereas their multi-pathway hypothesis seems to be 
confirmed by the decreased levels of the pro-inflammatory interleukin (IL)-1β and tumor 
necrosing factor (TNF) as well as the level of the marker of activated microglia, ionized calcium 
binding adapter (Iba)-1 level. With the results presented, the next phase, translating the results 
into humans seems justified.    
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7.3. Samenvatting: patiënt’s eigen beenmerg stamcellen om 
(neuro)degeneratieve aandoeningen aan te pakken 
 
Hoewel de oorzaken van de diverse neurodegeneratieve aandoeningen niet altijd bekend zijn, 
delen deze aandoeningen wel dezelfde pathofysiologie. De initiële celdood en necrose in het 
centrale zenuwstelsel zijn verantwoordelijk voor het activeren van de secondaire 
ontstekingscascades. 
In preklinische diermodellen voor acute (balloncompressie en slaggewicht-geïnduceerde 
ruggenmergletsels) en chronische (FUS-1-358 en SOD1-G93-A mutatie) neurodegeneratieve 
processen, is een uit menselijk beenmerg afkomstig stamcel preparaat (bm-SCs, Neuro-Cells) 
getest op veiligheid en werkzaamheid.   
Dit stamcel product is onder GMP-condities en met negatieve selectie tot stand gekomen. In een 
dubbelblinde studieopzet is het stamcel preparaat vergeleken met een niet-werkzame placebo, 
danwel ontstekingsremmers: (N)SAIDS zoals methyl-prednisolon, riluzole en celecoxib.  
In vergelijking tot placebo- en methylprednisolon-behandelde dieren, verbeterde de achterpoot 
functie van de met stamcellen behandelde dwarslaesie dieren significant sneller, en was er 
sprake van minder celdood en een lagere concentratie aan ontstekingscellen (astrocyten) in het 
beschadigde weefsel.  
Van de ALS-achtige dieren vertoonden de dieren behandeld met stamcellen significant minder 
uitval van de spierfuncties, hadden deze dieren minder spieratrofie en was er sprake van een 
significant hoger aantal intacte motorneuronen in het spinale weefsel in vergelijking tot de 
dieren behandeld met placebo, riluzole of celecoxib. Tenslotte bleken de met stamcellen-
behandelde FTLD-achtige muizen significant beschermd voor de normaal in deze dieren 
optredende verhoging van de IL-1β en GSK-3β concentraties. Ook bleken de hier optredende 
gedragsafwijkingen duidelijk afgenomen, veel meer dan na interventies met riluzole en/of 
celecoxib. 
 
De resultaten van de serum cytokinen en de western-blot weefsel preparaten in de bm-SC-
behandelde proefdieren maken het aannemelijk dat de stamcellen multi-taskers waren, die 
meerdere processen tegelijkertijd beïnvloeden, hierbij gebruik makend van extracellulaire 
vesicles als communicatoren voor de interactie. Op basis van ons onderzoek mag ervan 
uitgegaan worden dat bm-SCs (Neuro-Cells) in preklinische neurodegeneratieve ziekteprocessen 
vooral werkzaam is door het onderdrukken respectievelijk voorkomen van de in deze ziekten 
aanwezige progressieve activatie van het GSK-3β, die gepaard gaat met de aantasting van de 
verbindingen tussen het endoplasmatisch reticulum en de mitochondria, waardoor een tekort 
aan ATP met necrose optreedt. 
Op grond van de door ons verkregen preklinische resultaten lijkt het gerechtvaardigd de 
vastgestelde gunstige effecten van bm-SCs te vertalen naar een mogelijk ziekte-modificerende 
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